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SCOPE OF THE SYMPOSIUM 
SCOPE OF THE SYMPOSIUM 
The availability of meat products of good quality at affordable prices is a generally accepted 
right for an increasing part of world's population. Meeting consumers demand for these animal 
products was made possible by making use of achievements in animal science. A sharpening of the 
scientific tools by developing modern biotechnology is probably essential for meeting future 
( demands while coping simultaneously with the increasing constraints in production. Acreage for growing crops for animal feed is limited and the capacity of the environment to 
absorb polluting excreta has already been exceeded in some areas. The sustainability of the animal 
production system can therefore no longer be taken for granted. The requirements for product 
, quality and safety are defined more sharply. The wellbeing of the animals asks for a higher priority. 
J Advancements in biotechnology create widening perspectives for meeting these requirements 
effectively. Significant improvements in efficiency and quality in animal production come within 
reach. 
It is the objective of this symposium to study in a global context the potentials and constraints of 
emerging new technologies for controlling growth and product quality, in meeting requirements for 
consumer, animal and environment. 
Priorities for improving animal production 
Improving the conversion efficiency of feed into meat offers in many ways the most promising 
perspective for the long term sustainability of the animal production system. It reduces the acreage 
of feed crops to be grown for animal production and leads to lower meat costs. Last but not least it 
is a most effective way for reducing the environmental pollution from animal excreta. 
Product quality has to reflect demand for more lean and less fat as a result of the increasing 
awareness that excessive calory intake forms a human health hazard. Product safety as well as 
taste and tenderness remain a high priority. 
The wellbeing of the animals as expressed in health and behavioral parameters can be studied 
more effectively by advancements in animal physiology, ethology and immunology. 
Emerging biotechnologies 
For an analysis at this symposium, physiologically related technologies have been selected with 
demonstrated potentials in combining effectiveness with intrinsically favourable safety aspects. 
The technologies relate to the somatotropin axis. 
Growth of food producing animal species is controlled by the genome, expressing its potentials 
via this interacting system of Somatotropin releasing factor (GRF) - Somatostatin -
Somatotropin - Somatomedins. 
Since 6,000 years man has affected this axis by gradual modification of the genome of the 
animals through systematic selection and breeding in order to tune animal production to demand. 
In the last decades this process accelerated considerably through introduction of artificial 
insemination and embryotransfer while other advanced technologies are emerging. 
A more selective modification of the genome has recently been achieved by the insertion of 
growth controlling genes in the genome of food producing animals. 
An even more selective impact on the growth controlling physiological axis has been obtained 
by changing the level of the various earlier mentioned messengers. This has been achieved by direct 
administration of Somatotropin and Somatotropin Releasing Factor. 
The latest addition to the techniques allowing for impact on constituents of the somatotropin 
axis stems from immunization techniques. Potentiation of somatotropin and binding of 
somatostatin proved to be feasible with antibodies. 
Evaluation of safety and efficacy 
The common mode of action of these technologies leads in many ways to comparable effects on 
the target animals, their products and on the environment. It makes therefore sense to study them 
jointly for their common denominators. 
Since biotechnology made key elements of the growth controlling system in the somatotropin 
axis separately available for animal research, a better understanding of the effects has been 
obtained in recent years. 
With the rapidly accumulating scientific data it is increasingly possible to analyze the potential 
implications and acceptability aspects of the three above mentioned interrelated categories of new 
technologies for control of growth. 
Introductions of earlier innovations in animal production demonstrated repeatedly that such 
achievements easily lead to long lasting divergencies of opinion on their acceptability. Consumer 
safety aspects have been a central issue for a long time. More recently target animal safety, 
environmental impact and repercussions for the structure of the production system are taken 
into consideration as well. 
Questions on acceptability aspects of new technologies have often been defined rather late 
during their development. Insufficient awareness of the nature of these upcoming questions 
prevented their timely incorporation in the experimental designs. As a result relevant answers were 
produced later and at higher costs than necessary. 
To provide adequate guidance for research as well as for regulation of applications of these 
technologies, much can be gained by timely international consultations within the scientific 
research community involved. Such a consultation is visualized in this symposium. 
The state of the art is reviewed and further research priorities defined in an interaction between 
scientist from universities, industrial research groups and from the institutions which carry 
regulatory responsibility. The sponsorship and participation from all three sides illustrates the 
common awareness of the use of this joint scientific evaluation. 
The symposium may contribute furthermore to a harmonization in the approach of the 
technologies at stake in the geographic theaters which are at present of relevance. The negative 
consequences of discrepancies between these regions in acceptance and regulation need not to be 
elaborated upon for demonstrating the urgency of a joint scientific evaluation. 
THE CHALLENCE 
THE CHALLENGE 
BIOTECHNOLOGY, COMPETITIVENESS AND ACCEPTABILITY: 
THE CHALLENGE TO EUROPE 
M.F. Cantley 
Head of CUBE (Concertation Unit for Biotechnology in Europe) Commission of the 
European Communities 
(Opinions expressed engage only the author; not a statement of Commission policies except 
insofar as official documents are explicitly cited). 
Summary 
The author is not a biological specialist, but is involved in the conception and implementation of 
a strategy for biotechnology in Europe. Questions of implications and acceptability-have in recent 
years become prominent particularly regarding the applications in agriculture of recent advances in 
biological knowledge and biotechnology. 
An outline of the Community strategy is presented; its basic orientation is international 
competitiveness, assumed to underpin the pursuit of the broader objectives of the EEC Treaty. 
Public and political criticisms of biotechnology introduce broader dimensions, including ecology, 
economic structural impacts in agriculture, animal welfare, ethical issues, consumer rights and 
consumer safety. Those who perceive threat or feel outrage on one dimension seek allies amongst 
other critics. 
In this broader context, issues of global responsibility and societal or cultural values complicate 
the conventional emphases on economic competitiveness, but do not negate the benefits of 
innovation, and of competition within a common global framework based on shared perceptions of 
common interests - which can be pursued simultaneously in a liberal world trade system under 
GATT rules, or under agreed constraints for the benefit of the global ecosystem (cf. the limitations 
now agreed internationally on the production of chlorofluorocarbons). 
To promote these shared perceptions and raise the standard of public and political debate, more 
effective communication between the interested parties must be promoted in the public interest. 
Keywords: biotechnology, European Community, market competition, acceptability, swine. 
Introduction: The Community strategy for biotechnology in Europe, 1983-89 
This conference takes place at a time when the dramatic progress of recent decades in the life 
sciences is being translated into practical applications in many fields - notably, health care, and 
agriculture. These practical applications in many fields have been summarised in a broad and 
diffuse but convenient word : "biotechnology". 
The multi-disciplinary character and multi-sectoral applications of biotechnology pose many 
policy challenges to public authorities, at national or European Community level. It was in order to 
help respond to these multi-dimensional policy challenges that the Commission established in 1984 
its Biotechnology Steering Committee, with a supporting secretariat and working groups. This is 
not the occasion for a long history of the development and implementation of the Community 
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strategy for biotechnology in Europe, but in summary, it has over the past 5 years comprised action 
on six separate priorities : 
- Research and Training: the Biomolecular Engineering Programme ("BEP": 15 MECUs 
1982-86) focussed on aspects of genetic engineering and enzymology of relevance to their 
applications in agriculture and the food industry. It has been followed by the broader 
Biotechnology Action Programme ("BAP" : 55 MECUs 1985-89), which is uniting laboratories 
throughout the EEC area around various topics relevant to the reinforcement of Europe's 
capabilities in biotechnology. In particular, this programme has pioneered the concept of 
"European Laboratories Without Walls", and is attracting growing interest from industry. 
Proposals for a 100 MECUs successor programme (1990-1994), provisionally entitled 
"BRIDGE" (Biotechnology for Innovation Development and Growth in Europe) are currently in 
preparation. 
- Agriculture: new price regimes for sugar and starch were introduced in 1986, to facilitate and 
encourage the industrial uses of such materials. 
- Regulations: guided by a Biotechnology Regulation Interservice Committee established in July 
1985, the Commission is seeking to promote a harmonised regulatory approach to 
biotechnology; adding to the specific Community sectoral regulations (e.g. for foodstuffs, for 
pharmaceuticals, for agricultural products, etc.) three general proposals (March 1988) 
concerning the confined industrial use of recombinant micro-organisms, the field release of 
modified organisms, and the protection of workers against possible hazards of exposure to 
biological agents. 
- Intellectual Property: as in the area of regulations for biotechnology, the Commission is 
seeking to promote a harmonised Community-wide approach to the protection of intellectual 
property in biotechnology. Its October 1988 proposal would confirm the patentability of living 
organisms, subject to the exclusion (imposed by the European Patent Convention 1974) of 
animal and plant varieties. 
- Demonstration Projects: in order to promote the development and application of 
biotechnology, and to encourage the growth of new opportunities for adding value to the 
products of European agriculture, the Community has proposed the launching of programmes 
worth 105 MECUs (1988-1992) to promote biotechnology-based developments at the interfaces 
between agriculture and industry. A paper on agro-industrial demonstration activities has also 
been prepared following the February 1988 request to the Commission at the European Council 
(of prime ministers of the Member States). 
- Concertation: in order to promote awareness of the challenges of biotechnology, and greater 
coherence of policy responses across the Commission services and between Commission and 
EC Member States, the earlier mentioned Biotechnology Action Programme includes a 
"concertation action" charged with a range of strategic monitoring, information and coordination 
tasks. 
A five-year-old strategy is ripe for renewal, review and modification; especially given that 
action has already been initiated on each element of the old strategy. 
The renewal of Community strategy: biotechnology in Europe in the 1990s 
Amongst the many changes in the environment of biotechnology over the past five years, or in 
prospect during the coming years, particularly relevant are the following : 
- the Uruguay Round of GATT negotiations, and in particular their possible implications for 
some liberalisation of agricultural trade. 
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- the Single European Act, which came into effect from 1 July 1987. Reinforcing and updating 
the founding treaty of the EEC, this Act : 
• reinforces the role of the directly-elected European Parliament in the adoption of new 
Community policies and programmes; 
. facilitates (by the wider use of qualified majority voting by the Council of Ministers) the 
adoption of the harmonisation measures needed to create by 1992 a true Common Market; 
. adds a specific section on "Research and technological development" to the EEC Treaty; 
. defines in hard economic terms the objective of the Community's R&D activities (Article 
130F,1): "The Community's aim shall be to strengthen the scientific and technological basis of 
European industry and to encourage it to become more competitive at international level". 
This must be pursued with an awareness of Article 130A: "In order to promote its overall 
harmonious development, the Community shall develop and pursue its actions leading to the 
strengthening of its economic and social cohesion".; 
• requires the preparation of an overall, multi-year "Framework Programme" for Community 
R&D activities (to be unanimously agreed by the Member States), within which action has to 
be implemented through specific programmes (each to be adopted by majority decision); the 
current Framework Programme (1987-91) was agreed in September 1987. 
These considerations emphasise international competitiveness and the achievement of internal 
common market as strategic aims for Community policies for biotechnology. However, there are 
both broader social and global issues, to which biotechnology is relevant or central; and narrower 
technical issues relevant to Community policy initiatives. A possible inventory of strategic aims 
for biotechnology might therefore be summarised as follows : 
— Overall, continuing, long-term goal: 
. The beneficial application of biotechnology to the maintenance and improvement of health 
and wellbeing, local environments and the global ecosystem. 
— Major policies with specific implications for biotechnology: 
• Competitiveness and innovation in the bio-industries, with particular reference to the 
formation and growth of small and medium-sized enterprises; 
• Harmonised internal market (regulations, patents, standards), taking international dimensions 
into account; 
• Research (basic, pre-competitive and infrastructure), development and training; 
. International collaboration (scientific, technological and industrial). 
- Other current priority actions in support of the above goal and policies: 
• European biotechnology information policy (for infrastructure and competitiveness); 
. Communication : public, consumers, political leaders and legislators. 
Of these seven strategic aims, some are particularly relevant to the topics of the current 
conference, and in the following sections, these are the points emphasised. 
The benefit and the necessity of biotechnology 
Of the seven proposed strategic aims above, only the first can be defended as unequivocally 
worthwhile in itself. The pursuit of this goal is not optional; it is a fundamental imperative. 
Biotechnology is by definition the collected knowledge relevant to purposeful use or maintenance 
of living systems, whether the system be a micro-organism or an inhabited planet. We hope to 
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sustain a human population rising from the current five billion to a likely 10 billion within our 
grandchildren's lifetimes. To sustain such a growing population in civilised conditions without 
destroying the planet's continuing ability to support human and other life, will call for all the 
intelligence and understanding which we possess concerning the management of living systems. 
The other six aims are essentially instrumental, in support of this over-riding goal; and the 
subject of this conference, the pursuit of growth and product quality in swine, is one important 
example of the competitiveness which features next on the list of strategic alms. We review below 
the implications and acceptability of this pursuit. 
Do we want competitiveness, intensification and productivity growth in 
agriculture ? 
Doubts have in recent years been expressed about the pursuit of higher productivity in 
agriculture. These doubts reach beyond economic arguments, to areas which the classical economist 
might term "externalities" - and then ignore. The attack on productivity has several bases, of which 
four are particularly emphasised : 
— deleterious effects on the environment; 
— concern for the suffering and "rights" of animals; 
— recepticism about the need for higher output in agriculture, at least in areas of the world 
characterised by saturated markets and apparent structural surpluses; 
— disruptive impacts on economic structures, particularly if the "rationalisation" of agriculture into 
fewer, larger, units is accelerated. 
These are seen as some of the implications which influence the acceptability of biotechnology, 
or at least, of some of its specific applications in agriculture. 
Biotechnology and environment 
Consider first the concern sometimes expressed about the impact of biotechnology on 
agriculture and the environment. Around the world, some two hundred million people are engaged 
in "slash and burn" agriculture. Of course, they are driven by their local necessities; but by their 
actions, they are destroying the remaining areas of tropical forest, with a loss of species estimated 
at several hundred per day. We are likely to lose half of all current species within twenty years; it is 
an environmental catastrophe, a species extinction of a magnitude unparalleled since the death of 
the dinosaurs. It is not hypothetical; it is happening now. Yet biotechnology can offer the means to 
feed the world's whole population more than adequately, using far less land than we cultivate today. 
Further major gains in agricultural productivity are now seen to be possible, such as those 
deriving from our ever-increasing understanding of animal and plant nutrition and metabolism. By 
pursuing higher productivity, we can reduce the pressure on environmentally sensitive areas, such 
as the uplands and the wetlands, the unique ecological habitats. Biotechnology offers the means to 
defend our forest, be it in temperate or in tropical zones, and to restore our environment, replanting 
appropriate species in degraded areas such as, here in Europe, parts of our Mediterranean littoral. 
The political and economic difficulties should not be understated. But it is essential that interest 
groups seriously concerned with the maintenance and restoration or enhancement of the 
environment, of ecosystems, should recognise the potential of the recent advances in biotechnology 
for enabling their objectives to be achieved. 
Clearly mismanagement of intensive agricultural systems can create environmental problems, 
for example from the waste products of intensive animal units. But both public regulations and 
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economic self-interest militate in favour of reducing the volume of such wastes, by enhancing the 
animal's food conversion efficiency. Moreover, the methods for treating wastes and for converting 
them into acceptable or even useful products are themselves a matter of biotechnology. 
Biotechnology and animal rights 
Turning to the questions of animal suffering and rights, the industry must recognise constraints, 
and adjust its methods to remain within the limits of what is acceptable in our societies for the 
treatment of sentient fellow-species. This is currently given operational and legal definition through 
such instruments as the Council of Europe conventions on the treatment of animals used in 
agriculture, and of animals used in research. There is, in my opinion, no new problem of principle 
posed by the advances in genetics or biotechnology, relative to the issues of humane treatment with 
which we are already familiar. It may reasonably be argued that a healthy and more productive 
animal has higher value, and is therefore likely to be better cared for. 
In some cases, we may hope that advances in biotechnology may enable us to diminish the use 
of animals in laboratory experimentation, for example through the use of in vitro tests. For meat 
animals, or animals castrated to control their behaviour, there is no escaping what some writers 
term, the associated "mixture of necessity and guilt" short of a completely vegetarian ideology. This 
remains a minority conviction, albeit a growing one. Biotechnology will again offer, if the market 
or the vegetarians demand it, the means for developing meat substitutes, of texture and flavour ever 
closer to the natural product. The ICI-RHM "Quorn" from the fusarium fungus, tastes better than 
the textured vegetable proteins of a few years ago; and in terms of land use, must be a substantial 
gain in the population sustainable from a given land area. 
Pursuing this line of argument, one might in a hungry world draw a moral distinction, between 
the monogastrics (pigs and poultry) competing with human diet; and the polygastric, 
cellulose-digesting ruminants traditionally used as scavenging animals on terrain not otherwise 
adaptable to human sustenance. In a world less hungry, where the cattle are fed on oil-seed cake, the 
moral distinction is difficult to sustain, and the choice of production routes for protein supply 
returns to questions of economics. It should not be assumed, however, that the "consumer" is a 
"theoretical economic individual", indifferent to the means used, the circumstances and the origins 
of the products and services offered for consumption. To the acceptability issue we return below. 
Let us first consider the critique based on the "surpluses" argument. 
Biotechnology and surpluses 
The pursuit of higher productivity in agriculture is currently out of fashion in some political 
circles in Western Europe. This is a simplistic and dangerous reaction to the short-term problems of 
surpluses. It is worth reiterating the several reasons why the pursuit of efficiency and productivity 
remains vital. 
The most obvious reason is the general welfare : it is clearly in the interest of the consumer and 
of society as a whole to produce needed goods with less materials energy or other costly inputs. 
Agricultural surpluses in the European Community are a soluble and transient problem. The 
policy instruments - primarily prices, quotas and stabilisers - are already in operation, to bring 
supply and demand into balance over the next two or three years. 
To satisfy current demands for agricultural products with a lower level of inputs provides a 
welfare gain. The distribution of this gain between the supplier of better inputs to the farmer, the 
farmer himself, the consumer, or the Community taxpayer, is a matter for political decision, or 
economic negotiation through the marketplace. Few consumers complain of a surplus of spending 
power. 
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Biotechnology and economic structure 
The above aggregate economic arguments do not describe the detailed structural implications 
associated with the "lower level of inputs" - including the input of labour. This means a declining 
number of farms and farmers, for the rate of progress of productivity in agriculture is likely to 
continue to exceed the rate of growth of population, certainly in the developed world, and 
fortunately also on a global basis. In spite of the sometimes traumatic personal consequences of this 
structural change, it is difficult to dispute the desirability of a continuing decline in the real costs of 
agricultural production and the consequent capacity to supply food at affordable prices for a 
growing world population. 
Europe cannot isolate its agriculture from these trends. It is above all a bloc of trading countries 
- more so than the United States or Japan - as the following figures make clear : 
United States Japan EC Member States * 
Imports as 8,8 6,5 22,8 
% of GNP 
Exports as 5,2 10,8 22,8 
% of GNP 
Source: The OECD in figures, July 1988; figures relate to 1986 
* the fact of including intra-Community trade does not diminish the force of the argument. 
Agriculture forms a major element of this trade. France alone is second only to the United States 
in the value of its agricultural exports. Whatever the current differences between the groups 
negotiating in the GATT Uruguay round, it seems certain that the coming years are going to see 
some greater liberalisation of world trade in agriculture with a concomitant dismantling of 
production supports. 
Any country or region which seeks to become or to remain a major participant in agricultural 
trade in the 1990s must therefore continue to pursue increased efficiency and productivity in 
agriculture, in particular via research and extension or training, and the application of advanced 
biotechnology in agriculture. 
Consumer and political acceptability, and the need for communication 
In reviewing some of the criticisms levelled at the pursuit of competitiveness through 
biotechnology, we have sought to defend it as a pursuit essential for the overall aims of health, 
wellbeing and environment. Most of the other earlier listed aims - the harmonised internal market, 
research, international collaboration, information infrastructure - contribute also to the pursuit of 
competitiveness. There remains the proposed aim: "Communication: to public, consumers, political 
leaders and legislators". 
The emphasis on this aim is related to the aims of this conference, and to the criticism reviewed 
above : the implications of applying biotechnology for competitiveness in agriculture are far from 
accepted. Even within a general acceptance of the aim, there is extensive debate about specific 
practices going far beyond the traditional regulatory concerns of quality, safety, efficacy, and safety 
for the environment. 
It is one of the Community's stated aims to raise the level of public understanding of the nature, 
potential and risks of biotechnology. An educated public is fundamental to democracy, and it is 
clear that a growing and influential proportion of today's consumers want to be as fully informed as 
possible. Such purchasers of goods and services are not indifferent to the production technology, to 
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the suffering of animals, or to the impacts on the environment (witness the companies now seeking 
to profit from alternatives to chlorinated fluorocarbons as aerosol propellants). 
In a recent work (Elkington et al., 1988) the "Green Consumer" gets frank and detailed advice 
on how to shop for a better environment - how to "buy products that don't cost the earth". 
Industrialists may bow to such demands, or argue with them, but above all will be expected to offer 
transparency and integrity. 
Scientists acquainted with biotechnology can easily see why potentially, and generally in 
practice, biotechnology can be the perfect ally of such trends in consumer behaviour; and this has 
been argued above. But such arguments are by no means self-evident and there are strong opposing 
voices. Some of these criticisms are fair. They may be motivated by ecological concerns over what 
are in fact bad and short-sighted agricultural practices, by sincere objections to the use of animals 
as food producers, or simply by a deep-seated conservatism that yearns in vain for a stable and 
organic society . Other criticisms are less honest, either masking a self-interested sectoral 
protectionism in the guise of pretended concern for consumer safety, or participating in a 
misleading and alarmist attach on modern science and its applications. 
Lady Warnock (1988), for example writes of "the barbarians at the gate, seeking to take us back 
to the Middle Ages. What alarms me today is that the power of antiscientific rhetoric has grown so 
quickly that it may be impossible for us to set up a regulatory body not prey to such rhetoric". 
There is indeed in some countries and in some interest groups an upsurge of public disquiet 
about the implication of progress in the life sciences, and their applications. The reasons are less a 
fear of specific consequences, than a fear of the unknown, and a facile transfer of concerns 
appropriate to one specific danger to other areas in which they may be irrelevant. 
Such sloppy thinking is dangerous; it costs lives. As the Bodmer report (1985) puts it, in the 
absence of widespread understanding, we "shy at kittens and cuddle tigers". 
Issues are not resolved by statistical analysis, however, but by public confidence; as Harry 
Otway has expressed it : "if the public cannot evaluate the risk, they will evaluate the regulator". 
Confidence has to be built upon trust and the trust has to be built upon regulations and practical 
experience which are scientifically based and scientifically evaluated. 
The scientific method is one of the supreme achievements of human culture over the past three 
or four centuries, and is the direct lineal descendant of Renaissance humanism. It is the most 
effective societal learning instrument ever developed. It is naturally international in character. 
Key features of science are its cumulative character - we build on the achievements of our 
predecessors - and its openness to correction. In spite of its achievements, this openness to 
correction implies an essential humility, which Karl Popper expressed in his phrase "the conjectural 
status of knowledge". All scientific knowledge is hypothesis, subject to refutation or refinement by 
new evidence or experiment. 
Thus to refuse the further expansion of science, or to be nervous of its application to useful 
purposes, implies a failure of self-confidence in human capacities and of confidence in our 
societies' abilities to learn, to correct and to improve. 
Biotechnology is important for human progress, and for the management of the global 
ecosystem, a responsibility which we cannot escape or "leave to nature". 
Public understanding, attitudes and acceptance will increasingly be of strategic significance for 
the progress of biotechnology. Public education/information is therefore of strategic importance; 
arguably, the single most important strategic instrument in a society's self-management, learning 
and survival, and whether we define "society" in global, regional or national terms. 
To the process of enlightenment of the public and our political leadership, conferences such as 
this can greatly contribute. 
The phrase "organic society" is here used, as by Karl Popper (1945), in antithesis to the less rooted but more 
liberal and iconoclastic "open society" characteristic of the Western economies. 
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BIOTECHNOLOGICAL 'TOOLS' TO REGULATE GROWTH IN 
SWINE 
R.Dean Boyd and Diane Wray-Cahen 
Department of Animal Science, Cornell University, Ithaca NY 14853-4801 
Summary 
Growth is a highly orchestrated process invoking a multiplicity of hormones and requiring 
substantial quantities of nutrients. The hormone somatotropin (ST) has been shown to exhibit 
regulatory effects on metabolism and to occupy a central role in determining how absorbed 
nutrients will be partitioned postnatally. Exogenous administration of ST markedly alters the rate 
and pattern of tissue growth in growing swine by directing nutrients toward or diverting them from 
specific tissues in a highly coordinated manner. Unprecedented increases in lean tissue accretion 
have been observed, coincident with a simultaneous decrease in the rate of lipid accretion. 
Strategies that increase the blood concentration of this naturally occurring polypeptide will provide 
swine producers with the opportunity to simultaneously effect dramatic changes in production 
efficiency and to provide consumers with a truly lean food constituent. Recent innovations in 
biology are giving rise to new biological 'tools' which will permit Animal Scientists to employ a 
variety of approaches to achieve the ST response. In this review, we will discuss five potential 
approaches which are presently under systematic study. Techniques discussed are (a) exogenous ST 
and (b) secretogues of ST, (c) insulin-like growth factor (IGF-1), (d) immunological manipulation 
of ST secretion or potency and, (e) gene insertion or regulation of gene expression (eg., ST, GRF). 
In the 'near' future, the ST response may be achieved through exogenous ST, appropriate 
secretogues of ST release, or by employment of site specific antibodies which enhance the 
biological activity of the endogenous hormone. Important biological questions remain before 
Scientists can determine if mediation of the ST response by IGF-1 is appropriate for commercial 
development. In the 'long-term', it seems conceivable that the ST 'axis' may be manipulated 
genetically as techniques for genetic improvement evolve to sophisticated and specific methods for 
controlled gene expression (ie., gene amplification) or gene insertion (ie., gene optimization - ST, 
GRF). We anticipate that approaches for manipulating the ST 'axis' may be of sufficient breadth to 
accommodate directed nutrient partitioning while satisfying public mandates against the use of 
certain technologies in meat animal production. Finally, the over-riding importance of ST is that it 
has become an invaluable 'probe' into the mechanisms of postnatal growth and metabolic 
regulation. 
Keywords: biotechnology, growth regulation, nutrient partitioning, somatotropin, insulin-like 
growth factor, gene insertion, swine. 
Introduction 
The mission of Animal Science Research is to provide biological and management 'tools' to 
animal agriculture which facilitate efficient animal production and products acceptability. 
Productive efficiency of growing swine is determined by the growing of nutrients partitioned to fat 
relative to muscle and by the rate at which tissue accretion occurs (ie., dilution of total maintenance 
cost). Acceptability of the meat product is markedly influenced by fat content. A recent report from 
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the National Research Council (1988) cites the recommend of both medical and health 
professionals who urge reduced consumption of dietary fat; particularly that of animal origin. 
Furthermore, consumers are becoming more health conscious with a growing preference for leaner 
meat. Present efforts by Animal Scientists in the area of growth regulation are timely indeed. By 
attempting to alter the rate and composition of gain, we simultaneously address the issues of 
productive efficiency and product acceptability. 
Techniques for altering the balance between lean and adipose tissue growth in swine have 
previously involved genetic selection and employment of a variety of management strategies (eg., 
intact males, limit feeding, lower slaughter weights). Recent advances in recombinant DNA 
technology are giving rise to a technological revolution that will permit Animal Scientists to employ 
new 'tools' which dramatically alter growth and development. For example, we now have the 
ability to produce recombinant products such as somatotropin (ST) which exhibits regulatory 
effects on metabolism during postnatal growth. Administration of ST to young growing swine has 
yielded unprecedented results with respect to the rate, efficiency and composition of gain (Evock et 
al., 1988; Campbell et al., 1988; Boyd and Bauman, 1988). These achievements would normally 
have required 10 to 20 years of intense genetic selection (Table 1). 
The data in Table 1 show the estimated rate of progress achievable through a genetic selection 
program. The paper by Mitchell and co-workers (1982) was selected for presentation because the 
selection objectives and criteria for simultaneous emphasis were most relevant to the needs of 
commercial swine production. The response to ST affirms that considerable time would be required 
for similar changes to be achieved by selection alone. Further, genetic capacity is far greater than is 
presently expressed in the growing pig and circulating levels of ST are clearly a limit to expression 
of growth potential. Its administration should be considered as an adjunct to genetic selection since 
even highly selected strains exhibit a marked response (Campbell - this volume) and since 
performance 'maxima' are not yet evident. Although the responses to ST (as shown in Table 1) are 
dramatic, they are nevertheless conservative. We now appreciate that the ST response is a function 
of diet adequacy and that increases in the order of 30-40% are achievable for rate and efficiency of 
gain. We published theoretical estimates of the amino acid requirements for growing swine (50-100 
kg) in a recent report (Boyd et al., 1988b). These have served as the basis for subsequent studies in 
which greater relative responses were observed. We have assumed an amino acid requirement 
appropriate for accretion of 300 grams of protein per day in highly selected strains of swine (Krick 
and Boyd, unpublished data). 
Table 1. Comparison of relative responses to genetic selection and somatotropin administration. 
Item 
Dally gain, g/d 
Feed:galn. units 
Dally Intake, g/d 
Lean gain, g/d 
Feedilean gain 
Loin eye area, mm2 
Backfat depth, mm 
Carcass protein, g/d 
Carcass lipid, g/d 
Genetic Selection0 
Absolute Change 
per Generation 
+ 5.0 
-.03 
-7.3 
+ 6.0 
-.17 
+27. 
-1.8c 
ND 
ND 
% 
Change 
+ 0,7 
-1.0 
0.4 
+ 2.1 
-2.4 
+0,8 
-5.5 
— 
— 
Somatotropin6 
Absolute 
Change 
+ 100. 
-.87 
-590. 
ND 
ND 
+ 449. 
-7. 
+ 54, 
-204 
% 
Change 
+ 10.5 
-28.5 
-20.3 
— 
— 
+ 13.1 
-25.0 
+ 54.0 
-69.0 
Data from Meat & livestock Commission (1970-1977), Mitchell et al., 
Boyd et al., 1986; Boyd and Bauman, 1988 (120 ug ST/kg BW). 
Cleveland et al., 1982 (5 generations of selection). 
1982. 
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The absolute levels of performance are not evident from Table 1, however, a minimal statement 
is warranted so that the capacity for response is evident. For example, rates of carcass protein 
accretion in the order of 250-280 gram/day (50- 100 kg pigs) have been achieved while 
simultaneously accruing only 30-50 gram lipid/day. This alteration in rate of tissue development 
makes it possible to achieve feed to gain (live weight) ratios of 1.6-1.8 in swine (50-100 kg), which 
are highly selected for lean tissue growth and feed conversion (Boyd and Krick - Unpublished data; 
Campbell - personal Communication). It is important to appreciate that levels of performance 
achieved in practice depend on the genotype and blood levels of ST achieved by the delivery 
system. 
Control of somatotropin secretion 
Somatotropin is a protein secreted by the anterior pituitary gland. An overview of the controls on 
ST secretion and its direct and indirect involvement in tissue metabolism is portrayed in Figure 1. 
Since exogenous administration of ST enhances the rate and composition of growth, any strategy 
that increases blood concentrations of ST would potentially be a feasible approach for manipulating 
growth. For example, manipulation of endogenous ST secretion can occur by overriding the 
inhibitory effects of somatostatin or by increasing the secretory stimulant — growth hormone 
releasing factor (GRF). Also, one component of the ST response is an increase in the concentration 
of insulin-like growth factor I (IGF-I). Since IGF-I appears to mediate many of the'effects ascribed 
to ST, it has been considered as a possible 'target for manipulation. 
Growth Hormone 
Releasing Factor Somatostatin 
,.vr~v [Somatotrophs! 
Enkephalins- ' » V / 
<+'V / 
i 
Growth 
Hormone 
\ * . Growth ^ ^ 
Factors 
Target Tissues 
Adipose Tissue 
Figure 1. Regulation of somatotropin synthesis and secretion Is determined by the hypothalamic 
hormones, growth hormone releasing factor (GRF-stlmulatory) and somatostatin 
(SRIF-lnhlbltoryXFIgure from Convey, 1987). 
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Given the technologies which presently exist and our understanding of the biology, there are at 
least 5 'targets' or approaches to manipulation of the ST 'pathway': 
- Exogenous ST; 
- Exogenous GRF or other ST secretogues; 
- Insulin-like growth factor - 1; 
- Immunological manipulation of ST secretion or potency; 
- Gene Insertion (ST, GRF). 
Pharmacological alternatives also exist and are under investigation (eg., repartitioning agents 
such as ß-adrenergic agonists). A discussion of these is beyond the scope of this paper. We intend 
to confine our discussion to those techniques associated with the ST 'axis' and which are under 
serious and systematic investigation. 
Somatotropin 
Somatotropin appears to be a family of peptides with the major component being a 22 kDa form 
consisting of 191 amino acid residues. A recent paper from laboratory demonstrates that the potency 
of ST can be increased by structural modification of the ST molecule. We compared the biological 
activity of a novel recombinantly derived 21 kDa variant of porcine ST to the 22 kDa form (Boyd 
et al., 1988a). This form is missing a deletion peptide (amino acids 32-38). In preliminary 
experiments with heterologous models, the variant form of ST exhibited substantially greater 
activity as determined by rat liver membrane receptor binding and the hypophysectomized rat 
growth bioassay systems. The variant also exhibited significantly greater nutrient partitioning 
activity in swine, with improvements in compositional gain (lipid, protein) and in the efficiency of 
growth. A parallel example is cited below for GRF in which the potency was markedly improved 
(ten fold) by structural alteration. 
The limiting step in administering ST to farm animals is in the development of a suitable 
delivery system. ST must be administered in a vehicle that provides controlled delivery over a 
sustained period of time (eg., 30 days). It is difficult to assess the progress in this area since much 
of the research is occurring within the private industry sector. Reports have been published recently 
by researchers from Monsanto Company (Knight et al., 1988) and by Wang and Kothe (1988). 
Alternative strategies to ST administration may be sought for reasons other than administration 
mode and cost effectiveness. For example, exogenous administration represents to some a 
'hormone' approach to animal production. Even if concerns of safety to animal and consumer are 
completely satisfied by regulatory agencies, approaches appearing to be more 'natural' (eg., 
immunological route) may in some cases prove to be publicly more acceptable. This may be 
especially true for some European countries. 
Somatotropin releasing factor and releasing peptides 
As shown in Figure 1, ST secretion is regulated by two hypothalamic neuropeptides - GRF and 
somatostatin. GRF is a potent and specific stimulant of ST release. In the short time since the 
isolation and characterization of human GRF (hGRF; Guillemin et al., 1982; Rivier et al., 1982), it 
has proven to be an effective treatment for ST-deficient children (Gelato et al., 1984; Thorner et al., 
1985) and to have potential application to farm animal species for performance enhancement. There 
is considerable sequence homology between hGRF (l-44)-NH2, and that isolated from several 
animal species. This is particularly true for the first 29 amino acid residues from the NH2 terminus 
(Schanbacher, 1986). Structure-activity studies have shown that full activity lies within this region. 
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Porcine GRF is identical to hGRF in the 1-29 amino acid region, hence the expectation that hGRF 
or expression of the hGRF gene might elicit biological activity in swine similar to porcine GRF. 
GRF increases serum ST concentration in a dose dependent manner in humans and in a number 
of farm animal species (Schanbacher, 1986; Convey, 1987) including swine (Kraft et al., 1984; 
Etherton et al., 1986; Johnson et al., 1988). There are few published studies, however, on the effects 
of long-term administration of GRF on the growth performance of swine or meat animals in 
general. Early attempts to investigate the effect of GRF administration involved intermittent 
injections. This was due to evidence in rats which suggested that a pulsatile pattern of 
administration (versus continuous infusion) was necessary to cause ST release (Clark & Robinson, 
1985; Jansson et al., 1982). However, studies with GRF given either in multiple injections or as a 
continuous infusion have yielded equivalent increases in nitrogen retention in growing calves 
(Moseley et al., 1887) and in milk production for dairy cows (Enright et al., 1986) and ewes (Hart 
et al., 1985). This observation dispelled early concerns that pituitary somatotrophs may become 
refractory to continuous GRF exposure and suggests that GRF or other ST releasing peptides are 
viable 'targets' for promoting growth. 
Recently, a series of studies were conducted with growing swine using a novel and potent 
analogue of hGRF (1-29) (Heimer et al., 1988). These studies demonstrate the potential for a 
GRF-mediated route of growth promotion and show the merit of using structural modification to 
enhance biological activity. Scientists at Hoffman-La Roche altered the biologically active region 
of hGRF by substitution of 3 amino acids. The molecular basis for the structural modification and 
evaluation for activity are published in an excellent paper by Heimer and co-workers (1988). The 
tri-substituted GRF (des-NH2 Tyn, D-Ala2, Alais, [GRF 1-29 NH2]) exhibited greater potency in 
swine than the 1-44 hGRF construct (approximately ten fold). The increase in potency was 
attributed to the enhanced stability of the NH2-terminus to enzymatic degradation by a plasma 
diaminopeptidase. This enzyme degrades GRF by metabolizing GRF(1-44)NH2 to GRF(3-44)NH2. 
Since the structurally modified GRF is a poor substrate for the diaminopeptidase, its clearance rate 
is considerably slower than observed for the parent compound. 
Table 2. Effect of a potent analog of hGRF (1-29) on growth performance and carcass 
characteristics of growing swlnea 
Item 
No. Swine 
Gain, g/d 
Feed/Gain 
Feed Intake, g/d 
Loin area, cm2 
Backfat, mm 
Dissected: No. 
Ham 
- Muscle kg 
-Fat kg 
- Bone kg 
Shoulder 
- Muscle kg 
-Fat kg 
- Bone kg 
Saline 
16. 
1.06 
2,97 
3.01 
34.1 
27.1 
8, 
5.35 
2.65 
.92 
5,69 
2,70 
1.36 
hGRFb 
16. 
1.12e 
2,38° 
2,57° 
38.4° 
19.5e 
8. 
6,05e 
1.94e 
1.03e 
6.61° 
2,34 
1.72° 
SE 
„ 
,02 
,07 
.03 
.8 
1.0 
— 
.16 
.14 
.04 
.15 
,14 
.03 
% Difference 
_ „ 
+ 5.7 
-19.9 
-14.6 
+12.6 
-28.0 
-
+13,1 
-26.8 
+12,0 
+16.2 
-13.3 
+26.5 
a
 Dubreuil et al., 1988 & Pommier et al., 1988. Selected tits. Start wt. 49 kg; End wt. 106 kg. 
b
 Desamino - Tyr1 - Ala2...Ala15 - hGRF(l-29)NH2 Analog. Injected 3 times daily. 
CP<.05. 
Following a study to determine the optimum dose and periodicity of injection (Pelletier et al., 
1988), Canadian scientists administered this analogue to growing swine (6.7 ug/kg BW three times 
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daily) to determine the effects on growth performance and carcass characteristics (Pommier et al., 
1988; Dubreuil et al., 1988). Results were similar, in magnitude, to those achieved when ST is 
administered exogenously (Table 2). It is noteworthy that the dose of GRF analogue required to 
elicit dramatic changes in performance and composition of gain is relatively low. This and the fact 
that the peptide is relatively small are attractive features for potential commercialization. 
Other approaches to stimulation of endogenous secretion of ST include small somatotropin 
releasing peptides such as the enkephalin analog, Tyr-D-Tyr-Gly-Phe-Met-NH2 (Bowers et al., 
1981). This peptide is also specific for ST secretion. Another compound of this series 
(His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) has been shown to increase serum ST concentration in 
growing swine (Doscher et el., 1984) and cattle (Kraft et al., 1984), but we are not aware of 
demonstrated effects on performance of farm animals by either of the ST releasing peptides. 
Mediation of somatotropin effects - IGF-1 
Another possible way to elicit the ST response is via a 'down-stream approach'-administering 
factors which mediate the ST response. One component of the ST response is an increase in IGF-1 
(somatomedin-c) concentrations. Since many of the growth-promoting effects observed with ST 
administration are thought to be mediated by these elevated levels of IGF-1, it is reasonable to 
speculate that direct administration may enhance growth performance. The most direct evidence for 
the 'somatomedins hypothesis' is that IGF-I can stimulate growth in rats. Several researchers have 
reported increases in growth indices when hypophysectomized rats (Schoenle et al., 1982; Schoenle 
et al., 1985; Skottner et al., 1987; Guler, 1988) and normal rats (Hizuka et al., 1986) received 
infusions of IGF-I. In general, the growth response elicited by direct administration of IGF-I has not 
been as great as that observed with ST. In many of these studies the blood levels of IGF-I achieved 
by infusion were not as high as those achieved with ST administration even though the amount of 
IGF-I infused was quite large. This may account for the reduced response. Most experiments 
designed to study the effects of IGF-I on various tissues have been performed in vitro and often 
using supra-physiological concentrations of IGF-I; many of the effects observed in such studies 
may be due to IGF-I binding to the insulin receptor. To date, there has not been enough IGF-I 
available to study the in vivo effects of long-term administration of exogenous IGF-I in farm 
animals. 
In swine, somatotropin treatment results in an elevation of IGF-I levels (Chung et al., 1985; 
Etherton et al., 1987; Campbell et al., 1988; Evock et al., 1988). Low levels of IGF-1 have been 
observed in small breeds of dogs (toy poodles; Eigenmann, 1985) and swine (minipigs; Buonomo 
et al., 1987), although levels of ST were normal. Elevation of circulating IGF-I levels may be 
necessary for the expression of ST's effects on growth performance. However, IGF-I may not be an 
effective growth promoter without the interaction with ST. ST may modulate some of the effects of 
IGF-I on target tissues — either directly or via induction of the 150 kDa binding protein (Zapf and 
Froesch, 1986). Walton et al. (1987a,b) demonstrated that pST suppresses insulin- and 
IGF-I-stimulated lipogenesis and that the 150 kDa binding protein can block the IGF-I insulin-like 
lipogenic response in porcine adipose tissue. 
The large (150 kDa) IGF binding protein is ST-dependent, while the small (40 kDa) IGF binding 
protein appears to be ST-independent. When ST is administered the large binding protein increases 
in concentration along with IGF-I (Etherton, 1988; Zapf and Froesch, 1986; Buonomo et al., 1987); 
the concentration of this binding protein is greatly depressed in hypophysectomized swine 
(Buonomo et al., 1987). The large binding protein thus may be playing an important role in the 
regulation of IGF-I function. For instance, the binding proteins could be maintaining IGF-I levels 
in the blood stream, allowing their effects to be sustained. Or perhaps the large binding protein 
could inactivate locally produced IGF-I by binding and transporting it to catabolic sites. Its affinity 
for IGF-I is quite high and the half-live of IGF-I is greatly increased when bound. When IGF-I is 
infused into rats very little of the free form is detectible. While a single bolus of IGF-I disappears 
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rapidly, a constant infusion of IGF-I in rats seems to allow the IGF-I to equilibrate with the binding 
protein, allowing blood levels to rise (Zapf et al., 1985). However, a constant infusion of IGF-1 in 
lactating cows does not result in an elevation of blood IGF-I (Plaut et al., 1988) and free IGF-I 
injected into swine disappears rapidly (Etherton, 1988). The binding proteins in both cases appear 
to be saturated. Although IGF-1 infusion has been shown to reproduce many of the effects of ST 
administration, much more IGF-1 is required to achieve the same level of response as ST. On a 
molar basis ST is 10- to 15-fold more potent than IGF-I (Clemmons et al., 1987). Structurally 
modified forms of IGF-I which are more potent than the native compound have now been produced 
(Cascieri et al., 1988). However, other problems with IGF-1 as a growth promoter exist. It is not 
clear what the active form of IGF-1 is in vivo (bound vs free). Unbound IGF-1 mimics insulin, 
stimulating lipogenesis and causing hypoglycemia in pigs (Etherton, 1988); neither is desirable in 
meat producing animals. It is uncertain whether or not binding protein synthesis would be induced 
with IGF-1 administration and without its presence (or that of ST) the insulin-like effects of IGF-1 
would ensue. Although Guler (1988) reported that the epididymal fat pad was decreased in 
hypophysectomized rats treated with IGF-I, it appears that the decreased adipose accretion rates 
observed in ST-treated pigs are a direct effect of ST (Boyd & Bauman, 1988). Local production of 
IGF-I (stimulated by ST) may be more important than circulating IGF-I levels. Such a scenario 
would mean that only a transgenic approach — insertion of the IGF-I gene and possibly that of the 
binding protein into the genome of farm animals — would be likely to succeed. 
At least two problems must be seriously considered when discussing IGF-I as an alternative to 
ST for growth promotion. First, it is unclear whether IGF-I is capable of orchestrating the diverse 
effects on tissue metabolism ascribed to ST. Particularly important may be the direct effects ST 
seems to have on bone and adipose (Boyd & Bauman, 1988). Second, it is possible that any 
technique which does not increase production of the binding protein in conjunction with elevation 
of IGF-I may not be effective. The roles of ST, binding proteins, and local IGF-I production in the 
regulation of IGF-I must be more completely understood before the application of direct 
administration of IGF-I can be considered commercially as a means of achieving the ST response. 
Immunological intervention 
The recent ban by the European Economic Community (EEC) on hormone- based growth 
promotants has focused attention on alternatives to exogenous hormone administration. 
Immunological manipulation of specific endocrine events is an attractive alternative since it may be 
perceived as a more 'natural' means of promoting growth. Certain immunological approaches 
appear to improve the efficiency of ST use or mimic its action. This suggests possible advantages 
in the cost-benefit relationship. Strategies presently under investigation include (1) active 
immunization against somatostatin to increase ST secretion, (2) use of monoclonal antibodies with 
specific antigenic determinants to increase biological activity of ST and, (3) use of 'surrogate' 
molecules to mimic the ST effect. 
Somatostatin, which is the counter-regulatory peptide of ST secretion, inhibits GRF release. 
Neutralization of somatostatin was conceived early in the search for alternatives to ST 
administration. Attempts to alleviate the effects of somatostatin by immunization has resulted in 
mixed results to date with respect to plasma ST concentration and growth enhancement in 
ruminants (Schanbacher, 1986; Schelling & Byers, 1988). We are not aware of any credible report 
on somatostatin immunization in swine, however, given the relative response of swine to ST, this 
might be the more sensitive species. Nevertheless, failure to achieve more consistent and dramatic 
results in growing sheep and cattle, in addition to a lack of specificity for ST (eg., inhibits at least 8 
other hormones) seem to make this a less likely 'target' for manipulation. 
A novel and intriguing biological phenomenon results when specific monoclonal antibodies 
(Mab) interact with ST. Mab have been shown to enhance the effectiveness of hST with respect to 
the rate, efficiency and composition of gain in dwarf mice (Aston et al., 1986; Holder & Aston, 
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1988). This find is unequivocal, nevertheless unexpected since binding of antibodies to hormones 
generally inhibits hormone, activity. At the present time, the mechanism of Mab-mediated 
enhancement of ST action is unclear and speculative. 
The first report testing the possibility of Mab-enhanced ST action in farm animals was by Pell 
and coworkers (1988). They observed that Mab, with specific antigenic determinants, increased 
milk production of lactating ewes treated with bST, above that elicited by bST alone. We are not 
aware of any report on the effects of Mab on growth and composition in meat animals. However, 
the results provide incentive for further pursuit of this route to improve the efficiency of ST use by 
farm animals. 
Another immunological strategy for manipulation of growth is to use the immune system's 
anti-idiotype network to produce antibodies which structurally resemble ST and which are capable 
of mimicking its action (Hannah report, 1986; Flint, 1987). Such antibodies (or hormone 'images') 
have been raised to rat and ovine ST. They effectively compete with ST for liver and adipose 
receptors of the respective species (Hannah report, 1986). Hypophysectomized rats have responded 
with an increase in body weight gain similar to that observed with ST administration. Although we 
are not aware of any report demonstrating this to be a feasible approach for ST enhancement of 
growth in meat animals, this is a conceptual possibility worthy of careful consideration. The 
attractive feature of this and other immune approaches is the induction of antibodies in high 
concentrations which would be expected to circulate in the bloodstream for prolonged periods 
without further treatment. 
Transgenic technology 
The emergence of recombinant genetic technology and embryo manipulation have provided the 
facility for controlled genetic alteration of the genome via gene insertion. Significant developments 
in biology are still required, however, before this tool for increasing endogenous production of ST 
can be commercialized. This technology integrates the most sophisticated approaches from a 
number of fields of investigation and represents another alternative to administration of peptide 
hormones. 
Rat (Palmiter et al., 1982) and human (Palmiter et al., 1983) structural genes, ligated to a 
metallothionein-I (MT) promoter or regulatory region, were introduced into mice via 
micro-injection of fertilized eggs. Mice that incorporated and expressed the foreign gene produced 
large quantities of ST and grew more rapidly than littermate controls. Similarly, the MT-hGRF gene 
clone has also been introduced into mice. Those expressing the gene had elevated ST levels 
resulting in marked increases in weight gain relative to littermate controls (Hammer et al., 1985a). 
In neither instance, unfortunately, was the composition of gain determined. This information is 
essential for determining the effectiveness of a growth promoter in meat animals. 
Recently, genes coding for ST and GRF have been inserted into the genome of farm animals via 
micro-injection into the pronucleus or nucleus of fertilized ova. The first report to transgenesis in 
swine involved insertion of the structural gene for hST with a MT-I promoter region (Hammer et al., 
1985b). Since then structural clones for the gene of bovine (Pursel et al., 1987; Wieghart et al., 
1988) and rat (Ebert et al., 1988) ST have been inserted into the genome as has that for hGRF 
(Pursel - personal communication). With the exception of a recent paper by Vize and co-workers 
(1988), the gene construct cloned for insertion has been non-porcine. Despite the enormous effort 
to produce swine with enhanced ability for ST secretion, only one study has had sufficient 
'littermates' to document the potential for improved growth and carcass composition of transgenic 
pigs (Pursel et al., 1988a; Table 3). 
Results presented in Table 3 clearly demonstrate that enhanced rate and efficiency of gain may 
be achieved in swine with insertion of the ST gene. In accordance with studies using exogenous ST 
treatment, subcutaneous fat was dramatically decreased, thereby implying increased lean mass. 
Ultrasonic estimates of backfat thickness (10* rib, approximately 90 kg) were 20.5 mm and 7.9 mm 
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for control and MT-bST pigs respectively (Pursel et al., 1988b). However, this is a slight 
overestimate of the actual backfat thickness since skin thickness over the respective rib was 
approximately 1 mm thicker than in the littermate controls. Although transgenic pigs grew more 
rapidly and efficiently, they also exhibited a number of adverse effects. These included lameness, 
ulcers, lethargy and susceptibility to stress, hence the disproportionate number of animals actually 
completing the study as noted in Table 3. These adverse effect are believed to be caused by 
prolonged exposure to the pharmacological levels of plasma ST expressed by most of the 
transgenics studied thus far by Pursel and co-workers. 
Table 3. Growth potential of Metallothloneln-bST transgenic swine fed ad libitum from 30 to 90 kg 
body weight.0 
Period 
30-60 Kg 
60-90 Kg 
Treatment 
Control 
Transgenic 
%Dlfference 
Control 
Transgenic 
%Dlfference 
No./Trt 
8 
4 
-
7 
3 
-
Gain, g/d 
761 ±35 
988±44b 
+30% 
884 ±28 
948 ±38 
+ 7% 
Intake, kg/d 
2.08 ± .05 
2.12+.07 
ND 
2.93 ±, n 
2.39 ±. 15b 
-18% 
FeediGaln 
2.77 ±.14 
2.21 + .17b 
-20% 
3.33±.18 
2.58 + .25b 
-22% 
a
 Pursel et al., 1988a and personal communication. Diet contained 18% CP with .25% Lysine. Eight pigs 
allocated per treatment with disproportionate numbers of transgenic pigs due to health problems. 
b P<.05. 
The remarkable accomplishments of transgenesis must not over-shadow the fact that critical 
biological questions must be addressed before application to farm animals can be truly successful. 
First, the basic mechanisms responsible for regulation of gene expression in mammalian cells are 
not yet understood. There are several levels of gene control, hence different control elements may 
exist. This facet is discussed in a review by Wagner and Jochie (1986). Second, the process of 
insertion into the genome of the germ-line is largely 'random'. At present, there is generalized 
incorporation across tissues and uncertainty relative to the determination of gene placement and 
integrity of associated genomic sequences (ie., those on either side). Finally, the specific approach 
to transgenesis will undoubtedly evolve and have multiple approaches for a given endpoint as we 
learn more about the biology, recognize specific points of regulation, and determine how amenable 
they are to regulation at the gene level. 
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REGULATORY AND PUBLIC ACCEPTANCE OF BIOTECHNOLOGY 
FOR CONTROL OF GROWTH AND PRODUCT QUALITY IN SWINE 
P. van der Wal 
Wageningen Agricultural University, Wageningen, Netherlands. 
Summary 
Control of growth and product quality in swine can be achieved via the Somatotropin axis by 
administering its constituents, by affecting these through immunization and by inserting the related 
gene constructs in the genome of the animal. 
The legal regulations for these three technologies differ according to type of technology and 
regulatory region. Yet they exert a comparable impact on efficacy and safety aspects by the same 
mode of action. 
Harmonization of the requirements for approving these technologies is essential for serving 
effectively the purpose of guarding the safety of consumers, animals and environment and for 
creating well defined objectives for research and development. 
The unprecedented challenge in animal and food sciences requires international cooperation in 
research. Such joining of efforts allows for coping adequately with generic issues in safety and 
efficacy of those technologies. The issues do not differ for regions and they require research 
capacity and specific expertise which is limited anywhere. 
International tuning of expertise in these fields will contribute to international regulatory 
harmonization, the key to preventing disruptive disputes in international trade. 
The somatotropin related technologies have for core issues in regulation a combination of 
effects in common. 
For efficacy the impact on production efficiency and product quality, resulting from more 
protein accretion and less fat deposition, is characteristic. 
For product safety the proteinic nature of the constituents of the somatotropin axis, which results 
in easy degradibility in intestine and environment, offers good perspectives. 
For public acceptance of these technologies adequate well balanced information about their 
potential contributions to cost and quality of foods and to safety of consumer, animal and 
environment is crucial. 
There is no substitute for a strong and well staffed regulatory system in creating a solid base for 
consumer acceptance. Credibility of the system depends on optimizing guidelines and procedures 
and on ensuring compliance with regulatory decisions. 
Keywords: growth control, biotechnology, somatotropin, acceptance, regulations. 
Introduction 
A variety of new biotechnologies for control of growth and product quality in animal production 
is at present in the pipeline. They already form increasingly effective tools for improving efficiency 
and product quality. 
In view of the rapidly widening perspectives one can envisage a future where these technologies 
are indispensable tools for meeting the prime objectives of food production: adequate availability at 
affordable prices of food of good quality for the world population. 
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A manageable framework of guidelines for developing and implementing these technologies 
effectively and safely is therefore a matter of high priority. 
The tap at the end of the pipeline with new technologies, to be passed for their introduction into 
the production system is virtually controlled by two mechanisms: regulatory approval and public 
acceptance of the technologies and the products derived therefrom (Figure 1). 
Regu la to ry 
P r o c e s s 
P u b l i c 
A c c e p t a n c e 
New T e c h n o l o g i e s 3S 
O 
o 
Figure 1. Controlling the Introduction of new technologies. 
Regulatory systems are operational in the highly industrialized countries for systematic 
evaluation of innovations in the production system on the basis of detailed requirements for efficacy 
and safety. Conclusions about regulatory acceptability of technologies reached here are often 
adopted or taken as guidelines by the rest of the world. 
Public acceptance of the technologies and of the resulting food products follows a less well 
defined course but is obviously of decisive relevance for the successful implementation of new 
technologies. 
Discrepancies in conclusions on acceptability of innovative technologies between the official 
regulatory agencies and the general public may present a problem. The prevention of a credibility 
gap should be feasible when recognizing that a sustainable production leading to an adequate 
supply of safe animal products forms a common goal. 
The technical complexity of the criteria for evaluating technologies and end products for their 
safety and efficacy contributes to the confusion in discussions about their acceptability. 
For closing the credibility gap it seems attractive to look for alternative, simplified and widely 
understood selection criteria as: natural, biological or long established. 
Such selection criteria however have proved not to be effective. In the animal production system 
for instance one is well aware of the carcinogenic potential of biological naturals like aflatoxins on 
the one hand and the safe and benificial use of widespread synthetic chemicals like the amino acid 
methionine on the other hand. 
Adherence to already well known technologies is sometimes seen as another realistic option for 
risk prevention. It would at present probably indeed not interfere with an adequate and affordable 
food supply for the affluent in the industrialized countries. However, to improve the perspectives 
for getting beyond that achievement, now and in the future, a sharpening and renewing of the 
technological tools for animal food production seems to be advisable, if not a must. Furthermore old 
production systems do not necessarily imply product safety either. Contaminations, for instance 
with pathogenic organisms or environment pollutants, can be more difficult to prevent as under 
advanced management and housing conditions. 
While there seems to be then no simple substitute for a regulatory system based upon detailed, 
objective, scientific criteria for evaluating biotechnologies in animal production, it is essential that 
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the system is designed and operated in a credible way in the eyes of the general public, intended to 
consume the food. 
This paper will deal with the regulatory systems, and the way they may effectively face the 
challenge of biotechnology for control of growth and product quality in animal production. Options 
for preventing a credibility gap between the system and the general public are considered. The 
systems in the EC and the USA, which at present are already being applied to the technologies of 
relevance, are primarily taken into account. To a lesser extent those in Japan and P. R. China are 
mentioned. 
Objectives in food production, the core of regulatory requirements 
The objectives in animal food production , 
In terms of efficiency and safety the animal food production system is facing increasingly sharp 
and detailed requirements. These requirements find their reflection in the regulatory systems for 
approval of technological innovations in the production system. 
Meeting the demand for animals products, adequate in quantity and quality and available for 
affordable prices, requires efficiency in production. Increase in demand resulting from higher 
standards of living of an ever increasing world population lends priority to the development of 
efficient technologies which make optimum use of available resources. , 
Advancement of science and better standards of living have led to increasing emphasis on the 
safety aspects in animal production. Product safety for consumers has been a core issue for a long 
time. Safety for target animals and environment has recieved increased attention in the last decade. 
The above mentioned objectives can be well measured by objective scientific criteria and are 
reflected in the regulatory requirements as summarized in Figure 2. 
Ef f icacy 
P e r f o r m a n c e ( a v a i l a b i l i t y 
a n d c o s t p r i c e of p r o d u c t s ) 
P r o d u c t q u a l i t y ( n u t r i t i o n a l a n d 
or g a n ol e p t i c a I c h a r a c t e r i s t i c s 
S a f e t y 
H u m a n c o n s u m e r 
T a r g e t a n i m a l s p e c i e s 
E n v i r o n m e n t 
( P r o d u c t i o n s y s t e m ) 
Figure 2. Objectives In animal food production reflected In regulatory requirements. 
This is not yet the case for the socio economic impact of new technologies. The issue is hotly 
debated because of the difficulty in analyzing and measuring it objectively in a meaningful way. 
The criteria in this field seem to depend strongly on political preferences. 
Regulatory systems serving a dual purpose 
In animal production the regulatory system exerts its influence in two ways by: 
- Assuring efficacy and safety for consumer, target animal and environment, leading to public 
confidence that in food production only useful technologies without risks are applied. 
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Meeting this objective in a credible way is essential for acceptance of new technologies and the 
derived products in domestic and export markets. 
- Setting targets for research and development in animal food production for industry by defining 
criteria for approval of innovations for use. When these targets are considered by industry as 
realistic to reach, they will stimulate and guide research and development. Consistency in 
regulatory requirements over longer periods and objectivity of criteria allow for long term 
research planning. Advances in science can be translated into technology contributing to 
efficiency and quality in production. 
When consumers feel uncertain that the first objective is met, a reluctance is seen in buying food 
of animal origin. 
When in industry doubt predominates that regulatory requirements can be met, spending for 
research and development is hard to justify. Research efforts may then be suspended accordingly. A 
remote and possibly moving target is not readily aimed at. 
A decrease in innovative research will slow down the improvements in production efficiency 
which have been achieved in the last decades. Such a decrease would interfere with future potentials 
in meeting demand and when not universally applied, have an impact on competitiveness on world 
markets. 
Such a setback cannot easily be redressed. Building up research capacity and expertise in fields 
of high technology is both time consuming and costly. 
Shaping of regulations an ongoing process; the challenge of biotechnology. 
The gradual shift in emphasis on the objectives in food production as well as developments in 
science and technology have had a strong impact on regulatory requirements in the recent past. The 
fast developments in biotechnology form an unprecedented challenge for the regulatory system in 
the near future. 
On the one hand the emerging potentials for improving efficiency and product quality in animal 
production make the definition of requirements a matter of urgency for creating a realistic and 
consistent framework for the necessary long term research and development efforts in the 
biotechnological and animal industry. 
On the other hand the degree of novelty may interfere with public acceptance if the regulatory 
proces is not going to be handled in a way deserving and gaining credibility. 
The regulatory systems 
Regulations applicable; differences according to technology and country 
The Somatotropin axis (Figure 3) for the physiological control of growth consists of 
Somatotropin itself, Growth hormone Releasing Factor or GRF (promoting its release), 
Somatostatin (inhibiting its release) and Somatomedin C or IGF-1 (mediating its effect). 
Three categories of biotechnologies may be used for controlling growth and product quality of 
animals by affecting the Somatotropin axis. Figure 3 shows in which cases (+) research has 
demonstrated the feasibility of controlling the elements of this axis by their injection as such, by 
inserting the corresponding genes in the genome of the animals, or by means of immunological 
techniques. 
The three types of biotechnology are at present subject to different sets of regulations and 
managed by different regulatory authorities. 
When administered by injection to food producing animals, Somatotropin, GRF, and IGF-1 are 
regulated as Animal (production) Drugs in the USA and as Veterinary Medicinal Products in the EC. 
Established guidelines for evaluating their efficacy and safety have been applied for many years in 
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this field. Judging from the massive scientific evidence published on the impact of Somatotropin 
administration by injection, (Boyd, 1988; Fowler and Kanis, 1988; Fung and Qi, 1988; Steele 1988) 
this technology is a regulatory item of relevance for the immediate future. 
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Figure 3. Biotechnologies tor control of growth. 
In the USA the Center for Veterinary Medicin (CVM) of the Food and Drug Administration 
(FDA) of the Department for Health and Human Services is responsible for the implementation of 
the regulations. The Center provides for the evaluation of safety and efficacy of the drugs 
guidelines, based on the Federal Food, Drug, and Cosmetic Act (USA, 1906) and the pertinent 
regulations implementing the statutory provisions (USA, 1987). Sponsors may rely upon these 
guidelines for general safety evaluation, efficacy studies, and safety for target animals, with the 
assurance that, they describe procedures acceptable to FDA. The guidelines are detailed and are 
updated when necessary. 
In the EC the Commission for Veterinary Medicinal Products (CVMP) of the 
Directorate-General HI for Internal Market and Industrial Affairs is responsible for the regulation 
of animal production drugs, referred to here as "Veterinary Medicinal Products". The regulations, 
defined in Council Directives 81/851/EEC and 81/852/EEC (1981) have been adopted for 
high-technology products after procedural adaptations in Council Directive 87/22/EEC (1987), 
aimed at a further approximation of the laws in the member states. 
For a further completion of the common market an updating of the directives is at present 
prepared to establish a fully centralized Community procedure. 
In the P. R. of China the principles adhered to for the regulation of veterinary drugs seem 
somewhat less detailed in their definition (P.R.China, 1985). From the guidelines it can be 
concluded that largely the same criteria are used as in the EC and the USA. Data on safety and 
results of clinical trials have to be submitted to the Ministry of Agriculture. 
In Japan drugs for animal use are regulated under the jurisdiction of the Ministry of Agriculture. 
For safety evaluation detailed guidelines for testing are provided by the Ministry of Health and 
Wellfare (Japan, 1984). 
An increase in the level or a potentiation of Somatotropin can also be achieved in various ways 
by immunological techniques. Active immunization against Somatostatin has been shown to 
increase Somatotropin (Spencer et al., 1983). Enhanced Somatotropin activity by administering 
monoclonal antibodies has been demonstrated by Aston et al. (1986) and by polyclonal antibodies 
by Pell (1988). 
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Vaccination for control of growth and product quality has so far not been a regulatory item. It 
can hardly be covered satisfactorily by the regulations for vaccines for disease control. 
In the USA these regulations fall under the Animal and Plant Health Inspection Service (APHIS) 
of the United States Department of Agriculture (USDA). However, if production improvements by 
other means then diagnosis, prevention or teatment of diseases are aimed at, a joint approach with 
the C.V.M. of FDA is foreseen. In the EC it has recently been proposed to apply for vaccines the 
same regulations as for the other "Veterinary Medicinal Products". 
When an increase in the Somatotropin level of swine is obtained by the insertion of ST gene 
constructs in the genome of these animals, the effect on the metabolism, reflected in increased 
meatiness and less fat, is comparable to that in swine to which recombinant Porcine Somatotropin 
(rPST) has been administered by injection (Pursel, 1987; Wieghart et al., 1988). 
The regulations for genome modifications and their application are still under development in 
the USA as well as in the EC. The definition and implementation of these regulations does not at 
present fall under the same authorities as the earlier mentioned animal production drugs. APHIS of 
the USDA is actively preparing the regulatory policy in the USA and the Directorate General VI for 
Agriculture has taken responsibility for the regulation of this technology in the EC. 
At present in both theatres the patent situation, the ethical aspects, and the proper regulation of 
research with transgenic animals draw still more attention than the requirements to be met for safety 
and efficacy under production conditions. 
We may conclude that the technologies under discussion, designed for the same production 
system, are under the present regimes going to be evaluated and eventually applied under different 
regulatory regimes. Yet, from the commonality in mode of action and from the available scientific 
evidence it can be expected that the impact on performance, product quality and product safety of 
all three technologies is to a large extent comparable. 
Need for commonality in criteria for technologies of different origin 
Harmonization and strong coordination, if not unification in the further definition and 
implementation of regulations in the above mentioned intertwined technologies seem necessary, 
both for equality in law and for an optimum use of the highly specialized expertise in the regulatory 
field. The alternative could well lead to disastrous confusion among producers and consumers. 
Commonality in regulation of biotechnology and traditional technology is an explicit objective 
in the "Coordinated Framework for Regulation of Biotechnology" (USA; 1986). The Food and 
Drug Administration (FDA), the Environmental Protection Agency (EPA), the U.S Department of 
Agriculture (USDA), the Occupational Safety and Health Administration (OSHA), and the National 
Institute of Health (NIH) contributed for their respective fields. It is stated that: "The manufacture 
of food, the development of new drugs, medical devices, biologies for humans and animals and 
pesticides will be reviewed by FDA, USDA and EPA in essentially the same manner for safety and 
efficacy as products obtained by other techniques". 
"Jurisdiction over the varied products is determined by their use, as has been the case for 
traditional products". This seems to ask for further coordination between the agencies for the 
closely related technologies for growth control as discussed above. 
For "Veterinary Medicinal Products" the EC is heading for revised regulations which do no 
longer differentiate between biotechnological and traditional production in either procedure and 
criteria. A further harmonization will here be achieved when animal vaccines will be regulated, as 
intended, under the same directives. 
Need for international harmonization of regulatory requirements 
Although the various regulatory systems may cover largely the same safety and efficacy aspects, 
the remaining differences in criteria, and procedures allow for substantial discrepancies in the 
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admission of new drugs and technologies. The point is illustrated well enough by the case of the 
anabolic steroids, approved for selective use in the USA and banned in the EC. 
The advantages of better regulatory harmonization are obvious enough to make its realization 
mandatory: 
- Frictions in the international trade resulting from regulatory disagreements would be avoided. 
The present clash between the EC and the USA may easily lead to economic losses and further 
political irritations. They might be turned into a blessing when leading to the awareness that 
effective steps have to be taken for their elimination and for the prevention of their future 
recurrence. 
- Closer cooperation in research and development would be facilitated. The development of 
effective and safe biotechnologies for animal production requires an unprecedented research 
effort in the related sciences. Effective, coordinated use of expertise and research capacity in the 
fields of relevance is nearly a must. Worldwide this research capacity is the bottle neck in 
developing and evaluating biotechnology. Defining jointly basic issues underlying the common 
regulatory objectives for efficacy and safety form an effective step towards a common approach 
of generic potentials and problems in animal biotechnology. Such issues, being largely 
precompetitive, lend themselves for involvement of governmental and industrial research 
groups. 
International harmonization at the regional level is making progress at the EC/where a steady 
approximation of national laws of the member states is a key element in establishing the common 
market. The Community research programs contribute to this approximation. The enlargement of 
the economic and regulatory framework in Europe may allow for further intensification of research 
in animal biotechnology over its present level. 
In North America commonality in regulations is aimed at, between the USA and Canada. 
In Figure 4 research papers of the last three years have been quantified for the three main regions 
where experimental work on biotechnology for growth control has been performed with farm 
animals. (Database: Commonwealth Agricultural Bureau - CAB). The figure illustrates that 
research capacity and expertise are available and actively engaged in all three regions. Knowhow is 
however predominantly concentrated in North America. This is the case to an even larger extent 
than shown in Figure 4 because the production of the active ingredients and of the genetic 
constructs for the research in Europe and along the Western Pacific Rim is nearly exclusively 
located in the USA. 
N-Americi Europe W-P«cRim 
Figure 4. Research In biotechnology for growth control of farm animals. Technical papers 1986-1988 
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Effective contributions to worldwide international harmonization are being made within the 
framework of international organizations. Their successful examples encourage further steps in this 
direction. 
The Organization for Economic Cooperation and Development (OECD) has contributed to the 
standardization of methodologies and to regulations for Good Laboratory Practice. 
The Committee of the Codex Alimentarius for Residues of Veterinary Drugs in Foods (CCVRF) 
is active in defining internationally acceptable tolerance levels for residues of animal drugs. 
Perspectives and constraints in regulatory acceptability 
The technologies for control of growth and product quality via the Somatotropin axis (Figure 3) 
form a new regulatory ballpark in more than one way. The fact that the same impact is obtainable 
via three different technologies is without precedent. The major impact on product quality 
characteristics and the proteinic nature of the active substance were not met in earlier rounds of 
animal production drugs. 
The regulations for evaluating efficacy and safety of Animal Production Drugs in the USA and 
the comparable category of Veterinary Medicinal Products in the EC have now been operational for 
many years. They offer a foothold for analyzing some perspectives for the related technologies for 
growth control as well. The regulations under development for these technologies will have to adopt 
largely the same approach anyhow. 
Efficacy 
The efficacy of somatotropin by injection on performance has been demonstrated already 
worldwide (Fowler and Kanis, 1988; Fung and Qi, 1988 and Steele et al., 1988). Comparable 
improvements in feed conversion efficiency in particular have not been shown before by growth 
promoting drugs for swine. 
The strong improvement in product quality by the reduction of carcass fat in favour of lean tissue 
has not been achieved before with animal production drugs either. It can put especially fat breeds in 
a higher class of slaughter quality. In order to be able to evaluate the resulting product quality 
claims adequately, the Center for Veterinary Medicine of the FDA in the USA is updating its 
guidelines for testing efficacy. At FDA's request the American Society of Animal Science (ASAS) 
has established a committee to provide expertise in redefining the requirements for demonstrating 
improvements in product quality. 
Product safety 
The proteinic nature of the active elements of the Somatotropin axis puts them in a potentially 
safer category as earlier animal production drugs with regard to risk of residues. Even if an increase 
in residue levels might occur in consumable products, proteins are degradable in the intestinal tract 
"of consumers" and these large molecules are normally not absorbed from the intestinal tract 
anyway (Apostolou, 1988). 
Firm data have to further substantiate the issue regarding the occurrence and safety of possible 
residues of active substances in edible products. 
The considerable reduction in fat creates perspectives for improving nutritional safety by 
reducing the main threat for human safety attributed to animal products, namely excessive fat 
consumption. The earlier mentioned redrafting of the related regulatory requirements may assist in 
measuring the extent and the relevance of this effect of Somatotropin based technologies as well as 
determining its possible impact on other potentially positive or negative factors. 
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Target animal safety 
Somatotropin injections so far have not shown any appreciable effects that can not be coped with 
in the existing regulatory requirements. The impact of somatotropin administration on a variety of 
physiological mechanisms (Boyd and Bauman, 1988) seems to be reasonably well balanced. 
The potential repercussions of genetic modifications on the animals' physiology (Pursel, 1987 
and 1988; Wieghart et al., 1988) have been shown to go beyond those obtained with the other two 
technologies. Scientific exploration of animal safety aspects of genome modifications requires 
adequate and early attention. Control of the expression of the inserted genes (Mc Crane et al., 1988) 
is considered by Pursel (1987) as a potentially effective tool in controlling negative effects on 
animals. 
The results obtained with genome modifications so far raise the question as to whether in 
particular growth rate of domesticated animals will be changed by a quantum leap over their present 
ceiling by this technology. The genome has already been optimised for this parameter by selection 
during many generations. The observation that insertion of ST genes in swine affected leanness and 
feed conversion ratio rather than growth rate is here of interest. 
By contrast, in mice strains, not selected for weight gain, body weight nearly doubled as a result 
of insertion of an MThGH construct (Nieuwhof and Kanis, 1988). A comparable increase in body 
weight of mice has been obtained by selection over several generations by Bakker (1974). 
Environmental impact 
The degradability of the active substances involved in Somatotropin related technologies seems 
to eliminate virtually the risk for environmental pollution with residues. 
The potentially positive impact of its use on the environment deserves attention. The decreased 
excretion of pollutants as a result of the improved utilization of nutrients may prove to be of 
particular significance under present production conditions in some regions (Van Weerden and 
Verstegen, 1988). 
Social and economic impact 
Results reviewed by Fowler and Kanis (1988), Fung and Qi (1988) and Steele et al. (1988) show 
that the technologies under discussion will have a strong impact on production efficiency and 
product quality of swine. 
The introduction of these technologies will therefore be of obvious significance for the 
competitiveness in pig production, both domestically and in export markets (Steele et al., 1988). As 
a consequence the survivability on these markets of farmers and countries which will abstain from 
the introduction of these technologies is going to be affected accordingly. This phenomenon forms 
a familiar pattern in animal industry when new technologies are emerging. 
It seems to be a matter of political opinion rather than a regulatory issue, whether one should 
control competitiveness, domestically and internationally, by selectively deciding on the 
introduction of technological innovations on the base of their potential effectiveness. This 
viewpoint is obviously followed by the EC. It is proposed in the draft for revised regulatory 
directives to have in the EC the social and economic impact weighed and decided upon separately 
from the normal regulatory procedure. 
The issue is of high and basic relevance because adoption of the proposal would introduce a 
double track system for the approval of new technologies. Objective and consistent paramaters for 
measuring social and economic impact will be difficult to define. 
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Public acceptance 
Role of adequate information in public perception and acceptance 
Public perception of biotechnology comprising only production tools with a high degree of 
novelty, seems to be gradually overcome by increasing awareness that such technology has 
contributed for ages in many forms to the production of food and more recently to the manufacture 
of pharmaceuticals. 
Yet there is sometimes still a touch of magic in biotechnology. The eagerness to illustrate the 
advancement of science by claims which made the public unjustifiably believe that quantum leaps 
in animal production are around the corner evoked more emotions than necessary. 
The decision to evaluate in the USA and the EC biotechnologically derived products essentially 
by the same criteria as traditional products contribute to placing biotechnology in the right 
perspective. 
Recent reviews about public acceptance in the USA and Europe (Cantley, 1987; Van den Broek, 
1988) lead to the conclusion that an open information and communication are crucial for 
acceptance. The report of the Office of Technology Assessment (1987) found that in the USA 
acceptance improves with increasing knowledge. 
Public trust in University scientists proved to be particularly strong when it comes to evaluation 
of risks in biotechnology. It seems to imply a specific responsibility for the Universities with regard 
to risk assessment and acceptability of technological innovations. 
Need for strengthening credibility of the regulatory system 
Cantley (1987) points at the vulnerability of a society in developing innovative technologies 
effectively when the credibility of the regulatory system is low. The public, when unable to evaluate 
the risk, evaluates the regulator. When not satisfied, ways will be found for rejecting the regulatory 
decisions. 
The need for strengthening the credibility of the regulatory system is being increasingly 
recognized as the key to public acceptance. 
The regulation authority is the only institution where enough highly qualified expertise can be 
made operational for defining and handling effectively the rules for admission of innovative 
technology. Objectivity, consistency in policy, and therefore predictability in maintaining the rules 
seem essential for building public confidence and hence acceptance of regulatory decisions. 
A further strengthening of the system will be allowed for in the EC as a result of the proposed 
centralization of the regulatory procedure. It seems to lead unavoidably to the creation of a central 
body with expertise which is already operational at the comparable Center for Veterinary Medicine 
of the FDA in the USA. 
Making the regulatory system better known 
In discussions about public acceptance, it is frequently overlooked that too often the general 
public is not aware of the unique power given to the regulatory authority in controlling the 
admission of new technologies and thus safeguarding public interests. 
Even those who take widely publicized views in regulatory affairs tend to overlook that in 
principle the mechanism has been created to cope with problems regarding acceptability of new 
technologies. Regulatory agencies might be able to find ways to create and maintain more public 
awareness of their specific responsibilities and capabilities. The FDA in the USA has the benefit of 
having been operational for a long time and has gained public prestige in the proces. 
Confusion from bypassing the regulatory system in making decisions 
Participation in making decisions about the introduction of new technologies in animal 
production from outside the designated regulatory framework (Figure 5) is sometimes considered 
as necessary. 
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In the case of anabolic steroids, and more recently in the case of Bovine Somatotropin the 
European Parliament and the Council of ministers of the EC adopted resolutions and made 
decisions which affect the regulatory situation. The US Congress interfered in a technical 
regulatory issue by adopting the Delaney clause on carcinogens. In most of these cases public 
opinion exerted pressure on these institutions. 
Conclusions have been reached and implemented here on specific items before the necessary 
facts had enabled the regulatory bodies to reach a decision. Control in this form is confusing for 
consumers and producers by the unpredictability of ad hoc applied criteria. The somewhat 
Babylonic situation is likely to interfere with confidence in the regulatory systems and with 
acceptance of its conclusions. 
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Figure 5. Options for controlling Introductions of biotechnology. 
If lack of acceptance of regulatory conclusions is spreading to the animal production system it 
may contribute to the leakage of technologies from the pipeline, thus reaching the food production 
system without passing through the officially controlled tap. A subsequent lack of consumer 
acceptance of food products, domestically or on export markets would not seem to be merely 
theoretical. 
Increasing credibility by updating regulatory guidelines and procedures 
The ad hoc interventions in the regulatory process signify a lack of consensus on the regulatory 
requirements that have to be met for accepting technological innovations for introduction. 
Much might be gained in credibility and hence in acceptance of regulatory conclusions when 
such a consensus on requirements is reached by the usual democratic interaction between public 
opinion, parliament and executive body and is reflected in the regulations. 
It can provide for a regulatory framework within which the regulatory authority can act 
indepently on objective and consistent guidelines without interference (Figure 5). 
It does not in itself seem to be very far fetched, since it would merely reflect the practice already 
followed in the not unrelated field of civil procedures in law. That practice gained credibility for a 
long time because of adhering to well defined laws and their independent implementation. 
Much of the discussion in this field will focus on the degree to which requirements on social and 
economic impact of new technologies shall and can be incorporated in the regulations, an item 
covered already earlier in this paper. While in the USA the item tends to be covered within the 
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context of the environmental impact, in the EC the discussion is initiated by provisions in new draft 
Directives. 
Making key facts available to the public on generic issues 
In meeting the demand for adequate public information the regulatory system could play a useful 
role. 
There is a strict limit to the information that can be made available from dossiers for approving 
drugs for use. Proprietary data on specific technological achievements are gathered at a high cost 
and are of decisive relevance to the competitive position. 
It is, however, information on the impact of a category of drugs or technologies, the generic 
effects, rather than the impact of a specific proprietary achievement which is of relevance for public 
acceptance. For instance, impact of somatotropin on their level in consumable products, impact of 
these substances on longevity and reproductive performance of breeding stock, and impact on the 
endocrine balance are largely inherent to the category of compounds. The availability of such 
information to the public might be promoted by regulatory institutions in conjunction with existing 
national or international cooperative research programs. 
Before approving a new product or technology for use, a public hearing would serve the purpose 
of providing a possibility for bringing up questions at a place of relevance. Such questions can now 
only be addressed via informal channels not likely to produce expert answers, if any. 
Compliance with decisions crucial to system credibility and acceptance 
Bypassing the control tap of the regulatory authorities by illicit applications of biotechnological 
achievements is an obvious undermining of the credibility of the system. It interferes with public 
confidence in the safety of animal products. The enforcement of regulatory decisions is beyond the 
scope of this paper but it needs to be characterized here as an essential element in public acceptance 
of biotechnologically derived products. 
Law enforcement is difficult to bring about if the law does not have firm roots in the sense of 
justice of those who have to comply. When doubts are rising about optimum compliance with 
regulatory decisions in the production system this aspect deserves more attention than it usually 
seems to get. 
Safety related issues in animal production, as encountered in the EC with clenbuterol and 
anabolic steroids and in the USA with sulfa and aflatoxins can only be solved when industry and 
farmers are deeply aware that compliance with regulations is in their own best interest. 
This awareness is stimulated when confidence is created that effective innovations are made 
available to the system when their efficacy and safety allow for it. Prohibition was not an effective 
instrument in preventing alcohol abuse. 
Conclusions 
A strong and credible regulatory system has a unique potential in serving both the development 
of new technologies for food production and public acceptance of these technologies. 
The credibility of the system in adequately handling both objectives depends greatly on its 
application of objective scientific criteria in a consistent manner. Credibility can be ensured and 
strengthened further by: 
— Guidelines and procedures which reflect the state of the art in technology and are accepted by 
parliamentary and executive bodies. 
— International harmonization of guidelines and evaluation criteria. 
— Qualified scientific staff for covering the various regulatory issues. 
— Independent decision procedures with the right for appeal. 
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Contribution to public information on generic safety and efficacy issues by initiating hearings 
and by stimulating cooperative research efforts in these fields. 
Ensuring compliance with regulatory decisions by effective enforcement and by contributing to 
the awareness of the participants in food production that law abidance is in their best interest. 
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Summary 
Various technologies now available to alter livestock growth and composition, specifically 
exogenous treatment with species-specific growth hormone (GH), GH releasing factor and 
somatostatin autoimmunization, all operate at some level of the GH axis and as such alter 
production, secretion or metabolism of this hormone. Exogenous administration of porcine GH, or 
somatotropin (PST), has marked effects on the growth and development pattern of swine favoring 
lean tissue gain with minimal fat deposition. World-wide interest in the use of this technology is 
based on the presumption that this technology would be equally efficacious regardless of 
management conditions. European swine management conditions favor such factors as 
limit-feeding, marketing of intact male pigs, heterogeneous mixes of dietary protein sources, 
division of growth for light and heavy pig marketing and similar factors. Western production 
practices as evident in North America favor ad libitum feeding, use of gilts and castrate males, 
comparatively high intake of good quality protein, and exclusively a heavy pig market. In several 
recently completed experiments, different management variables affecting PST efficacy have been 
evaluated. Results indicate PST is a major physiological constraint on lean tissue growth both for 
young pigs and animals in the fattening stage of growth. Additionally, feed intake, specifically 
energy intake, can constrain the response to PST; however, PST will essentially negate sex effects 
such that female and castrate male pigs will respond to PST and display protein accretion rates 
comparable to the intact male. Results of current research indicate that PST technology is adaptable 
within current management systems, but swine management practices characteristic of North 
America are particularly suited for application. This implies that pork production for the purpose of 
export to the global marketplace will become much more competitive in that a means for greater 
uniformity in the production of lean pork of high quality is now available. 
Keywords: swine, growth hormone, composition, management. 
Introduction 
Growth hormone (GH), somatotropin and ST are synonyms for a single- stranded, 191 amino 
acid residue, nonglycosylated, protein containing two intramolecular disulfide bridges which is 
secreted by the anterior pituitary gland in response to positive (GRF; growth hormone-releasing 
factor) and negative (STH; somatostatin) effector secretions from the hypothalamus. GH has long 
been associated with growth processes (Walker et al., 1950), but only with the recent advances in 
recombinant DNA technology have sufficient quantities become available for long-term animal 
experimentation and to attract industrial interest toward product development for livestock 
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application. In the United States, the livestock industry represents a $61 billion market 
(Agricultural Statistics, 1987) and, specifically, the $9.8 billion swine industry has been targeted as 
likely clientele for this technology. Due to productive efficiency currently constrained by 
physiological factors, the inherent tendency to synthesize and deposit excessive quantities of body 
fat and a very negative public image with respect to pork as a healthful meat product, the swine 
industry should benefit greatly from this technology. Several excellent references are cited 
(Macblin, 1972; Chung et al., 1985; Etherton et al., 1987; Etherton et al., 1986; Boyd et al., 1986) 
for background on the use of GH in swine. The purpose of this report is to describe the recent 
experiments with porcine GH (pGH) conducted at the Beltsville Agricultural Research Center. As 
designed, these projects did not represent efficacy tests of the technology, but were intended to 
provide data which might have global interest in swine production practices. Less pragmatically, we 
wish to quantify the absolute ceiling or limit for protein deposition by swine and pGH represents 
only a tool in pursuit of this goal. 
Overview of Growth Biology 
Growth of any species represents the accumulation of body weight due to hypertrophy of 
component tissues. Those tissues most critical for survival of a species have the highest priority for 
nutrient use and as such are supported even in marginal nutritional environments at the expense of 
tissues less critical for species survival. Sir John Hammond expressed this priority for nutrient use 
in a treatise describing the concept of nutrient partitioning (Hammond, 1952). Figure 1 paraphrases 
the Hammond nutrient partitioning concept for growth of individual tissues and physiological 
function. On the abscissa, a qualitative weighing of genetic and environmental determinants of 
tissue hypertrophy are proposed. According to this model the elevation of extracellular nutrients 
occurs with increased plane of nutrition and neural and bone tissues extract with high priority 
nutrients for maintenance and growth. Once differentiated, the hypertrophy of muscle and adipose 
tissue will occur in response to environmental factors, including nutrition, only to the degree 
permitted by genetic composition. Livestock production practices have focused on the maximum 
yield of lean tissue with modest accretion of body fat and within the specialty of animal nutrition 
one often assumes that genetic potential toward this end point is fully realized. 
low -
a metabol ic ' adipose 
muscle 
mammooenesis 
PLANE OF NUTRITION 
Figure 1. Hammond (1952) model or nutrient partitioning. Note that arrow boldness of a given tissue Is 
Indicative of the hlerarchlal need of the tissue for survival of the species and coincides with 
nutrient partitioning, or use, priority for maintenance and growth. 
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According to this model of nutrient partitioning the relative accretion of muscle and adipose 
tissues could be altered either by increasing the slope of the line or altering the position of adipose 
tissue priority relative to muscle growth. These possibilities can be classified as partitioning (i.e., 
slope change) or repartitioning (i.e., relative position of component tissue growth) strategies. 
Partitioning strategies rely on genetic tools (gene optimization, gene amplification and transgenic 
manipulations) to affect livestock performance. 
Repartitioning strategies rely on pharmacological, site-specific, alterations of metabolism. 
Examples of the latter include beta adrenergic agonists, thyroid active compounds and steroid 
implants. 
The genetic tool most recognized for the modification of livestock growth are the gene 
optimization procedures used by animal breeders. A classical example is the Beltsville selection 
experiment for or against subcutaneous fat thickness (Davey et al., 1969) which simultaneously 
effected both muscle tissue deposition and skeletal growth. Recently a strain of swine has been 
characterized with an apparent infinite capacity for protein growth compared to typical commercial 
strains (Campbell and Taverner 1985, 1988). In this genotype, appetite is the only factor limiting 
protein accretion. These examples emphasize that gene optimization techniques can markedly 
influence both adipose tissue and muscle protein priorities for nutrient use. Such techniques as 
practiced over many centuries of livestock domestication are characteristically very slow and 
costly, but highly effective and generally regarded as safe with respect to environmental concerns. 
Unfortunately, the lack of knowledge regarding specific genes involved in growth and development 
processes and the inability to manipulate such genes within large populations of animals prevents 
rapid progress to reduce fat and increase lean tissue deposition using gene optimization procedures. 
Recent progress in foreign gene insertion and expression (Hammer et al., 1985) has led to the 
production of agriculturally important "transgenic" animals. The promise of this procedure is that 
not only the slope of the nutrient partitioning priority line, but also the absolute genetic ceiling for 
both muscle protein and fat accretion can be altered by the only method capable of truly altering 
genetic composition. However, elucidation of mechanisms involved in the control of gene 
expression and the subsequent impact on growth and development as well as the remarkable 
negative public image of this technique will require considerable research investment and a lengthy 
education of the consuming public to be realized. 
Yet another technique available to alter nutrient partitioning priority would be to preferentially 
increase the efficiency of muscle protein deposition assuming that full genetic potential has been 
underestimated and constrained within normal physiological processes. In effect this strategy 
involves "gene amplification" and describes those efforts which manipulate rate and composition of 
growth by ST administration. With strategic application of species-specific ST to induce 
supra-physiological concentrations of primary growth stimulants, those genes normally involved 
with growth processes are activated more completely and over longer periods of time permitting a 
species to more fully express genetic potential for protein deposition. According to the Hammond 
model, pigs the size of steers, or steers the size of elephants, could not result from ST-induced gene 
amplification for protein deposition independent of proportionate increases in skeletal growth. 
However, pigs with feed efficiency comparable to broilers and dairy animals with 25% greater milk 
yields could enter the animal production system. This point is emphasized such that public concern 
regarding ST-induced growth alteration is not construed to be a violation of animal rights, 
specifically the genetic destiny of livestock. 
An obvious example of naturally occurring gene amplification is the classic sex effect difference 
in rate and composition of gain comparing the intact male to the female pig (Campbell et al., 1985). 
Genetic composition does not differ greatly in this example, but expression of genetic potential for 
protein deposition is constrained in the female by the lack of androgen stimulation. 
53 
STEELE, CAMPBELL. CAMPERNA, MURTRY AND SOLOMON 
Porcine Somatotropin: Historical Information 
Growth hormone has long been associated with long bone growth and nitrogen retention in 
laboratory animals (Li et al., 1948; Greenspan et al., 1949). Giles (1942) reported that injection of 
pigs with a pituitary-derived growth hormone preparation over a four month period increased the 
width of the epiphyseal growth plate of long bone, but otherwise was without biological 
consequence. The biological potency of the GH preparation and lack of sufficient experimental 
detail prevents discussion for the lack of growth promotion. Turman and Andrews (1955) reported 
that a porcine pituitary preparation increased the efficiency, but not rate, of body weight accretion 
in swine. Significant increases of body water and protein content with a reduction in body fat was 
reported. Again, the biopotency of the GH preparation was unknown, but the authors noted that of 
those animals treated at a high dose (6 mg/15 kg body weight daily), mortality rate was 100%. In 
these pioneering studies much of the same potential as apparent in contemporary experiments for 
GH to alter nutrient partitioning in swine was noted, but hormone purity confounded the design of 
experiments and interpretation of results. 
More recently, the research by Machlin (1972) and the efforts by Pennsylvania State (Chung et 
al., 1985; Etherton et al., 1986; Etherton et al., 1987) and Cornell (Boyd et al., 1986) University 
investigators must be regarded as the basis for current interest in GH technology. Machlin found 
that treatment of growing pigs with a commercial preparation referenced to a rat tibia bioassay 
significantly improved rate and efficiency of body weight gain and the gain was generally of lean 
tissue mass and not lipid. In one experiment, GH treatment at levels of 220 and 1100 ug/kg body 
weight resulted in liver and kidney degeneration and a high mortality rate. Based on current 
information, doses used were far in excess for maximal biological benefit and reinforce that a 
dose-optimum does exist for pGH treatment. 
With the resurgence of the National Pituitary Program in the early 1980's, Chung reported that 
daily administration of pGH (pituitary derived) at a dose level of 22 ug/kg body weight for a 30 day 
period improved rate of gain by 10%, efficiency of gain by 4%, increased muscle mass by 5% and 
did not influence adipose tissue mass. Blood plasma glucose and insulin concentrations were 
increased by pGH while blood urea nitrogen concentration was decreased. This study was 
significant in that anabolic actions of GH were apparent in young pigs over a relatively short period 
of hormone treatment without induction of animal health complications. Subsequently, the optimal 
dose was tested by animal bioassay using levels of pituitary GH ranging from 10 to 70 ug/kg body 
weight daily and various production and carcass characteristics as end point measurements. Rate 
and efficiency of gain improved over the doses tested and muscle mass continued to show fractional 
increase between a dose range of 35 and 70 ug/kg body weight. 
Apparent in the Pennsylvania State University studies were the marked effects of pGH on 
nutrient partitioning in the pig and the potential for this technology to greatly alter swine production 
systems. However, of equal, if not greater, importance was the emergence of recombinant DNA 
technology permitting the mass production of species-specific rpGH to provide a commercial 
product with marketing potential in the pork industry. Etherton and co-workers (1986) were the first 
to report that rpGH, rpST, was indistinguishable from pituitary derived material in animal bioassay 
response. In a similarly designed dose response titration experiment Boyd and co-workers at 
Cornell University reported that pituitary derived pGH had optimal effects on most end point 
parameters at a dose of 90 to 100 ug/kg body weight daily. Therefore, in two independent studies 
the dose optimum of pGH, natural or recombinant, is approximately 70 to 120 ug/kg body weight 
daily. 
A consistent effect of pGH treatment is the reduction of voluntary appetite which in itself 
confounds the quantitation of GH effects on carcass components from those effects attributable to 
feed restriction. In part, the greater improvement of feed efficiency compared to the effect on rate 
of gain would be anticipated considering the change in composition of gain (i.e., less fat and greater 
muscle protein and associated water). Several studies which have utilized either pituitary-derived 
(Wolfrom et al., 1986) or recombinant pGH (Kraft et al., 1986) found little if any benefit to growth 
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and composition in pigs; however, nutrient intake, in particular protein content and composition, 
was marginal. Boyd and co-workers (personnel communication) and recent efforts at Illinois 
(Easter, 1987) have revealed that protein intake can constrain realization of pGH benefit. 
Porcine Somatotropin: Beltsville Studies 
Within the discipline of nutrition one often loses the perspective that the mass and specific 
composition of the target tissue deposited defines the nutrient requirement of an animal. The diet 
with adjustments for obligatory losses associated with tissue deposition is merely the vehicle to 
supply the tissue requirement. With greater emphasis on lean tissue deposition and less lipid, the 
absolute and quantitative genetic potential for protein deposition is a very important concept in that 
this potential, or ceiling, defines the protein requirement of the pig. 
Underlying efforts at the Beltsville Agricultural Research Center was the thought of defining in 
quantitative terms the genetic potential for protein deposition. To this end several studies have been 
conducted with designs to address this question. Simultaneously, several aspects pertinent to global 
swine production practices were addressed. Growth hormone within these experiments was used 
merely as a tool, albeit a very powerful tool, to maximize genetic potential for protein accretion. 
Interaction of dietary energy intake and pST administration: 
Common in US production practices is the use of ad libitum feeding systems /which, to some 
extent, reflects the availability of grain resources. European feeding systems, in contrast, utilize 
limit-feeding due to the expense of grain resources, but additionally as a means to enhance lean 
tissue deposition. As reported (Etherton et al., 1987; Boyd et al., 1986) the beneficial effects due to 
pGH were confounded by ad libitum feeding and the reduction (10-15%) of voluntary appetite 
resulting from treatment. 
Table 1. Effects of energy Intake and porcine growth hormone (pGH) administration on the growth 
performance of pigs from 25 to 55 kg live weight. 
Energy Intake 
Ad libitum (A) 
80% Ad libitum (80%A) 
60% Ad libitum (60%A) 
SJEM 
Model R2 
Significance of contrast 
OpGHvslOOpGH 
A vs (80% A + 60% A) 
80%Avs60%A 
pGH dose 
(ug/kg/d) 
0 
100 
0 
100 
0 
100 
P<: 
pGH x (A vs (80% A + 60% A)) 
pGHx(80%Avs60%A) 
(No./trt.) 
(6) 
(6) 
(6) 
(6) 
(5) 
(5) 
Feed Intake 
(kg/d) 
2.32 
2.08 
1.64 
1.62 
1.38 
1.34 
.03 
.98 
.01 
.01 
.01 
.01 
.76 
Energy Intake 
(Mcal/d) 
8.10 
7.28 
5.72 
5.65 
4.83 
4.70 
.09 
.98 
.01 
.01 
.01 
.01 
.73 
Dally gain 
(g) 
905 
1052 
670 
842 
543 
681 
22 
.93 
.01 
.01 
.01 
.80 
.42 
Feedigaln 
2.57 
1.96 
2.45 
1.91 
2.54 
1.95 
.06 
.85 
.01 
.31 
.27 
.65 
.67 
Therefore, dietary energy was selected as the initial nutrient variable to reconcile possible 
synergistic effects as intake and pGH alter nutrient partitioning. Additionally, Etherton and 
co-workers (1987) reported that benefit from pGH administration increased with increasing 
amounts of body fat. Shields et al. (1983) had previously reported that protein accretion rate was 
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greatest in pigs between birth and approximately 55 kg live weight and decreased slowly with 
further weight accretion. Therefore, the interaction of energy intake and pGH was examined over 
the live weight phase during which protein accretion is greatest (25 to 55 kg body weight). 
Data in Table 1 summarizes the growth performance of barrows fed at one of three intake levels 
(AL- ad libitum, 80% AL or 60% AL) a common diet and injected daily into the extensor neck 
muscles with excipient buffer or buffer containing pituitary derived GH at a dose of 100 ug/kg body 
weight over the live weight phase of 25 to 55 kg. Pigs were individually penned and feed intake and 
GH dose was adjusted weekly based on change of body weight. Consistent with previous reports 
(Etherton et al., 1987; Boyd et al., 1986), GH reduced voluntary appetite (10%) of pigs fed AL. 
Intake restriction masked this effect and animals consumed all feed offered regardless of GH 
dose. Growth rate increased linearly with increased feed intake and was amplified by 16 to 25% by 
GH treatment; however, feed efficiency was similar regardless of intake treatment and was 
consistently improved 23% by GH. During the course of the experiment two animals were removed 
due to problems unrelated to treatment. 
Chemical analyses of carcass and visceral components permitted the calculation of accretion 
rates for water, protein, fat and ash (Table 2) and using standard energy values, maintenance energy 
expenditure was estimated from the protein and fat components of growth. Body water, protein, fat 
and ash all increased as a linear function with feeding level and, with pGH treatment, protein 
accretion increased by 35 to 49% while fat accretion was decreased by 25 to 32%. To emphasize 
this effect, pigs fed 40% less feed and treated with pGH (60% AL) exhibited protein accretion rates 
comparable to pigs fed AL and excipient-treated. Maintenance energy expenditure estimated at total 
energy retention of zero was increased by 17% due to pGH. This increased energy expenditure is 
due to the increase of lean body mass (i.e., metabolic rate of muscle > metabolic rate of adipose 
tissue) and a possible direct thermic effect of GH. 
Table 2. Effects of energy Intake and porcine growth hormone (pGH) administration on the rates of 
deposition of water, protein, fat and ash and the fat:proteln ratio In the empty body of pigs 
at 55 kg live weight. 
Energy intake 
A d libitum (A) 
80% A d libitum (80%A) 
60% A d libitum (60%A) 
SEM 
Model R2 
Significance of contrast 
OpGHvs lOOpGH 
A vs (80% A + 60% A) 
80% A vs 60% A 
pGH dose 
(ug/kg/d) 
0 
100 
0 
100 
0 
100 
P<: 
pGH x (A vs (80% A + 60% A)) 
pGH x (80% A vs 60% A) 
Water 
416 
567 
310 
498 
279 
388 
18 
.88 
.01 
.01 
.01 
.91 
.05 
Accretion rates, g /d : 
Protein 
no 
151 
85 
127 
78 
105 
4 
.92 
.01 
.01 
.01 
.26 
.02 
Fat 
283 
193 
171 
127 
110 
76 
11 
.89 
.01 
,01 
.01 
.01 
.64 
Ash 
20.4 
36.8 
15.4 
22.2 
11.9 
17.1 
2.2 
.77 
.01 
.01 
.05 
.01 
.69 
Fat: Protein 
2.58 
1.28 
2.04 
.99 
1.41 
.73 
.13 
.85 
.01 
.01 
.01 
.05 
.15 
Related to the mechanism of GH action, several studies have suggested that GH acts primarily 
on adipose tissue to decrease basal and insulin-stimulated lipogenesis (Walton and Etherton, 1986; 
Walton et al., 1987). Thereby energy normally utilized to support fat accretion is available for 
protein synthetic processes. Data from this energy study revealed that the rate of lipogenesis as 
indicated by fat accretion rate is identical comparing excipient to pGH-treated pigs, but that the rate 
of body lipid turnover is increased. The increased feed energy required to maintain a unit of body 
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fat results in a net reduction of body fat deposition. These data circumstantially imply that GH acts 
primarily on muscle tissue because if muscle protein effects were secondary to those on fat tissue 
the slope of the line describing energy retained as fat should be reduced compared to the slope for 
excipient-treated animals; this was not observed. 
The following list describes conclusions from the dietary energy x pGH experiment: 
- GH is a limiting physiological factor for lean tissue deposition in the young pig. Accretion of 
body fat reserve is not a prerequisite to demonstrate benefit from pGH administration. 
- GH markedly increases the rate of protein deposition, regardless of energy intake, and, 
therefore, pGH effects as reported are independent of and additive to the effects of such 
treatment on energy nutriture. The magnitude of benefit from pGH administration will be more 
fully realized with ad libitum feeding systems. 
- As a qualification to the above statement, pGH increases maintenance energy expenditure by 
17% and energy intake must be adjusted accordingly to realize full benefit from pGH treatment. 
- Changes in rate and efficiency of growth attributed to pGH administration are direct 
consequences of stimulating protein deposition and energy associated with protein deposition 
combined with increased maintenance expenditure denies energy supportive of lipogenesis. 
Interaction of dietary protein intake and pST administration: 
In a recent study, the interrelationships between protein intake and pGH responsiveness were 
examined. Young crossbred barrows were used and dietary protein was varied between 11 and 27%. 
The diets were prepared to be isocaloric (3.8 Meal DE/kg feed) and each formulation, regardless of 
protein content, contained the same lysine concentration (4.9 g lysine/ Meal DE). Thus, the 
influence of protein intake could be evaluated independent of lysine which is the primary limiting 
amino acid for growth of pigs. Soybean meal provided the variable source of dietary protein and 
was diluted with corn starch to yield five diets containing 27, 23,19, 15 and 11% crude protein. 
Table 3. Effects of protein Intake and porcine growth hormone (p©H) administration on growth 
performance and selected carcass characteristics of pigs. 
Dietary 
Protein 
(%) 
11 
11 
15 
15 
19 
19 
23 
23 
27 
27 
SEM 
rpGH 
dose 
(ug/kg/d) 
0 
100 
0 
100 
0 
100 
0 
100 
0 
100 
Initial 
weight 
(kg) 
32.3° 
32.1 
30.6 
31.2 
30.9 
31.3 
30.8 
30.6 
29.0 
29.4 
1.3 
Final 
weight 
(kg) 
51.8 
56.0 
51.8 
62.1 
53.4 
62.9 
52.7 
64.0 
49.8 
60.7 
2.1 
Dally 
gain 
(g) 
464 
569 
(23%)b 
504 
736 
(46%) 
536 
760 
(42%) 
520 
796 
(53%) 
496 
744 
(50%) 
33 
Feed: 
gain 
3.39 
2.90 
(14%) 
3.07 
2.28 
(26%) 
2.93 
2.23 
(24%) 
3.05 
2.12 
(30 %) 
3.02 
2.15 
(29%) 
0.12 
Loin eye 
area 
(cm sq) 
19.4 
21.5 
(11%) 
22.5 
27.0 
(20%) 
21.9 
28.0 
(28%) 
22.5 
27.6 
(22%) 
20.4 
27.8 
(37%) 
1.2 
Average 
backfat 
(cm) 
1.66 
1.24 
(25%) 
1.58 
1.17 
(26%) 
1.66 
1.09 
(34%) 
1.59 
1.17 
(20%) 
1.21 
0.99 
(21%) 
0.15 
a
 Values are means, n=6 pigs per treatment group. 
Values in parentheses represent percent change of pGH-treated pigs compared to excipient-treated controls. 
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The rations were limit-fed daily (approximately 20% restriction vs. ad libitum) to eliminate 
confounding effects of altered energy intake on interpretation of results. Recombinant pGH (rpST*) 
was injected daily (100 ug/kg) into five groups of six pigs (i.e. one group on each of the five dietary 
regimes). An equal number of control pigs were treated with a similar volume of excipient buffer. 
Pigs were placed on treatment at 30 kg live weight and were treated for 6 weeks. Amounts of feed 
and pGH were adjusted weekly based on change of body weight. 
The purpose of this experiment was two-fold. First, to determine whether pGH could in fact 
stimulate lean tissue growth in diets deficient (or marginally deficient) in protein and second, to 
determine whether the protein requirement is altered for pigs treated with GH. At present only 
preliminary growth performance data are available and shown in Table 3. The data indicate that 
substantial changes in growth characteristics were evident at all levels of dietary protein intake as a 
result of pGH treatment. Generally, it is apparent that at 15% protein (and higher) growth 
characteristics were quite similar. Furthermore, the improvement in performance of pigs treated 
with pGH and fed diets containing 15 to 27% protein diets were similar, at least in the parameters 
examined. In contrast, at 11% protein the magnitude of improvement in daily gain, feed:gain and 
loin eye area was found to be approximately 50% that observed at higher levels of protein intake. 
However, the net change in backfat due to pGH administration was similar at all levels of protein 
intake. This finding is in agreement with data from the previous study which demonstrated that 
aspects of fat metabolism were energy dependent and that the influence of pGH on protein and fat 
metabolism could be separated by nutritional manipulation. Furthermore, final interpretation of 
these data must await proximate analysis of the whole body and determination of protein and fat 
accretion rates in these animals. From the data presented here, it seems unlikely that the protein 
requirement for growing pigs is altered greatly as a consequence of GH administration. 
Effect of genotype on realization ofpST benefit: 
Virtually all reports of GH efficacy have utilized castrate males, barrows, which have the 
greatest rate of fat accretion and intrinsically the poorest rate of protein deposition. In addition, 
many countries market intact male pigs to take advantage of their superior growth characteristics. 
Table 4. Effects of animal sex and porcine growth hormone (pGH) administration on the growth 
performance of pigs from 60 kg live weight and treated for 31 days. 
Animal sex 
Male (B; boar) 
Female (F;gllt) 
Castrate male(Ba; 
barrow) 
SEM 
Model R2 
Significance of contrast 
OpGHvslOOpGH 
M vs (F + Ba) 
F vs BA 
pGH x (Mvs(F + Ba)) 
pGH x (F vs Ba) 
pGH dose 
(ug/kg/d) 
0 
100 
0 
100 
0 
100 
P<: 
(no.trt.) 
(6) 
(6) 
(6) 
(6) 
(6) 
(6) 
Weight 
(kg) 
97.8 
102.8 
91.8 
98.8 
93.7 
98.1 
1.5 
.53 
.01 
.01 
,68 
.81 
,38 
Feed Intake 
(kg/d) 
3.22 
2.96 
3.38 
2.73 
3,67 
2.84 
.13 
.55 
.01 
.56 
.13 
,04 
.50 
Dally gain 
(g) 
1186 
1342 
1011 
1236 
1057 
1225 
43 
,57 
,01 
.01 
.69 
.59 
.50 
Feed: gain 
2.72 
2.21 
3.34 
2.21 
3.46 
2.33 
.07 
.92 
.01 
.01 
.09 
.01 
.96 
* rpST was generously provided by IMC-Pittman-Moore, Terre Haute, IN. 
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Therefore, genotypic effects were evaluated initially at the most fundamental level of genetic 
difference; animal sex. Subsequently, Campbell and Taverner (1988) repeated these efforts using 
pigs which differed not only in sex, but also realization of protein deposition potential through 
genetic optimization. 
Data in Table 4 describes the response of female, castrate male and intact male pigs fed a 
common diet and treated with either excipient buffer or pGH (100 ug/kg) for a 31 day period 
starting at 60 kg live weight. Apparent in the data was the superior rate (excipient buffer treated; 
male > female and castrate by 15%) and efficiency (male > female and castrate by 20%) of gain of 
intact male pigs. The sex effect difference was minimized with respect to rate of gain and 
eliminated with respect to feed efficiency by pGH administration. Chemical analysis of the 
components of growth confirmed that the vast improvement of feed efficiency observed in females 
and castrates was the result of accelerated protein and associated water deposition (Table 5). 
Table 5. Effects of animal sex and porcine growth hormone (pGH) administration on the rates of 
deposition of water, protein, fat and ash and the fatiproteln ratio In the empty body of pigs 
treated for 31 days. 
Animal sex 
Male (B; boar) 
Female (F;gltt) 
Castrate male (Ba; 
barrow) 
SEM 
Model R2 
Significance of contrast 
OpGHvslOOpGH 
B vs (F + Ba) 
FvsBA 
pGH x (Bvs(F + Ba)) 
pGH x (F vs Ba) 
pGH dose 
(ug/kg/d) 
0 
100 
0 
100 
0 
100 
P<: 
Water 
467 
676 
342 
680 
383 
615 
29 
.84 
.01 
.01 
.54 
.12 
.07 
Accretion rates,g/d: 
Protein 
196 
238 
148 
235 
139 
225 
9 
.78 
.01 
.01 
.26 
.01 
.99 
Fat 
317 
202 
411 
185 
462 
223 
27 
.79 
.01 
.01 
.07 
.01 
.73 
Ash 
23.6 
29.9 , 
24.1 
37.8 
27.4 
29.2 
1.9 
.56 
.01 
.09 
.17 
.66 
.01 
Fat: Protein 
1.40 
1.02 
1.84 
1.04 
2.17 
1.22 
.06 
.91 
.01 
.01 
.01 
.01 
.23 
Therefore, GH technology will be of most benefit in those production environments which 
utilize pigs with the poorest protein accretion rates (i.e., female and castrate male pigs as typical in 
the US swine industry). Furthermore, the lack of pGH effects of the same magnitude when 
administered to intact male pigs did not suggest that androgens and GH are additive stimulants of 
growth and development processes. 
The effect of pGH technology on strains of pigs which have diverged from commercial-type 
pigs with respect to growth characteristics was recently reported by Campbell and colleagues 
(1988; Table 6). Pigs of strain A represent a population with an infinite capacity for protein growth 
constrained only by appetite, while pigs of strain B are commercial-type animals typical of 
Australia. Intact male and female animals within strain were treated with either excipient buffer or 
pGH over the live weight phase of 60 to 90 kg and fed ad libitum a common diet. Consistent with 
the lack of GH x genotype interaction, pGH minimizes genetic differences. Within genotype, GH 
negates sex effects on the efficiency and composition of live weight gain. 
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Table 6. Genotype and sex effects on the responsiveness of growing pigs to exogenous growth 
hormone administration (Campbell and Taverner, 1988). 
Strain: 
pGH dose: 
Item Sex: 
Dally gain, g 
lntake,kg/d 
Feed/Gain 
Back fa imm 
Visceral wt, kg 
Carcass length.cm 
0 
M 
1177 
3.14 
2.70 
26.4 
7.8 
78.2 
A 
F 
894 
3.05 
3.43 
32.5 
7.4 
76.2 
100 
M 
1519 
2.76 
1.90 
20.4 
7.5 
80.0 
F 
1250 
2.63 
2.10 
21.3 
8.5 
77.9 
0 
M 
992 
3.24 
3.28 
32.3 
7.4 
77.1 
B 
F 
737 
2.77 
3,76 
34.2 
7.1 
77.3 
100 
M 
1292 
2.61 
2.07 
24.9 
8.4 
78.3 
F 
1080 
2.48 
2.23 
23.6 
8.6 
79.6 
SEM 
17 
.32 
.24 
2.8 
.74 
2.2 
AOV" 
G,S,GH 
S,GH 
G,S,GH,S-GH 
G,S,GH,S-GH 
GH.S-GH 
GH.S-GH 
* P <.05. Effects: G=strain; S=sex; GH=pGH; and S-GH interaction. 
With the original objective of defining protein accretion capacity in the pig, data in Table 5 has 
substantially refined the estimate. Previously, protein deposition capacity in the range of 180 
grams/day has been considered an "ideal" reference (Whittemore, 1983). Regardless of animal sex, 
we report accretion rates for body protein between 235 to 250 grams/day. Considering the goal of 
animal agriculture to maximize protein output per animal unit, swine nutrition practices should 
adapt to satisfy this genetic potential. Considerable trade-offs exist in practical swine management, 
but the economic basis for these trade-offs must be recognized in the perspective that the genetic 
ceiling, or capacity, for protein growth in the pig is approximately 40% greater than previously 
estimated. 
Sustained effect ofpST administration: 
Ideally any manipulation of animal growth should involve those processes described as 
homeorhetic adaptations. Homeorhesis is defined as the chronic integration and coordination 
ofmetabolic processes to support a specialized physiological state (Bauman et al., 1982). Both for 
economy of GH used in the treatment of animals and ease of animal management, some advantage 
Table 7. Effects of porcine growth hormone (pGH) administration from 30 to 60 kg live weight on the 
growth performance of pigs. 
pGH dose Live weight 
(ug/kg/d) (kg) 
(Treated) 
0 30-60 
100 
SEM 
Significance of contrast, P<: 
0 pGHvs 100 pGH 
(Withdrawal) 
0 (0) 60-90 
100 (0) 
SEM 
Significance of contrast, P<: 
0 pGH vs 100 pGH 
(Overall) 
0 30-90 
100 
SEM 
Significance of contrast, P<: 
OpGHvs lOOpGH 
Days 
39.8 
29.5 
.6 
.01 
32.7 
29.1 
.7 
.01 
73,6 
58,7 
.9 
,01 
Feed Intake 
(kg/d) 
1.98 
1.94 
.04 
.50 
3.30 
2.96 
.96 
.02 
2.58 
2.43 
.04 
.02 
Dally gain 
(g) 
798 
1041 
35 
.01 
887 
1020 
31 
.01 
804 
1009 
12 
.01 
Feed/gain 
2.84 
1.86 
.04 
.01 
3.75 
2.92 
.14 
.01 
3.08 
2.41 
.10 
.01 
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to the treatment of relatively small growing pigs could be realized if the pGH effects were sustained 
during the finishing phase of growth. In part, this challenges the homeorhesis theory of hormone 
action with respect to GH effects on growth. Assuming GH action is primarily exerted on those 
mechanisms controlling muscle protein deposition (i.e., satellite cell integration into myofibrils), 
decompensation of benefit following treatment withdrawal should not occur. This concept is also 
relevant should licensing approval mandate a lengthy withdrawal period following hormone 
treatment. 
Barrows were treated daily with either excipient buffer or buffer containing pituitary derived 
pGH (100 ug/kg body weight) over the live weight phase of 30 to 60 kg. Pigs treated with excipient 
buffer were pair-fed to the intake noted in pGH-treated pigs to avoid energy consumption as a 
confounding factor. From 60 to 90 kg live weight no further injections were performed and all pigs 
were fed ad libitum. Growth performance segregated by live weight period is summarized in Table 
7. Of the original 36% benefit in daily gain favoring pGH treatment, a 14% residual benefit was 
sustained during the finishing phase of growth. The 28% improvement of feed efficiency observed 
during the treatment phase deteriorated slightly (-6%) during the finishing phase of growth. 
Overall, treatment of young pigs with pGH accelerated growth velocity sufficient to reduce by 15 
days the time interval to achieve 90 kg live weight utilizing 22% less feed. 
Accretion rates of water, protein and ash were significantly increased during the treatment 
phase, while carcass fat accretion rate was decreased, compared to excipient-treated control pigs 
(Table 8). During the withdrawal period, carcass water, protein and ash deposition rates were 
significantly greater in pigs previously treated with pGH compared to excipient-treated, control, 
animals. Fat deposition rate was comparable regardless of prior treatment. These data indicate that, 
at minimum, the pGH benefit to somatic components of growth (i.e., water, protein and ash) are 
maintained over control values during withdrawal and do not decompensate. The increased fat 
deposition of pigs previously treated with pGH suggested that the decrease in magnitude of 
stimulated protein deposition in effect created an energy surplus resulting in a large increase of 
lipogenic rate. Whether these data provide evidence for a homeorhetic adaptation is inconclusive, 
but at least the benefit derived from treatment of young animals with pGH results in a sustained 
benefit to growth velocity and lean body mass. 
Table 8. Effects of porcine growth hormone administration (pGH) from 30 to 60 kg live weight on the 
rates of deposition of water, protein, fat and ash and the fat; protein ratio In the carcass of 
pGH dose Uve weight 
(ug/kg/d) (kg) 
Created) 
0 30-60 
100 
SEM 
Significance of contrast, P<: 
0 pGHvs 100 pGH 
(Withdrawal) 
0 (0) 60-90 
100(0) 
SEM 
Significance of contrast, P<: 
OpGHvslOOpGH 
(OveralD 
0 30-90 
100 
SEM 
Significance of contrast, P<: 
OpGHvslOOpGH 
Water 
311 
529 
53 
.01 
229 
314 
31 
.01 
253 
347 
30 
.01 
Accretion rates.g/d: 
Protein Fat 
98 
153 
16 
.01 
91 
121 
11 
.01 
97 
131 
8 
.01 
164 
100 
27 
.05 
329 
358 
44 
.50 
233 
226 
37 
.75 
Ash 
18.3 
28.0 
3.7 
.05 
16.7 
24.9 
7.2 
.05 
17.5 
27.2 
4.6 
.01 
Fat: Protein 
1.67 
.65 
.39 
.05 
4.30 
2.90 
.72 
.01 
2.43 
1.74 
.43 
0.1 
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Conclusions 
Recombinant DNA technology has made available sufficient quantities of somatotropin which 
could vastly alter the development pattern of livestock through amplification of genetic potential 
favoring the accretion of lean tissue and reducing the extent of fat deposition. Application of this 
technology in the swine industry should negate certain advantages in production practices of 
European countries thereby making North American swine production more competitive in the 
world marketplace. Hindering application at this time is the development of a sustained release drug 
delivery system; however, demonstration of a sustained effect in the young animal following a 30 
day treatment regime may facilitate development. As this technology affects meat processing 
practices, competition among species with respect to market share for consumer selection, the 
impact on cereal grain utilization and similar economic issues are beyond the scope of this report. 
Biologically, the effects of ST on reproductive performance, immune system function, progress in 
classical animal breeding practices, etc. are all researchable questions awaiting. 
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USE OF RECOMBINANT PORCINE SOMATOTROPIN (rPST) IN 
EUROPE; RESEARCH EXPERIENCE AND PERSPECTIVES. 
1 2 
Vernon R. Fowler and Egbert Kanis 
Rowett Research Institute and School of Agriculture, University of Aberdeen, 
Scotland 
Wageningen Agricultural University, The Netherlands 
Summary 
European pig production is carried out within a distinctive agricultural, social and scientific 
environment. For many years there has been an intensive effort to breed for pigs which are both 
efficient in their use of feed and which can conform to very demanding grading standards set by the 
processor. A major issue is whether or not the use of recombinant porcine somatotropin (rPST) 
results in significant improvements in efficiency under all the conditions of production which 
prevail in Europe. 
Experiments with rPST using European breeds at different centres in The Netherlands, West 
Germany and in the United Kingdom (Scotland) have all showed clearly that it was possible to 
achieve very considerable improvements from using rPST both in terms of growth rate and feed 
efficiency and particularly in the leaness of the carcass. The most dramatic increases were in the 
rate of deposition of the lean tissue and in daily nitrogen retention. This was true over all weight 
ranges varying between 35 to 140 kg depending on the period of administration and on dose rate. 
In the Scottish work, where treatments were applied between 35 and 95 kg liveweight, the dose was 
at the high rate of 7 mg per day of rPST and where protein was supplied at 190 g per kg in the diet, 
daily gains of the treated group were 20% above that of the control and the N content of the carcass 
was increased by over 10%. The Dutch work on N-balances with restricted feeding indicated 
increases in daily weight gain of over 10%, in daily protein gain of about 30% and decreases in 
daily fat deposition of about 10%, even in the Pietrain breed. In general, the effect of rPST was to 
reduce voluntary feed intake by about 5% but in the Dutch experiment with ad libitum feeding there 
was a major exception to this in the case of Pietrain and cross-bred pigs growing from 100 to 140 
kg liveweight which increased their intake by about 8%. 
The protein concentration in the diet was important for the full expression of the effects of rPST 
administration on protein deposition. There is clearly an immense opportunity for modelling 
exercises which will determine the best combinations of genotype, diet, slaughter weight and rPST 
dose rate to obtain the best advantage from this new and exciting technology. 
Keywords: somatotropin, swine, carcass quality, growth rate, feed efficiency, Europe. 
Introduction 
There have been several reports from the United States indicating a very positive response by 
pigs to injections of both natural and recombinantly derived PST (Boyd et al., 1985; Etherton et al., 
1986; Kraft et al., 1986). A major issue is whether or not the use of rPST results in significant 
improvements in efficiency under all the conditions of production which prevail in Europe. 
European pig production is carried out within a distinctive agricultural, market, social and scientific 
environment. For many years there has been an intensive effort to breed for pigs which are both 
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efficient in their use of feed and which can conform to very demanding grading standards set by the 
processor. These pigs normally receive high-quality, protein-rich diets throughout the growing 
period and typical marketing weights range between 85 kg liveweight at the lower end to about 125 
kg at the upper end of the spectrum. 
Among the favoured European genotypes in some European countries are pigs of the Retrain 
type either bred pure or as cross-breds. This type is noted for its extreme leaness, sensitivity to 
stress and its compact appearance. These attributes are now believed to be mainly the result of a 
particular metabolism associated with a relatively simple gene known as the 'halothane sensitivity 
gene', because of the tendency of pigs which are homozygous for this trait to exhibit a characteristic 
rigour of the muscles and malignant hyperthermia when the anaesthetic substance halothane is 
administered. The extreme attributes of the Pietrain breed contrast markedly with those of the 
Duroc breed which is widely used in the United States and which tends to be rather fatter and, in a 
relative sense, stress resistant. The characteristic meat producing pigs of North West Europe tend to 
be based on hybrids or crosses of pigs of the Large White (Yorkshire) and Landrace types together 
with a varying degree of Pietrain blood depending on the market demand. 
The experiments described below include representatives of these genotypes and relate to pigs 
grown on typical European diets under European conditions of husbandry. The main studies 
reported relate to work by Kanis and Van der Wal (1988) in The Netherlands, Fowler et al. (1988) 
in Scotland and reference is also made to work from the Federal Republic of Germany by Ellendorff 
et al. (1988). All the studies were conducted using rPST provided by Pitman-Moore, Inc. Terre 
Haute, USA. Much of this work has not yet been published in full scientific form, and the results 
given in this paper should be treated as provisional. 
Experimental background 
Many of the European experiments have been conducted using the same basic methods of 
administration of rPST, namely daily subcutaneous injection of a fixed dose over the relevant 
experimental period either in the shoulder or over the ham. In the Dutch experiments a fixed dose 
of 4 mg per day was administered over the entire liveweight range of 60 to 140 kg. In the Scottish 
experiments there were three dose rates 1.75 mg, 3.5 mg and 7.0 mg per day administered to pigs 
which were much lighter at the start than those in the other experiments (30 kg) and which 
continued until the pigs weighed 95 kg liveweight. In the West German experiments, a fixed dose 
of 5 mg rPST was used over the weight range 50 to 105 kg (70 days from 50 kg). 
The breeding of the animals in the Dutch experiment was a comparison of purebred Pietrain and 
purebred Duroc with a typical cross between Dutch Yorkshire and Dutch Landrace. In the West 
German experiment, Pietrain were again used but in this case the second breed was the German 
Large White (Deutsche Edelschwein). In the Scottish experiment, the pigs were the product of a 
breeding company (National Pig Development) and were the result of crossing a Large White boar 
with a Large White x Landrace female. Feeding was close to ad libitum in all experiments although 
in the Scottish experiment a scale of feeding was used, intended to be just below appetite. Diets 
were typically based on cereals, barley and wheat supplemented with protein-rich materials 
including extracted soya-bean and fishmeal. In the Dutch and West German trials the concentration 
of protein in the fresh diet was about 190 g per kg but in the Scottish trial two protein concentrations 
were compared, 165 g per kg and 190 g per kg. In terms of the sex of the experimental animals the 
Dutch and Scottish experiments included females and castrated males but the West German 
experiment was based only on females. 
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Results 
It is impossible to give a comprehensive listing of all the results without writing three or more 
papers. However it is possible to draw together some of the main features. 
Growth rate 
The response of growth rate differed between the centres. In the Dutch and Scottish experiments 
there were major increases in growth rate resulting from the treatment but in the West German 
experiments this was not demonstrated and in fact in the case of the Large White breed there was a 
slight reduction ( see Table 1 ). 
Feed gain ratio 
Liveweight feed conversion was markedly improved in the Scottish and Dutch Experiments 
each kg of gain requiring about 10% less feed with the Pietrain on the West German experiment 
showing the least response (see Table 2). 
Voluntary feed intake 
In general, the effect of rPST was to reduce voluntary feed intake by approximately 4 to 12%, 
but there was a major exception to this in the case of Pietrain and cross-bred pigs growing from 100 
to 140 kg liveweight in the Dutch experiment which actually increased their intake by about 8%, 
(see Table 3). ' 
Carcass leaness 
Without exception the effect of rPST increased in a most dramatic way the leaness of the carcass 
this being very sensitive to actual dose of rPST (see Table 4). The greatest increases were of the 
order of 15% and this was independent of the degree of leaness in the first instance. 
Rate of gain of protein and lipid 
A most impressive feature of rPST is the increase that it effected in the daily rate of protein 
deposition. This is illustrated by the data of Kanis and van der Wal from their metabolic 
experiments (see Table 5). The increases are virtually 25 % for the treated versus the control 
animals and there are corresponding reductions in the rate of deposition of the lipid, although the 
proportional change is not as great. 
Chemical composition 
The chemical composition of the carcass reflects the greater leaness and reduced fat of the 
carcasses and also shows that in general the normal proportions between protein, ash and water 
content are maintained. The data given in Table 6 are from the Scottish series of experiments and 
show consistent responses to the rPST dose rate in terms of increasing protein in the carcass for the 
high dietary protein treatment (190 g/kg) but a tendency to plateau for the low protein diet (165 
g/kg). The same but opposite tendency is apparent in the concentration of lipid in the carcass. The 
ratio of water to protein and of ash to protein was unaffected by the rPST treatments suggesting that 
the physiological relationships between these components of the lean body remained completely 
normal. 
Physical proportions 
It is interesting to note that in so far as it was possible to determine the relationships between the 
physical entities of the body it appeared that rPST did not have any major effect in changing the 
proportions of the components of the fat-free body (see Table 7). 
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Fitness and health 
In none of the experiments was any detrimental effect reported of the use of rPST found in terms 
of health or fitness. Ellendorff et al. (1988) examined the major endocrine glands of treated and 
untreated pigs including pituitary, thyroid, adrenals and ovaries and found no differences except in 
the case of the adrenals of the Pietrain breed for which organ the animals receiving rPST had an 
increase in size over the control of about 24%. 
Eating quality 
Kanis and van der Wal (1988) examined the meat quality parameters including tenderness, 
odour, taste, fat content and drip loss. Of the whole range of quality measures only meat colour 
showed a difference although this did not approach significance, see Table 8. However, in the work 
of Ellendorff et al. (1988) a difference was found in the amount of lipid in dry matter of the 
longissimus dorsi, the change being about a reduction of one third for both the German Large White 
and the German Pietrain. However, the amount of fat in the control animals was only about 3% of 
the dry matter, and it is unlikely that such a change would have a material effect on the eating 
quality. 
Discussion 
The effect of the use of rPST in pigs typical of the European breeds and under conditions of 
management and husbandry typical of North West Europe was dramatic. It not only increased the 
lean content of pigs considered to be already genetically lean, but also always increased the growth 
rate of the lean tissue and reduced that of fatty tissues. These improvements were usually 
accompanied by a reduction in daily feed intake and an improvement in feed gain ratio. At the 
higher weights, that is from 100 to 140 kg liveweight, greater growth rates were achieved in lean 
animals by an actual increase in the daily feed intake. 
From this experience it appears that rPST is extraordinarily effective at increasing the rate of 
deposition of lean tissue or daily protein accretion rate. This appears mainly to have been achieved 
by diverting some of the metabolizable energy which would otherwise have been deposited as lipid 
towards protein deposition. However, when energy for protein deposition becomes otherwise 
limiting, pigs treated with rPST exhibit an increase in feed intake. This is particularly interesting in 
view of the fact that these pigs may actually have been selected over recent years in such a way that 
their appetite potential has been genetically reduced. 
From the one experiment in which dose rate was incorporated as a factor, it appeared that dose 
rate is extremely important in determining the extent of the effect. Indeed, when 7 mg per day of 
rPST was administered to pigs from a light weight, that is 30 kg, the rate of fat deposition was so 
reduced that in some cases there was barely any visible fat over the eye muscle (longissimus dorsi) 
when the pigs were slaughtered at 95 kg liveweight. 
The protein concentration in the diet appeared to be important for the full expression of the 
effects of rPST administration on protein deposition. There is clearly an immense opportunity for 
modelling exercises which will determine the best combinations of genotype, diet and 
slaughter-weight and rPST dose rate to obtain the best advantage from this new and exciting 
technology. 
It appears that even for the sophisticated genotypes and diets used in North Western European 
pig production that the use of rPST could make an enormous impact on the efficiency of production 
and on the leaness of the carcass without detriment to the health of the animal or to the eating 
quality of the meat. 
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Table 1. Treatment means for dally llvewelght gain for the Scottish (series 1), Dutch (series 2) and West 
German (series 3) experiments. 
Breeds are designated as Large White x Landrace (LW/LR), Pletraln (FT), Duroc (DC), and 
Large White (LW). 
Series 
No 
Weight 
Range (kg) 
Breed Dose 
(mg/d) 
Uve-welght 
gain (kg/d) 
% change 
30-95 
60-100 
100-140 
50-100 
LW/LR 
PT 
LW/LR 
DC 
PT 
Fl 
DC 
LW 
PT 
0.0 
1.75 
3.50 
7.00 
0.0 
4.0 
0.0 
4.0 
0.0 
4.0 
0.0 
4.0 
0.0 
4.0 
0.0 
4.0 
0.0 
5.0 
0.0 
5.0 
0.871 
0.938 
0.966 
0.974 
0.952 
0.985 
0.962 
1.019 
0.868 
0.902 
0.670 
0.882 
0.693 
0.883 
0,765 
0.786 
0.901 
0.857 
0.789 
0.797 
+ 8.0 
+10.9 
+11.8 
+ 3.5 
+ 6.0 
+ 3.9 
+31.7 
+27.4 
+ 2.7 
-4.9 
+ 1.0 
Table 2. Treatment means for feed/gain ratio for the Scottish (series 1), Dutch (series 2) and West 
©erman (series 3) experiments. Breeds are designated as Large White x Landrace (LW/LR), 
Pletraln (PT), Duroc (DC), and Large White (LW). 
Series 
No 
Weight 
Range (kg) 
Breed Dose 
(mg/d) 
Feed/ 
gain 
% change 
30-95 
60-100 
100-140 
50-100 
LW/LR 
PT 
LW/LR 
DC 
PT 
LW/LR 
DC 
LW 
PT 
0.0 
1.75 
3.50 
7.00 
0.0 
4.0 
0.0 
4.0 
0.0 
4.0 
0.0 
4.0 
0.0 
4.0 
0.0 
4.0 
0.0 
5.0 
0.0 
5.0 
2.51 
2.33 
2.25 
2.22 
3.18 
2.92 
3.02 
2.72 
3.37 
3.13 
4.71 
3.82 
4.39 
3.70 
4.45 
4.16 
2.83 
2.50 
2.52 
2.44 
-7.2 
-10.4 
-11.6 
-8.2 
-9.9 
-7.2 
-19.0 
-15.8 
-6.5 
-11.7 
-3.2 
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Table 3. Treatment means for feed Intake for the Scottish (series 1), note not true ad libitum, the Dutch 
(series 2) and West German (series 3) experiments. Breeds are designated as Large White x 
Landrace (LW/LR), Retrain (FT), Duroc (DC), and Large White (LW). 
Series Weight Breed Dose Feed Intake change 
No Range (kg) (mg/d) (kg/d) 
30-95 
60-100 
100-140 
50-100 
LW/LR 
PT 
LW/LR 
DC 
PT 
LW/LR 
DC 
LW 
PT 
0.0 
1.75 
3.50 
7.00 
0.0 
4,0 
0.0 
4.0 
0.0 
4.0 
0.0 
4.0 
0.0 
4.0 
0.0 
4.0 
0.0 
5.0 
0.0 
5.0 
2.16 
2.18 
2.17 
2.15 
3.01 
2.85 
2.89 
2.77 
2.93 
2.82 
3.11 
3.36 
2.99 
3.24 
3.39 
3.21 
2.02 
1.78 
1.80 
1.74 
-
-5.2 
-4.2 
-3.6 
+ 8.0 
+ 8.3 
-5.4 
-11.9 
-
-3.4 
Table 4. Treatment means for feed/gain ratio for the Scottish (series 1), Dutch (series 2) and West 
Germain (series 3) experiments. 
Breeds are designated as Large White x Landrace (LW/LR), Pletraln (PT), Duroc (DC), and 
Large White (LW), castrated males are designated (M*) and females as (F). 
Series 
No 
1 
2 
3 
Weight 
Range (kg) 
30-95 
60-100 
100-140 
50-100 
Breed 
(sex) 
LW/LR 
M* 
F 
F 
PT 
LW/LR 
DC 
PT 
LW/LR 
DC 
LW 
PT 
Dose 
(mg/d) 
0.0 
7.0 
0,0 
7.0 
0.0 
4.0 
0.0 
4.0 
0.0 
4.0 
0.0 
4.0 
0.0 
4.0 
0.0 
4.0 
0.0 
5.0 
0.0 
5.0 
Lean 
% 
54.9 
63.6 
59.6 
66.0 
56.1 
57.8 
59.9 
52.7 
56.6 
52.2 
56.8 
54.2 
58.5 
50.4 
55.1 
49.4 
55.5 
55.4 
63.0 
% change 
+15.8 
+10.7 
+2.30 
+3.70 
+ 7.4 
+ 8.8 
+ 7.9 
+ 9.4 
+12.3 
+13.7 
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Table 5. Treatment means for protein and lipid gain per d based on metabolism trials from the Dutch 
work of Kanls and van der Wal (series 2). The values given are the means of two experimental 
periods. Breeds are designated as Large White x Landrace (LW/LR). Retrain (PT), Duroc (DC), 
and Large White (LW) with % change from control In brackets. 
Series 
No 
2 
Weight 
Range (kg) 
60-100 
Breed 
(sex) 
PT 
LW/LR 
DC 
Dose 
(mg/d) 
0.0 
4.0 
0.0 
4.0 
0.0 
4.0 
Protn 
(g/d) 
144 
187(+29.9) 
167 
211 (+26.3) 
116 
146(25.9) 
Upld 
(g/d) 
260 
243(-6.54) 
276 
213(-22.8) 
265 
220(-16,9) 
Table 6. Treatment means for the chemical annlyses of the carcasses for the Scottish experiments 
(Fowler et al) series 1. The data are given as the means for castrates and females combined. 
The results are classified to give the full Interaction between the rPST treatments and the 
protein concentration of the diet given between 30 and 95 kg llvewelght. 
Crude 
protein 
(g/kg) 
Lipid 
(g/kg) 
Water 
(g/kg) 
Ash 
(g/kg) 
Water/ 
protein 
Ash/ 
Protein 
Diet 
Protein 
(g/kg) 
165 
190 
165 
190 
165 
190 
165 
190 
165 
190 
165 
190 
0.0 
177.3 
185.4 
242.5 
218.5 
548.0 
564.1 
32.2 
32.1 
3.08 
3.04 
0.18 
0.17 
1.75 
184.9 
194.2 
213.7 
182.5 
569.8 
590.6 
31.6 
32.7 
3.08 
3.04 
0.17 
0.17 
rpST (g/d) 
3.50 
195.9 
203.2 
180.7 
156.9 
588.6 
603.5 
34.8 
36.4 
3.00 
2.97 
0.18 
0.18 
7.00-
191.7 
206.0 
177.2 
123.3 
597.4 
635.2 
33.8 
35.6 
3.12 
3.08 
0.18 
0.17 
SED 
3.13 
8.37 
7.63 
1.50 
Table 7. Treatment means for the dissection of the carcasses and ratios between major parts for the 
Scottish experiments (Fowler et aD series 1. The data are given separately for castrates and 
females. 
0.0 
rPST (g/d) 
7.0 
Sex M M SED 
Muscle % 
Fat and skin % 
Bone% 
Bone as 
% muscle 
Longlss. 
Dorsl as 
% muscle 
54.9 
33.5 
5.97 
59.6 
29.2 
5.88 
63.6 
23.9 
6.58 
66.0 
22.1 
6.50 
2.24 
1.92 
0.02 
10.9 
10.3 
9.9 
11.5 
10.9 
10.3 
9.9 
10.5 
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Table 8. Treatment means for parameters of meat quality from pigs on series 2 (Kanls and van der Wal. 
1988) and on fat In dry matter from Ellendorff et al. (1988), series 3. 
rPST(18) Control (18) Slg. 
SERIES 2 
Tenderness 7.40 
Odour 7.73 
Taste 7.58 
Moisture % 73.81 
Fat% 2.17 
Protein % 23.27 
Drip loss % 4.41 
Cooking loss % 28.93 
Instron Shearforce 3.55 
Colour(Hunter)10a 5.13 
SERIES 3 
Large White 
%FatlnDMof 
Long, dorsl. 1.80 3.19 
Pletraln 
% Fat In DM of 
Long, dorsl. 2.69 1.78 
7.50 
7.80 
7.54 
73.69 
2.05 
23.09 
4.39 
28.28 
3.39 
5.85 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
00%) 
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PROSPECTS FOR USING PORCINE SOMATOTROPIN IN CHINESE 
PIGS 
K.F. Fung1 and S.Z. Qi2 
South China Agricultural University, Guangzhou, China 
Beijing Agricultural University, Beijing, China 
Summary 
Porcine somatotropin was administered to 44 Chinese Large Black-white and Landrace cross 
hogs in Guangdong Province. The average daily gain response was more prominent in Fl 
(+15.32%) than the Grading-up F2 (+11.26%). However the latter had much less backfat (-19.15%) 
and much more lean tissue (+17.00%) than the former (-10.54% and +9.77%, respectively) in 
response to PST treatment. 
Porcine somatotropin was also administered to 48-Beijing Black finishing hogs in Beijing. The 
pigs fed 18% crude protein in diet had greater average daily gain, better feed efficiency and much 
more lean tissue than those fed 16% and 14% crude protein in response to PST treatment. 
The results show that the Chinese breeds of hogs can be greatly improved in terms of greater 
gain, better feed utilization, less backfat and greater lean meat with PST treatment. 
Keywords: somatotropin, swine, growth rate, feed efficiency, China. 
Introduction 
Pork is the most important meat for Chinese people so far. The total number of pigs is over 300 
million in this country. However, China has a large population and the pork production, especially 
the lean meat, can not meet the needs of the people with their living level on the increase. The grain 
yield per capita in China is much lower than that in developed countries so they need to increase the 
feed efficiency and lean meat percentage of the Chinese pigs which are much lower than that in the 
American and European breeds. Of course, the Chinese breeds mature earlier and have higher 
fertility rate. It seems to be a good suggestion to enhance Chinese pig performance by 
administrating porcine somatotropin, besides by means of breeding and improvement. With this 
idea in mind, we have conducted experiments in Guangdong Province and Beijing. 
Materials and methods 
In Guangdong experiment, two groups of crossbreds between Chinese Black-white and 
Landrace were available. The first batch was the cross (Fl), consisting of 45 barrows and gilts, with 
an initial average weight of about 30 kg; the second batch was Landrace Grading-up (F2), 
consisting od 46 castrated barrows and gilts, with an initial average weight of about 31 kg. The 
crude protein content of the diet was 16%. The PST group was administered intramuscularly 4 mg 
per day for 70 days. The amount of feed consumed was measured every day. The pigs were weighed 
every two weeks. All the pigs were slaughtered after 77 days of the experiment. 
In Beijing experiments, three groups of Beijing Black finishing hogs were fed diets containing 
14,16 and 18% crude protein; there were 36,36 and 24 castrated barrows and gilts in these groups. 
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The initial average weight was 67 kg. The PST hogs of each group were administrated 
intramuscularly 2 mg per day for 28 days. The pigs were weighed every week and slaughtered on 
29th day. 
All the carcasses were dissected according to a standard commercial dissection method. 
Results 
Experiment on Chinese Large Black-White and Landrace cross: 
The average daily gain response was more prominent in Fl than that of the Grading-up F2, but 
the latter had much less backfat and much more lean tissue than the former (Table 1). 
Table 1, Production performance and carcass quality of Chinese large Black-white and Landrace 
cross by treatment (PST; 4 mg for 70 days). 
Group 1 
Group 2 
Crossbreed (Fl) 
Average Dally Gain (g) 
Feed Efficiency (kg/kg) 
Backfat Thickness (cm) 
Lean Meat Percentage 
Gradlng-up (F2) 
Average Dally Gain (g) 
Feed Efficiency (kg/kg) 
Backfat Thickness (cm) 
Lean Meat Percentage 
PST 
n=22 
512 
3.48 
2.77 
56.83 
n=22 
494 
3.41 
2.28 
59.68 
Control 
n=23 
444 
4.07 
3.10 
51.77 
n=24 
444 
4.00 
2.82 
51.01 
Dlfference% 
+15.32 
-14.50 
-10.65 
+ 9.77 
+11.26 
-14.75 
-19.15 
+17.00 
Experiment on Beijing Black finishing pigs: 
The pigs fed 18% crude protein level had greater average daily gain, better feed efficiency and 
much more lean tissue than those fed 16,14% crude protein levels (Table 2). 
Table 2. Production performance and carcass quality of Beijing Black finishing hogs by treatment (PST; 
2 mg for 28 days). 
Group 1 
Group 2; 
Group 3 
(14% crude protein) 
Average Dally Gain (g) 
Feed Efficiency (kg/kg) 
Backfat Thickness (cm) 
Lean Meat Percentage 
(16% crude protein) 
Average Dally Gain (g) 
Feed Efficiency (kg/kg) 
Backfat Thickness (cm) 
Lean Meat Percentage 
(18% crude protein) 
Average Dally Gain (g) 
Feed Efficiency (kg/kg) 
Backfat Thickness (cm) 
Lean Meat Percentage 
PST 
n=18 
940 
3.70 
2.38 
56.3 
n=18 
1029 
3.41 
2.49 
57.4 
n=12 
1050 
3.19 
3.03 
55.5 
Control 
n=18 
817 
4.35 
2.70 
52.8 
n=18 
867 
4,20 
2.76 
52.7 
n-12 
860 
4.11 
3.33 
48.5 
Dlfference% 
+15.1 
-15.0 
-11.9 
+ 6.6 
+18.7 
-18.8 
- 9.8 
+ 8.9 
+22.1 
-22.4 
- 8.9 
+14.4 
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Discussion 
According to the experiments, the Chinese breed pigs which have a slower growth rate, less 
efficient feed utilization, more fatty tissue and less lean tissue are more responsive to porcine 
somatotropin. 
From the results, it is worthwhile for Chinese breed pigs to use porcine somatotropin to increase 
daily gain, feed utilization and lean meat and to decrease backfat to meet the demands of marketing 
at home and abroad. 
These studies have demonstrated the potential of PST to improve the performance and carcass 
composition of crosses of Chinese breeds with leaner Western breeds. The Chinese breeds are 
typically slow growing, inefficient converters of feed, fat, light muscled and early maturing. They 
are also very prolific and certain breeds are known for sweet-tasting meat. 
The Chinese are very interested in improving pigs in their country to reduce the need for 
imported feed sources and to improve the public diet by reducing fat intake. Many Western 
countries are interested in improving the reproductive efficiency of the typical Western breeds. 
It has been shown that PST administration to a Chinese Western crossbreed (Beijing Blacks) 
improves performance and reduces fat thickness if dietary protein is adequate. Many countries are 
interested in utilizing the Chinese breeds to take advantage of the prolificacy of these breeds. 
However, use of these breeds causes a proportional sacrifice in performance and carcass traits. This 
trial demonstrated that by using a grading-up F2, the maternal lines used to produce the commercial 
pigs were 1/2 Chinese and 1/2 Western breeds. In this way, great advantage of the reproductive 
ability of the Chines pigs was realized with only 1/4 of the terminal pigs being Chinese, thereby 
causing minimal decrease in the level of performance and carcass measures. Use of PST in these F2 
pigs during the growing-finishing phase caused a restoration in these traits up to the levels generally 
seen with crossbred Western pigs. 
This set of trials proved that PST has positive effects on crosses of Chinese and Western breeds 
to obtain reproductive improvements without sacrificing performance and carcass measures. 
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DIRECT MODIFICATION OF THE LIVESTOCK GENOME 
Thomas E. Wagner, Ph.D. Director 
Edison Animal Biotechnology Center, Ohio University Athens, Ohio 45701 U.SA. 
Summary 
Current methods for introducing genes into the germline of laboratory and livestock animals are 
reviewed. These methods include direct gene transfer by pronuclear microinjection or of fertilized 
eggs, infection of embryos by retroviral vectors, and the production of animals from totipotent 
embryonal stem cells grown in continuous culture. Although transgenic livestock (pigs) have, to 
date, only been produced by pronuclear microinjection, an embryonal stem cell line from porcine 
embryonic cells is described for use in the production of transgenic or clonal swine. The phenotypic 
characteristics of transgenic swine expressing growth hormone are discussed in detail including the 
positive characteristics of 50% or greater reductions in body fat and 30% or greater increases in 
feed efficiency and the negative effects of increased structural difficulties and stress susceptibility. 
It is suggested that the negative effects of growth hormone expression in transgenic pigs may be 
overcome by controlling the time of expression of growth hormone to only a portion of the life of 
these animals. With this goal in mind chimeric genes containing the P-enolpyruvate carboxykinase 
(PEPCK) promoter ligated to the structural gene for bovine growth hormone (bGH) were 
introduced into the germlines of mice and pigs. Results confirm that growth hormone expression in 
these animals does not occur during embryonic development and may be controlled by diet. Diets 
high in carbohydrate reduced the concentration of bGH in mice to 5% of basal levels and refeeding 
a diet high in protein but devoid of carbohydrate resulted in a 20-fold increase in serum bGH within 
one week. Studies of the control of bGH expression by diet are in progress in the pig, but 
PEPCK/bGH transgenic pigs do not show the many of the disabilities of transgenic pigs expressing 
growth hormone under the control of a constitutive promoter. 
Keywords: gene transfer, growth, swine, regulation promoter. 
Introduction 
Traditionally, improvement in livestock production has centered around breeding programs 
which take advantage of spontaneous mutations in the animal's genome. Selective breeding 
programs, because they do not require any knowledge of the physiological basis of the desired 
phenotype, can be successful without an understanding of the molecular basis of a trait. But, such 
approaches to animal improvement require decades or centuries to achieve their goals. 
With an increased understanding of the physiological and molecular basis of performance traits 
in animal, new approaches to animal improvement are now possible. One very effective approach 
is the administration of a key physiological modifying intermediate, such as a hormone, to the 
growing animal. The administration of somatotropins to livestock is the subject of this symposium 
because of the dramatic improvement in livestock performance demonstrated as the result of 
somatotropin administration by many of those gathered here. But, modification of the genome of 
the animals to "deliver" somatotropins naturally within the permanent make-up of the animals 
might be an even more effective, convenient and acceptable means of livestock production 
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improvement. The emergence of transgenic animal technology has provided the means to attempt 
improvement of livestock by direct genome modification. 
Contrary to common opinion, the ability to insert a genetic sequence into the germ line of 
animals is only one of several technological hurdles necessary to overcome prior to producing 
useful and practical transgenic livestock. For most applications it is necessary to not only express 
the transgene within the animal but to regulate the expression to specific target tissues and during 
the life cycle of the animal. Such exquisite control of transgene expression has not yet been 
achieved in the laboratory animals let alone livestock, but some important progress towards this 
goal has been achieved. In the ensuing text a review of the present state of the science of transgenic 
animals is presented. This presentation is divided into three sections: (1) gene transfer technology, 
(2) control of tissue specific expression and (3) external regulation of transgene expression. 
Gene transfer technology in animals 
Transgenic animals may be produced by the introduction of discrete genetic sequences into the 
permanent chromosomal composition of animals by three different methods including pronuclear 
microinjection of one cell fertilized embryos, infection of embryos by viral vectors and the 
production of germline chimeras from embryonal stem (ES) cells containing added genes. Since a 
thorough review of these methods has recently been published by the author (Strojek and Wagner, 
1988), the important features of these procedures are reprinted here. 
The term "transgenic" was introduced originally by Gordon and Ruddle (1988) for mice which 
had integrated a foreign gene into all somatic tissues examined. This had been achieved by injecting 
these genes into the pronuclei of fertilized mouse ova. Since it became evident later (Wagner et al., 
1981) that the offspring of these mice can inherit the foreign genes in a Mendelian fashion, the word 
transgenic is now commonly used to refer to a stable germ line integration of foreign genes. At 
present three different approaches have been reported which succeed in the establishment of 
transgenic mouse lines. These methods include pronuclear injection of DNA, infection of 
embryonal stages with recombinant viral vectors and the production of germline chimeras which 
consist partially of totipotent, genetically transformed, cell lines. 
Pronuclear Injection 
Several groups (Wagner et al., 1981; Gordon et al., 1980; Wagner, Stewart and Mintz, (1981); 
and Constantini and Lacy, 1981) were involved in the establishment of this method of gene transfer 
showing that by using this technique integration of the introduced foreign gene into all somatic and 
also into the germ cells of the developing animal can be achieved. In order to achieve optimal 
results, approximately 1 pi of a DNA suspension containing 200 to 2000 linearized copies of the 
foreign gene is injected into either pronucleus of fertilized mouse eggs (Brinster et al., 1985). After 
overnight cultivation cleaved eggs (50% to 75%) are transferred to the oviducts of foster mothers. 
Of these 10% to 25% usually develop to term and about 15% to 37% of the born young inherit the 
injected genes, which leads to an overall efficiency rate of 1% to 4% based on the total number of 
zygotes manipulated. 
Provided the introduced genes are integrated into the genomic DNA before the zygote enters 
cleavage, all embryonal cells will contain the same integration site and copy number of the foreign 
gene. Integration after the first cleavage will give rise to chimeric animals, which consist of at least 
two genetically different cell populations. According to Wilkie, Brinster and Palmiter, (1986) the 
latter seems to be true in at least 30% of the mice born after microinjection of DNA. 
Infection of Embryos by Viral Vectors 
Infection of blastocysts by SV40 (Jaenisch and Mintz, 1974) was the first evidence that foreign 
genes could be integrated into the genome of embryonal cells and lead to their stable integration 
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into somatic tissue. Jeanisch (1976) also observed that the M-MuLV provirus was not only retained 
by somatic cells after embryonal infection but was also transmitted to the offspring of the resulting 
mature mice. 
Viral infection of the preimplantation embryo is naturally prevented by the existence of the zona 
pellucida. This barrier can be overcome by either enzymatic digestion of the zona, so that 2-cell to 
morula stages can be infected (Jaenisch, Fan and Croker, 1975; Rubenstein, Nicholas and Jacob, 
1986) or direct microinjection of virus particles into the blastocoel cavity (Jaenisch and Mintz, 
1974). This procedure has been used successfully to introduce proviruses into the germ line of mice. 
However, the resulting embryos generally are mosaic, as different integration events can take place 
in a variable number of embryonal cells (Jaenisch et al., 1981). 
To transfer foreign genes into the germ line of mice, recombinant retroviral vectors can be used 
which contain the gene of interest. Since recombinant retroviruses generally are replication 
incompetent, they require the presence of helper virus f or propagation. Stublmann et al. ( 1984) have 
thus infected day-9 mouse fetuses with recombinant and helper virus simultaneously and observed 
subsequent integration and expression in the resulting offspring. However, their results suggested, 
that the superinfection with helper virus in these mice had interfered with the spread of the 
recombinant virus and therefore limited the number of transformed somatic cells. 
collection of fertilized 
oocytes 
DNA suspension 
microinjection 
cleavage 
transfer to foster mothers 
Figure 1, Pronuclear Injection of DNA. 
(Reprinted, with permission, from Generic Engineering, Principles and Methods, Vol. 10, Edited by Jane 
K. Setlow) 
79 
WAGNER 
As Separation of recombinant and helper virus yet cannot be achieved, an alternative 
propagation method using psi-2 cells (Mann, Mulligan and Baltimore, 1983) can be chosen if 
viremia from the helper virus is to be avoided in the resulting animals. Psi-2 cell lines have 
incorporated a retroviral genome which cannot be packaged into virus particles itself because of a 
mutation in its psi-region, but it delivers all the information needed for the propagation of 
recombinant virus with an intact psi-region to the cell. Consequently, the yield of recombinant virus 
will be lower in these cell lines, but is not accompanied by the production of helper virus. 
Van der Putten et al. (1985) and Rubenstein, Nicholas and Jacob (1986) have infected 
pre-implantation mouse embryos with recombinant replication-incompetent retrovirus without the 
use of helper virus. 197 denuded 8-cell stages cultivated over psi-2 monolayers for 16 hours and 
subsequently transferred to foster mothers gave rise to one animal which had incorporated the 
recombinant provirus including the foreign gene and transmitted it to its offspring (Van der Putten 
et al., 1985). Rubenstein, Nicholas and Jacob (1986) co-cultivated 278 4 -cell-stage mouse embryos 
over psi-2 cells and obtained 76 (30%) live fetuses after transfer, of which one contained the 
recombinant provirus. 
a.) Infection of Early Cleavage Stages 
collection of cultivation over transfer to 
early cleavage stages virus producing cells foster mother 
b.) Infection of Blastocysts 
transfer to foster mothers 
Figure 2. Infection of embryos with viral vectors. 
(Reprinted, with permission, from Genetic Engineering, Principles and Methods, Vol. 10, Edited by Jane 
K. Setlow) 
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Production of Germline Chimeras 
Chimeras can be produced either by aggregating two embryos or by injecting embryonal cells 
into expanded blastocysts, a procedure that results in the formation of individuals which consist of 
two or more genetically different cell lines (McLaren, 1976). When totipotent embryonal cell lines, 
which can be grown in culture for many generations, are genetically transformed before using them 
for chimera formation, this technique offers another route of producing transgenic animals, 
provided that the transformed cells will participate in the formation of germ cells. 
The first embryonal cell line used for this purpose were murine embryonal teratocarcinoma 
(EC-) cells (Watanabe, Dewey and Mintz, 1987). However, these cells appeared to have the 
disadvantage of showing a tendency to loose their euploidy during the in-vitro cultivation process 
and therefore loose their totipotency, especially to contribute to the germ line. Also the development 
of abnormal fetuses was observed in EC-cell derived chimeras (Rossant and McBurney, 1982). 
More stable results can be obtained with embryonal stem ES-cells (Evans and Kaufman, 1981), 
which can be isolated from in vitro attached mouse blastocysts and grown in culture for many 
passages. After microinjection of EK-cells into expanded mouse blastocysts, Bradley et al. (1984) 
obtained an average birth rate of 70%; about 50% of the born young proved to be chimeric, of which 
20% also showed germ line chimerism. Stewart, Vanek and Wagner, (1985) aggregated 8-cell-stage 
mouse embryos with ES-cells and received birth rates of 36%, 20% of the pups being chimeric. The 
successful us of genetically transformed ES-cells (Stewart, Vanek and Wagner, 1985; Robertson et 
al., 1986) led to the expression of the transferred genes within somatic tissues of the chimeric 
animals. Robertson et al. (1986) injected 10 to 12 ES-cells, which had been repeatedly exposed to 
psi-2 cells for transfection and selected for transformation, into expanded mouse blastocysts. Out of 
21 mice born after transfer 20 proved to be chimeric, of which two were reported to have transgenic 
offspring. According to Evans (1987), 20% to 30% germ line chimerism can be achieved by this 
method. 
A very critical step in this approach of producing transgenic animals is the successful 
transformation of the ES-cells. There are several possibilities to introduce foreign genes into the 
genomes of these cells with variable degrees of efficiency and technical equipment and skill 
required. The calcium-phosphate-precipitation method, which is comparatively simple, yields only 
very few transformants (frequency 10 " to 10 " ), but can be used if large numbers of totipotent cells 
are available (Pellicer et al., 1980; Lovell-Badge, 1987; Lovell-Badge et al., 1985). 
One alternative method to transform EC- of ES-cells more efficiently is the use of recombinant 
retroviruses (Stewart, Vanek and Wagner, 1985; Robertson et al., 1986; Rubenstein, Nicholas and 
Jacob, 1984). Rubenstein, Nicholas and Jacob (1984) infected EC-cells with psi-2 cell propagated 
recombinant retrovirus and demonstrated that 1 of 250 EC-cells had incorporated the retrovirus 
without observing any further multiplication of the virus in these cells. The efficiency of this 
retrovirus-mediated transformation method can be further increased depending on the infectivity 
and the titer of the recombinant virus as well as on the time of exposure (Robertson et al, 1986). 
If retroviral infection cannot be established for some reason, microinjection of DNA into the 
nuclei of totipotent embryonal cells offers a third most effective but cumbersome method of gene 
transfer with a frequency of 10 "2 to 1 (Lovell-Badge, 1987). 
Control of tissue specific expression 
Most transgenic animals produced to date or planned for agricultural use utilize fusion genes 
composed of genetic regulatory regions from one or more genes fused to the structural gene coding 
for the protein product desired to be delivered to the resulting transgenic animal. One of the 
purposes of the regulatory regions of these fusion genes is to direct expression of the transgene 
product to a specific tissue or group of tissues within the animal. Tissue specific expression of a 
constructed fusion gene was first demonstrated by Ornitz and coworkers (1985) who linked the rat 
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elastase regulatory region to the human growth hormone structural gene and produced transgenic 
mice expressing growth hormone exclusively in the pancreas. Since then, much transgenic research 
has focused on the development of fusion genes which contain the information necessary for tissue 
specific expression patterns. Although eukaryotic gene regulation, especially in mammals, remains 
unclear in many respects, in particular when the involvement of cell specific trans-acting factors is 
considered, some cis-acting elements have been found to provide tissue specific expression in 
transgenic mice when fused to structural genes. These elements, termed tissues specific enhancers, 
are discrete DNA sequences which, apparently, interact with some protein factor in specific tissues 
to "open" or activate the promoter of the associated fusion gene. In the absence of this factor, in 
non-target tissues, these sequences may block or repress the action or the promoter. Some examples 
in which gene expression was strictly directed into promoter specific tissues in transgenic animals 
are listed in Table 1. 
Table 1. Promoter Specific Expression of Foreign Genes In Transgenic Mice 
Promoter Structural Gene Reference 
elastase I 
(rat) 
elastase I 
(rat) 
myosln-L-chaln 
(rat) 
beta-globln 
(human) 
beta-globln 
(mouse) 
Insulin II 
(rat) 
alpha-a-crystallln 
(mouse) 
alpha-l-collagen 
(mouse) 
Insulin 
(human) 
skeletal muscle actin 
(rat) 
whey acidic protein 
(mouse) 
delta-crystalling 
(chicken) 
alpha-J-arrtttrypsIr» 
(human) 
pancreatic amylase 
(mouse) 
elastase I 
(rat) 
growth hormone 
(human) 
myosln-L-chaln 
(rat) 
beta-globln 
(human) 
beta-globln 
(human) 
SV40 T antigen 
CAT 
(prokaryotlc) 
CAT 
(prokaryotlc) 
Insulin 
(human) 
epsllon-globln 
(human) 
Ha-ras oncogene 
(human) 
delta-crystallln 
(chicken) 
alpha-l-arrttttypsln 
(human) 
pancreatic amylase 
(mouse) 
Swift et al„ 1984 
Omltzetal., 1985 
Shanl, 1985 
Townesetal., 1985 
Chadaetal., 1985 
Hanahan, 1975 
Overbeek et al., 1985 
Khlllanetal., 1986 
Bucchlnl et al„ 1986 
Seiden et al., 1986 
Shanl, 1986 
Andres et al.. 1987 
Kondoh et al., 1987 
Slfersetal., 1987 
Osborn et al., 1987 
External regulation of transgene expression 
Often, for livestock applications, it is not sufficient to regulate the expression of the transgene to 
a specific tissue or set of tissues since the continued expression of the transgene is detrimental to the 
animal. An excellent example of this problem is provided by growth hormone transgenic pigs. 
While pigs injected with growth hormone for discrete periods of their growth phase remain healthy 
and differ significantly from untreated pigs only in performance traits, which are improved (Chung, 
Etherton and Wiggins, 1985; Etherton et al., 1986), transgenic swine expressing growth hormone 
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continuously in several tissues throughout the animals life cycle display gross abnormalities 
(Pursel, 1987; Hammer et al., 1986). On this basis, it seems likely that external regulation of a 
growth hormone transgene in swine, and, perhaps, other livestock species, allowing expression of 
the gene only during the preferred period, would result in improved and highly useful animals for 
agriculture. An experiment involving the external regulation of a growth hormone transgene in mice 
and pigs, performed in our laboratory recently, serves as a good example of the value of external 
regulation of transgene expression. 
a.) Aggregation of Cleavage Stages with ES-Cells 
-ee© 
8333=^0-
aggregates compacted 
morula 
^_( A
 fc transfer tn 
V ^ / foster mothers 
blastocyst 
b.) Injection of ES-ceils into Blastocysts 
transfer to foster mothers 
Figure 3.Productlon of chimeras with transformed totipotent cells. 
(Reprinted, with permission, from Genetic Engineering, Principles and Methods, Vol. 10, Edited by Jane 
K. Setlow) 
The gene for the cytosolic form of the gluconeogenic enzyme, P-enolpyruvate carboxykinase 
(GTP) E.C.4.1.1.32 (PEPCK) in most mammalian species is expressed primarily in the liver and 
kidney cortex (Machlin, 1972; Johnsson, Hart and Butler-Hogg, 1985). This enzyme is generally 
regarded as catalyzing the pace setting step in hepatic gluconeogenesis (Eisemann et al., 1986). In 
all mammalian species, PEPCK is absent during fetal development and appears initially at birth 
(McKeith, 1987; Pursel, 1987) when the transcription of the gene is markedly stimulated by the 
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rapid fall ia the concentration of blood glucose in the neonate (Hammer et al., 1986). The rate of 
synthesis of the enzyme is regulated by hormones such as glucagon (acting via cAMP), 
glucocorticoids and thyroxine, which increase its synthesis and by insulin which markedly 
suppresses the synthesis of the enzyme (Nordlie and Lardy, 1963; Hanson and Mehlman, 1976; 
Rognstad, 1979). The major point of regulation of the expression of the PEPCK gene is at the level 
of gene transcription, which is rapidly altered by the hormones mentioned above (Ballard and 
Hanson, 1967; Yeung and Oliver, 1968). The gene for the enzyme has been isolated (Girard, Bol 
and Asson, 1972), the cDNA sequence (Tilghman et al., 1974; Gunn et al., 1975) and the 
promoter-regulatory region characterized by a systematic series of deletions through the first 400 
BP of the 5' flanking DNA (Tilghman et al., 1976, Lamers, Hanson and Meisner, 1982). This 
segment of DNA contains a cAMP regulatory element at -80 to -91, two putative glucocorticoid 
regulatory elements and an insulin responsive region (Lamers, Hanson and Meisner, 1982). This 
region of DNA contains multiple binding domains for specific proteins which control the complex 
pattern of expression characteristic of the PEPCK gene (Granner et al., 1983). 
Recently, we reported that 450 bp of the promoter-regulatory region of the PEPCK gene can 
drive the specific expression of the bGH structural gene in the liver and kidney of transgenic mice 
(Yoo-Warren et al., 1983). A series of mice were produced in these experiments, which contained 
serum bGH levels ranging from a low of 5 ng/ml to more than 2000 ng/ml. Mice with high rates of 
bGH production were often double the weight of their littermates which did not contain the 
transgene. Furthermore, expression of the chimeric PEPCK/bGH gene was regulated by diet and by 
hormones in a manner predicted from our previous studies on the expression of the endogenous 
PEPCK gene in rat liver (Beale et al., 1985). Feeding animals a diet high in carbohydrate for one 
week caused a 90% reduction in the concentration of bGH in the serum, suggesting that the 
regulation of the chimeric PEPCK/bGH gene is sensitive to insulin. Furthermore, when the same 
animals were re-fed a diet high in protein devoid of carbohydrate, the concentration of bGH in their 
protein devoid of carbohydrate, the concentration of bGH in their blood was induced by 30-fold in 
a week. The administration of Bt2cAMP to transgenic mice cause a 2-3 fold induction of bGH in 
the serum within 90 min. The animals all appear healthy and are reproductively active. More 
recently, the total absence of bGH messenger RNA in any tissue of these transgenic mice during all 
stages of embryonic development and before birth has been confirmed by sensitive Northern 
hybridization analysis. 
Thus, the PEPCK promoter-regulatory region seems to be an excellent vehicle for acutely 
regulating the tissue specific expression of linked structural genes, when introduced into the germ 
line of animals by microinjection into the male nucleus of the one cell embryo. Through the use of 
the native PEPCK promoter-regulatory region or specific modifications of this region allowing 
absolute regulation of any structural gene fused adjacent to these sequences, it may be possible to 
generate transgenic animals which will not express their transgene product until they are fed a diet 
devoid of carbohydrate. These animals might then harbor "dormant" transgenes which otherwise 
might be lethal, debilitating or restrictive to reproduction. Such animals might be of real value as 
research tools. 
The success with the mouse system regulated by the PEPCK promoter-regulatory region 
suggested its potential value in transgenic livestock applications as well. In order to produce 
transgenic swine with a phenotype mimicking the performance traits of swine injected with the 
growth hormone protein, a linear fragment containing the PEPCK-bGH gene (Yoo-Warren et al., 
1983) was injected into the pronuclei of fertilized swine eggs and over 100 swine were produced. 
The approximate number of integrated PEPCK-bGH gene sequences in these animals was 
determined by dot hybridization and positive animals were demonstrated to contain the integrated 
sequences with copy numbers ranging from 1 to 200 copies per cell. Over 20 transgenic animals 
showed significant levels of bovine growth hormone protein in their circulating serum, with 
concentrations ranging from 5 ng/ml to 200 ng/ml, as determined by radioirnmune and ELISA 
assays. These animals showed remarkable improvements in performance traits including a 30% 
increase in the efficiency of feed utilization and a greater than 65% decrease in back fat, while 
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remaining healthy and free from any infirmities well beyond market weight. They also have been 
proven to be reproductively normal. 
These experiments demonstrate that, when appropriately regulated, genes transferred into the 
germline of agricultural animals can have a profound and positive effect on animal performance and 
the economics of animal husbandry. During the last several years, studies in mice have proven that 
transgene expression may be regulated as to the time and tissue of choice. Application of these 
principles, through the use of the PEPCK promoter/regulatory element, has resulted in the 
production of lines of transgenic swine with increased economic efficiency (feed:gain ratios) which 
produce a leaner meat product. In economics of swine husbandry, animals like these could have a 
significant positive influence on the health of the consumer of pork products, since the U.S. 
National Academy of Sciences has recently reported that the consumption of excessive animal fat 
is the most significant contributor to diet-related disease in the U.S. and probably many other 
countries (Cook et al, 1986). 
The growth hormone transgenic swine serve as an example of the potential of transgenic 
livestock in agriculture. Applications of the technology to increase disease resistance and enhance 
prolificacy in a wide variety of livestock, in addition to enhancing growth characteristics are 
underway in several laboratories throughout the world. The ability to externally regulate the 
transgene in transgenic livestock using systems like the PEPCK regulatory region enhances the 
potential of producing useful and practical transgenic livestock. 
Future prospectives 
If the technology to introduce and appropriately regulate transgenes in livestock becomes 
perfected in the near future, it will have a major impact upon animal breeding. With transgenics it 
should be possible to select animals with native genomic traits which are more supportive of 
transgenic effects yielding an animal superior to both an unselected transgenic and a "classically" 
bred animal. The combination of transgenic technology and established selective breeding methods 
appears to offer unique opportunities for the animal breeder and suggests a resurgence of basic 
research in animal breeding. 
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SOMATOTROPIN RELATED TECHNOLOGIES: IMPLICATIONS FOR 
PIG BREEDING 
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6700 AH Wageningen, The Netherlands 
Summary 
The use of present and future biotechnological techniques for control of growth and body 
composition will have important implications for pig breeding programs. This can be expected from 
somatotropin related technologies in particular, because of the marked positive effects of 
somatotropin on feed conversion ratio and body composition. In this paper the implications of 
porcine somatotropin (PST) administration and the use of animals which are transgenic for 
somatotropin genes are considered. 
Administration of PST on a large scale may have indirect consequences for selection intensity 
and genetic response. Breeding goal traits and their economic values have to be re-evaluated. In 
case of interactions between genotype and PST administration it is recommended to administer PST 
to nucleus animals during performance tests. Genetic and phenotypic parameters (heritabilities and 
correlations) should be re-estimated. 
PST can open new possibilities for introduction of very prolific (Chinese) breeds as dam line in 
the breeding program. Negative impact of Chinese genotypes on carcass composition can be 
counteracted by PST administration. PST will increase the optimum slaughter weight and so 
decrease the number of pigs to be produced per year if the total pork production is fixed. As a 
consequence fewer commercial sows are needed and production costs will decrease. 
Successful transfer of the somatotropin gene into the germ line of pigs will eventually have 
implications for growth and body composition similar to PST administration. In addition, however, 
the use of transgenic pigs will have enormous implications for the breeding strategy in the nucleus. 
Variation between the produced founder transgenics is expected to be high and many animals will 
have to be culled because of negative characteristics. The remaining transgenics should be utilized 
for breeding very intensively, giving problems of small population sizes. The optimum breeding 
strategy depends on whether homozygosity is desired in the commercial end product and whether 
introduction of other foreign genes can be continued successfully in lines that are already transgenic 
for a somatotropin gene. 
It is concluded that development and introduction of transgenics in the nucleus of a pig breeding 
program is very capital and research intensive. This can only be successful by combining the efforts 
in joint ventures of breeding organizations. 
Keywords: somatotropin, transgenics, pig breeding, biotechnology. 
Introduction 
Animal improvement by human beings has already a long history. As symbolized in Figure 1, 
(after Skjervold, 1976) genetic improvement occurs partly in steps and partly as gradual progress. 
Starting as hunters, man selected some of the animal species for domestication. During many 
centuries these species have been gradually changed and improved by means of selection and 
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adaptation to the environment and care that man offered his animals. Different breeds and strains 
emerged because of geographical isolation and different selection directions. Crossbreeding created 
new ways for improvement by utilization of heterosis. Some examples of inter-species crossing are 
known, such as horse and donkey but, fitting into the definition of a species, their progeny is not 
fertile. At present it is possible to transfer single genes from one species to another (Palmiter et al., 
1982; Hammer et al., 1985). Some of the resulting transgenic animals are fertile and some are not 
(Pursel, 1987). It is conceivable that it will be possible and worthwhile in future to combine several 
kinds of favourable genes into one new species. In the last 50 years most of the genetic 
improvement came and now still comes from intensive selection of better genotypes in purebred 
lines. Developments in artificial insemination and embryo handling increase selection intensity and 
contribute strongly to that improvement. 
Progress 
Inter species 
crossbreeding A
 5 
Inter lines 
crossbreeding 
99 
Gene transfer 
(New species) 
3. Gain due 
to selection 
2. Selection of strains 
1. Selection of species 
Time 
Figure 1. Schematic representation of genetic progress with different methods, after Skjervold (1976). 
Length of arrows Is not related to relative progress. 
Genetic values for traits which are controlled by many genes, such as growth, feed conversion 
ratio and slaughter quality can normally not be measured because of the inability to identify all 
single genes and gene combinations in question. Therefore, estimation of breeding values and 
selection is based on phenotypic information from the potential breeding animals themselves and 
from relatives. Smith (1984) showed that the rate of genetic change is in the range of 1 to 3 % per 
year for most economic traits. The accuracy of selection increases by the use of more phenotypic 
information. However, with present selection methods it is inevitable that apart from favourable 
genes also a proportion of unfavourable genes is carried over to the next generation. 
By means of biotechnology it is now possible to change specific single genes or gene products. 
One of the genes that can play a major role in further improvement of production traits in pigs is the 
somatotropin gene. Together with somatotropin releasing factor, somatomedins and somatostatin, 
somatotropin has a large impact on growth and body composition. The somatotropin gene has been 
cloned and transferred into bacteria and higher animal species, including swine. In the first case 
bacteria are activated to produce recombinant porcine somatotropin (PST) which can be 
administered to pigs. In the second case transgenic pigs produce the extra somatotropin themselves. 
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Although several other related biotechnologies for control of growth are available (Van der Wal, 
1988), this contribution is focussed on administration of PST and on use of animals which are 
transgenic for the somatotropin gene. Particularly concerning the administration of PST a lot of 
experimental data are available about effects on production performance. Transgenic pigs are a 
relatively new phenomenon and there is not a clear picture yet about effects on different aspects of 
production. 
For both technologies literature on implications for breeders and breeding programs is scarce. 
Concerning the impact of repartitioning agents on genetic improvement programs a review has been 
presented at the Pork Industry Conference in Illinois by McLaren (1987). Literature about 
implications of the use of transgenic animals (transgenics) in pig breeding programs was not found, 
although work by Smith et al. (1987) concerning use of transferred genes (transgenes) in livestock 
in general has many applications in swine. The purpose of this contribution is to consider the 
possible implications for genetic improvement of administration of PST and use of transgenic pigs 
in swine production. 
Administration of PST 
Effects of daily PST administration on production performance of fattening pigs are described 
by many authors (e.g. Chung et al., 1985; Etherton et al., 1987; Campbell et al., 1988). In general 
an increase in growth and carcass meat content and a decrease in feed intake, feed conversion ratio 
and carcass fat content are found in animals treated from 60 to about 100 kg live weight. There is 
evidence that effects are smaller in leaner animals (Hüster et al., 1988; Kanis et al., 1988a) and 
larger in animals treated till higher weights (Kanis et al., 1988a). Data from Boyd (1987) show that 
milk production of lactating sows and growth of nursing piglets can be significantly improved by 
daily treatment of lactating sows with PST. 
Present constraints for use of PST in practice are the facts that it is not yet approved and that no 
practical method for administration is available at the moment. Till now most results concerning 
PST are based on daily intra-muscular injections. However, in intensive pig production systems as 
in West-European countries, only one or two administrations per animal during the fattening period 
can be considered as practicable. If PST is approved and if a practical and effective method of 
administration is available at an acceptable price, then PST will have a substantial effect on total pig 
production. 
In this part of the paper implications of administration of PST are discussed for: 
- selection and genetic response, 
- possibilities for hyper-prolitie breeds, 
- slaughter weights. 
Implications for selection and genetic response 
Modern pig breeding programs have a more or less pyramidal structure (Figure 2) with a 
relatively small number of nucleus breeders on top who sell purebred animals or semen to 
multipliers that produce crossbred parents. From these parents crossbred piglets are produced by 
commercial producers who sell these piglets to the commercial fattening farms where they are 
fattened. Sometimes two layers (for example multiplier sows and fattening pigs) can be found on 
one farm. It should be realized that the bottom layer consists of the end products whose financial 
returns should balance all costs made in the total pyramid. 
It has been proved that genetic improvement in all layers of the pyramid (and so in the bottom 
layers of commercial producers) fully depends on the genetic improvement in the nucleus. 
(Bichard, 1971). The genetic lag (or time lag) between the lower layers of the pyramid and the 
nucleus depends on efficiency of the dissemination of genetic superiority from the nucleus through 
the pyramid. 
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figure 2. Production structure In pig breeding programs. 
Genetic response to selection in a nucleus line can be predicted by 
R = (i HHOH) / L 
where R = predicted genetic response per year, 
i = selection intensity, 
riH = selection accuracy, 
on = standard deviation of the breeding goal or aggregate genotype, 
L = generation interval in years. 
Administration of PST to fattening pigs does not create a genetic effect in itself, but may have 
indirect consequences for each of these four parameters or for the genetic lag between nucleus and 
fattening pigs. 
Selection intensity and genetic lag 
Use of PST in fattening pigs will not directly influence the selection intensity for replacement 
animals in a nucleus of fixed size. However, because of faster growth of fattening pigs, more 
slaughter pigs can be produced per year with fixed fattening facilities. Therefore, more commercial 
sows are needed and particularly in the dam lines, more nucleus females must be assigned for 
replacement of sows in lower layers of the pyramid. These extra sows will on average have a lower 
genetic superiority and therefore an increasing effect on the genetic lag between nucleus and 
fattening pigs. 
Use of PST in lactating commercial sows might result in shorter intervals between successive 
farrowings. Assuming a fixed nucleus size, no change in number of farrowings per sow and 
sufficient fattening facilities, this results in more commercial sows needed per year and an 
increasing genetic lag. 
The opposite happens if the amount of pork to be produced per year is fixed. Because of higher 
meat percentage per pig or a possibly higher slaughter weight with use of PST, the same amount of 
pork can be produced by fewer sows and slaughter pigs. With a fixed size of the nucleus this results 
in a shorter genetic lag. It should be realized, however, that eventually a decreasing number of 
slaughter pigs may also have a decreasing effect on the size of the nucleus dam lines. This will then 
result in lower total production costs. 
Selection accuracy 
The accuracy of selection depends on heritabilities, genetic and phenotypic correlations of the 
traits involved and on the amount of own performance data and information from relatives. It is 
unknown whether administration of PST has influence on heritabilities and correlations. For 
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instance, if PST is able to neutralize certain negative environmental effects, as is sometimes thought 
from antibiotics and feed additives, this may reduce phenotypic variation and thus increase 
heritabilities and selection accuracies. 
Use of PST in fattening pigs may cause genotype by environment interaction if the nucleus 
animals are not selected in a PST environment. This results in a lower selection accuracy because 
the breeding goal should be defined at the level of commercial fattening pigs (Merks, 1988). There 
fore, if PST would be generally used, it is recommended to administer PST during performance test 
in the nucleus in order to create an environment similar to that in fattening farms. In addition, 
because of faster growth in the nucleus more animals can be tested and selection intensity might 
increase. Another way to cope with this type of genotype by environment interaction is to base 
selection on information from PST treated relatives. 
It is not known whether administration of PST has impact on puberty and fertility of potential 
breeding animals. This is also relevant to commercial producers who practice rotational 
crossbreeding and select female replacements from the finishing pens (McLaren, 1987). Data from 
McLaren (1987) show that weights of ovaries and uteri of PST-treated gilts are significantly 
increased. Functional effects of these higher weights are unknown. 
In case of selection based on "on the farm testing", as is carried out in Dutch pig herdbooks to 
select females, the farmer can apply preferential treatment by administering PST to some animals 
only. If it is not recorded which animals are treated, then an unbiased estimation of breeding values 
is impossible and PST treated animals will be overestimated. If recording of PST treatment (and the 
doses used) is reliable, which is impossible to check, then corrections for these environmental 
effects could be carried out. For bovine somatotropin the potential impact on dairy sire evaluation 
has been simulated by Burnside and Meyer (1988). 
Aggregate genotype 
Use of PST may have important implications for the traits to be incorporated in the aggregate 
genotype (breeding goal) and the relative economic weight of each trait. Because PST has a 
decreasing effect on appetite, feed intake capacity will become of greater economic importance, 
whereas lean percentage will become less important because of its increased level. Furthermore, 
meat quality traits may get higher economic values because of lower intra-muscular fat contents 
(Beermann et al., 1988; McKeith et al., 1988). 
Although genetic differences for response to PST treatment may exist, it is probably not 
advisable to select for PST responsiveness in cases PST is used on a large scale. Kanis et al. (1988a) 
showed that, with respect to carcass composition, fatter breeds respond more to PST administration 
than leaner breeds. It is likely that also within breeds, animals with the highest response to PST have 
the highest genetic potential for fat production. Moreover, the response to PST administration in 
terms of improvement of production traits is hard to measure in individual animals. 
Generation interval 
Impact on generation intervals depends on effects of PST on age at puberty in young breeding 
stock and on intervals between subsequent farrowings in case lactating nucleus sows are treated. 
Moreover, a higher slaughter weight in commercial fattening pigs, if treated with PST (see part c, 
below) could ask for performance tests of nucleus animals till higher weights. However, because 
performance test will normally be finished before puberty is reached, it is not expected that PST has 
much influence on average generation intervals. 
Quantification of the potential implications above is difficult because of the many unknowns. 
Heritabilities, genetic correlations and genotype x environment interactions should be estimated in 
datasets of a large size with an appropriate genetic structure. Adaptations that are needed for 
optimization of breeding programs with use of PST can be sufficiently quantified only after 
introduction of PST on a large scale. Simulation studies may give some extra insight in the 
complications for breeding. It is foreseen that use of PST may change the ranking of breeding 
organizations for their final products because of different responses. Furthermore, efficiency of 
selection may be temporary decreased because of the use of unadapted genetic, phenotypic and 
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economie parameters. At this moment no great long term implications of the use of PST for genetic 
improvement are expected. 
Possibilities for hyper-prolific breeds 
Commercial fattening pigs are often produced as three- or four-breed crossbreds from 
specialized sire and dam lines. One of the main advantages of crossbreeding is utilization of 
heterosis which can be subdivided into genetic heterosis due to increased heterozygosity and 
sire-dam heterosis (Moav, 1966). Genetic heterosis is assumed to be positively correlated with the 
genetic distance between breeds. Genetic heterosis can be expected for production traits if the 
fattening pig is a crossbred, and for maternal traits such as litter size at weaning, if the dam is a 
crossbred. Sire-dam heterosis can be utilized by mating females with excellent fertility to males 
with good fattening and slaughter qualities. Relative to the average of both parental genotypes 
sire-dam heterosis will result in more piglets weaned of average production performance, giving a 
higher total economic merit. 
Currently, the use of hyper-prolific Chinese breeds in pig breeding programs is considered. 
Females of the Chinese Meishan breed produce three to four weaned piglets more per litter than 
French Landrace females (Sellier and Legault, 1986). However, daily gain and feed conversion 
ratio of Meishan pigs are unfavourable and the carcasses are very fat. Crossbreeding to European 
breeds may partly remove these negative characteristics. However, according to Gueblez et al. 
(1987) the increased productivity of various types of crossbred Chinese sows is insufficient to 
compensate for the poorer carcass merit of the offspring. 
Results from purebred Meishan fattening pigs treated with PST indicate that improvement in 
carcass composition is larger than in leaner breeds. (Kanis et al., 1988b). Particularly in cases of 
unacceptable carcass conformation, administration of PST to crossbred Chinese fattening pigs will 
improve carcass conformation so much that such a crossbreeding system becomes economically 
attractive. 
Possibilities for higher slaughter weight 
Results by Kanis et al. (1988a) show that with administration of PST from 60 kg live weight 
onwards, the response in carcass lean percentage in animals slaughtered at 140 kg was about double 
the response in animals slaughtered at 100 kg. Averaged over three genotypes, PST-treated animals 
had 4.4 and 8.7 % more carcass meat at 100 and 140 kg than control animals. The response for daily 
gain and feed conversion ratio was also much higher in the weight range from 100 to 140 kg than 
from 60 to 100 kg. Present work (unpublished) on growth curves indicates that PST-treated animals 
have a more persistent growth and that deposition of extra fat is delayed. Although, over the full 
range from 100 to 140 kg feed conversion ratio in treated animals is too high from an economic 
standpoint, PST makes it possible to slaughter animals at higher weights than the usual 100 kg, 
without excessive production of fat. Assuming a fixed amount of pork to be produced per year, this 
can then be done with less growing pigs and less sows at lower production prices. On the other 
hand, higher slaughter weights may require investments for adaptation of slaughter houses and 
subsequent meat processing chains. Computer simulation can help to determine the optimum 
slaughter weight from the viewpoint of production costs, costs of slaughtering and processing, 
production of manure and a shorter genetic lag between nucleus and commercial fattening pigs. 
In the points above it is assumed that PST is used as a routine in all situations where it can be of 
economic advantage. We should be aware, however, of a trend for an increasing consumers' interest 
for "naturally" produced pork. It may well be that eventually two categories of production systems 
and breeding programs can exist, with and without use of advanced (bio)technologies. 
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Transgenic pigs 
Literature 
Palmiter et al. (1982) were probably the first who published results on transgenic animals 
carrying extra somatotropin genes. Mice with the structural gene for rat somatotropin and the 
mouse metallothionein (MT) gene as promoter had a dramatically increased growth rate compared 
to littermate control mice. At present, an increasing number of publications is available on different 
farm animals, being transgenic for somatotropin genes from different species, fused to different 
promoter genes (e.g. Hammer et al., 1985; Wagner, 1988). A number of criteria (Kräusslich, 1986) 
and limitations (Renard and Babinet, 1987) for useful gene transfer in farm animals have been 
mentioned in the literature. Land and Wilmut (1987) stated that the favourable effect of a particular 
gene should be at least 10% to make transfection useful. 
Pursel (1987) defined a long-term research goal for insertion of the somatotropin gene into 
swine DNA as: "to produce transgenic boars that will transmit a controllable somatotropin gene into 
the genome of their progeny". Specific goals that must be achieved in sequential order to 
successfully achieve the long-term goal are: 1. Microinjection of a gene into the pronucleus; 2. 
Integration of somatotropin genes into the pig genome; 3. Expression of the integrated somatotropin 
gene; 4. Transmission of somatotropin genes to progeny; 5. Regulation of the integrated 
somatotropin gene. 
Recent research has clearly demonstrated that it is possible to achieve goals 1 to 4, however, 
several abnormalities in transgenic pigs have been observed (Pursel, 1987). It was concluded that 
tight control over the level of somatotropin production is essential to obtain only the positive effects 
of transferred somatotropin genes on growth performance. Wagner (1988) states that the 
Phosphoenolpyruvate carboxikinase (PEPCK) promoter offers great possibilities for external 
regulation (via the carbohydrate content of the diet) of transgene expression. Moreover, in contrast 
to for example the widely used MT promoter, the PEPCK promotor is only active after birth and 
primarily in the liver and kidney cortex. Pigs transgenic for PEPCK/BST (bovine somatotropin) 
showed remarkable improvements in performance traits, remained healthy and free from any 
infirmities well beyond market weight and have been proven to be reproductively normal (Wagner, 
1988). 
It can be concluded from the literature that the five specific goals presented by Pursel (1987) and 
given above are at least partly achieved on an experimental scale. However, the technology is at 
present far from perfect and a lot of problems have to be solved. Nevertheless, substantial progress 
is still being made and it can be anticipated that within a few years the long-term goal is achieved 
and that transgenic boars (and sows) become available with controllable somatotropin genes. With 
present techniques it is not possible to control the number of copies and the site of integration of the 
transferred gene in the genome of the receptor embryos. This may be a source of variation in 
expression of the transferred gene between transgenic animals and may also influence other 
characteristics. The question then is how to make optimal use of these animals in pig breeding 
programs. This question has been dealt with for livestock in general by Smith et al. (1987). In this 
paper their approach will be followed and applied to somatotropin transgenics in pig breeding. 
Breeding goal 
The aim of a breeding program with pigs that are transgenic for somatotropin is to produce 
commercial fattening pigs that are all transgenic for the somatotropin gene and have, therefore, a 
higher economic merit. It is assumed here that the general structure of breeding programs is 
maintained and that crossbreeding is still more economical than purebreeding. 
At this moment it is not clear whether it is desirable to produce fattening pigs that are 
homozygous for the extra somatotropin genes. If so, then both sire and dam lines should preferably 
be homozygous for the transgene. If not, then it is enough to have homozygous sire lines only. The 
number of copies seems not to be strongly related to the somatotropin level in the blood (Rexroad 
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et al., 1987). Therefore, it is assumed here that there is not much difference between homozygous 
and heterozygous animals and that heterozygosity for the transgene is sufficient in commercial 
fattening pigs. The specific goals then are to maintain and select one or more homozygous 
transgenic nucleus sire lines with better performance than the existing lines and to keep the genetic 
lag between nucleus and commercial as short as possible. 
If the developed transgenic founder pigs do not belong to a high performance sire line, then 
backcrossing to the existent sire lines with selection for the transgene may be considered. This 
process of introgression is similar to introduction of major genes as the Booroola gene in sheep or 
the gene for halothane insensitivity in swine (e.g. Smith, 1985). However, this is not likely to be an 
efficient procedure, because it should be possible to directly produce transgenic animals from 
existing high performing sire lines. Moreover, during introgression a new and better transgene may 
become available and the whole process should start again. Therefore, to make optimum use of new 
developments it should be possible to transfer better genes into animals that are already transgenic 
for another gene. 
Homozygous or heterozygous breeding stock 
It is assumed now that transgenic founder pigs are offsprings from the best parents of the sire 
lines and that they are heterozygous for the transgene (carry one copy or a tandem array of copies 
on one chromosome). Heterozygous animals will transmit the transgene to half of their progeny, 
whereas homozygous animals transmit it to all progeny. Therefore, if the transgene has a large 
effect on economic merit, the fastest genetic response can be obtained by making a homozygous 
line (Smith et al., 1987). With avoiding too much inbreeding this will take at least three generations 
during which time little selection for production traits can be done. This should be compared with 
the normal selection response of about two percent per year in pigs (Smith, 1984). 
For example in a three-way cross with a generation interval of one year, the economic merit of 
the transgenic should be at least six percent higher than of normal animals to make homozygosity 
worthwhile. In that case after three years, fattening pigs from heterozygous sires have on average a 
three percent higher merit because of transgenity plus six percent because of normal selection in 
sire and dam lines. After three years, fattening pigs from homozygous sires have six percent higher 
merit because of transgenity plus three percent because of selection in dam lines only. General 
formulas are given in Table 1. 
In a four-way cross a crossbred boar is used as sire of the commercial fattening pigs. Assuming 
that 25% of the crossbred male offsprings from two heterozygous sire lines carries transgenes from 
both lines (called homozygous) and can be separated from the 50% heterozygous animals, then only 
these homozygous boars should be used as sire to the fattening pigs. This means that extra parental 
animals are needed to produce the required number of crossbred boars, which reduces selection 
intensity. If homozygous animals can not be separated from heterozygous animals, then it may be 
considered to produce first homozygous sire lines in order to get 100% homozygous crossbred 
boars. In that case the transgene should increase economic merit by at least twelve percent to get 
better fattening pigs from homozygous (after four years) than from heterozygous purebred sire lines 
(Table 1). In both examples an extra benefit from using heterozygous sire lines, compared with 
waiting for homozygous sires, is that the first transgenic fattening pigs are produced much earlier. 
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Table 1. Dissemination of genetic progress with use of heterzygous vs. homozygous nucleus animals. 
Normal genetic progress Is a % per generation and effect of the transgene Is t_. Generation 0 
are the founder transgenics In the nucleus. 
Generation: 
Genetic level of growing pigs 
1 2 3 
Situation I: three way cross 
(A sire x BC dam) 
Direct use of heterozygous 
A sires and selection 
In line A, B and C 
Use of homozygous A sires, 
no selection In A during 
three generations 
Situation II: four way cross 
(AB sire x CD dam) 
Direct use of heterozygous 
A and B sires and of homo- and 
heterozygous AB sires 
Use of homozygous A and B sires, 
no selection In A and B during 
three generations 
a+.50t 2a+.50t 3a+.50t 4a+.50t 
,50a 1.50a+t 2.50a+t 
2a+.67t 3a+.67t 4a+.67t 
,50a 1.50a 2a+t 
Selection within transgenic lines 
Transgenic pigs have to be multiplied by selection and pure breeding, to develop a transgenic 
breeding pool or line (Smith et al., 1987). It could remain open for new transgenic animals, carrying 
the same or other transgenes. By means of normal testing and selection procedures the favourable 
transgenes will be fixed, while others will be gradually eliminated. The chance of fixing a transgene 
by selection for a quantitative trait depends on the effective population size, the selection intensity, 
the effect of the transgene and the initial transgene frequency (Smith et al., 1987). To increase the 
chance of fixation, laboratory tests with DNA probes should be used during the first generations of 
development. 
Although the five conditions given by Pursel (1987) have been met on an experimental scale and 
transgenic animals can be produced in reasonable numbers, it should be realized that many of the 
heterozygous and homozygous transgenics may not be useful as breeding stock in a pig breeding 
program. All transgenic animals should be tested and evaluated thoroughly on a large number of 
different traits before they can be used for breeding. Those traits are not only the normal production 
and reproduction traits, but concern for example also the requirements for housing, feeding and 
hygienic measures. Probably a second selection step is required where selection of transgenics is 
based on progeny performance. This has an increasing effect on the generation interval and so on 
the benefits of transgenics relative to normal selection. Particularly from the newly produced 
transgenics probably many individuals have to be culled. The number of culled animals may even 
increase if transfer of genes is continued for several different genes, because it may be expected that 
in "multi-transgenic" animals it is more difficult to find suitable breeding animals than in 
"uni-transgenic" animals. 
The relatively few remaining animals should be used for breeding very intensively. This means 
that techniques as artificial insemination, multiple ovulation and embryo transfer, embryo splitting, 
embryo sexing and freezing of embryos and semen will become more important parts of nucleus 
breeding. However, concentration on a few transgenic breeding animals implies small effective 
population sizes and risks of inbreeding depression. This should be controlled by production of a 
sufficient number of founder transgenics from different families and a gradual increase of the size 
of the line. Until a sufficient size has been reached use of an adequate number of sires per year, 
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combined with a good selection strategy will avoid the negative effects of inbreeding to a large 
extent (De Roo, 1988). 
Organization 
Successful production and introduction of transgenic animals into a pig breeding program will 
be very capital and research intensive. Considerable investments are necessary and these can only 
be afforded by large firms. Therefore breeding companies and other organizations involved in 
biotechnology should cooperate in joint ventures. A strong control of the flow of financial Teturns 
from the bottom of the production pyramid to the nucleus will be necessary. 
Introduction of transgenes will lead to an increase in the number of (experimental) selection 
lines because the standard lines will not be replaced immediately. Furthermore, new lines may be 
developed that are transgenic for different genes. 
Conclusions 
For administration of PST as well as for the use of animals which are transgenic for the 
somatotropin gene, many questions have still to be answered before implications for pig breeding 
can be quantified. 
Concerning PST administration a major problem is that new genetic and phenotypic parameters 
have to be estimated, which can only be done after introduction of PST. Breeding goal traits and 
economic values should also be re-evaluated. 
PST offers new possibilities to introduce prolific Chinese breeds in the breeding program. 
Administration to commercial fattening pigs, partly from Chinese origin, will counteract the poor 
carcass quality and the extra fecundity can be fully utilized. 
The optimum slaughter weight will increase with use of PST, although the extent depends on a 
number of economic factors. 
If transfer of somatotropin genes is completely successful (microinjection, integration, 
expression, transmission and regulation), and all commercial fattening pigs carry these extra genes, 
then the implications for the breeding program may be similar to implications of PST 
administration. However, many other questions have to be answered first. 
It is not known whether for optimum impact on production traits heterozygosity for the 
transgene is sufficient or that homozygosity should be aimed at. In the latter case all breeds that 
contribute to the commercial end product should carry the gene, preferably in a homozygous form. 
Another problem is the presumed variation between the produced (founder) transgenics. All 
animals should be tested for a lot of traits and only a few will be acceptable. Problems with small 
population sizes will arise. 
The optimum breeding strategy in the nucleus further depends on the economic merit of the 
transgene. This is not quantified yet and it may change when better structural genes are isolated and 
transferred, or when better promoters become available. An important point is whether and when 
genes can be transferred into animals which are already transgenic for another gene. 
Independent of the specific solutions to these problems it is quite clear that production of 
excellent transgenic animals is very much capital and research intensive. Everything should be done 
to utilize these animals for breeding as intensive as justified. This will lead to re-organizing of 
nucleus breeding and to more cooperation and joint ventures of breeding companies. 
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IMPLICATIONS OF SOMATOTROPIN TO THE PORK PROCESSING 
INDUSTRY 
F.K. McKeith, P.J. Bechtel and J; Novakofski 
University of Illinois, Urbana, IL U.SA 
S u m m a r y 
The pork processing industry includes slaughter and dressing, fabrication into fresh meat cuts, 
cured meats and sausage manufacture. Our studies have shown that somatotropin will reduce fat 
and increase muscle in finishing pigs. These large changes in composition may affect some or all of 
the different segments of the pork industry. Potential problems associated with the slaughter and 
dressing procedure include increased by-product mass, difficulty in removing the skin, changes in 
the carcass chilling rate and changes in cooler shrinkage. Potential problems associated with 
fabrication into wholesale cuts or joints include difficulty in cutting the soft pliable lean tissue, 
separation of muscles or muscle groups when retail cuts are prepared and difficulty in removing the 
skin from cuts without exposing the muscle surface. The increased lean content will affect water 
content and may require altered handling procedures to achieve desired composition end points and 
shelf live. The cured meat processor will be concerned with changes in the composition and 
thickness of the belly for bacon (particularly for the USA market). Also, the protein extraction 
properties of meat for boneless ham production will need to be reevaluated. Sausage makers will be 
concerned with the potential changes in meat properties, such as pigment concentration, moisture to 
protein ratio, water binding, pH, myofibrillar protein concentration, and the composition of the fat. 
Considerable information is available concerning the growth and composition of pigs treated 
with somatotropin; however, limited information is available concerning their processing attributes. 
The limited data available have not indicated problems with the slaughter and dressing procedures 
for somatotropin treated pigs. Only a very limited number of pigs have been slaughtered 
commercially in high speed operations. Fabrication properties of the carcass have been evaluated 
by several research groups and advantages in cutting yield and composition of the cuts have been 
reported. Incidence of potential slaughter problems such as an increased incidence of PSE have not 
been documented. Curing and sausage problems have not been addressed directly; however, the 
questions of pH, meat color, fat content, moisture to protein ratios and belly characteristics have 
been evaluated and few problems noted. One exception is belly thickness, which is direct correlated 
to backfat thickness. 
Although the use of somatotropin will require changes to be adopted by both the producer and 
processor, we do not believe it will cause insurmountable difficulties and problems can be handled 
with existing technology. 
Keywords: somatotropin, cutting yield, processing, cured meats. 
Introduction 
The composition of pigs has changed dramatically during the past four decades. Pigs are leaner 
and more muscular today due to improvements in genetics, management and nutrition. The 
improvements in composition are consistent with changes in consumer demand. Contemporary 
consumers are reducing animal fats and increasing the use of lipids from plant sources. In addition, 
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consumers are trying to reduce the caloric density of their diet by reducing lipids in the foods that 
they consume. Thus, consumers are demanding less fat in fresh and processed pork meats. 
Per capita consumption of pork in the United States has been relatively static in the past 50 years. 
The estimated market direction of boneless skinless pork in the United States is presented in Table 
1. Approximately 25% of the pork is consumed fresh (85% of the loin and 30% of the blade boston) 
and the remaining 75% of the pork is consumed as a cured or processed meat. 
Table 1. Estimated market direction of boneless, skinless pork. 
Leg 
Loin 
Blade (Boston) 
Arm Picnic 
Spare Ribs 
Neck Bones 
Belly 
Trimmings 
Jowls 
Fat Tissue 
Total 
Soft tissue 
Wt.to prod. 
(Bil.Lbs) 
2.8627 
2.2870 
.9536 
1.0989 
.3420 
.1228 
2.2576 
1.1518 
.3387 
.4275 
11.8426 
Percent 
fresh 
8 
85 
30 
5 
100 
100 
-
-
-
-
Billions 
of Lbs. 
.2290 
1.9440 
.2861 
.0550 
.3420 
.1228 
2.9789 
Percent 
processed 
92 
15 
70 
95 
-
-
100 
100 
100 
100 
Billions 
of Lbs. 
2.6337 
.3430 
.6675 
1.0439 
. -
, -
2.2576 
1.1518 
.3387 
.4275 
8.8637 
Consumers are eating more meals away from the home and purchasing more meals that are 
precooked and/or prepared quickly at home. Consumer surveys are indicating large increases in the 
number of people who have a active lifestyle and do not want or have the time to prepare meals at 
home (Burke Marketing, 1987). The same surveys indicate an increase in the awareness of 
consumers to nutritional quality of food. The demand for lean pork that is easy /convenient to 
prepare is increasing and the survival of the pork industry may depend on the development and 
adoption of technologies that will result in pork and pork products that meet consumer demand. 
The use of somatotropin has been shown to have dramatic effects on the composition of pork 
(Machlin, 1972; Etherton et al., 1986; Etherton et al., 1987; Steel et al., 1987). Carcass fat content 
may be reduced as much as 50 % (Beermann et al., 1988). The use of somatotropin will allow 
producers to achieve consumer demand very rapidly for pork low in fat. However, limited 
information is available regarding the processing properties of fresh and processed pork 
manufactured from somatotropin treated swine. The purpose of this report is to evaluate the current 
literature for information on the slaughter and dressing, fabrication into fresh meat cuts, cured meat 
processing and sausage manufacture. 
Overview of the Processing industry 
Slaughter and dressing is the first step in the processing scheme. Changes associated with 
somatotropin treatment that may affect these procedures include: increases in by-product volume, 
decreases in dressing percentage, difficulty in skin removal, changes in the rate of chilling and/or 
cooler shrinkage. By-product volume is increased significantly for pigs treated with various levels 
of somatotropin. Liver weights increased up to 33%, heart weights increased 21% and kidneys 
increased 39% (table 2). The increase in by-product volume does not reflect a problem other than 
developing uses and/or markets for 30% more by- products. The increase in by-product volume is 
also reflected in the dressing percentage of the animals. 
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Table 2. By-product yield of somatotropin treated pigs. 
Trait 
Dosage level (mg/day) 
3 6 
Liver wt. (g) 
Heart wt. (g) 
Kidney wt. (g) 
Stomach wt, (g) 
Leaf fat wt. (g) 
1517.5 
295.5 
344.5 
590.3 
1415.0 
1814.8 
339.2 
426.1 
617.6 
902.7 
1994.8 
366.1 
473.8 
644.9 
747.1 
2057.5 
376.3 
487.6 
672.2 
636.4 
Numerous studies have reported decreases in dressing percentage up to 3.5% (Baile et al., 1983; 
Machlin, 1972; Grebner et al., 1987). Dressing percentage will be a concern of processors in the 
United States, particularly if pigs are purchased live by the processor. The value of the animal is not 
truly reflected by carcass weight, however, the concept of value of the tissues obtained from the 
carcass has not been readily adapted at this time. Limited information is available regarding any 
potential problems associated with the slaughter/skinning, chilling rates and/or cooler shrinkage of 
animals processed in a commercial processing facility. Carcass fatness has been shown to affect rate 
of chilling in other species (Smith et al., 1977). Barton-Gade et al. (1987) reported that fast chilling 
can cause cold shortening in pigs with slow post-mortem glycolysis; however, the carcasses from 
most somatotropin treated pigs would normally have sufficient fat to protect against cold induced 
shortening. 
Fabrication of the carcass into wholesale cuts/joints is the next step in processing^ork carcasses. 
Fabrication of carcasses that are very lean has resulted in some concerns by processing plants. The 
limited amounts of subcutaneous fat will limit the speed and ability of existing equipment to remove 
fat and skin from some cuts (the use of a loin knife to remove the subcutaneous fat and skin from 
the pork loin is difficult when backfat thickness is less than 1.8 cm). Exposure of the lean surface 
will increase dehydration and/or purge loss in wholesale cuts packaged for distribution. 
Table 3. Effect of somatotropin on the carcass yield and composition of major wholesale cuts*. 
Side wt. 
Wholesale cuts 
Trimmed wholesale 
Cuts 
Boneless tr immed 
wholesale cuts 
Ham 
Ham 
Loin 
Belly 
Shoulder 
Ham 
Loin 
Picnic 
shoulder 
Boston butt 
Ham 
Water (%) 
Lipid (%) 
Loin 
Water (%) 
Lipid (%) 
Boston butt 
Water (%) 
Lipid (%) 
Picnic shoulder 
Water (%) 
Lipid (%) 
Control 
(kg) 
34.56 
9.24 
8.49 
5.39 
7.36 
8.21 
6.75 
3.85 
2.58 
6.16 
68.34 
12.48 
4.50 
56.74 
27.18 
2.43 
62.70 
20.99 
2.94 
67.35 
15.00 
(%) 
26.7 
24.6 
15.6 
21.3 
23.8 
19.5 
11.1 
7.5 
17.8 
13.0 
7.0 
8.5 
Treated 
(kg) 
33.79 
9.36 
8.28 
5.03 
7.22 
8.51 
7.07 
3.84 
2.75 
6.57 
71.67 
8.96 
4.99 
66.95 
14.05 
2.55 
70.92 
10.00 
2.89 
71.67 
9.34 
(%) 
27.7 
24.5 
14.9 
21.4 
25.2 
20.9 
11.4 
8.1 
19.4 
14.8 
7.5 
8.6 
»McKeith et al., 1988. 
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Retail cuts prepared from carcasses with less than 1.2 cm of P2 fat tend to have increased muscle 
separation when the retail cut is packaged for sale (Wood et al., 1988). In addition, the carcasses and 
wholesale cuts tend to be more pliable for handling since there is a limited amount of fat to aid in 
cut firmness. Carcass cutting yields are higher (up to 1.8% for trimmed boneless cuts) for most cuts 
(Tables 3,4 and 5) and the composition of the cuts is much more desirable (up to 50% reductions in 
fat content) for the somatotropin treated carcasses. 
Table 4. Carcass cutting yields of carcasses treated with somatotropin.* 
Loin 
Ham 
Shoulder 
Belly 
Kanis et al. 1988. 
Control 
6.93 
8.74 
4.45 
5.24 
100 Kg 
Treated (% +) 
+2.5 
+4.3 
+5.6 
-3.5 
Slaughter 
NS 
weight 
Control 
9.61 
11.79 
6.10 
7.68 
140 Kg 
Treated (% +) 
+7.0 • " 
+9.1 
+8.6 " * 
-2.9 NS 
Intramuscular fat content of the longissimus and semitendinosus muscle were significantly 
reduced with somatotropin treatment (Grebner et al., 1987). 
Table 5. Carcass cutting yields of pigs treated with human growth hormone releasing factor*. 
Human 
Control GRF 
Ham 
Loin 
Shoulder 
Flank 
Muscle 
Fat 
Bone 
Musle 
Fat 
Bone 
Muscle 
Fat 
Bone 
Muscle & fat 
Bone 
5.35 
2.65 
.92 
4.83 
4.28 
1.27 
5.69 
2.70 
1.36 
6.59 
.47 
6.05 
1.94 
1.03 
5.67 
2.96 
1.48 
6.61 
2.34 
1.72 
6.12 
.54 
P<.05 
P<.05 
P<.05 
P<.05 
P<.05 
P<.05 
P<.05 
P<05 
Pomnier et al., 1988. 
Reductions in all of the major fat depots (internal, subcutaneous, intermuscular and 
intramuscular) were observed. The role of intramuscular fat content in cooked pork palatability 
appears to be related to the acceptability of pork (Devol et al., 1988). However, Wood et al. (1988) 
reported that intramuscular fat content did not have an effect on meat palatability. Grebner et al. 
(1987), reported reduction in intramuscular fat content from 3.5% to 2.3% with somatotropin 
treatment (Table 6). 
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Table 6. Carcass and muscle composition of somatotropin treated pigs. 
Trait 
Dosage level (mg/day) 
3 6 
Longlsslmus 
Moisture 
Lipid 
Semltendlnosus 
Moisture 
Lipid 
Carcass 
Moisture 
Lipid 
73.04 
3.54 
71.93 
7.29 
51.91 
29.87 
74.15 
2.61 
74.19 
4.96 
57.93 
21.82 
74.03 
2.33 
74.61 
3.97 
61.32 
17.59 
72.68 
2.70 
74.92 
4.29 
62.07 
17.19 
Grebner et al., 1987. 
Cured meat processors will obtain cuts that are leaner (Tables 3,4 and 5) and these cuts will have 
similar processing yields and color properties (Table 7). Prusa and others (1988) evaluated the 
processing, visual and sensory properties of boneless hams, Canadian style bacon and traditional 
bacon. Results of their study indicated that few differences observed between control and treated 
products and that somatotropin had no detrimental effects on the processing characteristics of 
muscle. Warner-Bratzler shear force values of boneless hams were evaluated and no statistical 
differences were observed (Prusa et al., 1988). The lack of texture differences indicate that the 
products bound together effectively and no problems with muscle binding were mentioned in their 
report. 
Table 7. Processing properties of cured meat. 
Somatotropin level (mg/day) 
0 3.33 6.67 
Yields 
Belly 
Canadian style 
b a c o n 
Boneless ham 
Ham color (4 wks storage) 
L 
a 
b 
Ham composition 
Moisture 
Fat 
Protein 
Warner-Bratzler 
shear force 
* Prusa et al., 1988. 
86.3 
83.8 
77.6 
47.1 
9.0 
4.1 
68.3 
3.6 
22.0 
1.0 
84.8 
84.8 
77.2 
46.9 
9.2 
4.4 
68.1 
4.3 
22.2 
1.2 
84.3 
86.2 
76.6 
47.7 
9.3 
4.7 
67.6 
4.6 
22.7 
1.4 
One of the concerns that processors in the United States will have will involve belly thickness 
and suitability of the belly for bacon production. The effect of belly thickness on the processing 
charac- teristics and acceptability of bacon was evaluated at the University of Illinois. Bellies were 
obtained from a group of pigs treated with somatotropin and controls and evaluated based on belly 
thickness. Bellies were characterized and processing traits were characterized as well as visual 
evaluation of the cooked products (Table 8). Raw average belly thickness ranged from 2.1 cm to 3.3 
cm and the composition of the bellies ranged from 22.95 % fat to 42.51 % fat. Differences were 
observed in visual slice integrity, fat to lean ratio and overall appearance of the products; however, 
no sensory differences were observed. 
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Sausage manufacture involves a major proportion of the pork produced annually. Reducing fat 
content in carcasses will result in reduced fat in much of the trim utilized for sausage production. 
Reducing fat in sausage products will be perceived positively by consumers; however, the 
acceptability of reduced fat sausage has been evaluated and the textural properties of the sausage 
become less desirable using traditional processing techniques. 
Table 8. Belly characteristics and processing yields*. 
Trait 
Physical characteristics 
Green weight (kg) 
Raw average thickness (cm) 
Cooked average thlckness(cm) 
Processing yield (%) 
Chemical characteristics 
Moisture (%) 
Fat (%) 
Visual traits 
Slice Integrity 
Fat to lean ratio 
Overall appearance 
Mean 
4.71 
2.78 
3.25 
98.5 
53.71 
32.85 
8.87 
9.32 
8.23 
Maximum 
6.03 
3.30 
4.13 
104.1 
69.11 
42.51 
12.06 
12.75 
10.90 
Minimum 
3.74 
2.14 
2.29 
95.7 
45.77 
22.95 
4.90 
6.18 
3.50 
Probability 
of a linear 
ef fect 
.002 
.001 
.001 
.001 
.003 
.001 
.008 
.001 
.001 
* University of Illinois unpublished data. 
Valvano (1983) reported acceptable low fat sausage can be manufactured using some different 
processing techniques and Foegeding and Ramsey (1986) evaluated the use of carrageenan in low 
fat emulsion products. Research currently being conducted in our laboratory indicates that 
acceptable emulsified sausage products may be manufactured using less than 15% fat. Little or no 
information has been compiled on the functional properties of the muscle tissue or the composition 
of the lipids. 
Conclusions 
Numerous concerns were brought out in the discussion of the processing characteristics of 
somatotropin treated pork. Many of the potential concerns have been addressed and few differences 
or problems have been documented. Currently available technology should answer of alleviate any 
potential problems that arise. 
References 
Baile, C.A., M.A. Della-Fera & C.L. McLaughlin, 1983. Performance and carcass quality of 
swine injected daily with bacterially-synthesized human growth hormone. Growth 47:225-236. 
Barton-Gade, P.A., C. Bejerholm & U. Borup, 1987. Proc. 33rd Internatl. Congress of Meat 
Science & Technology, Helsinki, Finland, Vol. 1,181-184. 
Beermann, D.H., R.D. Boyd, G. Arnbruster, A.F. Deneergard, K. Roneker, T.D. Bartley & 
K.D. Fain, 1988. Dose response effect of native and recombinant porcine somatotropin (pST ) 
on growth performance, composition of gain and pork quality. Proc. 34th Internatl. Congress of 
Meat Science & Technology, Brisbane, Australia, Vol. 2,601-602. 
Breidenstein, B.C. & J.C. Williams, 1985. Contribution of red meat to the U.S. diet. National Live 
Stock and Meat Board, Chicago, IL USA. 
106 
IMPLICATIONS FOR PRODUCTION SYSTEM: PROCESSING 
Burke Marketing Research, 1987. Consumer climate for meat. National Live Stock and Meat 
Board, Chicago, IL USA. 
DeVol, D.L., F.K. McKeith, P.J. Bechtel, J. Novakofski, R.D. Shanks & R.D. Carr, 1988. 
Variation in the composition and palatability traits and relationship between muscle 
characteristics and palatability in a random sample of pork carcasses. J. Animal Science 66:385. 
Etherton, T.D., J.P. Wiggins, CM. Evock, CS. Chung, J.F. Rebhun, P.E. Walton & N.C 
Steele, 1987. Stimulation of pig growth performance by porcine growth hormone: determination 
of the dose-response rela- tionship. J. Animal Science 64:433-443. 
Etherton, T.D., J.P. Wiggins, CS. Chung, CM. Evock, J.F. Rebhun & P.E. Walton, 1986. 
Stimulation of pig growth performance by porcine growth hormone and growth hormone-re 
leasing factor. J. Animal Science 63:1389-1399. 
Foegeding, E.A. & S.R. Ramsey, 1986. Effects of gums on low-fat meat batters. J. Food Science 
51:33. 
Grebner, G.L., F.K. McKeith, J. Novakofski, R.A. Easter, D.G. McLaren, K. Brenner, PJ. 
Bechtel, R.W. Jones & R.H. Dalrymple, 1987. Carcass characteristics of pigs injected with 
different levels of natural porcine somatotropin (PST) from 57 to 103 kg weight. J. Animal 
Science 65:245 ( u str). 
Kanis, E., W. Van der Hel, J. Huisman, G.J. Nieuwhof, R.D. Politiek, M.N.A. Verstegen, P. Van 
der Wal & E.J. Van Weerden, 1988. Effect of recombinant porcine somatotropin (rPST) 
treatment on carcass charac- teristics and organ weights of growing pigs. J. Animal Science 
66:280 (Abstr). 
Machlin, L.J., 1972. Effect of porcine growth hormone on growth and carcass composition of the 
pig. J. Animal Science 35:794-800. 
McKeith, F.K., P.J. Bechtel, J. Novakofski, D.G. McLaren, R.A. Easter, R.W. Jones & D.L. 
Ingle, 1988. Effect of porcine somatotropin on composition of boneless retail cuts from pigs. 
Annual Meeting of the American Society of Animal Science. 
Pomnier, S., P. Dubreul, P. Gandreau, G. Pelletier, C Farmer, D. Petitclerc, H. Lapierre, Y. 
Couture & T. Mowles, 1988. Effect of a potent analog of human growth hormone releasing 
factor (hGRF) on the carcass composition of pigs. J. Animal Science 66:295 (Abstr). 
Prusa, K.J., J.G. Sebranek & J.A. Love, 1988. Processing and quality characteristics of Canadian 
style bacon, boneless ham and bacon from pigs treated with porcine somatotropin. J. Food 
Science (submitted). 
Smith, G.C, T.R. Dutson, R.L. Hostetler & Z.L. Carpenter, 1976. Fatness, rate of chilling and 
tenderness of lamb. J. Food Science 41:748. 
Steele, N.C, R.G. Campbell & TJ. Caperna, 1987. Update of porcine growth hormone research: 
practical and biological implications. Cornell Nutrition Conference, October 27,1987. 
Valvane, R.A, 1983. The effects of preblending and lowered fat content on processed meats. M.S. 
Thesis. University of Nebraska, Lincoln, NE. 
Wood, J.D., M. Enser & Moncraff, 1988a. Effects of carcass fatness and sex on the composition 
and quality of pig meat. Proc. 34th Inter- national Congress of Meat Science & Technology, 
Brisbane, Australia, Vol. 2,562. 
Wood, J.D., 1988b. Influence of the Duroc breed on pig meat quality. Proc. 34th Internatl. 
Congress of Meat Science & Technology, Brisbane, Australia, Vol. 2, 571-572. 
107 
EFFECT ON REQUIREMENTS AND WELL BEING 
OF THE TARGET ANIMAL 
Physiological mode of action 
Nutrient and management requirements 
Health and immune response 
Side effects 
Effects on reproduction and lactation 
IMPACT ON TARSET SPIECES: PHYSIOLOGICAL MODE OF ACTION 
MECHANISMS BY WHICH PORCINE GROWTH HORMONE (pGH) 
AND INSULIN-LIKE GROWTH FACTORS (IGFs) REGULATE PIG 
GROWTH PERFORMANCE: APPROACHES FROM THE pGH AND 
IGF RECEPTORS TO THE WHOLE ANIMAL 
T.D. Etherton 
Department of Dairy and Animal Science, University Park, PA 16802 U.SA. 
Summary 
Porcine GH is a naturally occurring protein hormone that has a wide array of biological effects 
in pigs. Treatment of growing pigs with porcine growth hormone (pGH) dramatically increases pig 
growth performance (the composite of average daily gain, feed efficiency and carcass 
composition). The biological actions of pGH can broadly be categorized as being either 
somatogenic or metabolic. In this chapter, I will discuss some mechanisms by which pGH affects 
growth and metabolism. The discussion will address: 1) the effects that pGH has on adipose tissue 
growth and metabolism, 2) the role that both pGH and insulin-like growth factor 1 (IGF-1) play in 
stimulating muscle growth, 3) the events that occur which lead to the hyperglycemia and 
hyperinsulinemia observed in pigs treated with pGH chronically, 4) the evidence which indicates 
that IGF-1 binding proteins (IGF-BPs) not only transport IGFs in the circulation but also modulate 
biological activity of IGFs and 5) the significance of the recently established amino acid sequence 
of cDNA clones that encode the human and rabbit GH receptors. 
Although it is now clear that pGH alters nutrient partitioning in meat animals, the biological 
mechanisms by which this occurs are not clear. Little is known about how the pGH receptor 
generates chemical signals nor the identity of those molecules that mediate the intracellular 
biological effects of pGH. As our understanding of the interaction between pGH and its receptor 
increases it will likely be possible to establish the amino acid residues of pGH that bind to the pGH 
receptor. This information may make it possible to "design" analogs of pGH that may have 
enhanced biological activity. Thus, the effects we have seen of treating pigs with exogenous pGH 
to date may represent only the first step in a series of advances that lead to economical and effective 
ways to manipulate meat animal growth performance. 
Keywords: growth hormone, insuline-like growth-factor, receptors, physiological mechanisms, 
swine. 
Introduction 
An exciting era is evolving in animal agriculture. Numerous studies have shown that treating 
pigs with exogenous pituitary pGH dramatically increases pig growth performance (Chung et al., 
1985; Boyd et al., 1986; Etherton et al, 1986,1987b; Campbell et al., 1988). Recently, it has also 
been established that recombinant pGH mimics the effects of pituitary GH (Evock et al., 1988). The 
magnitude of response in these studies has varied somewhat primarily because of differences in 
experimental design (e.g., initial pig weight, length of study, breed, sex, dose of pGH used and 
differences in diet). Despite these differences, however, it has become apparent that pGH increases 
average daily gain approximately 10 to 20%, improves feed efficiency 15 to 35%, decreases 
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adipose tissue mass and lipid accretion rates by as much as 50 to 80% and concurrently increases 
protein deposition by as much as 50%. 
These responses have sparked interest in developing a rpGH-based growth promotant for the 
pork industry world-wide. In addition to the economic benefits realized by the producer who 
integrates pGH into their production scheme, the other benefit of this new biotechnology will be to 
provide a leaner product for the consumer. In fact, the greatest benefit of this technology to society 
may be the ability to produce pork that is considerably leaner. This will be of particular interest to 
individuals concerned about the relationship between the consumption of saturated fatty acids and 
coronary heart disease. In the U.S.A. the present dietary recommendations are that consumption of 
saturated fatty acids be reduced to less that 10% of total calories. Thus, treating pigs with pGH 
provides an effective means of safely producing leaner, more nutritious pork that will enable 
consumers to include pork in their diet and still achieve the dietary recommendations. 
History of pGH 
Evans and co-workers first demonstrated the presence of a substance in the anterior pituitary that 
increased the growth rate of rats (Evans and Long, 1922a,b; Evans and Simpson, 1931). Lee and 
Schaffer (1934) subsequently established that pair-fed rats injected with an alkaline extract of 
bovine pituitaries not only gained more weight but the composition of the gain contained 
proportionally more muscle and less adipose tissue. It was not until 1951 that Raben and 
Weatermeyer (1951) described a method for the isolation of pGH. Because the preparation was 
quite heterogenous a complete chemical characterization was not presented. Subsequently, Papkoff 
et al. (1962) published a procedure for the preparation of pGH from freshly frozen pig pituitaries 
and reported that pGH had a molecular weight of 41,600 (ascertained by sedimentation velocity). 
With advances in protein chemistry and separation techniques further improvements in pGH 
purification were achieved (Chen et al., 1970). In the latter paper, a molecular weight of 22,000 was 
assigned to pGH. Also in 1970, Mills et al. (1970) presented the first partial amino acid sequence 
data for pGH. The complete amino acid sequence was not established until 1983 when Seeburg et 
al. (1983) deduced the sequence from a cloned cDNA for pGH. 
Porcine GH is a 191 amino acid protein that shares a high degree of homology with bovine 
growth hormone (bGH) (see Figure 1). There are 18 positions between pGH and bGH that have 
different amino acids whereas there are 59 residues that differ between pGH and human GH (hGH). 
Recently, the three-dimensional structure of recombinant pGH has been reported (Abdel-Meguid et 
al., 1987). In the future it should be possible to use structural studies such as this in conjunction with 
recombinant DNA technology to identify the amino acid residues that are involved in binding of 
pGH to its receptor. If this is achieved, it may be possible to design recombinant pGH analogs that 
have a greater biological activity. 
The awareness that the pituitary produces substances that play an important role in the growth 
process prompted animal scientists to treat pigs with pituitary preparations of GH. The early studies 
(Giles, 1942; Turman and Andrews, 1955; Henricson and Ullberg, 1960) were inconclusive with 
respect to the effects of these pituitary preparations on growth performance of pigs. These negative 
findings were due to the purity of the GH preparations. In 1972, Machlin (1972) established that 
treating pigs with pituitary pGH significantly improved weight gain and feed efficiency. At that 
time commercialization of a pGH-based product was not practical because of the availability of pig 
pituitaries and the cost of pGH purification. The emergence of molecular biology and the means to 
produce large quantities of biologically active recombinant proteins has resolved this issue. 
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i 
L 
10 20 30 40 50 
pGH AFPAMPLSSL FANAVLRAQH LHQLAADTYK EFERAYIPEG QRYS-IQNAQA 
bGH AFPAl^LSlL FANAVLRAQH LHQLAADTIK EFEPJIYIPEG QRYS-IQNIQI 
hGH AFP|§PLS§L F|NA|LRA|| LHQLA|DTY| EFE§AYIP|| Q§YS§|QN|Q| 
60 70 80 90 100 
pGH AFCFSETIPA PTGKDEAQQR SDVELLRFSL LLIQSWLGPV QFLSRVFTNS 
bGH AFCFSETIPA FTGKNEAQOj SDIELLRÏSL LLIQSWLGPI QFLSRVFTNS 
hGH HJCFSEflPi P|i||EiQQ| S$§ELLR§SL LLIQSWlfPV QFL||VF|NS 
110 120 130 140 150 
pGH LVFGTSDR-VY EKLKDLEEGI QALMRELEDG SPRAGQILKQ TYDKFDTNLR 
bGH LVFGTSDR-VY EKLKDLEEGI |ALMRELED| fPRAGQILKQ TYDKFDTNIR 
hGH LVfG§SDgf|VY §|LKDLEEGI Q|LM||LEDG SPRpQIFKQ TY§KFDTNl| 
160 170 180 190 
pGH SDDALLKNYG LLSCFKKDLH KAETYLRVMK CRRFVESSCA F 
bGH SDDALLKNYG LLSCFAKDLH KTETYLRVMK CRRFGEASCA F 
hGH |DDALLKNYG LLXCFAKDMD KVETFLRIVQ CR-SVEGSCG F 
Figure 1. Amino Acid sequence for pGH (Seeburg et al., 1983), bGH and hGH (Millerand Eberhard! 
1983). Amino acids highlighted differ from residues In pGH. A-Ala; C-Cys; D-Asp; E=Glu; 
F=Phe; G=Gly; H=Hls; Nile; K=Lys; L=Leu; M=Met; N=Asn; P=Pro; Q=Gln; R=Arg; S=Ser; T=Thr; 
Y=Tyr; V-Val; W=Trp. 
Metabolic effects of pGH 
Adipose tissue 
It is clear that pGH induces numerous metabolic effects that influence the partitioning of 
nutrients among various body tissues. The precipitous decrease in adipose tissue accretion rate is 
one important metabolic effect of pGH. The effects of pGH on adipose tissue metabolism are 
important because they: 1) establish the rate of adipose tissue accretion and, therefore, the extent to 
which pGH affects carcass composition, 2) play a key role in accounting for the effects that pGH 
has on feed efficiency and 3) likely play a role in the decrease observed in feed intake of 
pGH-treated pigs. 
Accretion of adipose tissue is a function of the relative rates of triglyceride synthesis and 
degradation (lipolysis). For pGH to decrease growth rate of adipose tissue it is clear that lipid 
synthesis must decrease, lipolysis increase or a combination of both occur. We have found that pGH 
affects lipid synthetic events on two levels: 1) there is a striking decrease in glucose utilization by 
porcine adipocytes and 2) the stimulatory effects of insulin on glucose metabolism are blunted. 
With respect to the effects of pGH on lipolysis, there is evidence which suggests that pGH 
potentiates the effects of lipolytic hormones (Boyd and Bauman, 1988). In the latter study, an 
epinephrine challenge caused a greater rise in plasma free fatty acid (FFA) concentration in pigs 
treated chronically with pGH than controls. There is no information which resolves whether pGH 
affects FFA turnover in vivo. Although pGH appears to affect mobilization of FFAs it is likely that 
the primary effect of pGH on adipose tissue accretion is mediated via changes in triglyceride 
synthesis when pigs are fed ad libitum. 
Considerable evidence exists to support the hypothesis that pGH affects glucose utilization and 
insulin sensitivity of porcine adipocytes. We have found that treating pigs with pGH for 7 d 
(70 (ig/kg body weight) reduces fatty acid synthesis 50 to 70% (Walton et al., 1987) and that this is 
paralleled by a decline in activity of several lipogenic enzymes (glucose-6-phosphate 
dehydrogenase, 6-phosphogluconate dehydrogenase, malic enzyme and fatty acid synthase; Magri, 
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1988). The extent to which pGH affects lipogenic enzyme activity is illustrated by the observation 
that fatty acid synthase activity is abolished after 7 d of pGH treatment. In addition to directly 
affecting glucose utilization, pGH also markedly decreases the stimulatory effects of insulin on 
lipogenesis and glucose transport (Walton et al., 1987; Magri, 1988). These effects of pGH are 
intrinsic properties since they are mimicked by recombinant pGH. 
To determine whether the effects of pGH are direct we have developed techniques for culturing 
porcine adipose tissue in defined medium that maintains lipogenic capacity for 48 h (Walton and 
Etherton, 1986; Walton et al., 1986; Walton and Etherton, 1987). These experiments have shown 
that pGH blunts the ability of insulin to maintain lipogenic capacity in a dose-dependent manner. 
Similar findings have been reported for ovine and bovine adipose tissue (Vernon et al., 1982; 
Etherton et al., 1987a). Based on these observations, it is evident that the effects of pGH on adipose 
tissue are direct and not the result of IGF-1 (discussed later). Furthermore, the effects of pGH in 
culture are not observed in short- term incubations (2 h), but rather are only observed after chronic 
exposure of the tissue to pGH. This suggests that pGH acts to inhibit glucose utilization by changing 
the mass of key lipogenic enzymes, second messengers or glucose transporters. 
There is considerable evidence (with rodents) to indicate that GH exerts an insulin-like effect in 
adipose tissue. This is only seen in adipose tissue from GH-deficient animals such as 
hypophysectomized rats or rats treated with antiserum to GH (Goodman and Coiro, 1981; 
Schwartz, 1980; Gause et al., 1983). This effect is not seen in the presence of GH (Eden et al., 
1982). Thus, under normal physiological circumstances (when GH is present) pGH has no 
insulin-like effects on adipose tissue accretion. Given this perspective, it is not clear why studies are 
conducted looking at the insulin-like effects of GH in adipose tissue when this does not occur in any 
meaningful physiological setting. This becomes particularly apparent when one considers the 
catabolic effects that pGH has on adipose tissue accretion which unquestionably is not an 
insulin-like effect. 
It can be speculated that the reduction in insulin sensitivity and responsiveness of porcine 
adipocytes may due to a pGH-dependent decrease in binding of insulin to the insulin receptor. To 
address this, we have quantified insulin binding to adipocytes from pigs treated chronically with 
pGH in which insulin sensitivity is blunted. We have found that insulin binding is unaffected by 
pGH (Magri, 1988). In addition, we have determined that insulin receptor tyrosine kinase activity is 
not affected by pGH in porcine adipocytes (Magri, 1988). Our interpretation of these findings is that 
pGH blocks insulin action at a site somewhere other than recognition of insulin by the receptor or 
phosphorylation of some critical intracellular protein involved in the cascade of events associated 
with the generation of chemical signals that mediate the intracellular effects of insulin. Nothing is 
known about the level at which this blockade occurs. 
Insulin sensitivity and glucose kinetics 
Numerous studies have shown that treating pigs with exogenous pGH increases plasma glucose 
and insulin concentrations (Etherton et al., 1987b; Evock et al., 1988). In addition, other studies 
using a euglycemic clamp technique have shown that pGH reduces uptake of glucose in response to 
insulin infusion in pigs chronically treated with the hormone (28 d) (see Boyd and Bauman, 1988). 
Recently, we have found that glucose and insulin tolerance tests are impaired in pigs treated 
chronically with pGH (Gopinath and Etherton, 1989a,b). This effect is not seen in pigs treated 
acutely with pGH. We have also found that hepatic glucose output is significantly increased by pGH 
treatment. Thus, the increase in circulating plasma glucose concentration in pGH-treated pigs is due 
to an increase in hepatic glucose output and a concurrent impairment in glucose clearance. The 
increase in hepatic glucose output appears to be associated with a reduction in the insulin sensitivity 
of liver (Gopinath and Etherton, 1989b). 
There are several issues that need to be resolved about the effects that pGH has on carbohydrate 
metabolism. The first is what is the significance of an increase in both plasma glucose and insulin 
in a physiological state where changes in growth rate and nutrient partitioning occur? This leads to 
the second question which is: what is the fate of the glucose in plasma? Based on some estimates 
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we have made (Etherton, 1989), a significant quantity of glucose (±20 to 40% of glucose cleared 
per day) is diverted away from deposition as lipid in adipose tissue. It is not clear where the glucose 
diverted away from adipose tissue goes. Given the marked increase in muscle protein deposition it 
seems likely that the requirement for ATP in muscle is increased. To meet this increased need for 
ATP it would appear that plasma glucose or FFA (due to changes in lipolysis) utilization by muscle 
would have to be increased in pGH-treated pigs. It has not been established whether indeed this 
happens. 
There are data which indirectly support the idea that amino acid flux from muscle to liver is 
perturbed by pGH. In all the studies we have done one of the most consistent findings is that pGH 
treatment decreases blood urea nitrogen concentration. This suggests that hepatic amino acid 
degradation is reduced and infers that delivery of amino acids from peripheral tissues to the liver is 
also reduced. It remains to be established whether this change in delivery of amino acids to the liver 
is a function of changes in amino acid uptake by muscle, release or both. Studies with 
hypophysectomized rats (Albertson-Wikland, 1980) and normal rats (Schwartz, 1982) have shown 
that GH stimulates protein synthesis in diaphragm muscle. There is some basis to suggest that the 
IGFs also play a role in protein synthesis and degradation. IGF-1 has been shown to stimulate 
protein synthesis in the soleus and extensor digitorum longus muscles of rats (Monier et al., 1983). 
Ballard et al. (1986) found that both IGF-1 and IGF-2 stimulated protein synthesis and inhibited 
protein degradation in rat L6 myoblasts. In vivo studies looking at the effects of pGH on protein 
synthesis and degradation in pigs are needed to resolve the contribution that changes in protein 
synthesis and/or degradation make to alterations in muscle protein deposition rates. 
The repeated observations that plasma insulin concentrations are higher and that insulin 
tolerance tests are impaired in pGH-treated pigs indicate that there is a significant impairment in 
insulin sensitivity in vivo. The role that this state of insulin insensitivity plays in pGH- treated pigs 
is not known. 
Somatogenic effects of pGH: The role of the IGFs 
Administration of GH to animals stimulates chondrogenesis and satellite cell proliferation (for 
reviews see Isaksson et al., 1987 and Allen, 1988). Both of these responses are an important 
component of the anabolic effects that GH has because of the rate-limiting role chondrocyte 
proliferation plays in regulating long bone growth and the similar role that satellite cell proliferation 
plays in regulating postnatal muscle growth. In 1941, Kibrick et al. (1941) found that epiphyseal 
plate width of hypophysectomized rats increased after treatment with GH. This finding formed the 
basis for a bioassay of long-standing for GH. It was subsequently established that GH increased the 
rate of sulfate incorporation into chondroitin sulfate proteoglycans of cartilage (Murphy et al., 
1956). This finding prompted Salmon and Daughaday (1957) to determine if GH stimulated sulfate 
uptake in vitro in cartilage from hypophysectomized rats. They found that GH did not directly 
stimulate sulfate incorporation whereas serum from GH-treated rats stimulated sulfate 
incorporation. This observation led to the somatomedin hypothesis which states that GH stimulates 
somatic growth indirectly via circulating sulfation factors. We now know these sulfation factors as 
insulin-like growth factor 1 (IGF-1) and insulin-like growth factor 2 (IGF-2). IGF-1 is a single 
chain peptide of 70 amino acids (Mr = 7649) whereas IGF-2 has 68 amino acids (Mr =1 7471) 
(Rinderknecht and Humbel, 1978a,b). IGF-1 is regulated by GH whereas IGF-2 is less GH 
dependent. We have found that treating pigs with exogenous pGH does increase IGF-2 (CM. Evock 
and T.D. Etherton, unpublished data), however, the response is less than that observed for IGF-1. 
The somatomedin hypothesis of GH action implies that GH stimulates longitudinal bone growth 
by increasing the concentration of circulating IGF-1 in plasma. Over the past six years, however, 
information has been published which demonstrates that administration of GH locally at the 
epiphyseal plate also stimulates bone growth in hypophysectomized rats (Isaksson et al., 1982; 
Russell and Spencer, 1985; Isgaard et al., 1986a,b). Other evidence such as the finding of specific 
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binding sites for GH on chondrocytes from rabbit ear and epiphyseal growth plate (Eden et al., 
1983) and the observation that GH stimulates DNA and proteoglycan synthesis in cultured 
chondrocytes (Madsen et al., 1983,1985) are incompatible with the effects of GH being mediated 
solely by circulating IGF-1. These findings imply that GH may stimulate local production of IGF-1 
and that locally produced IGF-1 plays an important role in mediating the somatogenic effects of 
GH. Recently, Isgaard et al. (1988). reported that treating hypophysectomized rats with GH 
increased IGF-1 mRNA abundance in rat rib growth cartilage in a dose-dependent manner. These 
findings are significant because they not only indicate that IGF-1 acts in an endocrine manner but 
also acts as a paracrine or autocrine growth factor and that local production of IGF-1 is under GH 
regulation. The finding that IGF-1 mRNA is also present in a variety of rat tissues (Murphy et al., 
1987) indicates that a number of other tissues expresses the IGF-1 gene. 
The awareness that the somatogenic effects of GH are mediated by IGF-1 has led to experiments 
to determine whether administration of exogenous IGF-1 increases growth rate. This approach has 
been facilitated by the availability of recombinant human IGF-1 (which has the same sequence as 
pig IGF-1; Tavakkol et al., 1988). There have been no studies reported in which pigs have been 
treated for more than 3 days with IGF-1. Nonetheless, studies with hypophysectomized and normal 
rats have shown that exogenous IGF-1 increases growth (see Table 1 for a summary). We have 
considered the possibility that treating pigs with exogenous IGF-1 might be alternative means of 
increasing pig growth performance. Several observations, however, suggest that while IGF-1 may 
increase growth rate in pigs (which remains to be established), IGF-1 treatment will not be 
comparable to the effects seen with pGH. This is because the metabolic effects of pGH in adipose 
tissue will not be mimicked by IGF-1 (specifically, the effects of pGH on glucose uptake, 
metabolism and insulin sensitivity). It is our contention that the metabolic effects of pGH play an 
integral role in regulating the rate of adipose tissue accretion and, hence, are an important 
determinant in establishing the changes in carcass composition and feed efficiency. 
Insulin-like growth factor binding proteins and receptors 
It has been known for some time that IGF-1 in human plasma circulates bound to insulin-like 
growth factor binding proteins (IGF-BPs) (Hintz, 1974; Megyesi et al., 1975; Hintz and Liu, 1977). 
In pigs, we have found that there is also no detectable free IGF-1 in the circulation (Walton, 1988). 
Approximately 70 to 80% of the immunoreactive IGF-1 is bound to a 150 kDa IGF-BP complex, 
with the remainder associated with a 40 kDa 125I-IGF-1 IGF-BP (Walton, 1988). When porcine 
serum is incubated with I-IGF-1 and then fractionated over a FPLC sizing column little is bound 
to the 150 kDa IGF-BP (which is pGH-dependent), approximately 40% is bound to a smaller 
IGF-BP (ca. 40 kDa and not regulated by pGH) and the remainder is free. Thus, the high molecular 
weight IGF-BP is saturated with endogenous IGF-1 and is the major IGF-1 transport protein in 
porcine serum. Evidence which corroborates the finding that porcine IGF-BPs are highly occupied 
with endogenous IGF-1 in vivo comes from studies in which pigs have been treated with exogenous 
IGF-1 (Walton et al., 1988b). In this study, recombinant human IGF-1 (either 4 or 8 mg/day) was 
administered daily (as a single intra-arterial injection) for three consecutive days, blood samples 
were taken frequently and IGF-1 clearance determined. IGF-1 was cleared quite rapidly (viz- ca. 6 
min). In addition, administration of free IGF-1 caused hypoglycemia. The temporal profile of the 
elevation in serum IGF-1 following administration of exogenous IGF-1 differs markedly from that 
observed after pGH treatment where serum IGF-1 concentrations are elevated for 2 to 12 hours 
(Sillence and Etherton, 1987). The rapid clearance of exogenous IGF-1 ia apparently a function of 
the available binding sites for IGF-1 on the IGF-BPs. When the IGF-BPs are highly occupied with 
endogenous IGF-1 little exogenous IGF-1 binds and the ability of the IGF-BPs to inhibit clearance 
of IGF-1 is lost. 
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Table 1. Studies to assess the effects of exogenous IGFs. 
1 Schoenle et al. (1982). IGF-1 Infused continuously via sc Implanted mlnlpumps, Increased body 
weight gain, tibial epiphyseal width and costal cartilage mltogenesls In 
hypophysectomlzed rats. 
2. Schoenle et al. (1985). IGF-1 administered as above Increased tibial epiphyseal width and costal 
cartilage mltogenesls In hypox rats. 
3. Russell and Spencer (1985), Isgaard et al. (1986). IGF-1 Injections directly Into the tibial epiphyseal 
plate stimulated cartilage growth In hypophysectomlzed rats. 
4. Hfeuja et al. (1986). IGF-1 vla sc Implanted mlnlpump Increased body weight gain, body length 
and tibial epiphyseal width In normal rats. 
5. Van Buul-Offers et al. (1986). IGF-1 Injections Increased body weight and length In Snell dwarf 
mice. 
6. Skottner et al. (1987). IGF-1 by Iv bolus Injection caused a dose-dependent decrease In blood 
glucose and an Increase In disappearance rates of labeled amlnolsobutyrtc acid from 
the circulation of hypophysectomlzed rats. IGF-1 given by continuous Iv or sc Infusion or 
by sc injection Increased body clear weight gain and long bone growth only when given 
continuously at the highest dose. 
To gain insight into the physiology of the IGF-BPs several of these proteins have been purified. 
An acid-stable subunit of the 150 kDa IGF- BP that is GH-dependent has been purified from rat 
serum, human plasma and porcine serum (see Figure 2). In pigs, this protein had a molecular weight 
of 45 kDa under reducing conditions and shares homology with acid- stable IGF-BPs purified from 
rat serum and human plasma (see Figure 2). In addition to the binding proteins found in serum, ca 
30 kDa IGF-BPs have also been purified from human amniotic fluid (Drop et al., 1984; Povoa et al., 
1984), placenta (Koistenen et al., 1986) and conditioned medium of HEP G2 hepatoma cells (Povoa 
et al., 1985). The IGF-BP originally isolated from human placenta has been shown to be synthesized 
in secretory endometrium (Rutanen et al., 1986) and decidua (Rutanen et al., 1985) but not in the 
placenta (Rutanen et al., 1985). The IGF-BP isolated from amniotic fluid is identical to the IGF-BP 
secreted by HEP G2 hepatoma cells (Povoa et al., 1985). There is evidence that antibodies raised 
against the amniotic fluid IGF-BP cross-react with the small serum IGF-BP in humans that is not 
GH-dependent which suggests that these are similar if not identical proteins (Baxter and Cowell, 
1987). 
2 4 6 8 10 12 14 
Pig Serum G-K-G-A-V-G-A-G-P-V-V-R-
Rat Serum G-I-G-A-V-G-A-G-P-V-V-R-C-E-P-
Human Plasma G-A-S-S-A-G-L-G-P-V-V-R-C-E-P-
Flgure 2. N-termlnal amino acid sequence of IGF-BPs purified from pig serum (Walton et al., 1988a), rat 
serum (Baxter and Martin, 1987) and human plasma (Baxter et al., 1986). Amino acids 
highlighted differ from residues In porcine IGF-BP. Amino acid code Is presented In Figure 1. 
Polyclonal antiserum raised against the acid-stable IGF-BP recognizes the 150 kDa IGF-BP in 
porcine serum (Walton and Etherton, 1988). This finding indicates that we purified a component of 
the large complex (150 kDa IGF-BP) and this protein is a heterogenous complex of subunit 
proteins. An RIA established for this IGF-BP in porcine serum has been used to ascertain whether 
pGH affects circulating IGF-BP concentrations (Walton and Etherton, 1988). When pigs are treated 
with pGH acutely (10 to 1000 g/kg BW) serum IGF-BP concentration is unaffected. Chronic 
treatment with pGH, however, increases IGF-BP concentration significantly (Walton and Etherton, 
1988). In the studies we have done, it takes approximately two days for pGH to increase IGF-BP 
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concentration. The rise in IGF-BP concentration is paralleled by an increase in serum IGF-1 
concentration. Hypophysectomy reduces IGF-BP concentration by 60 to 70%. When pigs are 
treated with daily intra-arterial injections of IGF-1 for three days there is no increase in IGF-BP 
concentration (Walton and Etherton, 1988). This suggests that IGF-BP concentration is not under 
IGF-1 regulation. Studies are needed, however, to establish whether chronic infusion of IGF-1 
affects IGF-BP concentration in domestic animals. It is possible that because exogenous IGF-1 was 
cleared so rapidly (see above) plasma levels were not elevated for a sufficient length of time to 
answer the question of whether exogenous IGF-1 affects IGF-BP synthesis and secretion. 
Recently, Baxter (1988) suggested that the human 150 kDa IGF-BP is comprised of an 
acid-stable IGF-binding subunit (analogous to the porcine acid-stable IGF-BP) with a Mr of 53 and 
a 100-110 kDa acid-labile subunit. This would suggest that there is only one binding subunit for 
IGF-1 in this complex. What is not clear is that when porcine serum is subjected to ligand blotting 
that six IGF-BPs are observed (McCusker et al., 1988). It may turn out that the use of gel 
chromatography and FPLC to determine of the distribution of I-IGF-1 in pig serum does not 
resolve heterogenous forms of ca. 150 kDa IGF-BP that exist. It is also important to realize that 
simply evaluating chromatographic profiles of I-IGF-1 specific binding to serum proteins as 
means of identifying IGF-BPs is constrained by the availability of unoccupied binding sites (i.e., if 
all the sites are occupied with endogenous IGF-1 then no exogenous IGF-1 will bind and the 
IGF-BP not recognized). 
The observation that the GH-dependent IGF-BP concentration is not affected by exogenous 
IGF-1 suggests that IGF-1 treatment may not be as effective as treating pigs with pGH. Other 
studies provide evidence to support this assertion. Since adipose tissue plays such an important role 
in the adaptive response to exogenous pGH we asked whether this may be mediated by the elevation 
in IGF-1. In vitro, IGF-1 is an insulin mimic in porcine adipose tissue and stimulates both 
lipogenesis and glucose oxidation (Walton et al., 1987; Walton et al., 1988c). This effect is inhibited 
by physiological concentrations of the purified acid- stable IGF-BP (Walton et al., 1988c). This is a 
specific effect of IGF-BP because insulin action is not blocked by addition of the binding protein. 
In summary, it appears that IGF-1 does not mediate the effects that pGH has on adipose tissue 
metabolism because: 1) the effects of free IGF-1 are insulin-like whereas the effects of pGH both 
in vivo and in vitro are to antagonize insulin action in adipose tissue and decrease adipose tissue 
growth rate; 2) the IGF-BPs block the insulin-like effects of free IGF-1; and 3) there is no 
detectable free IGF-1 in porcine serum. Even if free IGF-1 were present in adipose tissue it appears 
that the insulin-like effects would be blunted in pGH-treated pigs because pGH decreases adipose 
tissue sensitivity and responsiveness to free IGF-1 (Walton et al., 1987). 
IGF-BP cDNAs 
As noted above, the IGFs bind to IGF-BPs in serum in addition to the type 1 and 2 IGF receptors 
(discussed later) on target cells. In addition to merely acting as binding proteins, it is apparent the 
IGF- BPs affect IGF-1 removal from blood and act to modulate bioactivity of IGF-1. Based on the 
finding that a small molecular weight IGF-BP is present in the secretory endometrium and decidua 
together with the observation that the 150 kDa IGF-BP is present in a variety of biological fluids in 
pigs (follicular fluid, amniotic fluid, allantoic fluid, colostrum and milk) (Walton and Etherton, 
1988) indicate that the IGF- BPs are produced locally. To determine whether IGF-BPs are produced 
locally studies have been undertaken to clone the IGF-BP cDNAs and then use these as probes to 
determine if IGF-BP mRNA can be detected in various tissues. To date, there have been no studies 
with tissues from domestic animals. 
Initial efforts to determine whether IGF-BP genes are being expressed by peripheral tissues have 
focused on cloning the small Mr rGF-BP secreted by HEP G2 cells and found in amniotic fluid. 
Studies have been conducted in which the IGF-BP from HEP G2 cells (Lee et al., 1988), human 
placenta (Brinkman et al., 1988; Grundmann et al., 1988) and human decidua (Brewer et al, 1988; 
Julkunen et al., 1988) have been cloned. The amino acid sequence deduced from the cDNA clones 
indicates that the IGF-BP produced by HEP G2 cells and the human placenta/decidua are identical 
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(Brinkman et a., 1988; Grundmann et al., 1988, Lee et a., 1988, Julkunen et al., 1988). There is one 
residue difference in the sequence reported by Grundmann et al. (1988) and Lee et al. (1988) versus 
the sequence reported by Brinkman et al. (1988) and Julkunen et al. (1988); however, for practical 
purposes these two proteins are identical. In contrast, the deduced amino acid sequence reported by 
Brewer et al. differs markedly from the sequences reported for the other IGF-BPs. It is interesting 
to note that sequence reported by Brewer et al. (1988) is similar to the other clone in that the first 
30 amino acids at the NH4 terminus are identical, the next 15 amino acids are different, the 
sequence for residues 45-144 of the open reading frame are the same, however, they are off register 
by one residue when compared with the sequences reported for the other IGF-BP clones. The 
remainder of the sequence reported by Brewer et al. (1988) is off register by two residues. The 
meaning of this is not clear at this time. The availability of cDNAs will enable studies to be 
conducted to establish what tissues synthesize which IGF-BPs and whether GH regulates transcript 
abundance. The limited information available indicates that the transcript for the small IGF-BP is 
detected only in human liver, secretory endometrium and late-pregnancy decidua (Julkunen et al., 
1988). 
IGF-1 receptors 
Three types of cell surface receptors bind IGF-1: the insulin receptor and the IGF type 1 and 2 
receptors. The type 1 and 2 IGF receptors and the insulin receptor exhibit different binding 
affinities for insulin and the IGFs. The insulin and type 1 receptors bind IGF-1 and 2 as well as 
insulin. The relative affinities of the insulin receptor for these ligands is in the order insulin >= 
IGF-2 >= IGF-1, whereas for the type 1 IGF receptor it is IGF-1 >= IGF-2 >= insulin (Nissley and 
Rechler, 1984; Rechler and Nissley, 1985). Type 2 receptors have a greater affinity for IGF-2 and 
do not bind insulin or IGF-1 (Rosenfield et al., 1987). 
Growth hormone receptors 
Because the biological effects of pGH are initiated at the level of the receptor in target cells there 
has been considerable interest in looking at the effects of pGH treatment on binding to the receptor, 
the structure of the pGH receptor and the means by which the receptor generates chemical signals 
that mediate the many diverse biological effects of the hormone. Unfortunately, there is little 
information in the literature about the pGH receptor. This paucity of information about the 
signalling systems used by the GH receptor is also true for other species. There is, however, some 
information about the structure of the GH receptor. The most definitive information is the recently 
published amino acid sequences for the hGH and rabbit GH receptors (Leung et al., 1987). Both 
rabbit and human GH receptor clones contain an open reading frame of 638 amino acids which 
includes an 18 amino acid membrane signal sequence. Thus, the mature form of the receptor is 620 
amino acids with an Mr of 70 kDa. This is much smaller than the 130 kDa molecular weight 
determined by SDS-gel electrophoresis. The difference is likely the result of glycosylation and the 
presence of covalently bound ubiquitin (Leung et al., 1987). Cloning of the GH receptor from 
porcine and bovine tissues will permit studies to be conducted in the future to clarify the effects of 
exogenous GH on GH receptor mRNA abundance. In studies we have conducted, treating pigs with 
pGH caused an up-regulation of GH binding to porcine liver microsomes. It is not known whether 
this is the result of differences in pGH receptor mRNA or reflects other changes (such as 
translational regulatory events). 
The amino acid sequence data presented by Leung et al. (1987) indicate that the soluble GH 
binding protein found in rabbit serum also has the same sequence as the extracellular domain of the 
receptor. This suggests that the protein could be released by proteolysis of the receptor near the 
transmembrane domain. 
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Conclusion 
A remarkable era has occurred in animal agriculture over the past eight years. The emergence of 
recombinant DNA technology has provided sufficient quantities of previously scarce proteins to 
enable scientists to test hypotheses not previously addressed. Based on our progress to date, it is 
reasonable to speculate that as we gain a better understanding of the GH receptor and the 
mechanisms by which GH mediates its biological effects it will be possible to develop second 
generation approaches that provide either more potent GH analogs or alternative methods to 
increase GH biopotency. Irrespective of when this happens the progress made to date has shown 
that treating pigs with exogenous pGH markedly enhances pig growth performance. 
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INFLUENCE OF PORCINE SOMATOTROPIN ON ENERGY 
METABOLISM IN PIGS 
M.W.A. Verstegen, W. van der Hel, E.J. van Weerden 
Agricultural University Wageningen and Institute of Animal Nutrition and 
Physiology, ILOB, Wageningen, The Netherlands 
Summary 
There is evidence that application of porcine somatotropin (pST) to growing pigs increases the 
metabolic rate. The magnitude of this increase seems to be most clear at similar intake of 
metabolizable energy in both pST and control animals. At present there is inadequate information 
on the cause of the increased metabolic rate in treated pigs. The magnitude of the increase from two 
studies seems to be comparable to an increase of about 10% in maintenance. Whether this is related 
to increased muscle mass is not clear. Also reduced efficiency of protein and far gain may be 
associated with this. It was calculated that at similar maintenance the deposition of fat and protein 
does not occur at a lower rate of partial efficiency. The possibility of increased metabolic rate due 
to reduced fatness and thus insulation and therefore increased thermal demand can not be excluded. 
It needs to be evaluated further what the relation of this heat production is with protein and fat 
synthesis and what the nutritional consequences are. 
Keywords: porcine somatotropin, metabolic rate, maintenance, partial efficiency. 
Introduction 
Administration of exogenous porcine somatotropine (pST) has been the subject of various 
studies: Machlin (1972), Chung et al. (1985), Rebhun et al. (1985), Verstegen et al. (1989). 
It was found in these studies that protein accretion is markedly increased and that fat gain is 
drastically impaired by pST. It is important to discuss how metabolism is altered as a result of 
administration of pST. 
Effect on production 
Campbell et al. (1988) found with administration of endogenous porcine somatotropin that 
growth rate in pigs of 25 to 55 kg increased with 16 to 22% and protein deposition with 34 to 50%. 
These results showed that effects on growth performance and energy and protein metabolism were 
largely independent of and additive to that of the energy intake. In experiments at our university of 
Huisman et al. (1988) and Van der Hel et al. (1988) it was found that rate of gain in animals 
(Pietrain, Duroc and crossbreds between Dutch Landrace and Dutch Yorkshire) from 80 kg onwards 
with recombinant pST was increased with about 100 g/day at constant feeding level (2.6 times 
maintenance). 
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Table 1. Rate of gain (kg/d) and feed conversion of animals of three genotypes at constant feeding 
level during 6 weeks (5-10 weeks after Initial administration). 
Rate of gain Feed/gain 
Retrain 
Duroc 
DYxDL 
C 
T 
C 
T 
C 
T 
.87b 
.99a 
,72d 
.80° 
.92b 
1.04a 
2.94b 
2.79° 
3.40a 
3.19a 
2.90b 
2.70d 
In Table 1 data on performance are given. Data clearly show an increased rate of gain and a 
concomitant decreased feed to gain ratio in animals given the same feeding level. In the 
experiments of Huisman et al. (1988) and Van der Hel et al. (1988) protein and fat gain were 
measured with control and with pST treatment. In Table 2 data on these aspects are given for 
animals of about 80 kg. 
Table 2. Effect of pST on rate of gain In protein and fat (g/d). 
Genotype Treatment protein (g/d) Fat (g/d) 
Retrain 
Duroc 
DYxDL 
Control 
pST 
Control 
pST 
Control 
pST 
142 
191 
119 
166 
168 
210 
263 
249 
275 
215 
280 
218 
On an average protein gain was increased with about 40 g/d and fat gain was decreased with 47, 
18 and 64 g/d in Duroc, Pietrain and DyxDL respectively in these experiments (Table 2). 
In addition Reeds (1987) stated that ß-adrenergic agents also have a marked repartitioning effect 
associated with increased energy expenditure. 
Table 3. Manipulation of growth by alterations In growth hormone status (Reeds, 1976). 
1. Immunization against somatostatin: The removal of a constraint on growth hormone release. 
Responses In protein deposition associated with enhanced skeletal growth. 
2. Administration of growth hormone: A forced Increase In systemic growth hormone levels. Pigs: 
Tendency towards lower food Intake with ad libitum feeding. Marginal to zero effect on 
skeletal growth. Marked repartitioning effect. 
3. Introduction of growth hormone or growth hormone releasing factor gene: Persistent secretion of 
growth hormone. Marked Increase In skeletal growth In mice. Presumably marked 
Increase In appetite. No published Information on body composition. 
According to Table 3 a characteristic effect of alterations in growth hormone is a coordinated 
growth with all components of the body increased in size. In addition Campbell et al. (1988) 
concluded that an increased energy expenditure occured with the use of endogenous somatotropin. 
It is not clear why increased energy expenditure is associated with the application of extra 
somatotropine or with the application of ß-adrenergic anabolic agents. 
According to Machlin's work (1972) with pigs, pST directs nutrients to the muscle during 
growth. To understand the metabolic effect of somatotropine on metabolism it is important to note 
that any intervention that alters the rate of a major route of nutrient (or energy) storage will also 
alter the rate of storage pathways (Reeds, 1987). Therefore it is important to distinguish between the 
mechanisms which are responsible for a reduction in e.g. fat deposition that might arise from a 
specific stimulus of protein deposition and those that appear to stem primarily from an increase in 
energy expenditure. It is not clear how the increase in serum glucose and insuline levels after 
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somatotropin applications in pigs (Etherton et al., 1986; Boyd, 1987) is associated with increased 
energy expenditure. Campbell et al. (1988) showed in pigs that changes in lipid and protein 
metabolism elicited by pST were largely independent of energy intake. 
Metabolic heat production 
Energy expenditure in animals can be calculated as follows: We first assume that animals are 
kept at thermoneutral conditions. Heat (or thermal losses) is produced as a result of the many 
metabolic processes occurring within the animal, the extent to which it occurs is not only 
characteristic of the animal per se but it is also dependent upon nutritional, productive, 
environmental and other related factors. Thus no simple system can be used to describe the 
contribution made by the various factors to metabolic heat production. 
In practice, and in order to facilitate the application of energy evaluation systems, it has been 
customary to divide thermal losses into those associated with maintenance, on the one hand, and 
those resulting from the deposition of tissue or products formed within the body, on the other. The 
former, the maintenance heat loss, represents an animal in a state of energy equilibrium, that is 
neither losing nor gaining energy, so that the intake of dietary energy exactly balances the animal's 
heat output. The heat arising from the accretion of tissues or products within the body represents the 
amount of work done in their deposition and varies with the nutritional state of the animal, so that 
the higher the level of feed intake, the higher the rate of tissue accretion and the greater the heat 
output associated with these processes, i.e. the heat increment of feeding (which is synonymous 
with "specific dynamic action" and "dietary induced thermogenesis"). Both the maintenance heat 
loss and heat produced as a result of tissue deposition are influenced by a number of factors. As the 
rate of the animal's heat loss increases at any given level of feed intake, there will be a reduction in 
the rate at which energy is retained and hence a change in the energetic efficiency of growth. For 
practical purposes it is important to know to what extent heat production varies in relation to those 
factors which influence it, since this determines the extent and efficiency of energy utilisation. 
It is appropriate to express the energy retained by an animal as a function of its body weight and 
the quality and quantity of the ration provided. Food can then be described in its capacity to sustain 
maintenance (MEm) and to promote energy gain (RE). This is illustrated in Figure 1, where 
Intake of metabolizable energy 
Figure 1. The Relation between energy retention (kJ/kgu '° per day) and metabolizable energy 
(kJ/kg0,78 per day) In the pig at thermoneutral condition. T8a Is partial efficiency above 
maintenance. MEm Is metabolizable energy needed for maintenance. 
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metabolizable energy (ME) intake, i.e. the gross energy of the feed minus the energy lost in faeces, 
urine and methane, is related to energy retained (RE). 
We assume that partial efficiency (tga in Figure 1) was not altered with increase in ME intake. 
The inefficiency l-tgCc is for heat increment. 
Above the basal or fasting level of metabolism, each increment in ME is associated with an 
increment in heat production (H). However, the increment in ME exceeds the increment in H so that 
the animal has the capacity to retain energy (RE), although RE only becomes positive at intakes 
above the maintenance energy requirement, that is at MEm - RE is zero. The efficiency with which 
energy is retained is equal to dRE/dME. As we are working with growing animals feed intake is 
normally above maintenance. We assumed linearity between energy retention and intake of 
metabolizable energy. Energy retention can be described as: 
RE= kg*ME-b (1) 
in which: RE = retained energy 
ME = metabolizable energy 
k g = dRE/dME 
b/kg = maintenance requirement. 
This procedure was applied by Campbell et al. (1988). They regressed RE on ME intake. They 
used digestible energy instead of metabolizable energy. This is justified because there is a nearly 
fixed ratio of digestible to metabolizable energy above maintenance. Since there is a very high 
correlation between metabolizable energy and digestible energy (DE) this formula (1) also holds for 
DE. The value (l-kg) represents the increase in energy expenditure with feed intake above 
maintenance (MEp). 
The efficiency is representative for total energy gain from ME and does not account for 
differences in its composition, reflected in the rates of protein and fat deposition. Separate estimates 
of the energetic efficiency of protein deposition (kp) and fat deposition (kf) can be calculated with 
the respective heat increments being MEprotein (l-kp) and MEfat (1-kf). Thus total thermal loss 
associated with he metabolism of dietary energy is the sum of the energy costs of maintenance 
(MEm) and the heat increment associated with the deposition of tissue, calculated as MEp (l-kg) or 
partitioned into that associated with protein deposition, ME
 Protein*(l-kp) and fat deposition, ME 
fat*(l-kf). 
Relation of partial efficiency and maintenance to metabolic rate 
In the literature there are many estimates of the partial efficiencies of fat and protein accretion 
kp and kf. Theoretically the efficiency of utilisation of ME for protein synthesis may be about 0.85 
(Van Es and Boekholt, 1987). In studies with young pigs mostly values of .35 to .60 are derived 
(ARC, 1981). It should be mentioned here that higher protein turnover may be responsible for the 
higher heat production per unit of protein gain compared to the theoretical values. In fat gain 
theoretical values for kf and measured values are nearly similar. This similarity can be explained by 
the low turnover in fat (see Van Es, 1978). In the ARC study of (1981) values of kp and kf were 
assumed at 0.54 and 0.77, respectively. These results mean that kg in formula (1) depends on the 
ratio in which protein and fat are deposited. The lower value with kp is generally associated with 
protein turnover. The protein gain accretion is then the net result of protein synthesis and 
proteolysis. If this ratio is altered with application of pST, kp will be altered. 
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Table 4. Heat production and energy balances In control (C) and pST (T) animais. 
Heat production (H) 
KJ/kg*76 
Retained energy (RE) 
kJ/kg076 
Pletraln 
Duroc 
Crossbred 
C 
T 
C 
T 
C 
T 
632 
653 
611 
669 
623 
682 
448 
427 
469 
418 
469 
427 
In the experiments of Van der Hel et al. (1988) heat production has been measured and also 
protein and fat gain were determined. From the data of Table 4 it is clear that heat production in pST 
animals was higher than in C animals and retained energy is reduced at the same feed intake 
(Figure 2). This increase can not be explained totally by the increase in protein accretion. 
RE 
c 
pST 
— ME 
Figure 2. Effect of pST on RE. 
In Figure 2 effect of pST on RE is given. The reduced RE can be related to ME intake in various 
ways: 
— Increased maintenance requirement. 
— Decreased efficiency of energy utilization for protein accretion. 
— Decreased efficiency of energy utilization for fat accretion. 
Maintenance requirement 
This way is depicted in Figure 3 where it has been assumed that the effect of pST is on 
maintenance and not on partial efficiency. Maintenance increase can be caused by various factors. 
It may be related to increased protein content in the body, activity and increased thermal demand. 
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RE 
— ME 
efficiency is similar 
Figure 3. Effect of pST on maintenance requirement (ME). 
Maintenance requirement (MEm) was calculated as: MEintake - Energy in fat retained/kf. Energy 
in protein retained/kp. If no change in energy requirement per kj retained in fat and protein is 
assumed, than maintenance requirement is as follows: 
Controls: MEm = 393 kJ ME/kg 
pST treated: MEm = 491 kJ ME/kg 
0.75; 
0.75 
Campbell et al. (1988) assumed a higher maintenance requirement for pST treated animals as 
well. Kanis et al. (1989) found in their experiments that lean in animals at 100 kg was increased 
from 55.5% to 59.5% with pST. 
With the following assumptions the calculations in Table 5 can be made: 
— mean weight of 80 kg during application in the second half of the fattening period. 
— carcass weight = 0.77 x weight = 61.6 kg (0.77 from Walstra, 1980). 
— lean in body = 1/0.58 x lean in carcass (from Whittemore, 1983). 
— protein in body = 1/4.39 lean (Metz et al., 1983). 
— calculated maintenance requirement for protein in the body as MEm (in MJ day) = 1.85 x 
protein0'78 (Whittemore, 1983) 
Tabel 5. Calculation of maintenance requirement for protein. 
Control pST treated 
Lean (kg) 
Protein (kg) 
Maintenance requirement 
for protein (MJ) 
Maintenance requirement 
for protein (MJ/kga75) 
33.14 
13.13 
13.70 
.51 
36.65 
14.52 
14.91 
.56 
By presenting results in this way part of the increased metabolic rate would be explained. In 
addition if pigs treated with somatotropine are more active and/or more sensitive to cold as 
132 
IMPACT ON TARGET SPIECES: REQUIREMENTS 
suggested by Curtis (1987) such an increased maintenance requirement would be expected. If we 
first assume that our animals were in the zone of thermoneutrality than increased metabolic rate is 
not due to coldness. Reeds (1987) and Campbell et al. (1988) indicate an increased metabolic rate 
with pST as well. 
In experiments of Kanis et al. (1988) it was found that with pST backfat was reduced with about 
18%. This may alter heat loss from animals to the environment. Heat transfer from the animal to the 
environmental depends on insulation value of: 
- Boundary layer of air around the animal. 
- Hair coat. 
- Tissue. 
The first two are termed external insulation. Maximal tissue insulation at vaso constriction 
depends on the layer of fat around the body. It can be easily calculated what the effect of reduced 
(backfat) thickness on tissue insulation and thus total insulation will be. Hovell et al. (1977) 
measured insulation value in thin and in normal sows. They calculated that the tissue insulation of 
a normal pig is less than half of the total insulation. Therefore it is important to note that Curtis 
(1987) calculated that a 50% reduction in fat layer reduced the insulation value by more than 10%. 
This means that one of the avenues of heat transport from the animal's core to the environment is 
easier. 
It depends on the contribution of the tissue insulation to total insulation how much the lower 
critical temperature is altered (increased) by this. Almost certainly the critical temperature is 
increased by some degrees by pST depending on the degree of reduction in the fat layer surrounding 
the body. On the other hand however, as metabolic rate is increased the critical temperature is 
lowered. It needs to be assessed what the consequences of the combination of the increased 
metabolic rate and decreased backfat thickness will be. In Figure 4 both situations have been 
depicted. 
RE 
— ME 
M E m Is similar 
Figure 4. Possible effects of pST on thermal demand. 
In Figure 4 the tga is for increased thermal demand below thermoneutrality and as insulation in 
pST animals is less than in controls, thermal demand is increased. 
Differences in maintenance requirement have been reported for pigs with different genetic 
capacities for growth (Campbell and Taverner, 1985) and in pigs selected for different backfat 
thickness (Sundst0l et al., 1979). Also in mice selected for low body weight Van der Wal et al. 
(1976) reported a higher maintenance compared to control animals. 
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Protein gain 
In Figure 5 it is shown how, with similar maintenance, differences in efficiency of retained 
energy can occur. Furthermore, this efficiency can be calculated from energy in protein or from 
energy in fat gain. 
c 
o 
•*-« 
u 3 
"O O 
«s 
X 
pST 
C 
Temperature 
Figure 5. Effect of pST on efficiency of feed utilisation above maintenance. 
Net protein synthesis is increased with the administration of pST. The efficiency of feed N 
utilization is greatly improved. However this does not mean that the partial energetic efficiency of 
protein accretion is also increased. It may be that the increase in protein accretion as a result of pST 
is associated with a more rapid protein turnover, resulting from simultaneously increased anabolic 
and catabolic processes. This would lead to an increased metabolic rate. 
0 75 
If we assume the same maintenance (420 kJ ME/kg ' ) in all animals and the same partial 
efficiency for fat deposition (kf= 0.74) in all animals, then the resulting partial efficiency of energy 
utilization for protein accretion (kP) is as follows: 
Controls: kp = .59; 
pST treated: kp = .48. 
Campbell et al. (1988) assumed that the higher metabolic rate with pST resulted from higher 
protein accretion. With the assumptions made above, our results showed that the partial energy 
efficiency of protein accretion in control animals (kp) was similar to the ARC (1981) estimate. 
However kp in pST animals was markedly reduced. 
Fat gain 
There may be a third reason for the increase in heat production. Increased lypolysis (Etherton et 
al., 1986) may increase fat "turnover" and as a result the partial efficiency of fat deposition from 
metabolizable energy is reduced. This implies that kf in pST animals should be less than .74 
compared to control animals. When we calculate kf by assuming that maintenance is equal in all 
groups (420 KJ ME/kg ) and partial energy efficiency for protein formation was also equal (kp = 
0.54) then the resulting energy required per kJ (kf) was as follows: 
Controls: kf=0.77; 
pST treated: kf=0.68. 
Campbell et al. (1988) mentioned that the inhibition of lipogenesis may cause the decrease in fat 
accretion. They however also suggest that the reduced amount of energy available for lipogenesis 
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may contribute in a passive way to reduction in fat accretion. Their results of increased fat accretion 
with extra energy intake and pST showed that the reduced availability of energy above that for 
protein synthesis and/or maintenance may be responsible for the lower deposition. It is possible that 
energy requirement for maximum protein gain is increased with pST. Thus metabolic changes in 
pST animals need to be assessed with regard to requirements of protein and energy. It can be 
concluded that pST increases protein gain, reduces fat gain and increases metabolic rate. Until now 
it is not clear, whether the cause is altered maintenance or lower efficiency of energy gain. 
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IMPLICATIONS OF BIOTECHNOLOGICAL TECHNIQUES FOR 
MANIPULATING ANIMAL GROWTH AND DEVELOPMENT ON 
TISSUE AND DIETARY NUTRIENT REQUIREMENTS OF PIGS 
R.G. Campbell, R.J. Johnson and R.H. King 
Animal Research Institute, Werribee, Victoria 3030, Australia 
Summary 
Exogenous administration of porcine growth hormone pGH, GH releasing factors and possibly 
IGF-1 enhance protein and mineral accretion rates resulting in more rapid skeletal development, 
improved growth performance and reduce carcass fat content. However the effect these 
technologies have on the growing pigs requirement for dietary nutrients remains unclear. For pigs 
30 to 60 kg exogenous GH administration increases protein deposition 25-40%, but because of 
unknown improvements in amino acid utilisation has little effect on the levels of dietary protein and 
amino acids required to support near maximum growth performance. In Contract pGH 
administration between 60 and 100 kg increases protein deposition 50 to 80 % (depend on animal 
sex) and there is a concomitant 30-45 % increase in the level of dietary protein (amino acids) 
required for near maximal growth performance. The stimulation of protein metabolism elicited by 
pGH is mediated via IGF-1 and results from increases in the rates of both protein synthesis and 
breakdown. However to fully evaluate the impact of pGH and related technologies on dietary 
nutrient requirements further information is required on the magnitude of increases in protein and 
mineral accretion rates able to be achieved by these technologies and on the associated changes in 
intermediary amino acid and mineral metabolism. 
Keywords: somatotropin, swine, nutrient requirements, protein, minerals. 
Introduction 
Research conducted over the last five years has demonstrated the potential role of biotechnology 
in improving the efficiency and profitability of animal agriculture. 
The marked improvements in growth performance and carcass merit which have been reported 
for pigs administered porcine growth hormone (pGH) have encouraged a number of companies to 
pursue the commercialisation of this and related technologies. 
However, the extent that the animals' dietary nutrient requirements and other management 
procedures might need to be altered to ensure the success of these technologies remain unclear. 
There is, nevertheless, increasing information becoming available on the response of treated pigs to 
nutrient intake and on the changes in tissue accretion rates elicited by the various technologies in 
growing pigs. The present paper attempts to review the relevant data and to highlight where this is 
either inadequate or misleading. 
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Effects on protein metabolism and dietary protein / amino acid requirements 
It has become clear from recent research findings that the endocrine system, and endogenous GH 
secretion in particular, is the major factor constraining protein accretion in growing pigs. This is 
illustrated in Tables 1 and 2 which show the changes in protein deposition and growth performance 
elicited by exogenous pGH administration in pigs growing from 25 to 55 and from 60 to 
approximately 100 kg live weight respectively. 
Table 1. Effect of exogenous pGH administration (0.1 mg pituitary derived GH.kg"'.d"') on protein 
deposition and performance of ad libitum fed castrated male pigs growing from 25 to 55 kg 
(Campbell et al., 1988a). 
pGH(mg.kg"1.cr1> 
0.0 0.10 
Protein deposition (g/d) 
Fat deposition (g/d) 
Dally gain (g/d) 
Feed Intake (kg/d) 
Feedigaln 
Carcass fat (%) 
110 
283 
905 
2.32 
2.57 
28.0 
151 
193 
1052 
2.08 
1.96 
20.0 
Table 2, Effect of exogenous pGH administration between 60 at approximately 100 kg on protein 
deposition and performance of boars, gilts and castrated male pigs (Campbell et al., 1989). 
SEX 
pGH (mg.kg-'.d"1 ' 
Protein deposition (g /d) 
Fad deposition (g/d) 
Dally gain (g) 
Feed Intake (kg/d) 
Feedigaln 
Carcass fat (%) 
BOAR 
0.0 
196 
316 
1185 
3.21 
2.72 
24.3 
0.1 
238 
202 
1341 
1.96 
2.21 
18.6 
GILT 
0.0 
148 
410 
1010 
3.37 
3.36 
28.7 
0.1 
234 
185 
1237 
2.73 
2,20 
18.9 
CASTRATE 
0.0 
139 
462 
1057 
3.67 
3.65 
32.7 
0,1 
224 
221 
1124 
2.84 
2.32 
21.5 
It is clear from these and other results that the marked increase in protein deposition elicited by 
pGH administration, which in turn appears to be medicated via the somatomedins (IGF-1), is the 
mechanism by which pGH therapy stimulates growth rate and feed conversion efficiency. Similar 
changes in protein accretion, growth performance and carcass composition would be expected to 
resume from any technology which increases circulating pGH and IGF-1 levels. 
Under 'normal' circumstances the initiation and maintenance of increases in protein accretion of 
the magnitudes shown in Tables 1 and 2 would be expected to require concomitant increases in the 
levels of dietary protein and amino acids. Indeed, using the factorial approach Boyd et al. (1988) 
predicted an almost two-fold increase in the dietary lysine requirement of pigs administered pGH 
(0.1 mg.kg" .d" ' between 55 and 100 kg liveweight. However, the factorial approach requires 
accurate information on the rate and amino acid composition of protein gain and relies on numerous 
assumptions regarding the efficiency with which dietary nutrients are metabolized and integrated 
into animal tissues. It takes no account of the extent that the increase in protein deposition elicited 
by pGH administration and any related technology results from relative changes in the rates of 
protein synthesis and breakdown or in the efficiency of amino acid transfer or intermediary amino 
acid metabolism. All these factors however, affect the amount of dietary protein required to support 
protein growth at the tissue level. 
Until more of this information is available the factorial approach will remain limited as a means 
of estimating the impact of biotechnological techniques for manipulating growth and development 
or the animal's dietary nutrient requirements. In the meantime, it is the empirical or descriptive type 
experiments which provide the more informative data. 
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A number of such experiments have been conducted with pGH treated pigs. Unfortunately, the 
value of most of these studies is limited by various design problems and/or by the narrow range of 
protein/amino acid inputs over which the animal's responses were assessed. 
It was concluded from the results of Studies conducted at Kansas State University (Goodband et 
al., 1988) that pGH administration (4.0 mg.pig^.d"1^ doubled the pig's dietary lysine requirement 
between approximately 60 and 100 kg liveweight (from 0.6 to 1.2% total lysine). However, the 
authors did not assess the responses of control animals to dietary lysine concentration beyond the 
lowest level tested (0.6%) and based their conclusion on the NRC (1988) estimate of lysine 
requirement for pigs between 60 and 100 kg. Based on growth performance it could also be 
suggested that there was little improvement in the growth rate or feed:gain of pGH treated pigs to 
levels of dietary lysine above 1.0% (0.68g total lysine/MJ DE) which is not much higher than the 
ARC (1981) estimate of requirement for female or castrated male pigs of similar weight and 
somewhat below the estimate of requirement for boars of slightly lighter body weight (ARC, 1981 ). 
Based on the results of a similar experiment conducted at the University of Illinois, Easter (1987) 
suggested that pGH administration (3mg.kg~ .d ) increased the dietary protein requirement of 
castrated male pigs growing between 45 and 100 kg from 14 to 23.6%. However, again the 
responses of control pigs to dietary protein were not assessed. The improvements in growth rate and 
feed:gain in response to increasing dietary protein were also small and appeared to peak between 17 
and 20% dietary protein. 
Similar difficulties apply with the data of Fowler et al. (1988) who compared the performance 
and carcass merits of pigs given four pGH dosages (0.0,1.75,3.50 and 7.0 mg.pig" .d" ) each at two 
levels of dietary protein (165 and 190 g/kg) between 30 and 95 kg. The results clearly indicated that 
the magnitude of the improvements in growth rate, feed:gain and in carcass quality (less fat) elicited 
by pGH were increased on the higher protein diet. However, because only two levels of dietary 
protein were tested, and the lower level was almost certainly deficient for pigs from 30 to 60 kg, the 
results do not provide the quantitative information required to determine the levels of dietary 
protein required to achieve the most economic responses in terms of growth performance and 
carcass characteristics for pGH treated pigs. 
The results of a more quantitative experiment in which the responses of control and pGH treated 
boars to six levels of dietary ideal protein (ARC, 1981) were assessed between 30 and 60 kg 
liveweight are presented in Table 3. 
Table 3. Effects of exogenous pGH administration on the responses of fast growing boars to dietary 
Ideal protein between 30 and 60 kg (Campbell et al., 1988b). 
Dietary * 
protein 
(g/kg) 
83 
114 
145 
176 
207 
238 
pGH 
(mg.kg" 
0.0 
0.09 
0.0 
0.09 
0.0 
0.09 
0.0 
0.09 
0.0 
0.09 
0.0 
0.09 
Protein 
deposition 
•cT0 (g/d) 
72 
71 
108 
111 
122 
152 
144 
166 
146 
173 
139 
174 
Fat 
deposition 
(g/d) 
234 
186 
208 
175 
210 
162 
200 
133 
192 
123 
187 
98 
Dally 
gain 
(g) 
605 
583 
712 
750 
776 
908 
871 
977 
790 
1007 
866 
1004 
Feedigaln 
(g/g) 
3.08 
3.18 
2.61 
2.47 
2.36 
2.03 
2.16 
1.87 
2.26 
1.81 
2.14 
1.78 
Carcass 
fat 
(%) 
31.1 
27.6 
24.7 
21.9 
24.2 
18.0 
20.8 
15.6 
22.1 
14.7 
21.2 
13.5 
All pigs given 1.85 kg feed/d. 
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The results clearly demonstrate that at the lowest level of dietary protein tested (83g/kg), protein 
intake was inadequate to enable pGH to exert its stimulatory effect (via IGF-1 ) on protein 
deposition. Fat deposition on the other hand, was reduced 20% on the same diet by pGH 
administration resulting in growth performance being depressed compared to that of control 
animals and an 11 % reduction in carcass fat content. 
Apart from demonstrating independent effects of pGH on protein and lipid metabolism, the 
results also show that the stimulatory effect of the hormone on protein deposition increased with 
increasing dietary protein to a maximal rate of approximately 173 g/d compared to approximately 
140 g/d for control pigs. More interesting however, was the fact that the level of dietary ideal 
protein required to support this 24% higher rate of protein deposition was only 4% above the 
required by control pigs (182 vs. 175 g ideal protein/kg). Similar results have been found for pigs 
of the same weight given diets of constant lysine content but varying widely in total nitrogen 
content by Stelle and Caperna (personal communication). 
The results presented in Table 3 could not be predicted using the factorial approach. They further 
indicate that pGH may exert its effect on protein deposition by inhibiting protein breakdown and/or 
by increasing amino acid transfer or the efficiency of intermediary protein metabolism. 
Effect of pGH administration on protein synthesis and breakdown 
To investigate the effects of exogenous pGH administration on protein turnover, an experiment 
was conducted at the ARI, Werribee in which N -glycine was administered to gilts fitted with 
indwelling bladder catheters and treated with pGH (0.1 mg.kg" 'd ) for a period of 18 days 
commencing at 60 kg live weight. The pigs were given a single diet in restrictive amounts 
(24 MJ DE/d) and N-balance and N enrichment was measured from faeces and urine collected 
every 12h for 72h. 
The results showed that pGH administration increased N-retention by 38% (7.5 g/d) and that this 
was associated with a 47% increase in N-synthesis and 48% increase in N-breakdown. 
These data (R.G. Campbell, R.J. Johnson, F. Thomas and R.H. King, unpublished results) 
demonstrate that pGH stimulates overall protein metabolism. The results also indicate that the 
positive effect of pGH on protein deposition occurs not because the hormone has a proportionally 
greater effect on protein synthesis than protein breakdown or vice versa but because in pigs up to 
90 kg, at least, protein synthesis exceeds protein breakdown. The results however, raise the question 
as to the effectiveness of pGH and related technologies in stimulating the performance of heavier 
pigs (150-200 kg) in which the rates of protein synthesis and breakdown approach one another. 
These findings clearly rule out an inhibitory effect of pGH on protein breakdown as a possible 
explanation for the similarity in the dietary protein requirements evidenced for pGH and control 
pigs in Table 3. Nevertheless, the proportional improvement in protein deposition elicited by pGH 
administration to the young fast growing boars used in this experiment (24%) is relatively small 
compared to that table to be achieved in heavier castrates and gilts. Clearly the extent that the 
treated pigs dietary protein requirement will be altered by any of the GH related technologies will 
be a direct reflection of the increase in protein deposition elicited by the technology. The magnitude 
of the improvement in protein deposition is known to be influenced by the age or weight of the pig, 
sex, dosage and by the technology employed. 
Effects of liveweight 
Any change in the dietary protein/amino acid requirements elicited by pGH or any of the related 
technologies will be less pronounced in light compared to heavy pigs, since maximal protein 
deposition (tissue requirement) is constrained by energy intake and by the endocrine system 
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respectively in the two groups. This was demonstrated by the results of a recently completed 
experiment at the Animal Research Institute, Werribee in which pGH administration 
(0.09 mg.kg" .d ) was found to increase the maximal growth performance and dietary ideal protein 
requirement of intact male pigs growing from 60 to 90 kg by 52 and 68% respectively compared to 
controls. 
Effects of sex and dosage 
Because boars are less responsive in terms of protein accretion to exogenous pGH 
administration (Campbell et al., 1988b) and presumably any other technology which acts through 
the GH axis, the dietary protein requirement of boars would be expected to be proportionally 
smaller than that of castrated males or gilts. Similarly because protein deposition responds in a 
linear fashion to increasing GH and GHRF dosage (Etherton et al., 1987; Dubreuil et al., 1988) up 
to the point that protein growth becomes constrained by intrinsic factors other than GH (Campbell 
et al., 1988d). The animal's requirement for dietary protein will probably be unaltered at low doses 
and increase at higher doses. 
Effects of feed intake / 
The reduction in voluntary feed intake induced by pGH administration, and observed in pigs 
transgenic for pGH (Seemark, personal communication) and bGH (Pursel et al., 1988) further 
complicates the interrelationship between these technologies and the animal's dietary nutrient 
requirements. 
It is generally assumed that reduction in voluntary feed intake immediately necessitates an 
increase in dietary protein to support even the same daily protein intake as control animals. 
However, this proposition is only valid if the animal is exhibiting maximum protein deposition or 
alternatively when the latter is not constrained by energy intake. For pigs to 50-60 kg this situation 
rarely exists since during these earlier stages of growth the pig's ceiling for protein growth 
generally exceeds its appetite. Under these circumstances there is a constant relationship between 
energy intake and the animal's tissue and dietary protein (amino acid) requirements. Furthermore, 
the latter are unaffected by feed intake. These facts are well established for 'normal' or untreated 
pigs (Campbell et al., 1985a). A constant or linear relationship between energy intake and protein 
deposition has also been demonstrated for pigs administered pGH between 25 and 55 kg liveweight 
(Campbelletal., 1988a). 
For adlibitum fed pigs above 60 kg the animal's dietary protein and amino acid requirements can 
only be expressed on a daily intake basis since protein deposition plateaus between 75 and 85% of 
adlibitum energy intake (Campbell et al., 1985b; Whittemore, 1986). Clearly, under these 
circumstances, any factor which affects voluntary feed intake will necessitate a change in dietary 
protein (amino acid) concentration. However, given the extremely large increases in protein 
deposition elicited by pGH administration in heavy castrates and gilts, it is possible that for treated 
pigs the relationship between energy intake and protein deposition no longer plateaus but remains 
linear as in the younger pig. 
Presently there is no quantitative information on the form of the relationship between energy 
intake and protein deposition for pGH treated pigs above 60 kg. Such information is crucial if the 
implications of pGH and related technologies on dietary and tissue protein requirements are to be 
fully evaluated. 
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Effects on lipid metabolism and energy requirement for maintenance 
Given the marked increases in protein turnover and lean body mass associated with pGH 
administration it is not surprising that the maintenance energy requirement (MER) of treated pigs 
has been reported to be 12-16% higher than that of control animals (Verstegen, personal 
communication; Campbell et al., 1988a). 
Similar differences in heat production or MER have been reported between lean and obese rats 
(Webster et al., 1978), boars and gilts (Campbell et al., 1985b) and between pigs with low and high 
capacities for protein growth (Campbell and Taverner, 1988). 
Increase in MER appears to be an inevitable consequence of raising an animal's capacity for 
protein accretion and although it cannot sensibly be counteracted at the dietary level, it clearly has 
to be taken into account when attempting to predict the changes in growth performance and carcass 
composition likely to be elicited by pGH administration or any related technology. 
From a more practical aspect, unless appropriate changes are made to the animal's thermal 
environment, the increased heat production associated with pGH administration and clearly 
evidenced by pigs transgenic for bGH, (Pursel, personal communication) may further depress the 
voluntary feed intake of such animals particularly during periods of hot weather. For the same 
reason the viability of these technologies may be seriously threatened in the more tropical regions 
of the world. 
The implications of the increased heat production associated with these technologies needs to be 
investigated over a range of environmental conditions and appropriate strategies developed to 
overcome any serious problems which are identified. 
Effects on dietary requirements for calcium, phosphorus and micro nutrients 
There is evidence that pGH administration increases the rates of deposition of calcium and 
phosphors (Campbell et al., 1988 a,b; Verstegen, personal communication). The changes elicited in 
calcium and phosphorus metabolism by pGH also appear more pronounced in pigs between 30 and 
60 kg compared to those of heavier weight and in gilts compared to boars and castrates (Campbell 
et al., 1988b). However, because of lack of information on the extent that the metabolizability of 
these nutrients is altered by pGH or related technologies, it is not possible to determine their impact 
on dietary requirements. Circumstantial evidence nevertheless, suggests that the dietary levels of 
calcium and phosphors recommended by the ARC (1981), which are considerably higher than those 
recommended by the NRC (1988), are adequate to ensure structural soundness even in animals 
administered even high doses of pGH. 
It is even more difficult to predict the effect of the various technologies for manipulating growth 
and development on pigs requirements for vitamins and other minerals, particularly as in the 
majority of experimental situations these are supplied in excess of currently recommended levels. 
Conclusions 
There is evidence that because of their dramatic effects on protein deposition, pGH and related 
technologies do increase the pigs requirements for dietary protein and amino acids and possibly for 
calcium and phosphors. The magnitude of changes however, are influenced by numerous factors 
including dosage, sex and live weight. Consequently, the most appropriate diet formulation will 
differ depending on the technology employed and the extent it stimulates protein and mineral 
metabolism. 
At present there is inadequate quantitative information on the responses of 'treated' pigs to 
nutrient intake to fully evaluate the impact of the various biotechnological techniques on either 
tissue on dietary nutrient requirements, although it would appear that the early predictions of the 
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impact of pGH administration, particularly on the pigs requirements for dietary protein and amino 
acids may in fact be overestimates. 
The data which is available is fragmentary, too imprecise and to some extent contradictory. 
Similar deficiencies in experimental design and lack of information on the interrelationships 
between the animal's tissue and dietary requirements have led to apparently contradictory theories 
concerning the nutrition of "untreated" pigs in the past. Because of the rapid development of these 
new technologies and the importance of nutritional management in ensuring their success, it is 
imperative that these problems be realized and rectified as soon as possible. 
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EFFECTS OF SOMATOTROPIN ON THE IMMUNE SYSTEM 
Keith W. Kelley and Carl K. Edwards, ffl 
Laboratory of Immunophysiology, Department of Animal Sciences, 162 ASL, 
1207 West Gregory Drive, University of Illinois, Urbana, Illinois 61801 USA 
Summary 
Somatotropin has long been suggested to affect cells of the immune system. It is now known to 
increase size of the thymus gland, augment a number of activities of lymphoid cells, prime 
macrophages for the release of reactive oxygen intermediates and augment the differentiation of 
neutrophils and erythrocytes. Somatotropin is even synthesized by lymphoid cells. These recent 
findings suggest that, in addition to augmenting growth rate and milk production, somatotropin 
modulates functional activities of lymphocytes and macrophages. 
Keywords: somatotropin, lymphocytes, macrophages, granulocytes. / 
Introduction 
Somatotropin consists of 191 amino acids and is synthesized in the adenohypophysis. This 
molecule is of great interest to animal scientists because it improves growth rate and feed efficiency 
in pigs and augments milk production by dairy cows. Somatotropin has also generated much 
interest in human clinical medicine. The recombinant form of this molecule was approved for 
human use in October 1985, and is now being extensively used to treat a large number of children 
born with a somatotropin deficiency. Other potential clinical uses of somatotropin have generated 
much excitement, and concern, by medical scientists. Somatotropin may be useful for controlling 
obesity in middle-aged humans, reversing some aspects of the aging process, improving wound 
healing in burn patients and augmenting the physical abilities of athletes. Unfortunately, however, 
it is unclear how somatotropin affects human and animal health. 
Cells of the immune system are absolutely essential for protection of the host against infectious 
diseases. A large body of literature has accumulated during the past twenty years which shows that 
somatotropin affects a number of functional activities of lymphocytes and macrophages. Pork 
producers in the United States loose more than $1 billion annually due to swine diseases, and 
respiratory diseases such as pneumonia cause the majority of these losses. It is therefore important 
to learn whether somatotropin positively or negatively affects the incidence, or severity of swine 
diseases. To answer this question, we have begun to investigate the role of somatotropin on 
macrophages from the lungs of domestic pigs. 
Somatotropin and the immune response 
Although somatotropin was discovered and has been classically defined by its ability to induce 
body growth, it seems likely that somatotropin affects other physiological responses as well. 
Similarly, certain immunologic events that were originally thought to be mediated by only one 
cytokine are now known to be affected by other lymphokines. For example, although 
IL-(interleukin) 2 was thought for a number of years to be the only molecule that was required for 
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the proliferation of T cells, it is now known that IL-4 also shares this biologic property. Similarly, 
interferon-y (IFN-y) was once defined as the only activator of macrophages, but now other 
molecules such as granulocyte-macrophage colony stimulating factor (GM-CSF) have also been 
shown to activate macrophages. These pleiotropic properties of cytokines clearly show that 
molecules that were intially discovered because of their activity in one bioassay may possess potent 
effects in completely different bioassays. Given the hormone-like nature of cytokines, it certainly 
seems possible that hormones produced by the pituitary gland can have biological properties in 
addition to the one that led to their initial discovery (e.g., effects on macrophages). This idea, in 
turn, has led to the concept that intricate and important communication systems exist between the 
immune and neuroendocrine systems (Kelley, 1988). 
Somatotropin affects a variety of activities of cells of the immune system, and these effects have 
been recently summarized (Kelley, 1989; Table 1). A deficiency of somatotropin in rodents leads to 
Table 1. Somatotropin regulated activities of cells of the Immune system (see Kelley, 1989 for 
references), 
Somatotropin Deficiencies and Immunoregulatlon: 
— Thymic atrophy and wasting In mice and dogs 
— Reduced antibody synthesis In mice 
— Delayed skin graft rejection In mice 
— Normal lymphoid cell subsets and thymic histology with reduction In peripheral T and B cells 
— Pituitary hypoplasia and thymic atrophy In humans 
— X-llnked somatotropin deficiency and complete Inability to synthesize antibodies 
— Reduction In activity of natural killer cells In humans 
— Defective allogeneic mixed lymphocyte reaction 
— Reduction In plasma thymulln In humans and mice 
— Normal Immunoglobulin concentrations and lymphoid cell subsets In humans 
— Decreased Insulin-Induced somatotropin response In patients with telangiectasis and bowel 
disease 
Somatotropin and the Thymus Gland: 
— Increases thymic size and DNA synthesis In young rodents 
— Improves thymic size and morphology In aged animals 
— Increases plasma thymulln In humans and dogs 
Somatotropin and Lymphoid Cells: 
— Lymphocytes have receptors for somatotropin 
— Augments antibody synthesis and reduces skin graft survival In vivo 
— Increases lectln-lnduced T cell proliferation and IL-2 synthesis in vivo 
— Stimulates proliferation of human lymphoblastold cells 
— Augments basal lymphocyte proliferation In vitro 
— Increases activity of cytotoxic T lymphocytes in vitro 
— Augments activity of natural killer cells in vivo 
— Synthesized by lymphoid cells 
Somatotropin and Phagocytic Cells: 
— Primes macrophages for superoxide anion release in vitro and in vivo 
— Augments respiratory burst In neutrophils from somatotropln-deflclent patients in vivo 
— Increases basal respiratory burst of human neutrophils and Inhibits activated burst in vitro 
Somatotropin and Hemopoiesis: 
— Augments neutrophil differentiation In vitro 
— Augments erythropolesls 
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thymic atrophy and wasting disease, which is coupled with delayed skin graft rejection and a 
reduction in antibody synthesis. In contrast, humans that are deficient in somatotropin do not show 
profound susceptibility to infectious diseases. This species difference may occur because of the 
strong similarity between human prolactin and somatotropin. It is likely that prolactin mimics many 
of the immunomodulatory properties of somatotropin in humans. 
One of the earliest and most consistent observations was that somatotropin augments thymic size 
in young rodents, and recently somatotropin has been demonstrated to reverse thymic atrophy that 
occurs in old animals. This improvement in thymic morphology is accompanied by an increase in 
plasma concentrations of a thymic hormone known as thymulin. 
Specific somatotropin receptors exist on heterogeneous populations of lymphocytes and 
macrophages, and these receptors probably mediate the effects of somatotropin on lymphoid and 
myeloid cells. Unfortunately, however, the distribution of somatotropin receptors on mononuclear 
cell subsets is not known; the receptors could be present on any of a number of cell types including 
T lymphocytes, B lymphocytes, monocytes, natural killer cells and null cells. Somatotropin 
stimulates cell proliferation in a variety of lymphoid cells and augments antibody synthesis and 
improves graft rejection in vivo. It also increases the activity of two different types of cytolytic 
cells: cytotoxic T lymphocytes and natural killer cells. The enhancing effects of somatotropin on 
granulopoiesis and erythropoiesis in humans appear to be mediated in a paracrine manner by 
stimulating the synthesis of somatomedin C by bone marrow-derived monocytes (Merchav et al., 
1988a, b). Transcripts for somatomedin C have been found in activated macrophages (Rappolee et 
al., 1988), and these transcripts are translated into the high molecular weight (26 kDa) tissue form 
of somatomedin C (Rom et al., 1988). Finally, another recent report (Weigent et al., 1988) has 
shown that somatotropin may even be produced by lymphoid cells, which creates the possibility 
that it may be synthesized locally at inflammatory sites. 
Functional Activities of Macrophages 
Macrophages are critical to the induction and expression of a number of immune responses 
(Adams and Hamilton, 1984; Unanue and Allen, 1987). Macrophages can be triggered to produce 
reactive oxygen intermediates, such as hydroxyl radicals, singlet oxygen molecules and superoxide 
anion (O2"), which nonspecifically kill ingested bacteria. Activated macrophages also process and 
present bacterial antigens to T cells, show enhanced expression of class II genes of the major 
histocompatibility complex, kill tumor cells and secrete a number of monokines, such as IL-1 and 
tumor necrosis factor-a. 
The first line of defense of mammals against bacterial and parasitic organisms that have entered 
the body consists of phagocytosis of the invading microbe by polymorphonuclear leukocytes and 
macrophages. These cells phagocytize foreign particles and compartmentalize them into 
phagosomes. Ideally, pathogenic microbes are then degraded by lysomal enzymes that enter the 
phagosome after fusion between lysosomes and phagosomes. However, many facultative 
intracellular organisms are not degraded once they are enclosed in the phagosome and, in fact, may 
multiply and divide, thus killing the macrophage. 
Macrophage Activation for Bacterial Killing 
Fortunately, the host has developed a means to activate macrophages such that they may destroy 
organisms that otherwise might kill the cell and possibly even the host. The concept of activated 
macrophages was first developed by Metchnikoff nearly 100 years ago. This model was more fully 
developed by George Mackaness in the late 1950s. Mackaness studied what has been called 
"nonspecific immunity" by examining the effect of infection with Mycobacterium bovis BCG on 
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the resistance of mice to the immunologically unrelated organism Listeria monocytogenes. 
Mackaness found that peritoneal macrophages from mice infected with the attenuated 
mycobacterial strain became larger and displayed increased biochemical and metabolic activities 
when compared to peritoneal macrophages from normal, uninfected mice. Furthermore, mice 
treated with M. bovis BCG had increased host resistance when challenged with a lethal dose of L. 
monocytogenes. These studies not only established that enhanced antibacterial resistance in vivo is 
related to an increase in the activity of macrophages, but also that one infectious organism can 
enhance the resistance of animals to completely unrelated pathogens. 
Emil Unanue subsequently showed that the increase in macrophage activity is directly 
dependent upon the specific antigenic stimulation of responsive lymphocytes which produce 
protein substances called lymphokines that act on the macrophage. It is now known that these 
lymphocytes are T cells, that they can be activated by microbial antigens to secrete a protein known 
as IFN-y, and that this protein stimulates macrophages to acquire an enhanced degree of 
microbicidal activity as well as other functional activités that were described above (Nathan, 1986). 
Macrophages exposed to IFN-y are known as primed macrophages, and these cells can 
subsequently be triggered by agents such as bacterial endotoxin to become fully activated 
macrophages. 
The Respiratory Burst of Phagocytic Cells 
Phagocytic cells consume oxygen during the process of ingestion, an effect which is probably 
mediated by an increase in activity of a cell membrane NADPH oxidase. Oxygen consumption by 
macrophages is induced by substances that are active at the cell membrane, such as opsonized- or 
complement-activated particles, or phorbol myristate acetate, which activates the calcium- and 
phospholipid-dependent enzyme protein kinase C. Most of the oxygen is reduced to O2" and the 
;nzyme superoxide dismutase converts two moles of O2" in the presence of reducing equivalents to 
molecular oxygen and hydrogen peroxide (H2O2). In the presence of catalase (and the cofactor 
iron), H2O2 generates hydroxyl radicals. Furthermore, singlet oxygen can form spontaneously from 
Ox" Hydroxyl radicals and singlet oxygen are the primary agents responsible for killing of 
intracellular bacteria. Interferon-y is one product of activated T cells that enhances the production 
of reactive oxygen intermediates by macrophages, and this enhancement is known as priming. 
Since O2" is the earliest product of the respiratory burst and because the bulk of it is released into 
surroundings of the cell, measurement of O2" in the medium in which macrophages are suspended 
is an accurate method for quantitation of the suspended is an accurate method for quantitation of the 
respiratory burst. 
Priming of Macrophages by Somatotropin 
Although IFN-y has been identified as the primary T cell product that primes macrophages, other 
macrophage activating factors such as GM-CSF, IL-4 and tumor necrosis factors-a and -ß also can 
augment the respiratory burst. Studies conducted by Peter Heistand et al. (1986) at Sandoz in Basel, 
Switzerland showed that mRNA transcripts for somatotropin may actually be detected in activated 
lymphoid cells, which suggested to us that somatotropin may function as a cytokine. Similarly, as 
mentioned above (Weigent et al., 1988), Douglas Weigent and Ed Blalock have recently published 
convincing data that this mRNA is translated in both rat and human leukocytes, resulting in the 
synthesis and secretion of somatotropin. i. 
Several years ago, Astaldi et al. (1973) demonstrated that monocytes that were incubated 
overnight with somatotropin acquired morphological characteristics of activated macrophages. We 
also noticed in preliminary experiments that porcine liver suspensions incubated with somatotropin 
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contained macrophages (Kupffer cells) that were morphologically similar to activated 
macrophages. Because these morphological changes were easily detectable with a light microscope, 
we wondered whether somatotropin might also affect functional activities of macrophages. We 
chose to first investigate the effect of somatotropin on respiratory burst activity and secretion of 
reactive oxygen intermediates because of the direct role of these compounds in the killing of 
intracellular bacteria. 
We first incubated porcine peripheral blood monocytes overnight with increasing concentrations 
of native and recombinant porcine somatotropin and measured the O2" released from macrophages 
in response to opsonized-zymosan (op-zym) by a reduction in ferricytochrome c (Edwards et al., 
1988). We found that 100 ng/ml of either native or recombinant porcine somatotropin caused a 
twenty-fold increase in the production of O2". This enhancing effect could be totally blocked with a 
specific antibody to somatotropin, which indicated that macrophage priming was not caused by 
contaminating endotoxin in the hormone preparations. 
We wondered whether the increase in the production of O2" by macrophages stimulated with 
op-zym was caused by augmenting the release of IFN.yby residual contaminating T cells in the cell 
suspension or whether somatotropin was acting directly on macrophages. As an initial test of this 
possibility, we prepared highly purified populations of porcine alveolar macrophages (> 98% 
alpha-naphthyl butyrate esterase positive) and treated them with both native and recombinant 
porcine somatotropin (Table 2). As expected, op-zym caused a significant increase in the production 
of O2" (from 28 to 199 nMol 027mg protein/hr). This increase was specific because O2" is the only 
known substrate for superoxide dismutase, which totally blocked the augmentation caused by 
op-zym. Incubation of alveolar macrophages for 24 hr with 500 ng/ml of either recombinant or 
native porcine somatotropin more than doubled the production of O2", and this effect was 
completely blocked by a specific antibody to somatotropin. These data argued that somatotropin 
directly primes macrophages for augmented production of O2", rather than augmenting the 
synthesis of IFN-y by contaminating lymphoid cells. 
Table 2. Priming of porcine alveolar macrophages In vitro by native porcine somatotropin (npST) and 
recombinant porcine somatotropin (rpST). Means with different superscripts are different 
(P < .05). Data taken from Edwards et a l . (1988). 
Treatment nMol O2" /mg proteln/hr SEM 
Unstimulated 28a 14 
Stimulated with Op Zym 1996 48 
Op Zym + Superoxide Dismutase 28a 9 
Op Zym + npST (500 ng/ml) 430° 90 
Op Zym + rpST (500 ng/ml) 431° 81 
Op Zym + rpST + ST antibody 48a 20 
Op Zym + ST antibody 141a b 30 
Since somatotropin augmented production of O2" by macrophages in vitro, we asked whether it 
would also cause similar effects in vivo. This question was answered by injecting 
hypophysectomized rats with somatotropin (Table 3). The classic macrophage activating factor, 
recombinant rat IFN-y (500 units for 9 days), caused a 400% increase in the production of O2", and 
this treatment served as our positive control. Injection of various amounts of either native porcine 
somatotropin, recombinant porcine somatotropin or native rat somatotropin also caused significant 
increases in the production of O2" by resident peritoneal macrophages that were stimulated with 
op-zym, and the higher doses of somatotropin induced similar amounts of O2" as recombinant rat 
IFN-y. Heightened production of O2" by somatotropin occurred at doses of somatotropin that 
increased growth rate, which suggests that priming of macrophages by somatotropin occurs at 
physiologic levels. 
149 
KELLEY AND EDWARDS 
Table 3. Native, pltultary-derlved rat somatotropin (nrST), npST and rpST Induced respiratory burst 
activity In resident rat peritoneal macrophages In vivo (Edwards et al., 1988). Means with 
different superscripts are different (P < .05). 
Dose/ Growth nMol Oil 
Item Rat/Day (g/Day) mg proteln/hr 
Hypox Rats 
+ Vehicle 
+ Rat IFN-
+ npST 
+ rpST 
+ nrST 
200 ul 
500 Units 
6ug 
12 ug 
24 ug 
6ug 
12 ug 
24 ug 
12 ug 
24 ug 
48 ug 
96 ug 
0.392° 
0.282° 
0.252° 
1.322° 
1.633° 
2.060ef 
0.815b 
1.067b'° 
1.297° 
1.850d'e 
2.320f 
2.8709 
3.440h 
-40° 
-17° 
417b 
0° 
268° 
438b 
•62° 
280b 
344b 
3° 
267b 
247b 
309b 
These experiments demonstrated that both native and recombinant somatotropin can prime 
blood-derived monocytes, alveolar macrophages and resident peritoneal macrophages to produce 
enhanced levels of O2" in response to a particulate stimulus, op-zym. Since macrophages are critical 
to the initiation of many immune responses, a variety of immune events could be affected by 
somatotropin. We initially chose to study the role of somatotropin on the production of O2" by 
macrophages because of the known bactericidal role of reactive oxygen intermediates. These data 
therefore support the idea that a pituitary hormone, somatotropin, has important effects on 
functional activities of cells of the immune system, and that macrophages are one target for the 
action of somatotropin. This interpretation is entirely consistent with a recent preliminary report 
which showed that bovine somatotropin promoted a significant improvement in milk production 
after mastitis induced by Escherichia coli (Vandeputte-van Messom et al., 1988). 
b-Adrenergic Agonists and the Immune System 
A number of analogs of norepinephrine has been developed in an attempt to increase muscle and 
decrease fat mass in pigs. Although much of our research has concentrated on somatotropin, the 
literature clearly indicates that both and ß-adrenergic agents can affect cells of the immune system 
(Sanders and Munson, 1985a). Since it has been clearly established that both primary and secondary 
lymphoid tissues receive noradrenergic innervation (Feiten et al., 1987), it is likely that 
norepinephrine is an important immunomodulator in the local environment of lymphoid cells. Both 
porcine (Westly and Kelley, 1987) and bovine (Ogunbiyi et al., 1988) mononuclear cells have 
receptors for ß-adrenergic compounds. Indeed, ßi- but not ß2- adrenergic agonists inhibit the 
production of reactive oxygen intermediates by bovine alveolar macrophages (Ogunbiyi et al., 
1988). Similarly, both norepinephrine and epinephrine block the activation of macrophages to a 
tumoricidal and anti-viral state (Koff and Dunegan, 1985, 1986). It is unknown whether this 
inhibition can be overcome by either somatotropin or classic macrophage activators such as IFN-y. 
Stimulation of ß-adrenoceptors augments antibody synthesis in rodents (Sanders and Munson, 
1984a,b; Fujiwara and Orita, 1987), whereas ß-adrenergic stimulation enhances the production of 
complement components by monocytes (Lappin and Whaley, 1982) and has mixed effects on 
antibody synthesis (Sanders and Munson, 1985b). Epinephrine affects lymphoid cell distribution in 
vivo and proliferation in vitro (Crary et al., 1983) and the activity of natural killer cells in humans 
(Hellstrand et al., 1985). Since these and other studies have shown that stimulation of adrenergic 
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receptors modulates at least some activities of cells of the immune system, it is likely that 
administration of ß-adrenergic agents to domestic livestock affects their immune system as well. 
Conclusions 
A review of the literature indicates that somatotropin can affect a number of activities of 
lymphoid cells and macrophages. Other repartitioning agents, such as ß-adrenergic agonists, have 
also been shown to affect cells of the immune system. These data clearly establish that compounds 
which have been developed to modify animal growth affect the immune system. In general, almost 
all of the immunomodulatory effects of somatotropin have led to an enhancement in a given 
immunological property, whereas the use of beta-adrenergic agents has revealed both suppressive 
and enhancing characteristics. However, it is not yet known whether the kinds of cells that are 
affected or whether the magnitude of effects that are caused by growth-promoting compounds are 
sufficient to modify animal health in either a positive or negative manner. It is also not known 
whether the immunomodulatory effects of somatotropin that are so clearly demonstrated in 
hypophysectomized rodents occur in young animals with normal amounts of circulating 
somatotropin. 
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POTENTIAL SIDE-EFFECTS OF EXOGENOUS SOMATOTROPIN IN 
PIGS 
Stanley E. Curtis 
Animal Sciences Department, University of Illinois, Urbana, IL 61801 USA 
Summary 
Two aspects of the pig's nature that might be affected by exogenous somatotropin are 
thermoregulation (and thus the pig's thermal environmental requirements) and eating behavior (and 
thus the design of the pig's living quarters and feeding system). The net effect of exogenous 
somatotropin on a 75-kg pig would be a 6°C increase in its lower critical effective environmental 
temperature and a decrease of several degrees in its upper critical temperature. Thus, the pig would 
be more sensitive to its thermal environment at both low and high ends of the temperature range. 
The marked reduction in feed intake observed in pigs being administered exogenous somatotropin 
may be due to thermal stress, social problems, or inadequate access to the feed. These possibilities 
should be explored and means of alleviating any documented effects should be sought. 
Keywords: pigs, somatotropin, thermal environment, social environment, feeder design, feed intake. 
Introduction 
There would seem to be potential advantages to using exogenously administered porcine 
somatotropin to fashion pig growth so as to make pork more acceptable to consumers and pork 
production and processing more efficient. In the production phase, however, although we do not yet 
know much about the effects and side-effects of this new technology, what is known already has 
provoked questions regarding how swine management regimens might need to be changed in order 
to implement it in the pork industry. Two important aspects of the pig's nature that might be affected 
by exogenous somatotropin are thermoregulation (and thus the pig's thermal environmental 
requirements) and eating behavior (and thus the design of the pig's living quarters and feeding 
system). 
Thermoregulation 
The thermal status of a pig's body depends essentially on two factors: thermal insulation (which 
determines heat loss rate) and heat production rate. Somatotropin probably affects both. Therefore, 
the thermal environmental and dietary energy requirements of the pig might be affected by 
exogenous somatotropin. 
Thermal insulation 
The three thermal insulators between a pig's body core (the origin of most metabolic heat) and 
the surroundings (the animal's heat sink) are, from inside out: tissue insulation, hair insulation, and 
boundary insulation (the very thin layer of still air that envelopes the body). Total insulation equals 
the sum of the three. Hair and boundary insulations probably are independent of exogenous 
somatotropin, but the tissue insulation is not. 
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The contribution of hair insulation in a growing-finishing pig residing in a typical production 
setting averages ± .2°C m h/kcal, and that of boundary insulation, ± .1 unit. The two combined 
total ± .3 unit of insulation. 
Tissue insulation is due mainly to subcutaneous fat, which (when its blood vessels are 
constricted in response to a cold environment) yields a maximal insulation value of .1°C m h/kcal 
per cm of thickness. Therefore, tissue insulation depends on the thickness of the subcutaneous fat, 
which may be determined in turn partly by exogenous somatotropin. When the subcutaneous fat 
that covers the entire body effectively averages 1 cm thick, then maximal tissue insulation would be 
± .1 unit, and maximal total insulation (the sum of tissue, hair, and boundary insulations), ± .4 unit. 
But if effective subcutaneous fat thickness were reduced from 1 cm to .5 cm, then maximal total 
insulation would drop from ± .4 unit to ± .35 unit. 
A pig weighing 75 kg would have a body surface area of ± 1.25 m . Thus, it can be calculated, 
the slope of its environmental heat demand line would be 3.1 kcal/h°C if the pig had 1 cm of 
subcutaneous fat and 3.6 unit if it had .5 cm. In other words, for any given decrease in 
environmental temperature, heat loss rate from the pig with less subcutaneous fat would increase at 
a rate some 16% faster than that from the fatter pig. This would make the leaner pig more vulnerable 
to cold environments, but less vulnerable to hot ones, provided all other factors remained the same 
(see below). In particular, the somatotropin-treated pig's lower critical effective environmental 
temperature (the temperature below which the pig would need to raise its metabolic rate above the 
thermoneutral level in order to maintain a normal body temperature) might be as much as 12°C 
higher than that of an untreated pig. The treated pig's upper critical temperature also would be 
higher in the face of less insulation, but probably only a few degrees higher. 
Alas, other critical factors may not remain the same when exogenous somatotropin is being 
administered. Heat production rate must be considered, too. 
Heat production rate 
The metabolic stimulation due to exogenous somatotropin increases the pig's heat production 
rate. Present evidence indicates that this increase is associated at least partly with increased 
maintenance energy expenditure in the growing pig. Recent estimates are that maintenance energy 
expenditure is 17% to 24% higher in somatotropin-treated pigs, and this would be reflected by a 
commensurate increase in heat production rate. 
Regardless of how this extra metabolic heat may be partitioned, it would affect the pig's thermal 
environmental requirements. With respect to the extra metabolic heat, the somatotropin-treated pig 
would be less vulnerable to cold environments, but more vulnerable to hot ones, provided all other 
factors remained the same (see below). In particular, under such conditions, the lower critical 
temperature of the somatotropin-treated 75-kg pig might be reduced by ±6°C, and the upper critical 
temperature also would drop by several degrees. However, as has been mentioned, under exogenous 
somatotropin administration, other critical factors may not remain the same. 
Thermal environmental requirements 
How would the combined effects of exogenous porcine somatotropin on subcutaneous fat 
thickness (and thus on tissue and total insulation values during cold-induced peripheral 
vasoconstriction) and heat production rate affect a pig's thermal environmental requirements, 
assuming the scenario outlined above obtains? A pig's lower critical temperature is determined by 
the junction between the thermoneutral heat production rate and the environmental heat demand 
line. The combined effects of these two consequences of somatotropin would be, on the cool end of 
the effective environmental temperature range, a 12°C increase in lower critical temperature due to 
less thermal insulation, but this would be offset by a 6°C decrease due to the higher heat production 
rate. Hence, the net effect would be a 6°C increase in the lower critical temperature of a 75-kg pig 
due to somatotropin treatment. In other words, the treated pig would be considerably more 
vulnerable to cool or frankly cold environments. 
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As for the upper critical effective environmental temperature (the point above which the pig 
would need to start to pant or to increase evaporative heat loss rate by some behavioral means such 
as wallowing in mud), on balance it might be expected that this critical point would drop by a few 
degrees. That is, the effect of the somatotropin-induced increase in heat production rate would be 
expected to override the effect of decreased thermal insulation, resulting overall in the pig's being 
more vulnerable to high environmental temperatures, as well. Although it is not possible to be as 
precise quantitatively in estimating the effect of exogenous somatotropin on the pig at the warm end 
of the temperature range, it is likely that in practical production settings in most temperate regions 
the pig's heightened vulnerability to warm or frankly hot surroundings would be of more economic 
consequence than that to cool or cold environments. High temperature-induced reduction in 
appetite probably would be considerable in many cases. 
Eating behavior 
Growing pigs being administered exogenous somatotropin gain both lean mass and total mass 
both at a faster rate and at a higher gain/feed ratio. These effects are all the more remarkable 
because they are associated with a marked depression in feed intake. Would somatotropin-treated 
pigs gain mass even faster and even more efficiently if they ate more each day? 
Numerous physiologic mechanisms control feed intake in pigs. Several /dietary and 
environmental factors affect it, too. Before the limiting factors can be minimized - thereby letting 
the pigs eat more and grow faster - these phenomena and their interrelations must be elucidated, and 
once they are elucidated and documented, then ways and means of ameliorating such effects must 
be sought. 
Environmental temperature 
Perhaps exogenous somatotropin's lowering of the pig's upper critical effective environmental 
temperature has been responsible for some or all of the depression of feed intake that has been 
observed. The higher metabolic heat production rate of these pigs might alone have reduced the 
pigs' appetites. Conventional growing-finishing pigs voluntarily take in 60 to 100 g less feed daily 
for every 1°C that environmental temperature stands above 21°C. It is conceivable that 
somatotropin-treated pigs experience even larger depressions per degree, beginning at even lower 
environmental temperatures. 
Another possibility is that the somatotropin-treated pig in conventional thermal environments 
finds itself in a zone of effective environmental temperature in which it chooses consciously to 
reduce its physical activity so as to reduce the heat increment due to physical activity in attempting 
to establish thermal equilibrium with its surroundings. In such circumstances, the pig might need to 
be hungrier before it is motivated to get up and approach the feeder to start an eating bout. If this be 
the case, more accessible means of offering feed to somatotropin-treated pigs might encourage 
them to consume feed at a rate more nearly that of untreated pigs. Moreover, if somatotropin-
treated pigs indeed are relatively lethargic, and if this lethargy leads to fewer eating bouts each day, 
then any stimulation of feed intake that is due to social facilitation in conventional pigs presumably 
would be decreased in somatotropin-treated pigs. 
Social relations 
Dominance-subordinance relations among pigs in a group are important determinants of 
voluntary feed intake by the respective individual pigs. It is quite possible that metabolic changes 
(including increased heat production rate) due to exogenous somatotropin alter either the pig's 
perception of its individual groupmates or the thresholds of social-interactive behaviors in such 
ways that social inhibition of eating is magnified. For example, revolts occur even within 
established dominance orders of pigs, and it is possible that somatotropin-treated pigs are less prone 
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to completely resolve these conflicts, thus leaving the level of social tension in the group - which in 
turn may influence the effect of one pig on the eating behavior of another - relatively high. 
Accessibility of feed 
Providing the feed in feeders that have been designed and located in a quantitatively and 
qualitatively appropriate manner is crucial to ensuring that every pig in a group has unlimited 
access to feed, and thus the opportunity to maximize feed intake. Social effects on pig performance-
and especially on interindividual variation in performance - become more pronounced as general 
access to feed becomes more limited. 
When the pigs' environment is designed so only some of the individuals can eat at once, most of 
the pigs are drinking, dunging, or resting while some are eating. Therefore, appropriately designed 
and located watering, dunging, and resting places must be provided. Otherwise, pigs not even eating 
at some given moment can interfere with groupmates desiring to approach the feeder and eat. 
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THE EFFECT OF NEW GROWTH-PROMOTING TECHNOLOGIES ON 
REPRODUCTION AND LACTATION IN SWINE 
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MO 65211 USA 
Summary 
New biotechnologies are emerging that have been shown to be effective methods for major 
modification of growth and carcass composition of growing-finishing swine. Recent progress in 
gene insertion has resulted in the production of transgenic animals used for breeding purposes and 
offspring have been produced. However, major reproductive problems have been observed in 
transgenic boars and gilts expressing human growth hormone, including anestrus and lack of libido. 
Limited data have been reported to suggest that the lactation curve in sows can be altered and milk 
production increased by porcine pituitary growth hormone (pGH) or recombinant porcine growth 
hormone (rpST) treatment. 
Reproductive disorders including delayed puberty and cystic follicles have occurred in gilts 
treated daily with pGH near the time for the onset of sexual maturity and when given during the 
proestrus phase of the estrous cycle. However, there was no adverse effect on interval from boar 
exposure to estrus, age at puberty, proportion of gilts reaching puberty prior to 240 days of age or 
pregnancy rate in gilts injected daily with recombinant porcine somatotropin (rpST) during the 
growing-finishing phase of reproduction (50 kg to 110 kg body weight). Similarly, pregnancy rate 
and average number of embryos on day 25 of pregnancy were unaffected by the administration of 
rpST between day 4 and 18 of gestation. These results indicate that subsequent reproductive 
performance in gilts is unaffected by the administration of rpST during the growing-finishing phase 
of production. 
Keywords: swine, reproduction, growth hormone. 
Introduction 
Recent progress in efforts to alter the endocrine control of growth and development in swine has 
led to an interest in the effect of these emerging technologies on other components of the production 
cycle. For example, will transgenic pigs expressing a foreign gene for growth hormone production 
exhibit sexual behavior and be capable of producing offspring to amplify the presence of the foreign 
gene in the population? Can a technique that will effectively alter nutrient partitioning priority be 
used to an advantage during pregnancy and lactation? Further, what are the implications of major 
changes in growth rate and body composition during the growing-finishing phase of development 
on age at sexual maturity and subsequent reproductive performance of breeding replacement 
animals? 
It is only recently that the results of preliminary studies designed to examine these and related 
questions have started to become available. Further, most reproductive characteristics are highly 
variable economic traits and require relatively large numbers of animals of different genotypes 
produced under various environmental conditions in order to reach conclusive evidence of general 
effects. For example, several years of study will likely be required to determine any minor 
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differences in expected levels of reproductive and lactational performance in transgenic animals. 
Earlier conclusions may be expected, however, for technologies directed toward the direct 
administration of compounds to alter nutrient partitioning priority. In this paper, we will briefly 
review expected effects of major differences in growth rate and body composition during the 
growing-finishing phases of development on age at puberty in gilts. Results will be presented on the 
level of reproductive performance in gilts that had previously receive recombinant porcine 
somatotropin. Available data on the direct effects of increased growth hormone in transgenic 
animals and following hormonal injection on reproductive traits and lactation will also be reviewed. 
Growth rate, body composition and puberty 
Considerable controversy exists on the relative roles of age and weight as determinants of 
reproductive activity in pigs. Anderson and Melampy (1972) reviewed the literature on the effects 
of energy intake on age and weight at puberty in swine. Restricted energy intake was found to delay 
puberty an average of 16 days in nine experiments but hastened puberty an average of 11 days in 
five studies. Although it is reasonable to assume a minimal weight exists for the expression of 
puberty, the range in weight at which puberty will occur in gilts is wide. In a study reported by Knott 
et al. (1984), the interval to puberty was similar for groups of gilts boar exposed and relocated 
between 70 and 116 kg body weight. 
Since it does appear that differences in live weight above a minimal level exert only minor 
influence on puberty attainment, it follows that rate of growth during the prepuberal period would 
be without a major cause of differences in age at puberty within contemporary groups of gilts. 
Several studies have reported a lack of association between rate of gain and age at puberty (Burger, 
1952; Gossett and Sorensen, 1959; Goode et al., 1965). 
Only limited study has been made of the relationship between body composition and sexual 
maturation in the gilt. In humans, the adipose to lean tissue ratio is considered to be an important 
contributing factor to the attainment of puberty. However, although major breed differences exist in 
age at puberty and body condition, the relative effects of genotype and body composition have yet 
to be defined. Within genotype groups, the ability of gilts to exhibit puberty prior to time of rapid 
fat deposition would suggest a relatively low minimal body fat content requirement for the 
attainment of puberty. 
Growth hormone and reproduction in gilts 
Indirect effects 
The administration of pituitary porcine growth hormone (pGH) or recombinant porcine 
somatotropin (rpST) during the growing-finishing phase of development will enhance growth rate 
and feed efficiency as well as induce major changes in body composition including a marked 
decrease in fat deposition (Chung et al., 1985; Etherton et al., 1986; Etherton et al., 1987; McLaren 
et al., 1987; Campbell et al., 1988). Although differences in rate of gain and body composition do 
not appear to be major causative factors of variation in age at puberty within genotype group, the 
question arises as to whether or not these modifications in growing animals induced by 
somatotropin may affect subsequent reproductive performance of replacement gilts. An experiment 
has been conducted, therefore, to gain information on possible indirect effect of rpST treatment on 
puberty, ovulation rate and conception rate in gilts (Unpublished data). 
Forty crossbred gilts, including 19 littermate pairs, were assigned to the study at an average body 
weight of 50 kg. An equal number of gilts were randomly assigned within weight groups and litter 
number to control and rpST treatment groups. Control gilts received daily intramuscular injections 
of 1 ml of vehicle and rpST gilts were injected daily with 1 ml of vehicle containing 6 mg of prST. 
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The gilts were fed ad libitum a corn-soybean ration containing 18% protein and 1.2% lysine in a 
confinement facility. Gilts were located in five adjacent pens with four control and four treated gilts 
assigned to each pen. Treatment was continued until the pen average body weight reached 110 kg. 
The gilts were weighed periodically during the trial and body composition was estimated by 
ultrasonic determination at the end of the trial. The gilts were then moved to a confinement 
gestation unit and daily heat checks made with a mature boar to determine age at puberty. Gilts were 
bred at second estrus with embryo recovery made at day 11 of pregnancy to determine ovulation 
rate, conception rate and embryonic survival rate. The average age of all gilts at the initiation of 
rpST treatment was 102 days with last injections given at an average age of 162 days for a total 
treatment period of 60 days. 
Table 1 and 2 present the effect of rpST treatment on growth rate and ultrasonic measurements 
of body composition. Growth rate was increased significantly (P < .05) by daily injection of 6 mg 
of rpST. Injections were ended when the body weight pen average of four gilts reached 
approximately 110 kg. On that day all gilts were measured by ultrasound to determine subcutaneous 
backfat thickness and loin eye area. All mean values of fat thickness (shoulder, loin, ham) were 
significantly less (P < .05) for gilts injected with rpST as compared to control gilts. Also, as shown 
in Table 2, loin eye area was increased significantly (P < .05) by rpST administration. These growth 
and body composition data confirm a positive response to rpST during the growing-finishing 
period. 
Table 1. Effect of rpST on body weight gain In gilts treated from 50 to 110 kg body weight. 
Treatment 
Control 
rpST 
rpST/gllt/ 
day, mg 
0 
6 
No. of 
gilts 
20 
20 
Initial 
weight, kg 
53.9±l.lb 
53.8±l.lb 
Final 
weight, kg 
107.2±1.8° 
113.5±1.8d 
Total 
gain, kg 
53.51±.0e 
59.81±.0f 
a
 Least squares means ±SEM. 
'
c
'
 ,e
' Means within the same column with different superscripts are significantly different (P < .05). 
Table 2. Effect of rpST on ultrasound measurements of body composition of gllts.a 
Means adjusted for body weight 
Treatment No. of Body Backfat Loin eye 
gilts weight, kg thlckness.cm area,cm2 
Control 20 107.213 2.5b 32.2b 
rpST 20 113.5e 1.6° 36.9° 
a
 Least square means. 
'
c
 Means within column with different superscripts are significantly different (P < .05). 
All gilts were relocated to a breeding unit, mixed with different pen mates and boar exposed at 
an average age of 169 days. The range of the interval from end of rpST injection to initiation of 
stimuli to induce puberty was 4 to 11 days with an average interval of 5.1 days. Individual gilts in 
pens with slightly lower growth rates and longer injection period to 110 kg body weight target, 
exhibited puberty within 10 days following the last injection of rpST. 
Table 3 and 4 summarize reproductive characteristics of control gilts and gilts treated previously 
with rpST. All control gilts and 19 of 20 rpST gilts exhibited puberty prior to 8 months of age. One 
control gilt was behaviorally anestrus following the first estrus. Average age at puberty was 182 
days for both control and treated gilts. The average intervals from boar exposure to estrus, lengths 
of the first estrous and average intervals between first and second estrous periods were not 
statistically different for control and rpST gilts. Thirty-eight of forty gilts assigned to the study were 
artificially inseminated at the second estrus. All gilts inseminated were pregnant at laparotomy on 
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day 11 (day 0 = onset of estrus). Ovulation rate as determined by number of corpora lutea present 
on day 11 of pregnancy was 14.3 and 14.9 for control and treated gilts, respectively. Embryonic 
survival rate calculated as the percentage of corpora lutea represented by normal embryos was not 
different between experimental groups (76.2% and 87.9%, respectively, for control and rpST 
treated gilts). 
Table 3. Effect of rpST on age at puberty and estrus. alD 
Parameter 
Gilts, no. 
Gilts exhibiting estrus, no. 
Age at puberty, days 
Boar exposure to estrus, days 
Length of first estrous period, days 
Estrous cycle length, days 
Control 
20 
20 
182,1±3.1 
12.8±2.7 
1.8±0.1 
20.2±0.4 
rpST 
20 
19 
182.4±3.3 
14.2±2.8 
1.9±0.1 
20.6±0.4 
P 
NS 
NS 
NS 
NS 
"Least squares means ±SEM, days. 
Daily IM injection of 6 mg rpST from 50 to 110 kg body weight. 
Table 4. Effect of rpST on ovulation rate and embryo survival. a 
Treatment No. of gilts 
bred pregnant 
o n d l l 
Number of 
corpora 
lutea 
Embryonic 
survival 
rate,% 
Control 
Treated 
19 
19 
19 
19 
14.3±0.6 
14.9±0.6 
76.2 
87.9 
a
 Least squares means ±SEM 
These data provide initial evidence that changes in growth rate and body composition in gilts 
receiving rpST during the growing-finishing phase of development are without an adverse effect on 
age at puberty or fertility level at first breeding. A similar conclusion was reached by Bryan et al. 
(1988). Prepuberal gilts weighing an average of 80 kg received 70 g of porcine pituitary growth 
hormone per kilogram of body weight for 21 days and were then checked for estrus daily with a 
mature boar to stimulate the onset of puberty. A higher percentage of pGH-treated gilts (7 of 12) 
exhibited estrus during the experimental period (50 days), and of gilts exhibiting estrus, there was 
no difference between treatments in ovulation rate or number of embryos. The average interval 
from last injection of rpST to puberty was 3 weeks. 
Direct effects 
Follicular growth. Reproductive disorders have been observed when porcine pituitary growth 
hormone (pGH) was given to prepuberal gilts during the period puberty was anticipated and when 
given during proestrus in sexually-mature gilts. Hagen et al. (1987) compared age at puberty in gilts 
(mean weight = 72 kg) administered either vehicle or pGH (70 u/kg body weight/day) for 65 days. 
Gilts were checked for estrus during the last 35 days of the treatment period. Non-cyclic gilts were 
slaughtered on day 66 for ovarian examination. Of eight gilts per treatment group, seven control and 
one pGH treated gilts exhibited estrus. The authors concluded that exogenous pGH inhibited 
ovarian development of prepubertal gilts. However, in a subsequent study, gilts treated similarly 
with pGH for a 42 day period did not show delayed puberty in comparison with control animals 
(Bryan et al., 1988). Further studies will be needed to clarify this inconsistency in results. 
In a study involving sexually-mature gilts, Kirkwood and Aherne (1985) observed a high degree 
of anestrus in gilts administered exogenous growth hormone (90 ng/kg body weight/gilt/day) from 
day 14 after puberty until the end of the second estrus. Ovarian morphology was determined in gilts 
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failing to show a second estais by day 30 after puberty. In a related experiment (Kirkwood and 
Aherne, 1985), prepuberal gilts were injected with either vehicle or growth hormone from 150 to 
159 days of age. At 154 days, all gilts received an injection of pregnant mare serum gonadotropin 
followed by an ovulatory dose of human chorionic gonadotropin. Ovarian examinations were made 
on day 163. All control gilts had normal ovarian morphology whereas only 36% of gilts injected 
with growth hormone were classified to have normal ovaries due to the presence of large cystic 
follicles in the remaining gilts. 
The mechanism whereby exogenous growth hormone may interfere with ovarian function is not 
clear. In prepuberal gilts, ovarian activity appeared to be depressed as indicated by delayed puberty 
in some studies, whereas in sexually-mature gilts the presence of cystic follicles suggests 
hyperstimulation of follicular growth. In both instances, serum IGF-1 concentrations were higher in 
gilts receiving growth hormone than in control gilts (Hagen et al., 1987; Kirkwood and Aherne, 
1985). High corticoid concentrations have been reported to be a cause of anestrus (Esbenshade and 
Day, 1980) and also cystic follicles (Liptrap, 1970) in pigs. Further studies will be needed to clarify 
the suggested detrimental effects of exogenous growth hormone during the period follicles are 
approaching mature size and at the time of ovulation. Little is presently known about rpST dose 
response relationships or mechanism of action at these stages of the reproductive cycle. 
Early pregnancy. The effects of rpST on the uterine development and embryonic survival 
during early development is being examined in crossbred gilts bred at second estais (Unpublished 
data). Preliminary results are available from 24 animals bred. Gilts were assigned at random at 
breeding to receive one of the following three treatments as daily milliliter injections per gilt from 
day 4 to 18 of pregnancy (day 0 = onset of estais): (I) vehicle injection; (II) 3 mg rpST; (III) 6 mg 
of rpST. All gilts were checked for estrus until day 25 to 28 of pregnancy at which time a 
laparotomy was performed. All gilts were hysterectomized to obtain ovarian, embryonic and uterine 
measurements. Pregnancy rate, embryonic survival rate and number of normal embryos at 25 days 
after mating were similar for control and rpST gilts. Statistical analysis of measurements made of 
uterine and placental growth in control and rpST-treated gilts will be made following completion of 
the trial. 
Detrimental effects have been observed in sows administered pGH during late gestation. 
Kveragas and Seerley (1986) reported that of 20 gilts and sows receiving 10 mg of pGH daily 
during late gestation, four died during the trial. Three of the four animals died during the hours 
immediately prior to or following parturition. 
Transgenic animals 
Growth hormone genes have been inserted successfully into pigs by micro-injection into 
pronuclei and the transgenes are transmitted to progeny (Pursel et al., 1986). Insufficient 
observations are available to provide general conclusions regarding the direct effect of elevated 
growth hormone concentrations in transgenic boars and gilts. Present data does indicate, however, 
that reproductive performance is depressed severely in transgenic boars and gilts with high 
concentrations of human growth hormone (hGH) due to expression of fusion genes consisting of the 
mouse metallothionein-I promoter ligated to the structural gene for human growth hormone 
(MThGH). 
Boars expressing hGH failed to breed due to lack of libido, lethargy and leg ailments. 
Reproductive failure in gilts was characterized to be due to anestrus and ovarian examination 
confirmed the absence of ovulation (Rexroad and Pursel, 1988). Female transgenic mice that 
express the MThST of MTbST genes were also sterile (Hammer et al., 1984). 
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Growth hormone and lactation 
Considerable variation exists in pig weaning weights among herds and litters within a herd. A 
significant cause of these differences in performance of nursing pigs is level of milk production of 
the sow. Several factors are known to influence milk production in sows including genotype, feed 
intake, parity and farrowing room temperature. The enhancement of milk production by methods 
that did not reduce subsequent reproductive performance of the sow may be expected to result in 
increased efficiencies in the swine production system. 
The result of recent studies indicate that the administration of pGH or rpST to lactating sows 
alters both the level, and pattern, of milk production as well as milk composition (Boyd et al., 1983; 
Spence et al., 1984; Boyd et al., 1985; Harkins et al., 1985; Spence et al., 1985). Spence et al. (1984) 
determined the effect of pGH on lactation performance in sows. Daily injections of either a placebo 
or pGH (5.33 mg/sow/day) were given beginning on day 100 of gestation through a 21-day 
lactation. Control and pGH-treated sows had similar milk yields at two weeks but production was 
15% greater by three weeks for sows administered pGH. Percent fat was increased in the colostrum 
and at day 13 for pGH sows. In a related study, Spence et al. (1985) reported that colostral fat 
concentration was increased 26%, milk produced elevated 16.9% on day 21 and feed intake 
decreased 25% in sows receiving 11IU of pGH during the second and third week of lactation. The 
weaning weights of pigs from sows treated with pGH were similar to those weaned from control 
sows. Boyd et al. (1985) studied the effect of rpST on milk production, milk composition and pig 
weight at days 16, 22 and 28 of lactation. Subcutaneous injection of either placebo or rpST (8.22 
mg/sow/day) were given daily beginning on day 12 through day 28 of lactation. Control sows and 
milk production continued to increase to levels 11% and 22% higher than controls on days 22 and 
28, respectively. Total yield of solids, fat and lactose were, respectively, 24%, 29% and 30% higher 
in sows receiving rpST. Protein yield was not different. Pigs from sows receiving rpST were 
significantly heavier (0.34 kg) at weaning on day 28. Sows given rpST consumed 22% less feed and 
lost more weight and backfat during the lactation period than control sows. No adverse health 
effects were observed as a result of treatments. 
Insufficient data exists to predict the effect of decreased feed intake, increased weight loss and 
decreased percentage body fat during lactation on subsequent reproductive performance. Of 
particular concern would be reduced feed intake in first litter sows. Further, innovative management 
systems are yet to be tested that are specifically designed to maximize the benefits of increased milk 
production, such as cross fostering to increase number of pigs suckling individual sows and early 
breeding of remaining sows in a farrowing group. 
Further research will also be required to determine most suitable nutritional and management 
systems for sows administered pGH or rpST as well as preferred stage of lactation to wean the pigs 
of sows receiving exogenous growth hormone. Increased pig gains prior to day 21 to 24 may 
promote weaning at an earlier age whereas increases over controls in milk production are more 
pronounced after the third week of lactation. Changes in gestation management programs and early 
weaning may also provide a means of minimizing tissue loss during lactation to prevent depletion 
to a critical level that compromises post-weaning reproductive performance. 
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Summary 
While many of the developed countries of the world enjoy a protein-rich food supply, much of 
the world has a need for technologies which improve the quantity and quality of food proteins. 
Drugs used to enhance growth and improve feed efficiency along with improved genetic and 
nutritional factors have made available greater amounts of protein from food- producing animals to 
more people than ever before. Anabolic agents, in spite of the sometimes unfavorable^publicity they 
have attracted, have been especially advantageous in ensuring the feed efficiency of livestock. 
Protein synthesis and its regulation have been the object of intensive research, both at the 
biochemical and molecular genetic levels. The correlation of specific gene products such as 
somatotropins with increased growth rates, enhanced feed efficiency and fat/protein repartitioning 
has stimulated interest in the possibility of manipulating protein synthesis in farm animals. 
Somatotropin and the related compounds, somatostatins, somatomedins and growth hormone 
releasing factors are the first products of recombinant DNA technology that may be economically 
feasible for use in increasing production efficiency for domestic and world agriculture. 
If such products are to be used in the United States, approval for use must be obtained from the 
United States Food and Drug Administration (FDA). The safety and efficacy of these products must 
be demonstrated through well-controlled and properly designed scientific studies. 
Numerous experimental regimens involving somatotropin, somatomedin and other factors 
including releasing factors have been submitted to the FDA for approval as investigational new 
animal drugs. Regulation of these new agents through pre-marketing approval and post-approval 
monitoring must be sufficiently protective of the public health, must ensure that products are 
rational for their proposed use and must ensure that they are effective in the intended animal 
species. 
Keywords: biotechnology, food safety, animal drugs, public health. 
Introduction 
The use of agricultural chemicals in the second half of the twentieth century has been crucial in 
meeting the nutritional needs of an expanding world population. Pharmaceutical and other 
chemicals have been used destroy pests, enrich feed, control disease and promote to the growth of 
livestock and poultry. Today's farmer and veterinary practitioner can choose from a wide variety of 
drugs, medicated feed premixes and vaccines for maintaining animal health. Drugs used to enhance 
growth promotion and improve feed efficiency are making available greater amounts of protein 
from food-producing animals to more people than ever. Anabolic agents, in spite of the sometimes 
unfavorable publicity they have attracted, have been especially advantageous in ensuring an 
improvement in the feed efficiency of livestock. 
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Protein and fat synthesis and their physiological regulation have been the object of a significant 
amount of recent intensive research, both at the biochemical and molecular genetic levels. The 
correlation of specific gene products such as somatotropins (growth hormones) with increased 
growth rates, enhanced feed efficiency, adipose to muscle tissue repartitioning, and increased milk 
production in mature dairy cattle stimulated interest in the possibility of manipulating protein 
synthesis in livestock. These discoveries have been spaced over a period of three decades with data 
slowly accumulating as improved methods of biochemical purification of the test substances were 
developed. With the development and implementation of recombinant technologies, substantial 
amounts of natural anabolic agents will be available for large scale increases of production 
efficiency in the meat and poultry industry. Somatotropins, somatomedins and releasing factors are 
the first products of biotechnology with a potential for major impacts upon production efficiency 
for domestic and world agriculture. The use of exogenous somatotropins to supplement the natural 
level in livestock is a logical extension of the natural selection process practiced for decades by the 
farmer. Somatotropins are polypeptides of approximately 190 amino acids which are secreted by 
the anterior pituitary gland. They have anabolic activity and also have effects on fat and 
carbohydrate metabolism. Part of the growth promoting or anabolic effect is mediated by the 
secretion of other hormones, known as somatomedins, from the liver and other tissues. Because of 
its effects on tissue metabolism, there is great interest in the use of exogenous somatotropin to 
stimulate growth and lactation in farm animals (Norman and Litvack, 1987). The somatomedins 
have both insulin-like and cell proliferating-like activities. Consequently, somatomedins are also 
known as insulin-like growth factors. At present, two somatomedins have been identified, 
insulin-like growth factors -1 and -2 (IGF-1 and IGF-2). Somatomedins stimulate an increase in the 
number and size of a wide range of cell types. Specific receptors have been identified in many of 
these, e.g., in muscle and in fibrous tissue. Their stimulatory effect on bone growth is particularly 
important since that supports the greater disposition of soft tissue (Lamming and Peters, 1987). 
Somatomedins are thought to be produced by the liver under the influence of somatotropin, 
however, other tissues such as the kidney (Murphy et al., 1987) also produce somatomedins. Other 
endogenous hormones, e.g., prolactin, insulin, corticosteroids and thyroid hormones also influence 
the production of somatomedins. High rates of growth in farm animals have been correlated with 
high levels of somatomedins and recent experiments have demonstrated an increase in the growth 
rate of laboratory animals following the administration of somatomedins (Lamming and Peters, 
1987). 
Although its existence has long been suspected, the hypothalmic growth-hormone-releasing 
factor (GRF) has only recently been isolated (Esch et al., 1983). GRF is a polypeptide consisting of 
44 amino acids. Synthetic analogues of the factor have been prepared and have been shown to 
stimulate the release of somatotropins in animals (Moseley et al., 1984). 
One of the reasons for the long delay in the discovery of GRF was subsequently found to be the 
concurrent existence in the brain of a somatotropin inhibiting factor. This compound, known as 
somatostatin, is also a peptide and consists of only 14 amino acids (Lamming and Peters, 1987). 
Somatostatin inhibits the release of somatotropins and insulin (Koerker et al., 1974). 
There has been much recent interest in the practical exploitation of both GRF and somatostatin 
in controlling the growth of farm animals by the development of analogues of GRF and by 
immuno-neutralization of the effect of somatostatin (Lamming and Peters, 1987). 
Regulatory concern 
Certain regulatory concerns inevitably emerge from any new technological endeavor. With the 
development of the somatotropins and related compounds for food animal use, concerns relating to 
efficacy, animal safety and welfare and environmental safety have been expressed. Further, 
concerns regarding the patentability of transgenic animals have been mentioned and of paramount 
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concern are those factors relating to the human food safety aspects of new animal drugs, especially 
those produced by recombinant technology. 
Target animal safety, safety to the environment and animal welfare concerns of the 
somatotropins and related compounds have been adequately addressed in the scientific literature. 
Regarding the products of biotechnology and human food safety, the industrialized nations of 
the world have concluded that such products should be regulated under the same policies and 
procedures currently applicable to other animal drugs with the process of biotechnology regulated 
independently. The existing national regulatory processes are adequate to address the human food 
safety concerns of the somatotropins and related compounds (Anon, 1986). 
Fortunately, the concerns for safety of the somatotropins are minimal, since these peptides are 
digested in the gastro-intestinal tract and are species specific (Apostolou, 1988). 
The environmental effects of products produced by recombinant DNA technology are of 
considerable interest. It is possible that adverse effects could result from altering the genetic 
makeup of micro-organisms and allowing their inadvertent release into the environment. The 
concerns of responsible scientists and environmentalists are not to be dismissed since there are 
many examples of disastrous consequences resulting from organisms being introduced into new 
environments. 
Safety of somatotropins and related compounds in food , 
Somatotropins hold the promise of producing meat with less fat and more protein, and more milk 
with greater feed efficiency. Therefore, there is interest in developing these compounds for 
widespread use in food-animal production. At this time, more than 60 experimental regimens have 
been submitted to the United States Food and Drug Administration for approval to conduct research 
with these compounds in target animals. 
Although the primary species of interest at this Symposium is pigs, there are few 
non-proprietary data relating to products of biotechnology in these animals. Therefore, we must rely 
heavily on published information relating to bovine somatotropins (BST) in order to address in a 
public forum the human food safety aspects of porcine products. The data that have been reported 
in swine indicate that somatotropin has a pronounced effect on increasing muscle tissue while 
reducing fat synthesis. Dramatic alterations in the rate and efficiency of gain in swine have also 
been reported (Boyd, 1987). 
Bovine somatotropin for dairy cows will likely be one of the first commercial applications for 
biotechnology in animal husbandry. Dairy cattle treated with BST often secrete low levels of 
somatotropin into the milk. However, cows injected with up to 50 mg/day BST did not show 
detectable levels in milk when assayed by a radio-immunoassay with a validated sensitivity of 2 ppb 
(Hart et al., 1985). In another study, milk from control and treated cows (40 mg/day BST) contained 
less than 2.5 ppb (Simkins, 1987). The Milk Marketing Board of the United Kingdom could not 
distinguish chemically between milk from BST treated cows and untreated cows even as to BST 
content (Phelps, 1987). 
There are two primary reasons residues of BST in milk are unlikely to present a safety concern: 
- BST is not orally active because gastric and intestinal proteases such as pepsin, trypsin and 
chymotrypsin digest the protein molecule into its constituent amino acids. Recombinantly 
derived BST was ineffective in rats after oral administration of amounts up to 4 mg/day either in 
producing growth or in the appearance of immunoreactive BST in the serum (Seaman et al., 
1988). 
- Somatotropins are species specific except between primates where lowered responses can be 
observed. Bovine somatotropin when administered parenterally to humans is inactive. 
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Furthermore, pasteurization and other manufacturing processes may inactivate somatotropin. 
Activity of somatotropin is lost by immersion in boiling water at pH 4.0, 7.5 and 8.9. Activity of 
recombinantly derived BST was lost after pasteurization of milk (Kronfeld, 1987). 
Of course, these factors would be applicable to both BST and porcine somatotropin (PST) 
regarding potential residues of somatotropins in organ or muscle tissues. Thus, there is little 
likelihood of significant concerns resulting from residues of these proteins in meat from treated 
animals. 
An issue of some concern is the relationship between insulin-like growth factors, particularly 
IGF-1, and somatotropin which has the potential to increase concentrations of IGF-1 in milk and 
meat from cows treated with BST. This question regarding IGF-1 must be resolved and is critical 
because of the potential for these shorter chain peptides to be absorbed through the gut, especially 
in neonates. Furthermore, these protein mediators are believed not to be species specific as with the 
somatotropins. 
Satisfactory resolution of these issues will facilitate approval of these drugs in food animals, 
assuming all safety, efficacy and environmental standards are met. 
Regulatory process in the United States 
If somatotropins and related compounds are to be used in the United States, regulatory approval 
for on farm use must be obtained. The Food and Drug Administration (FDA) is responsible for the 
premarketing efficacy and safety evaluation and approval of new animal drugs and feed additives; 
for regulating their manufacture, sale and use; and for setting tolerances for residues permitted in 
food. 
Under the U.S. Federal Food, Drug and Cosmetic Act (CFR, 1988 a), the term 'drugs' means 
substances recognized in the United States Pharmacopeia, Homeopathic Pharmacopeia of the 
United States, or the National Formulary; substances intended for use in the diagnosis, cure, 
mitigation, treatment, or prevention of disease in man or other animals, and substances other than 
food intended to affect the structure or function of the body of man or other animals. It also includes 
substances intended for use as a component of a drug. The Act defines a new animal drug (in part) 
as any drug intended for use in animals other than man, the composition of which is not generally 
recognized among experts qualified by scientific training and experience, as safe and effective for 
use under the conditions prescribed, recommended, or suggested in its labeling. 
Before a new animal drug may receive formal FDA approval, it must be tested for effectiveness 
and safety by the sponsor of the drug product. If the product is intended for use in a food-producing 
animal, data must be obtained which demonstrate that the edible animal products do not contain 
unsafe residues. It is the responsibility of the drug sponsor to conduct the necessary tests. 
When the sponsors are confident that sufficient data obtained under research protocols have 
established the safety and efficacy of the drug, they may apply for marketing approval. A New 
Animal Drug Application (NADA) must be submitted along with all data obtained, including 
adverse effects associated with the drug's use. The NADA must also include information on the 
drug's chemistry; composition and component ingredients; manufacturing methods, facilities and 
controls; proposed labeling; analytical methods for residue detection and analysis; and 
environmental impact. 
The target animal safety and efficacy data for a drug product must relate to the dosage level and 
route of administration as proposed in the labeling. All data submitted must relate either directly or 
indirectly to the specific claims for the product. 
Development of adequate methods for detecting drug residues in animal tissues from treated 
animals is frequently the most time-consuming and expensive item in developing a new animal drug 
for food-producing animals. Development of residue methodology is based on toxicological studies 
to establish safe residue levels or tolerances for humans consuming food products derived from 
treated animals. Methods may have to be developed for muscle, liver, kidney, fat, and milk which 
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are sensitive to levels that assure food safety. The proposed residue methodology must be validated 
prior to approval of the NADA and must show satisfactory performance in one USDA and two FDA 
laboratories. If the method proves to be practical, of sufficient sensitivity and is validated in the 
three laboratories, FDA will recommend its acceptance. 
When a NADA is deemed approvable, a regulation is published in the Federal Register 
announcing its approval and it is incorporated into the Code of Federal Regulations. 
Regulatory status 
Based on the information previously presented, the Food and Drug Administration currently 
allows the marketing of edible products from animals which have been treated with BST or PST in 
investigational laboratory and field studies with no pre-slaughter withdrawal or milk discard 
restrictions. However, since U.S. food and drug law requires each new drug product to be supported 
by its own unique evidence of safety and because each proposed somatotropin product may be 
slightly different in amino acid sequence and physical formulation, certain safety data are required 
prior to approval of an individual application. Since recombinant BST molecules differ from the 
endogenous compound by only one to three amino acid groups (e.g., methionyl-BST), FDA does 
not consider these changes to be of toxicological concern. As new alterations to the molecule are 
developed, each will have to be tested to ensure that the alteration has not introduced toxic 
properties (Apostolou, 1988). ' 
Generally, data which confirm the lack of oral activity of the particular somatotropin market 
product in laboratory animals at exaggerated doses will be expected as part of the application. In 
addition, it must be demonstrated that somatomedins are not significantly increased in milk or 
tissue subsequent to somatotropin treatment or if they are, that these hormone mediators do not 
possess oral activity. This could be accomplished by direct measurement of IGF levels between 
treated and control animals and/or short term oral overdose studies similar to those for 
somatotropin. 
It is expected that somatotropins will be approved and regulated in the United States in a manner 
similar to the endogenous hormones (estradiol, progesterone and testosterone). A tolerance and 
preslaughter withdrawal period for these hormones are not necessary and no approved tissue 
residue method is required (CFR, 1988b). 
With respect to the transfer of new genetic material into the genome of an animal (transgenic 
animals), the regulatory response should depend on the types and magnitude of the genetic changes 
induced. In general, it is not anticipated that transgenic animals will differ substantially in 
appearance, behavior or general health from current food animals (Gilles, 1988). Following 
assurances that food from these animals is safe for human consumption, they will be inspected like 
their more traditional counterparts. 
Environmental impact 
Originally the source of these compounds was the abbatoir. Careful extraction of the anterior 
pituitary gland from beef and pork carcasses yielded small amounts for biochemical research but 
not enough for use in animal production (Gilman et al., 1985). As a result of improvements in 
biotechnology, systems have been developed which are capable of producing enough hormone 
products for animal production use. The genetic material from animal cells has been isolated and 
transferred to bacterial cells and the cells are reproduced using standard fermentation techniques. 
The bacteria produce the hormone which is coded for by the transferred genetic material. The 
resulting substance is then isolated, purified and made available for commercial use. 
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The difference between routine bacterial fermentation processes, carried out safely for many 
years with antibiotic production, and recombinant DNA technology is the potential for release into 
the environment of organisms that possess new genetic information. 
The FDA has determined that the investigational activities for BST will not significantly affect 
the human environment and has issued a Finding of No Significant Impact for each BST 
investigational application currently under consideration. The FDA will re-examine the 
environmental impact of the commercial-scale production and marketing of BST and PST and 
related compounds before approving their commercial use. 
The particular variety (K-12) of Escherichia coli used for the production of BST seems to be 
only an opportunistic pathogen, like the parent (unmodified) organism. Based on this, the 
Commissioner of FDA has proposed to the National Institutes of Health Recombinant-DNA 
Advisory Committee that the containments for micro-organisms such as E. coli K-12 "be no greater 
than those appropriate for the unmodified parental organisms". The Advisory Committee has 
accepted the proposed change (Apostolou, 1988). 
The production cost of synthetic hormonal proteins is important for commercial applications. 
Production costs for somatotropin have been estimated to be reasonable for their use in dairy 
animals to increase milk production (Fallen et al., 1987). Other issues of social and economic 
importance, particularly for many U.S. producers, such as the effect on the small farmer and 
changes in long term land usage, may also need to be addressed as part of an environmental impact 
assessment. 
Monitoring by FSIS 
Since 1967, the Food Safety and Inspection Service (FSIS), of the U.S. Department of 
Agriculture (USDA), has conducted a National Residue Program (NRP) to help prevent the 
marketing of animals containing illegal residues of drugs and other chemicals. FSIS is responsible 
for enforcing the Federal Meat Inspection Act (CFR, 1988c) and the Poultry Products Inspection 
Act (CFR, 1988d). Under these laws, the Agency ensures that meat and poultry products in 
interstate commerce and for import are wholesome, not adulterated, and properly labeled and 
packaged. The meat and poultry inspection laws provide for the retention or condemnation of 
carcasses suspected of containing or found to contain illegal drug and chemical residues. In 1987, 
USDA inspected 121 million head of livestock, nearly 5 billion birds, and 127 billion pounds of 
processed meat and poultry products. As part of this responsibility, samples of meat and poultry are 
collected at slaughtering establishments for further testing. Each year, over 2 million laboratory 
analyses and inplant tests are performed on over 450,000 samples to support the FSIS residue and 
microbiological monitoring and surveillance programs. 
FSIS carries out its residue control program in cooperation with other Federal agencies. For the 
most part, these efforts are coordinated among FSIS, FDA, and the U.S. Environmental Protection 
Agency (EPA). Both FDA and EPA establish tolerances for compounds to which livestock and 
poultry are exposed. They also determine the approved methods of use of compounds on specific 
crops or animals to ensure that tolerances will not be exceeded. EPA establishes tolerances for 
pesticides, while FDA sets tolerances for animal drugs and other non-pesticide contamination in 
food. 
If FSIS finds significant levels of residues in an animal, these findings are then reported to FDA 
which may subsequently decide to initiate a follow-up investigation to determine the source of the 
residue. If FSIS finds violative residues in an animal or group of animals, the meat or poultry may 
be condemned. 
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Criteria for compound evaluation and selection 
It is not feasible to monitor for residues of all chemicals in meat and poultry. Further, this is not 
necessary to adequately protect public health. It is, however, important to assess the likelihood that 
animals exposed to chemicals may contain residues at levels of concern, and to conduct monitoring, 
where test methods are available, for those chemicals that are most likely to present the greatest 
potential risk. A hierarchic compound assessment scheme is used for this purpose. 
Each compound is evaluated on a number of factors to judge the potential for animal exposure 
and significance for human health. These factors include: 
- Amount of actual or probable use. 
- Conditions of use as related to residues at slaughter. 
- Potential for misuse to result in harmful residues. 
- Metabolic patterns of the chemical in animals, plants, and the environment, including the 
bioavailability and persistence of residues. 
- Toxicity of the residue. 
Compounds are selected for monitoring after ranking and included in a plan for the calendar year 
based on several factors, including: 
- Compound ranking assigned. 
- Whether a practical test method is available and is suitable for regulatory use. 
- Whether the compound is measurable in a multi-residue method where many compounds, even 
though all may not be assigned a high ranking, can be tested for a relatively low cost. 
- Monitoring or other experience that shows whether adulterating residues are present in meat and 
poultry. 
FSIS works from a list of about 400 compounds that includes certain environmental 
contaminants in addition to animal drugs and pesticides. 
The process of compound evaluation and ranking is a dynamic one. Additional compounds have 
to be considered in the system as agricultural use practices change, and additional research on a 
compound's toxicity and its potential for leaving harmful residues may affect previous rankings. 
FSIS uses a Compound Evaluation System (CES) which is designed to provide the Agency with 
a systematic approach to the categorization of compounds and to the analysis of their likelihood of 
occurrence in meat and poultry and their potential impact on public health (Anon, 1988). 
Briefly, the CES addresses the risk of residues occurring in meat and poultry as a function of two 
major elements. They are hazard (adverse effects of a given compound) and exposure (residue 
level and amount of product consumed containing residues of concern). The system is a two-value, 
hierarchic compound ranking scheme that classifies a given pesticide, animal drug, or contaminant 
in any one of 16 categories. Compounds of greatest concern carry a designation of A-l (high health 
hazard potential; high likelihood of residue occurrence); those compounds of least concern are 
designated D-4 (negligible health hazard potential; negligible likelihood of residue occurrence). 
FSIS has tentatively assessed bovine and porcine somatotropins as D-4 using the CES system 
and available data from the scientific literature. 
Research animals slaughtered in federal establishments 
FSIS has the regulatory authority to perform ante-mortem and post-mortem inspection on 
livestock used in any research investigation involving an experimental biological product, drug, or 
chemical slaughtered at an official establishment. 
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Figure 1 describes the growing interest in the commercial use of these anabolic agents as 
evidenced by the dramatic increase in numbers of experimental animals. FSIS has inspected over 
the last few years more than 5,000 investigational animals that have been treated with 
somatotropins or related compounds. The only lesions noted have been injection lesions and 
abscesses. At this time, these compounds cannot be given in feed and must be injected, however, the 
future ideal delivery system for animal production will eliminate daily injections. These systems 
include depot injections of oil suspensions and the use of an osmotic pump. Both methods supply 
sustained release of BST for two or more weeks. The most extended release is from osmotic pumps, 
which must be excised at slaughter. 
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Figure 1. Number of research animals slaughtered In federally Inspected establishments after 
administration of growth regulating agents. 
Conclusion 
The approach to food safety described is scientifically defensible for the regulation of 
somatotropins and related compounds. It embraces the proper level of concern for public health 
while at the same time recognizes the practical advantage of using these compounds in the rearing 
of livestock. It is at Symposia such as these that an international scientific consensus can be reached 
on the proper degree of regulation to apply to new technologies and products. This, of course, is of 
extreme importance in terms of future trade between nations. 
The ideal situation occurs for consumers and fanners when the safety and efficacy of an animal 
drug have been demonstrated through scientific studies that form the basis for regulatory controls. 
Governments can then license such products and implement effective monitoring programs to 
ensure compliance with conditions of use. In order for this situation to be realized, public health 
decisions must be founded on scientific facts. When this is not the case, problems inevitably arise. 
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In the effort to harmonize international regulatory controls, there will be a continuing need for 
the exchange of scientific information and acceptance of shared data among trading nations. There 
must be a working relationship between industry, academia, and government, based on impeccable 
scientific principles that are comprehensible to the layman. That, will be the ultimate assurance of 
better international and regulatory cooperation. 
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POTENTIAL OCCURENCE OF RESIDUES AFTER TREATMENT OF 
PIGS WITH RECOMBINANT SOMATOTROPIN 
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Summary 
Recombinant porcine somatotropin (rpST) has in recent years shown to be highly effective 
improving growth characteristics such as average daily gain, feed efficiency and leaness of the 
animals treated. A first attempt is made to evaluate blood and tissue levels of pST, blood levels of 
IGF-1 prior and during slaughter of rpST treated pigs. 
In trial 1 (94 pigs) 5 factors were regarded.Three breeds (Pietrain, Duroc and^l from Great 
Yorkshire x Dutch Landrace); four litters per breed; two sexes (barrows and gilts); two treatments 
(rpST and placebo); two weights at slaughter (100 kg and 140 kg). Treatment (twice weekly, 14 mg 
rpST dissolved in buffer i.m./injection) started with 60 kg live weight. Blood from the jugular vein 
was collected 4.5 days after the last injection at slaughter. Trial 2; 36 barrows from 3 breeds; 
(Pietrain, Duroc and Fl) were treated from 60 kg up to 120 kg live weight with rpST twice weekly 
i.m. with 14 mg/injection. Blood from the jugular vein was collected after the last injection within 
1 h and 26-27 h later at slaughter. Additionally from 10 pigs (7 treated, 3 placebos) muscle tissue 
from the right shoulder was collected for pST residue analysis. 
Porcine somatotropin and IGF-1 were evaluated by RIA. In trial 1, 4.5 days after the last rpST 
injection blood levels of pST of treated animals were similar to controls or significantly lower in 
Pietrain and Duroc breed. In trial 2 within 1 h after the last injection there was a tremendous 
increase on average from about 2 ng/ml up to 240 - 321 ng/ml 26-27 h later values of treated 
animals reached already control levels. Tissue concentrations were not significant different and 
were below levels of 5 ng/g wet tissue. Blood concentrations of IGF-1 were not significantly 
different between controls and treated animals in trial 1 and in trial 2 within one hour after the last 
injection. Levels increased significantly 26-27 h later. In conclusion no measurable residues of pST 
or IGF-1 were found after treatment with pST in blood or muscle tissue 4.5 days after the last 
injection of pST. 
Keywords: somatotropin, insulin-like growth factors, residues, swine. 
Introduction 
Porcine somatotropin (pST) is a naturally - occurring protein produced by the pituitary gland. 
More recently material has been made available by recombinant gene technology. The particular 
molecule produced is identical to one of the naturally occurring somatotropins apart from an 
additional methionine at the N terminal end. Recombinant porcine somatotropin (rpST) has, in 
recent years shown to be highly effective in improving growth characteristics such as average daily 
gain, feed efficiency and leaness of the animals treated. Until now no data were published 
concerning safety and wholesomeness of products from pigs treated with rpST. A first attempt is 
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made to evaluate blood and tissue levels of pST and IGF-1 prior and during slaughter of rpST 
treated pigs. 
Materials and Methods 
Two trials of growth experiments were performed at Wageningen Agricultural University (for 
details see paper of V.Fowler and E.Kanis in this volume). 
Trial 1: The experiment performed included five factors. 
1. Three breeds: Retrain, Duroc and Fl (Great Yorkshire and Dutch Landrace) 
2. Four litters per breed 
3. Two sexes: gilts and barrows 
4. Two treatments: rpST or placebo 
5. Two weights at slaughter: 100 and 140 kg live weight 
pST application: rpST was dissolved in a buffer which also was used as placebo. The 
administration (14 mg intramuscularely twice a week) started with 60 kg live weight and was 
continued till four and a half days before slaughter. The animals were fed ad libitum.Blood was 
collected in heparinized tubes immediately after the killing by electrocution, centrifuged and 
plasma was stored until analyses at -20°C .96 samples (47 from rpST treated pigs and 47 placebo) 
were analyzed. 
The animals with 100 kg or 140 kg slaughter weight received in total about 12 or 26 injections 
respectively. 
Trial 2: Barrows of different breeds (Pietrain, Duroc and Fl (Great Yorkshire x Dutch Landrace, 12 
per group) were treated with rpST (14 mg twice a week intramuscular) or placebo from 60 to 120 
kg of body weight (about 18 injections for each individual in total). The first blood sample was 
taken by needle puncture of the jugular vein at the end of treatment period within 1 h after the last 
injection. The second sample was taken 26-27 h later right after the killing by electrocution. 
Tissue samples 
In trial 1 from six pigs (four treated, two controls) and trial 2 from four pigs (three treated, one 
control) tissue samples from the right hand shoulder were collected and kept frozen until assay. The 
last injection in that tissue was given 4.5 days before slaughter. In the six pigs from the first trial it 
was the last injection the animal had, the four pigs in the second trial had a consecutive injection in 
the left hand shoulder one day before slaughter. 
Determination ofpSTin blood plasma 
Porcine somatotropin was determined by radioimmunoassay employing rabbit antiserum raised 
against pig pituitary extracted growth hormone (USDA-pGH-Bi). This antiserum was highly 
specific and showed no cross reactions with other anterior pituitary hormones. A pure pST 
preparation (USDA-pGH-Ii) was used for iodination by the iodogen method (Salacinski et al., 
1981). After separation of unlabeled from labeled pST by an anion exchange resin (AG2 - X8; 
BioRad Laboratories, Richmond, USA) further purification was achieved by column 
chromatography (Sephadex G-75). Standard or unknown sample (200 |xl) plus 100 \xl antiserum 
were incubated for 24 h at 4°C, than labeled hormone (100 |al; 15000 counts/min) was added and 
further incubated for two days. Separation of bound and free hormone was performed by the second 
antibody technique. 
The pituitary preparation USDA-pGH-Bi (biological activity 5.4 IU/mg, tibia assay) served as 
reference preparation. The assay sensitivity was 0.25 ng/ml plasma. The intra-assay coefficient of 
variation estimated from control samples running at the beginning, middle and end of each assay 
was below 8 %.The inter-assay coefficient of variation estimated from four control samples of low, 
medium and high pST concentrations ranged from 7-14 %. 
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Evaluation ofpST in tissue samples 
Extraction procedure of tissue was carried out between 0 - 4°C. The extraction was modified as 
originally described for preparation of porcine growth hormone by Schleyer et al. (1974). Five gram 
muscle tissue was homogenized with an Ultra Turrax homogenizer (Janke and Kunkel, Germany) 
with five times tissue weight of precooled 2 % sodium chloride solution of pH 8.5, stirred for 1 h. 
After that time the homogenate was centrifuged at 17000 RPM. The pellet was homogenized again 
in 20 ml of 2% NaCl solution, stirred for another hour and centrifuged as described above. The 
supernatants were combined, an aliquot was assayed directly. 
Determination of IGF-1 in blood plasma 
IGF-1 was determined radioimmunologically after acid-ethanol extraction of plasma. 
Recombinant IGF-1 (Amersham, England) was used for iodination according to the lactoperoxidase 
method. As reference preparation synthetic IGF-1 (kindly supplied by C.H.Li, San Francisco, USA) 
was used for calibration of a plasma pool standard. The intra-assay variation was below 10 % and 
the inter-assay variation was 12-16 %. 
Results and Discussion 
The results of trial 1 for concentrations of pST and IGF-1 in blood 4.5 days/after the last 
injection are summarized in Table 1.While there was no clear difference between barrows and gilts 
and of different final weights an overall mean for each breed was calculated. There is no difference 
between the control and treatment group for pST in Fi (Great Yorkshire x Dutch Landrace). IGF-i 
tended to be a little higher. Concentrations of pST are lower after treatment in Duroc and Pietrain. 
For IGF-1 there is no difference visible. 
. The results suggest that treatment for about 6 weeks (100 kg) or 13 weeks (140 kg) may lower 
endogenous secretion of pST immediately at the end of treatment. Nevertheless the injected rpST 
was cleaned from the circulation 4.5 days after the last injection and IGF-1 levels are not different 
from controls. 
Table 1. Blood concentrations of pST and IGF-1 (ng/ml) at slaughter after treatment with rpST or 
placebo 4.5 days after the last Injection (trial 1 ; mean ± S.D.), 
Breed Control Treatment 
pST IGF-1 pST IGF-1 
Fl 
Duroc 
Pietrain 
1.8+0.7 
3.7±3.1 
2.3+0.9 
n=14 
n=17 
n=16 
299+130 
417±136 
264±138 
1.5+0.8 
1.6±0.8 
1.6+0.5 
n=16 
n=15 
n=16 
369±149 
432±217 
276+127 
As shown in Table 2 (trial 2) treatment with rpST caused tremendous increase in blood 
concentrations within 1 h after the injection. 26-27 h later levels decreased in the treatment group 
to control values. The mean was higher only in the Duroc breed due to one animal (85 ng/ml) which 
also had the highest value after the injection. IGF-1 values tended to be a little higher 1 h after the 
injection if compared with controls and increased significantly 26 - 27 h after the injection. The data 
obtained indicate that intramuscular injected rpST is cleared from the circulation within 26 h. 
Stimulated IGF-1 concentrations decreased to control levels at least after 4.5 days. In contrast daily 
treatment of veal calfs for 9 weeks with recombinant bovine somatotropin delayed the clearance 
rate of bST significantly (Kirchgessner et al., 1987). 
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Table 2. Blood concentrations of pST and IGF-1 (ng/ml) after treatment with somatotropin or placebo 
within 1 h and 26 - 27 h after the last Injection. 
Breed 
Fl 
Duroc 
Retrain 
treatment 
control 
rpST 
control 
rpST 
control 
rpST 
n 
6 
5 
6 
6 
6 
6 
within 1 h 
pST 
2.0±1.6 
240±113 
2.0+1.7 
321±84 
2.0±0.6 
266±46 
IGF-1 
437±110 
749±346 
391±73 
531±172 
193±81 
373±158 
26 - 27 h after Injection 
pST IGF-1 
2.1±0.5 231±37 
3.1±3.2 793±89 
2.9±0.5 398±58 
14.9±32 1310±217 
1.7±0.3(n=5) 
2.7±0.9 183±45 
2.1 ±0.5 720±j296 
Muscle tissue concentrations for pST are below 5 ng/g wet tissue and so within the range of 
levels measured in the peripheral circulation. 
Conclusions 
The studies have indicated that after treatment with rpST twice weekly (14 mg/injection) there 
are no residues measurable 26 - 27 h after the last injection in peripheral circulation for pST and at 
least 4.5 days later for IGF-1. Concerning rpST there seems to be no risk for the consumer 
especially because pST is a protein and is not biologically active either orally nor parenterally in 
man. 
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NUTRITIONAL AND SENSORY CHARACTERISTICS OF PORK FROM 
PIGS ADMINISTERED SOMATOTROPIN 
K.J. Prusa 
Department of Food and Nutrition, Iowa State University, Ames, Iowa 50011 U.SA. 
Summary 
Although measurable differences in nutritional composition and sensory quality between 
somatotropin-treated and untreated pork have been reported, no major concerns are evident. Several 
reports have indicated that intramuscular fat content is lowered in response to porcine somatotropin 
(pST) administration. Intramuscular fat contents of less than 1% due to pST treatment have been 
reported. Protein and moisture contents of muscle tissue increased slightly in studies that reported 
a decrease in intramuscular fat content. No differences were noted in the fatty acid profiles or 
cholesterol contents of longissimus muscle from animals treated and then removed from pST zero 
days before slaughter. However, polyunsaturated fatty acid contents of raw pork and cholesterol 
contents of cooked pork were reported to increase slightly in 7-day withdrawal animals. Thiamin 
content of the tissue tended to decrease slightly, in response to pST treatment. Several studies have 
reported that pST administration has no detrimental effects on the sensory quality of the 
longissimus muscle. In contrast, minimal decreases in muscle tenderness, juiciness and flavor 
intensity in association with a high level of pST treatment have been reported. 
Keywords: somatotropin, nutritional composition, sensory, quality. 
Introduction 
The use of biotechnology for the production of porcine somatotropin (pST) should have a 
dramatic impact on the future of the pork industry. Consumer demand for more uniform, 
lower-calorie pork should help secure a positive future for pST. However, it is imperative that all 
information, including meat product quality, be evaluated. Although pST administration opens a 
new avenue for the production of leaner pigs, the new technology may not reach full potential if 
consumer appraisal of the final meat product is negative. Research that focuses on nutritional 
composition and sensory quality of pork products from pST-treated pigs is essential for a full 
evaluation of somatotropin use. 
Somatotropin injection into growing and finishing pigs has the potential to alter every known 
aspect concerning pork quality. When the metabolism of a muscle has the potential to change with 
pST injection, the composition and eating quality of the resultant meat product also has the potential 
to change. Therefore, this review will evaluate studies concerned with the nutritional composition 
and sensory quality of pork from pigs administered somatotropin. 
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Lipid characteristics 
Intramuscular f at content 
Dietary fat intake has received considerable attention in recent years. Numerous groups 
(American Heart Association, 1985; United States Department of Agriculture, 1985; National 
Research Council, 1988a) have recommended limited intake of dietary fat, including consumption 
of lean, well-trimmed meat cuts. It is without a doubt that the amount of trimmable fat on a pork 
carcass can be reduced significantly through the administration of pST (Etherton, 1988). However, 
the obvious question arises if the significant reduction of trimmable carcass fat translates into a 
reduction of intramuscular fat. 
Several studies have indicated that intramuscular fat content is lowered or not affected in 
response to pST administration. Intramuscular fat contents of raw tissue (Beermann et al., 1988; 
Prusa, 1988b) and cooked tissue (Prusa, 1988b) of less than 1% have been found as a result of pST 
administration. The studies listed (Table 1) are a result of a variety of pST dose levels, injection 
periods and types of pST (natural or recombinant). 
Table 1. Effects of pST on the Intramuscular fat content of pork longlsslmus muscle. 
Reference Effect of pST 
Beermann et al., 1988 Decreased 
Ender, 1988 (Private Communication) Decreased 
Novakofskl, 1987 Decreased 
Prusa et al., 1988a Decreased 
Prusa, 1988b (Private Communication) Decreased 
Ellendorff, 1988 (Private Communication) Decreased 
Kanls et al., 1988 No effect 
Prusa et al., 1988c No effect 
Chung et al., 1985 Increased 
It is interesting to note that one study (Chung et al., 1985) found an increase in intramuscular fat 
content in response to pST treatment. Chung et al. (1985) indicated that an increased delivery of 
free fatty acids to the cell for metabolism may be responsible for the increase in lipid content. 
Animals removed from pST injections seven days before slaughter may have adequate time to 
metabolize the influx of free fatty acids and therefore have reduced intramuscular crude fat contents 
(Prusa et al., 1988a,d). But, if the animal is slaughtered with a zero-day withdrawal period (Chung 
et al., 1985; Prusa et al., 1988c), free fatty acids may be trapped in the cell and contribute to the 
intramuscular fat content. Therefore, the effects of pST on the intramuscular fat content may be 
related to the pST-withdrawal period. 
Fatty acid profiles and cholesterol content 
Generally, fatty acid profiles of the intramuscular fat extracted from raw and cooked longissimus 
muscle have been reported to not be affected greatly by pST treatment. No differences were noted 
in fatty acid profiles of intramuscular fat extracted from raw or cooked muscle from animals 
removed from pST treatment zero days before slaughter (Table 2). In a similar study, 
polyunsaturated fatty acid content of the intramuscular fat increased by 1.5% in response to 4 mg of 
pST per day (Prusa et al., 1988a). 
184 
I 
CONSUMER ASPECTS: NUTRITIONAL AND SENSORY CHARACTERISTICS 
Table 2. Effects of pST on the fatty acid profiles (%) of Intramuscular fat from raw and broiled 
longlsslmus muscle.' 
Somatotropin level (mg/day) 
0 4 8 
Raw 
saturated 
monounsaturated 
Polyunsaturated 
Broiled (7I°C) 
saturated 
monounsaturated 
polyunsaturated 
38.3a 
57.5a 
4.1° 
38.9a 
58.5a 
2.5a 
37. l a 
57.9a 
5.0a 
40.6a 
57.0a 
2.4a 
39.8a 
55.5a 
4.7a 
38.3° 
58.3a 
3.3a 
1
 From Prusa et al., 1988c. 
"Means in a row are not significantly different (P < 0.05). 
Fatty acid percentages reported by Prusa et al., (1988a,c) are well in the normal range reported 
for fresh pork (Skelley et al., 1975; Malmfors et al., 1978; Marchello et al., 1983). 
The cholesterol content of raw and cooked longissimus muscle has been reported to not be 
affected by pST administration (Table 3). In a related study evaluating a 7-day withdrawal period, 
cholesterol contents of cooked muscles from animals treated with 8 mg pST daily were found to be 
slightly greater than cooked muscles from controls or animals that received 4 mg p^T daily (Prusa 
et al., 1988a). The increase in cholesterol content (wet-weight basis) was relatively small with the 
muscles from the 8 mg treatment group containing approximately 5 mg more cholesterol than 
control muscles. The slight increase would be of little practical consequence for individuals 
concerned with cholesterol intake. 
Table 3. Effects of pST on the cholesterol contents (mg/IOOg) of cooked longlsslmus muscle.1 
Somatotropin level (mg/day) 
0 4 8 
Cholesterol (wet-weight, raw) 52. l a 54.0a 54.4a 
Cholesterol (wet-weight, cooked) 63.5a 65.2a 69,8a 
'From Prusa et al., 1988a. 
a
 Means in a row are not significantly different (P < 0.05). 
Protein and moisture contents 
Protein and moisture contents of the longissimus muscle have been found to increase slightly in 
I studies reporting a decrease in longissimus intramuscular fat content due to pST administration 
(Prusa et al., 1988a; Beermann et al., 1988). In studies reporting no effect of pST on intramuscular 
J fat contents, protein and moisture contents of pST-treated and untreated muscle samples were 
1
 similar. 
Thiamin and iron contents 
The thiamin contents of longissimus muscles from pST-treated animals have been reported to be 
less than the longissimus muscles from control animals (Table 4). 
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Table 4. Thiamin contents (mg/IOOg) of raw and broiled longissimus muscle from animals treated with 
pST.' 
Somatotropin level (mg/day) 
0 4 8 
Raw 
Thiamin (wet-weight) 
Thiamin (moisture, fat-free) 
Broiled (7I°C) 
Thiamin (wet-weight) 
Thiamin (moisture, fat-free) 
0,60a 
2.49a 
0.37° 
1.19a 
0.3«^ 
1.53b 
0.28b 
0.88b 
043b 
1.67" 
0.27b 
0.83b 
' From Piusa et al., 1988a. 
ab
 Means not followed by a common letter are significantly different (P < 0.05) 
Reduced thiamin contents of the tissue may be related to an altered animal metabolism. If greater 
amounts of fatty acids are present in the cell for metabolism (Chung et al., 1985), carbohydrate 
metabolism may be altered. Because thiamin is an essential component of carbohydrate metabolism 
(National Research Council, 1988b), the animal's need for thiamin may be decreased. Total iron 
contents of the longissimus muscle has been reported to not be affected by pST treatment (Prusa et 
al.„ 1988a,c). 
Sensory quality 
The use of intensity scales by trained sensory judges is the most beneficial for the measurement 
of the quality of pork from pST-treated animals. Studies that use a small number of judges with 
"liking" scales do not offer useful information pertaining to possible changes in tenderness, 
juiciness and flavor. Measurement of how much a specific attribute is "liked" will not relate to an 
increase or decrease in the intensity of that attribute. 
Tenderness - human perception 
Several studies have used sensory panels to evaluate the tenderness of the longissimus muscle 
from animals treated with pST (Table 5). 
Table 5. Perception of tenderness of the longissimus muscle from pigs treated with pST. 
Reference Effect of pST 
Prusa et al., 1988e Decreased at 8 mg/day 
No effect at 4 mg/day 
Beermann et al„ 1988 Decreased at 60 ug/kg/day 
No effect at 30 or 90 ug/kg/day 
Kanls et al., 1988 No effect 
Novakofskl, 1987 No effect 
Evock et al., 1988 Degree of "liking" decreased 
Althen, 1988 (Private Comm.) Degree of "liking" decreased 
Prusa et al. (1988e), using intensity scales, found a decrease in tenderness of the longissimus 
muscle from animals receiving 8 mg of pST daily; however, no differences were noted between 
control samples and muscles from animals receiving 4 mg pST daily. A slight decrease in tenderness 
between control muscles and muscles from animals receiving 60 ug pST/kg/day was noted by 
Beermann et al. (1988). In that study, no tenderness differences were noted between control 
samples and muscles from animals treated with 30 or 90 ug pST/kg/day. Kanis et al. (1988) and 
Novakofski et al. (1988) found no difference in tenderness of longissimus muscles due to pST 
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administration. Both Evock et al. (1988) and Althen (1988) indicated degree of "liking" scores for 
tenderness of the longissimus muscle decreased due to pST treatment. No reasons were reported 
why "liking" scores decreased. 
Tenderness - Warner-Bratzler shear 
The Warner-Bratzler shear is the most often used instrumental measure for the evaluation of 
meat texture (tenderness). Generally, no major differences have been reported for Warner-Bratzler 
shear values for muscles from pST-treated and untreated animals (Prusa et al., 1988e; Kanis et al., 
1988; Beermann et al., 1988; Althen, 1988). In one study, Warner-Bratzler shear values of the 
longissimus muscle from animals receiving 9 mg pST daily increased 0.32 kg when compared with 
muscles from control animals (Novakofski, 1987); however, that increase was not considered 
significant. 
Juiciness 
Perceived juiciness of pork is an area of interest because of the potential of pST to lower the 
intramuscular fat content. However, few measurable differences in sensory juiciness due to pST 
treatment have been reported (Table 6). 
Table 6. Effects of pST on the Juiciness of pork muscles. 
Reference Effect of pST , 
Prusa et al., 1988e Longissimus - no effect 
Semimembranosus - decreased at 8 mg/day 
Beermann et al., 1988 Longissimus - decreased at 60 ug/kg/day 
No effect at 30 or 90 ug/kg/day 
Novakofski, 1987 Longissimus - no effect 
Evock et al., 1988 Longissimus - no effect 
"degree of I 
Althen, 1988 (Private Longissimus - no effect 
Communication) "degree of liking" 
Roasted semimembranosus from animals treated with 8 mg pST/day were less juicy than 
samples from control animals (Prusa et al., 1988e). The lower juiciness scores could not be related 
to intramuscular fat content because fat contents of control and pST-treated roasts (in the cooked 
state) were similar. Following the same trend as for tenderness, (Beermann et al., 1988) reported 
decreased juiciness of samples from animals treated with 60 ug/kg/day; however, no differences 
were noted among samples from the control, 30 or 90 ug/kg/day treatments. Several studies 
detected no differences in juiciness or juiciness "degree of liking" due to pST administration. 
Flavor, aroma and off-flavor 
No major differences in flavor or aroma of pork have been reported in response to pST treatment 
(Novakofski, 1987; Beermann et al., 1988; Kanis et al., 1988). In contrast, Prusa et al., (1988e) 
indicated roasted semimembranosus muscles were judged lower in pork flavor than control roasts. 
Reasons why pork flavor was reduced is still under investigation (Prusa, 1988b). Generally, no 
off-flavors have been reported for pork from animals treated with pST. 
Color 
Few studies could be found that evaluated the color of muscles from pST-treated and untreated 
pork. Kanis et al. (1988) found longissimus muscles from pST-treated animals were lighter in color 
than muscles from control animals. In a different study, Prusa et al. (1988e) found no differences in 
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the color of broiled longissimus or roasted semimembranosus when pST-treated and control 
samples were compared. 
Conclusion 
Measurable differences in nutritional composition between pST-treated and untreated pork have 
been reported. The most notable effect is the potential to produce pork with intramuscular fat 
contents of less than 1%. A serving of cooked pork containing less than 1% fat would supply a 
minimal number of calories from the fat. With the potential of pST to lower dramatically 
intramuscular fat content, pork from pST-treated animals should rival other low fat meat sources. 
Although slight alterations in sensory quality due to high levels of pST have been reported, no 
major detrimental effects were noted. The interaction between elevated dietary protein levels and 
pST treatment on the sensory quality of pork is in need of investigation. The next logical step after 
completing sensory analysis with trained judges is to conduct consumer acceptance tests utilizing 
large numbers of subjects. Preference consumer testing will afford insight into consumer appraisal 
of pork from pST-treated animals. 
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Summary 
Results, published in detail elsewhere, illustrating effects of recombinant porcine, somatotropin 
(rPST) on carcass and meat quality of Belgian and Dutch pigs are summarized. Belgian finishing 
pigs ( 60 to ca. 100 kg) were treated with four levels of rPST ( 0,1.5, 3 and 6 mg per day) by daily 
injection. They were fed a high protein, cereal based diet ad libitum (Expt. 1). Dutch pigs, fed a 
similar diet over a similar finishing period, were treated with 0 and 14 mg rPST, injected twice 
weekly (Expt. 2). In both experiments, data on carcass and organ yield, carcass quality and yield of 
commercial cuts, meat sensory quality, proximate composition and muscle protein composition 
(Expt. 2 only) were collected. 
Carcass yields were slightly decreased, associated with increased yields of heart, liver and 
kidneys. Carcass quality was considerably improved, as indicated by decreases in various carcass 
fat measurements and improved carcass grades. Carcass meat joint yields were improved, with 
concomitant reductions in fat joints and trimmings. 
No significant differences for rates of muscle pH decline were apparent, but there was some 
indication of higher temperatures shortly post mortem. Ultimate pH values were slightly but 
significantly increased. Various measurements of texture, colour and water holding capacity of the 
meat showed a slightly less red colour as the only statistically significant effect. Myofibrillar 
protein composition and sarcomere length of long.dorsi muscle was not affected, but crude protein 
content was slightly increased. 
The studies demonstrated that various levels of rPST can increase meat yield and lower carcass 
fat, even in breeds selected for superior carcass composition, without further detrimental effects on 
meat sensory quality. 
Keywords: somatotropin, swine, carcass quality, meat quality, organ weights. 
Introduction 
Injection of both pituitary derived porcine somatotropin (nPST) and its analogue produced by 
recombinant DNA technology (rPST) considerably improves performance and carcass composition 
of finishing pigs between 50 and 105 kg (references in Fabry et al., 1988 ). Some evidence suggests 
a somewhat lower activity of rPST (Ivy et al., 1985). Most reports deal however with pigs, feed and 
management practices in the U.S.A. Pigs in Europe are leaner than in the U.S.A., because of intense 
selection for meat production, whereas cereal grains rather than corn are used in feed formulation. 
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Fabry et al. (1988) and Kouwenberg (1988) conducted experiments to evaluate rPST efficacy in the 
finishing of lean pig breeds. Their specific attention went to the evaluation of effects on meat yield 
and meat quality. Indeed, it could be expected that effects on meat yield would be less outspoken 
with leaner animals, whereas such animals are known to be very susceptible to meat quality defects 
associated with rapid rates of post mortem pH fall (Eeckhout et al., 1966). 
This paper summarizes results on carcass and meat quality, described in detail elsewhere.of the 
Belgian (Fabry et al., 1988) (Expt. 1) and Dutch (Kanis et al., 1988), (Kouwenberg, 1988) (Expt. 2) 
recent experiments. 
Materials and methods 
Details are described in Fabry et al. (1988) and Kouwenberg (1988). In both cases a total of 96 
(Expt. 1) or 36 (Expt. 2) pigs was finished from ca. 60 to ca. 100 kg on diets containing 20% (Expt. 
1) or 18.2% (Expt. 2) crude protein and 8.74 (Expt. 1) or 9.49 MJ net energy per kg Barley and 
wheat (Expt. 1) and tapioca (Expt. 2) were main energy sources. Treatments in Expt. 1 consisted of 
four ( 0 ; 1.5 ; 3 ; 6 mg/d ) and in Expt. 2 of two ( 0 ; 14 ) dose levels of rPST injected behind the 
ears daily (Expt. 1) or twice weekly (Expt. 2) respectively. One breed (Belgian Landrace) was used 
in Expt. 1, whereas Expt. 2 involved three breeds ( Pietrain, Duroc and a crossbred between Dutch 
Yorkshire and Dutch Landrace). Slaughtering and commercial jointing was carried out in both 
experiments following methods customary for the respective countries. Organ weights were 
recorded and carcasses evaluated through measurements of fat depths at various sites. Samples of 
Longissimus Dorsi muscle (36 animals only) were obtained in both experiments and used for 
determination of colour, texture and water holding capacity by various methods. Additional 
information on taste panel evaluation (Expt. 2) and myofibrillar protein composition (SDS-PAGE 
or sodium dodecyl sulphate Polyacrylamide gel electrophoresis) (Expt. 1) of the muscle was 
obtained. Animals were grouped for treatments, and results analysed statistically by analysis of 
variance ( Expt. 1 ) and using a linear model of additive effects ( Expt. 2 ). In this paper, mean 
results per treatment only are reported, with indication of statistically significant effects. 
Results and discussion 
Carcass and organ yield 
Table 1 shows that rPST slightly decreases carcass yield with slaughtering at 100 kg carcass 
weight (dressing %), although statistical significance is only reached in Expt. 2. A decrease, 
confirming earlier work (Evock et al., 1988 ), should obviously be observed however, because of 
associated significant increases in the relative proportions of mainly liver, kidneys and heart. 
Differences in carcass yields between experiments are due to differences in breeds, 
pre-slaughter fasting periods and hot vs. cold carcass weights. In earlier work (cited in 
Kouwenberg, 1988) absolute, but not relative organ weight increases were reported. Such increase 
is however not surprising, in view of the increased overall metabolic activity reflected in protein 
turnover, kidney N retention and blood metabolite concentrations (Kouwenberg, 1988). 
The latter author observed that expression of organ weights as proportion of fat free carcass 
weight did not abolish the enlarging effect of rPST and the same is true for the Belgian data: live 
weight % of liver, kidneys and heart are increased by 16 ; 33 and 18 % respectively at the highest 
rPST dose (Table 1), whereas calculated meat yield is increased by 9 % only (Table 2). 
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Table 1. Effect of Recombinant Porcine Somatotropin (rPST) on pig carcass and organ yields." 
rPST (mg/d) 
Carcass 
weight (kg) 
Dressing %c 
Organs <% of live weight) 
Intestine 
total 
empty 
Stomach 
Bladder 
Tongue 
Liver 
Kidneys 
Heart 
Lungs 
Spleen 
Pancreas 
Mesentery fat 
Expt. 1 (22-24)b 
0 
78.5 
83.0 
7.58 
5.55 
.98 
.16 
.40 
1.65 
.36 
.33 
1.24 
.17 
.19 
.64 
1.5 
79.1 
83.3 
7.08-
5.28 
.78 
.18 
.46 
1.68 
.40 
.35 
1.20 
.18 
.21 
.58 
3 
78.3 
82.6 
7.23 
5.33 
.84 
.19 
.41 
1.83 
.46 
.37 
1.26 
.19 
.19 
.63 
6 
79.5 
82.2 
7.65 
5.68 
1.03 
.14 
.49 
1.91 
.48 
.39 
1.21 
.20 
.19 
.53 
Expt. 2 (24) 
0 
76.5 
78.7 
1.68 
.34 
.35 
.18 
4 
75.7 
77.8 
1.74 
.39 
.36 
.17 
mean values 
( ) = no. of animals per cell 
c
 measured on hot carcasses in Expt. 1 
significant difference from control, max. p : 
Carcass quality 
.05 
Table 2. Effect of Recombinant Porcine Somatotropin (rPST): measurements on hot carcasses (before 
cooling)1 ' 
rPST (mg/d) 
Back fat deptha 
(mm Avge SKR) 
Length (cm) 
Meat%b 
Classification0 
pH 
.5 hrs gluteus 
long.D* 
4 hrs gluteus 
long.D.6 
Temp.(°C) 
.5 hrs gluteus 
long.D." 
4 hrs gluteus 
long.D.8 
Expt. 1 (22-24) 
0 1.5 
24.4 
79.9 
59.5 
7.0 
5.9 
5.9 
5.6 
5.5 
40.1 
40.7 
25.7 
24.2 
22.7' 
78.3 
61,9 
8,1 
5.7 
5.9 
5.6 
5.5 
40.6 
41.1 
25.5 
24.7 
3 
21.9* 
79.9 
61.5 
7.5 
5.8 
5.9 
5.7 
5.5 
40.3 
40.8 
24.4 
24.5 
6 
17.6* 
80.3 
64.8 
8.4 
5.8 
5.8 
5.7 
5.6 
40.8* 
41.3 
23.7 
23.7 
Expt. 2 (24) 
0 
20.2 
51.2 
2.1 
6.0 
4 
18.2 
53.7 
2.0 
6.0 
Mean values only (cfr. Table 1) 
a
 calculated as described by Casteels & Verbeke (1978) in expt. 1 and listed as "spekdikte" in expt. 2 
Meat % was calculated from average fat depth, cold halve carcass weight and carcass length in expt. 1 
(Casteels & Verbeke, 1978) and from muscle and fat depth measurements in expt. 2 (Kouwenberg, 1988). 
c
 expt. 1 : 10=EE,9=E,8=AA,7=A1,6=A2,5=A3,4=B1,3=B2,2=B3 and 1=IV (value increases with number) 
expt. 2 : 4=C,3=B,2=A and 1=AA (value decreases with number) 
measurement in "ham" for expt. 2, .75 hrs. post mortem 
e
 number of observations 20,16,8 and 14 respectively at increasing rPST levels in expt. 1 
significant difference from control, max. p = .05 
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Carcass fat measurements taken at numerous locations on the hot (Table 2) as well as the cold 
(Table 3) carcass, represent the major reference sites used over the world for commercial as well as 
scientific evaluation of carcass quality. 
The observed reductions in fat depth are clearly dose dependant in Expt. 1 (discussed in detail 
by Fabry et al., 1988) and of similar magnitude at all sites measured: 32 to 47 % reduction. Such 
reductions are reflected in meat yields calculated from established regressions involving fat 
depth:meat yield increases between 9 % (Expt. 1) and 5 % (Expt. 2) can be calculated (Table 2). 
They also explain the significant improvement in carcass grading in Expt. 1 as well as in Expt. 2 
(Table 2). 
Table 3. Effect of Recombinant Porcine Somatotropin (rPST): measurements on cooled carcasses and 
colour of cuts (after at least 24 hrs. of cooling)1. 
rPST (mg/d) 
carcasses: 
fat depth (mm)a 
USA last rib 
last lumb. 
10th rib 
UK long.D. Pi 
P2 
P3 
EEC gluteus Pi 
P2 
P3 
pH 
ham 18 hrs 
gluteus 24 hrs 
long.D. 72 hrs 
Meat cuts 
surface (cm2) 
long.D, 10th rib 
12th rlbb 
colour0 
long.D.d 
L 
a 
b 
Expt. 1 (22-24) 
0 
19 
17 
21 
15 
13 
13 
22 
16 
25 
5.7 
5.6 
37.5 
43.6 
52.9 
7.5 
9.4 
1.5 
18'" 
13." 
19.' 
12.* 
10.* 
10.* 
19.* 
13.* 
22.* 
5.7 
5.7 
43.5* 
48.7* 
54.3 
7.5 
9.6 
3 
16.' 
12." 
19." 
10'* 
10." 
10." 
19.' 
12.' 
20'* 
5.8 
5.7 
41.5* 
50.0' 
51.1 
7.4 
8.8 
6 
13." 
8." 
14." 
8'" 
7." 
7." 
15.' 
8.' 
17.' 
5.8' 
5.8' 
43.0" 
50.5' 
51.4 
7.9 
9.0 
Expt. 2 (24) 
0 4 
5.8 5.8 
2.2 2.5 
47.5 48.0 
5.9 5. f 
8.6 8.5 
Mean values only (cfr. Table 1) 
a
 USA = National pork producers council, 1985 
UK = Meat and Livestock Commission, 1980 
EEC = described in De Boer et al. (1979) 
after freezing at -20C and thawing 
c
 Subjective measurement using Japanese "Porcine colour scale" in expt. 2. 
Hunter colour values (L=lightness,a=redness,b=yellowness). 7th rib in expt. 1, 20 cm cranial from 1st 
lumbar in expt. 2 
significant difference from control, max. p = 0.05 
Such increases confirm results obtained for long.dorsi surface area (Table 3) and from carcass 
jointing (Table 4) and illustrate effects of PST on adipose as well as on muscle tissue. Both such 
effects appear to be direct as a reduction in adipose tissue was observed in the absence of a reduced 
feed intake (lowest rPST level in Expt. 1, discussion in Fabry et al., 1988). Accretion of muscle 
tissue (meat) was not found to be as dose dependant as depression of fat tissue in contrast to other 
work (discussed by Fabry et al., 1988). This may be related to the inaccuracy of the prediction 
regressions used, depending on a few measurements only. 
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Slight differences in muscle pH values measured the first hour after slaughtering at the highest 
dose level in Expt. 1 do not reach statistical significance. A slight but significant increase in the 
associated temperature measurements however suggests a somewhat accelerated rate of post mortal 
glycolysis at the highest dose levels, at least in the gluteus muscle (Table 2). Such effects however 
are minor, compared to the rapid rates of pH fall often observed in pig breeds, selected for meat 
production where pH drops to 5.5 within the first hour after slaughtering (Eeckhout et al., 1966) 
(Bekaert et al., 1987). A tendency to acceleration of post mortal glycolysis is corroborated however 
by the finding that rPST produced a less red meat colour in Expt. 2 (Table 3). No effect was 
observed however in a slice more cranial from the first lumbar, nor in Expt. 1 but here negative 
effects of accelerated glycolysis on colour may be offset by the slightly but significantly higher 
final pH values in the muscle, known to be associated with darkening of meat colour (see e.g. 
Demeyer, 1974). Higher final pH values indicate more pre-slaughter depletion of muscle glycogen, 
in line with accelerated overall metabolism. It should be stressed however that the small differences 
discussed here are not liable to further increase frequency of meat quality defects associated with 
breeds selected for maximal meat production : P(ale),S(oft) and E(xudative) as well as 
D(ark),F(irm) and D(ry) meat ( see e.g. Demeyer, 1974). This is illustrated e.g. by the absence of 
any effect of rPST on meat water holding capacity (Table 5). 
Yield of commercial cuts 
Table 4 summarizes the data collected during carcass jointing, separating one side of each 
carcass into trimmed lean and fat joints, following different but similar jointing methods in Belgium 
and Holland. Methodological differences are reflected in the % distribution of cuts over the 
carcasses, but it is clear that in both experiments a significant increase in yield of meat joints was 
obtained, associated with a lowered yield of fat joints. It is striking that in Expt. 2 an increased 
Table 4. Effect of Recombinant Porcine Somatotropin ( rPST ) on % distribution of carcass Jolnts( % of 
carcass weight)1. 
rPST (mg/d) 
L-»an Joints 
shoulder 
ham 
lolnd 
lean trimmings 
total lean joints 
Fat Joints 
belly 
back fatc 
flare fatd 
total fat Joints 
Other Joints 
Head 
shanks 
throat6 
Expt. 1 (22-24)a 
0 1.5 
15.0 
24.3 
25.0 
1.6 
65.9 
16.2 
5.9 
1.3 
23.4 
5.4 
1.9 
3.4 
15.7" 
24.6 
26.3 
1.7 
68.3' 
15.5 
4.8 
1.1 
21.4 
5.3 
1.8 
3.2 
3 
15.4 
24.9 
26.4 
1.7 
68.4* 
15.6* 
4.5 
1.0 
21.1 
5.3 
2.0 
3.2 
6 
16.0* 
25.5 
27.4 
1.8 
70.9* 
14.7* 
3.4 
0.8 
18.9 
5.4 
2.0 
3.0 
Expt. 2 (24)1 
0 
11.5 
22.5 
17.8 
2.9 
13.5 
6.7 
13.8 
4.9 
2.6 
3.8 
3 
4 
12.4* 
23.7 
18.5 
2.9 
13.1* 
5.5 
12.4 
5.3* 
2.7 
3.5 
mean values only are shown (cfr. Table 1). 
a
 jointing following the "Belgian national jointing method" ( Verbeke and Casteels, 1985). Percentages were 
adjusted to a sum of 100%. 
jointing following the IVO standard method (Kouwenberg, 1988). Joint weights were converted to % of 
calculated weight of carcass halves. 
c
 "rugspek" in expt. 2 
"vet, reuzel en krabbetje" in expt. 2 
" "kinnebak" in expt. 2 
significant difference from control, max.p = .05 
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proportion of some cuts high in connective tissue was observed. This is in line with the contention 
that rPST treatment would result in a body conformation equal to that of a younger, non treated 
animal, showing more bone and organs as well as less adipose tissue (Kouwenberg, 1988). Use of 
rPST would thus allow to reach higher slaughter weights/without loss of conformation 
(Kouwenberg,1988). 
Sensory meat quality 
Table 5 summarizes results of objective measurements of meat quality. Tenderness was 
evaluated using various texture measurements. Water holding capacity is reflected in various 
measurements of drip loss, after thawing.cooking and grinding followed by centrifuging. This first 
report on the effect of rPST on water holding capacity of pork meat, indicates that no statistically 
significant effect could be observed. 
table 5. Effects of Recombinant Porcine Somatotropin (rPST): sensory characteristics and myofibrillar 
proteins determined after freezing and thawing of Longlsslmus Dorsl muscle1 • 
rPST (mg/d) 
Texture: 
Shear force (N) 
Hardness (N) 
Coheslvenessa 
Drip Losses (%): 
during cooking 
thawing 
centrifuging 
Sarcomere 
length (urn) 
Myofibrillar proteins 
<ug/mg)b 
Troponln-T 
30 kD 
Tropomyosin 
27 kD 
Tltln 
Fllamln 
Expt. 1 (22-24) 
0 
49.5 
74.1 
.41 
28.4 
5.1 
22.6 
1.88 
6.7 
4.0 
14.7 
5.7 
33.5 
2.1 
1.5 
46.3 
80.2 
.40 
28.5 
6.2 
22.5 
1.87 
7.1 
3.9 
14.0 
6.5 
33.9 
2.3 
3 
52.2 
80.0 
.42 
27.8 
5.7 
21.7 
1.90 
7.5 
3.6 
13.8 
6.9 
36.0 
2.9 
6 
49.1 
78.5 
.42 
28.2 
6.1 
21.4 
1.93 
7.6 
3.1 
12.2 
7.4 
37.3 
2.3 
Expt. 2 (18) 
0 4 
33.2 34.8 
28.3 28.9 
4.4 4.4 
1
 Mean values only (err. Table 1). All determinations were done on samples of long.D. between the 9th and 
12th rib. 
* ratio of work for a 2nd compression to that for a 1st one. 
b
 separated by SDS-PAGE (Buts et al., 1986) and expressed as relative amounts of internal standard per mg 
of myofibrillar crude protein. 
All rPST treatments in Expt. 1 however increase drip losses after thawing on the border of 
significance (S.E. of mean = .16). Such finding is in line with the suggestion of an accelerating 
effect of rPST on glycolysis, as discussed earlier. It should also be realized however that changes in 
water holding capacity can be brought about by changes in muscle fat content: higher fat contents 
resulting in lower drip losses. It is clear that differences in drip loss after thawing between Expts. 1 
and 2 may be related to differences in muscle fat content for the breeds used (Table 6). It should 
finally be stressed that the processing properties of meat are probably best reflected in cooking 
losses and no effect of rPST on these losses was apparent. 
The results of the various texture measurements indicate that rPST did not affect meat 
tenderness in line with other work as discussed by Fabry et al. (1988). 
In general these results indicate that rPST treatments in amounts up to 6 mg/d did not 
significantly affect sensory meat quality measured objectively. A similar conclusion was reached by 
Kanis et al. (1988) and by Kouwenberg (1988), using subjective taste panel evaluation. These 
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authors stated furthermore that any slight effect observed (e.g. on colour) was negligible, compared 
with other sources of variation as genotype, sex and week of slaughter. 
The absence of a significant effect on muscle structure and function is further indicated by 
measurements of sarcomere length (from laser diffraction) and myofibrillar protein composition 
(from SDS-PAGE). In both instances values were found reflecting normal (?) rates of contraction 
and protein fragmentation respectively (Buts et al., 1986). Other growth regulating substances such 
as beta agonists do affect e.g. myofibrillar protein fragmentation as evidenced from SDS-PAGE 
analysis (Fiems et al., 1988). 
Proximate composition 
Proximate composition data collected on longissimus dorsi showed that the major change 
brought about by rPST was a slight increase in the crude protein content of the muscle reaching 
statistical significance in Expt. 1 (Table 6) and confirming earlier work by Beermann et al. (1988). 
Table 6. Effects of Recombinant Porcine Somatotropin (rPST): proximate composition of Longissimus 
Dorsi muscle1, 
Expt. 1 (22-24) Expt. 2 (24) 
rPST(mg/d) 0 1.5 3 6 0 4 
% Dry Matter 
% Crude Protein 
% Crude Fat 
collagen (% In 
Dry matter) 
25.9 
24.1 
1.2 
1.99 
26.3 
24.7 
1.2 
1.97 
26.1 
24.4 
1.2 
1.94 
25.9 
24.3 
1.3 
2.02 
26.3 
23.1 
2.4 , 
26.2 
23.3 
2.2 
Mean values only (cfr. Table 1) 
The latter authors also reported however that longissimus fat content decreased dramatically in a 
dose dependant manner from 2.02 % in the controls down to .74 % in the dosed animals ( ca. 4-9 
mg/d ). In contrast no significant change was observed in muscle fat content due to rPST treatment 
in either experiment. The inherently low muscle fat levels in the Belgian Landrace pigs may provide 
an explanation for the absence of an effect, but no such reasoning can be applied in the Dutch 
experiment. 
From nutritional point of view it is important to note that no change was produced in meat 
collagen content, indicating no change in protein quality. One should realize however that collagen 
content is positively related to fat as well as to connective tissue content ( Demeyer et al., 1984). 
General Comments 
The reported experiments on pork carcass and meat quality as affected by rPST treatment of 
animals clearly indicate that carcass quality is considerably improved, yielding more lean and less 
fat. Such shift is not associated with significant changes in sensory meat quality, even when animals 
selected for maximal meat production are used. The meat of such animals is however known to 
suffer more frequently from meat quality defects such as PSE and DFD conditions. Treatment with 
rPST does not significantly change that condition. 
It could be worthwhile to try and improve meat yield from animals less prone to yield meat of 
aberrant quality. It may be so that rPST increases meat yield in such breeds without generating the 
associated defects in meat quality. 
Such attempts may be even more indicated as direct introduction of chimeric growth hormone 
carrying genes has been achieved in pigs, resulting in reduction of back fat thickness (Wieghart et 
al., 1988). 
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CONSUMER PERCEPTIONS OF FOOD TECHNOLOGY AND 
BIOTECHNOLOGY 
Janet Graham 
Consumers in the European Community Group 
Summary 
This is a UK consumer view. It is not specifically about PST as consumer awareness about this 
product and its application has yet to emerge. But at CECG our research into BST and other 
advances in modern food technology has enabled us to arrive at certain conclusions concerning 
consumer perceptions of some of these new techniques and their applications. 
Consumers are increasingly concerned about modern methods of agriculture relying on the use 
of antibiotics, hormones, pesticides and genetically engineered proteins such as BST (Bovine 
Somatotropin) and PST (Porcine Somatotropin) is likely to come under similar scrutiny in due 
course. Some of the developments have contributed to bringing us attractive, consistent, plentiful 
supplies of an ever-wider range of food, but the advances have also alienated people who feel that 
their food is no longer "natural". 
We need to establish criteria for judging new processes which include an assessment of 
consumer need. This would examine whether a particular advance would secure benefits for the 
consumer. Will a product be safer, cheaper, more varied, more widely available, more durable, more 
convenient, better packaged? Will it take a long time to be accepted or will it encounter consumer 
suspicion leading to consumer resistance? If, as seems likely, some new process or scientific 
break-through has some advantages and some drawbacks for consumers, pluses and minuses should 
be made clear for the public to decide. 
Consumer rights in the affluent, developed countries include the very important right to choose 
the food we eat and to make that choice on the basis of full information: we do not wish to have our 
choice restricted by those who would ban new developments on principle. Equally, for our choice 
to be an informed one, those involved in food production and marketing from research to final sale 
must be more positive about providing information in a useful, useable form. 
Keywords: biotechnology, human food, consumers perception, swine. 
Introduction 
Consumers in the European Community Group consists of 29 member organisations for whom 
we act as an umbrella body on matters relating to the EEC. All of these organisations are 
well-established and well-known within the United Kingdom. Our job therefore is to inform our 
members of developments within the Community, and in turn to inform decision-makers in London, 
Strasbourg and Brussels of consumer views on consumer protection, safety, agriculture, food, trade 
and competition. We also work closely with BEUC, the European Bureau of Consumer Unions 
based in Brussels, which is the umbrella organisation for consumers from all twelve EEC Member 
States. 
As a consumer organisation, we are very much aware of the contribution of pharmaceutical 
industry to modern day life, particularly in eliminating disease. I hope we approach new 
technological advances in a positive manner. Similarly, we stress our support for a healthy pig 
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industry - healthy in all senses. Indeed, we have before now got together with UK pig producers to 
lobby our Agriculture Ministry for cuts in cereal prices, to benefit pig producers and consumers 
alike. 
In view of the title of your conference, I will concentrate today mainly on biotechnology in 
relation to pigs, and in particular porcine somatotropin. Inevitably, I will be referring to our 
experience so far with bovine somatotropin. I know that there are important differences between 
BST and PST, but similar principles and questions apply. These are, for consumers: 
- Safety. 
- Consumer information and choice. 
- Consumer demand. 
And, we must recognise too that, with developments in biotechnology, there are other, wider 
factors which governments must consider. 
Safety 
First, let me make some general points about hormone growth promoters and the European 
Community Directive banning their use. CECG did not campaign for a ban on hormone growth 
promoters, although we were not in the least surprised that many continental consumer groups 
demanded one. Nor could we disagree with their reasons for wanting a ban. Hormone residue 
scandals in Belgium, Germany and Italy made it inevitable. Consumers were scarcely reassured 
when one of those held in jail in Belgium on a charge of illegal dealing in hormones sent out for 
vegetarian meals rather than eat the meat provided! 
We would have preferred the suspension of growth promoters pending the report of the 
committee chaired by Prof. Eric Lamming, who has done so much to cast light on a difficult subject. 
The EEC scientific committee did of course eventually report that hormone growth promoters were 
safe, under proper conditions of use. However, the rush by EEC Farm Ministers to ban hormones 
was not the result of alarmist scares by consumers, or panic by the European Parliament. It stemmed 
directly from the failure of those responsible to put their own house in order by ensuring proper use. 
Things do not seem to have improved. Indeed, only this summer we have seen a further scandal 
at calf units in West Germany, near the Dutch border, with 14,000 calves being seized by the state 
agriculture ministry. Some calves treated with banned hormones are thought to have been smuggled 
out of the area. The German state minister for agriculture and the environment has called for 
international police co-operation against what he described as "the hormone mafia". You will 
understand therefore why consumer organisations are not enthusiastic about hormone growth 
promoters in general. 
PST falls into a different category of growth promotor and is, therefore, not covered by the EEC 
ban - a fact which has not escaped the notice of the consumer movement. From tests being carried 
out in the United States we gather pig producers are enthusiastic about the results. There is 
improved weight gain, giving a better food conversion rate and less carcass fat, leading to less fat 
meat. The fact that at the moment pigs have to receive a daily injection could, for emotive reasons, 
prejudice the public against the meat. No doubt this is why work in America is looking at 
long-lasting injections and slow release implants which would be altogether kinder to the pig, a 
sensitive animal capable of being easily stressed, and better for herd management. 
But could this alter the position regarding residues? Would a detection test be needed? Would the 
health of the pig suffer in any way - or would it improve? I am told that some scientists in America 
see PST as a route to eliminating the need for prophylactic antibiotics (of which consumers are 
rightly or wrongly suspicious) and the way forward to healthier herds. These are all questions which 
will need to be addressed to dispel possible consumer apprehension of this type of product. 
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I understand too, from work going on elsewhere on genetic engineering and embryo transplants, 
that the possibility exists of actually breeding stock with enhanced levels of PST and this may well 
raise questions of an ethical nature. It is therefore important that, if you believe PST is capable of 
providing a potential benefit to consumers, you try to convince the public and the EEC that this is 
the case, rather than hope no-one will notice. 
The relevance of biotechnology and its application to food production is increasingly being 
discovered by the consumer movement. Unfortunately few consumer organisations have the 
resources to enable them to carry out the necessary scientific research to enable them to discuss the 
technical aspects of biotechnology with the industry: consumers might be better reassured if they 
did. We can though call for the maximum possible independent assessment and scrutiny of PST 
before decisions are taken by governments, after an opinion has been sought from the EEC's 
Committee for Veterinary Medicinal Products. Indeed, it may be an appropriate subject for EEC 
legislation to prevent barriers to Community trade in meat. 
We hope that, in arriving at a view, the Community and governments will want to consult 
consumers. The National Consumer Council published a Report this summer on "Food Policy and 
the Consumer". In it we suggest that consumer confidence in food safety would be strengthened if 
consumer representatives were more closely involved in decisions about food policy which are 
made on their behalf. The Report singled out two Commission bodies, the Consumers' Consultative 
Committee (CCC) and the Advisory Committee on Foodstuffs (ACF) for criticism, saying they had 
inadequate structures and resources, and describing them as wholly inadequate to represent the 
views of consumers on food policy matters. This needs Commission action. 
As much information as possible should be made public, with the debate conducted in language 
non-scientists can understand. If this is neglected, the vacuum you leave will be filled by 
sensationalism, bad science and misleading information. 
Information and choice 
Second, information for consumers when they buy meat. Consumers must know what they're 
getting so that they can make an informed choice, and this means clear labelling. I must say that I 
disagree strongly when spokesmen for industries say that consumers don't want information, won't 
understand it and will find it confusing. This is patronising and, as experience with food labelling 
shows, simply untrue. 
Out there, there are millions of people who because of their education, their jobs or their 
hobbies, understand micro-circuitry, the internal combustion engine, word-processing, astronomy, 
musical counter-point and double-entry book-keeping. They are not illiterate or innumerate. If in 
the past they have failed to grasp, for example, the difference between antibiotics used for human 
therapy and those used for animal growth promotion, the least likely explanation is that they are 
stupid. The most likely explanation is that no-one has taken the trouble to put it over to them. 
In the case of bovine somatotropin, it has been suggested that labelling would obscure 
consumers' real choice, because, it is claimed, there is no difference between milk from cows 
produced with BST, and milk produced without. That appears to us irrelevant, and it would be just 
as irrelevant if the same was claimed about pork from pigs produced with PST and pork produced 
without PST. 
Consumers are still entitled to the information. And they may want to buy meat from animals 
that have not been treated with PST for other reasons - such as their concerns about animal welfare, 
or doubts about the long-term effects of PST on human health. It also seems also to us that, without 
proper consumer information at the point of sale, the market would not be able to decide on PST. If 
producers are to gain or lose from public reaction, favourable or unfavourable, to PST, then it seems 
only reasonable that the benefits or losses should go to the appropriate producers. 
It has not been helpful when industry spokesmen say in the farming press that there would be no 
public concern about animal drugs if only farmers would keep quiet about them. As history teaches 
203 
GRAHAM 
us, the more you try and cover something up, the more people, particularly journalists, want to 
know about it. Secrecy breeds suspicion. 
Other factors 
Before I go on to talk about consumer demand, we should note that decisions about 
biotechnology must not be taken only on safety grounds. It is increasingly the case that 
governments will wish to take economic, social, environmental and employment factors, and 
questions of need, into account in biotechnology, as well as safety. Is PST, in the words of a farmer 
describing BST, "More clever than useful?". Will it lead to less agricultural employment? Will the 
benefits claimed work through to the shopping basket? How will it affect trade in agricultural 
produce, inside and outside the Community? Governments are entitled to take a view on these 
matters, as well as on safety. We hope that the European Commission is already looking closely at 
all these issues. 
Consumer demand 
But once a product has been cleared as safe and useful by the appropriate authorities, its use 
becomes a matter for commercial judgement. Now, it is of course the perfectly legitimate role of 
manufacturers and their advertisers to make people think they need something, whether they 
actually do or not. If I may quote two examples, consumers did not know that they wanted very 
small portable personal cassette players until they were developed by Sony. They did not know that 
they definitely did not want a very small car until one was invented by Sir Clive Sinclair! 
If the use of PST were made legal, and all tests of safety and need had been met, it would then 
be up to consumers to decide for themselves - provided they are given the information to enable 
them to make that choice. We think however that pig producers would still want to consider very 
carefully three points before using PST: 
— The image of meat and public opinion. 
— Current trends in demand for food. 
— Growing consumer concerns about animal welfare issues. 
The American writer Marshall MacLuhan wrote, about television, that the medium was the 
message. The appearance of reality, he observed, was more important than what reality actually 
was. Similarly, it may make no difference whether or not PST is a perfectly safe, useful product. It 
will have been in vain if the public at large thinks, even wrongly, that it is not. This may be unfair, 
but life is fundamentally unfair! And fairness and the ultimate state of scientific knowledge have 
little to do with marketing or public demand. 
Perhaps I may quote from an issue of the UK magazine Farming News for 14 October 1988: 
"Britain's meat industry has a serious image problem and 47% now believe that meat is unhealthy". 
"Vegetarian or anti-intensive farming campaigns will intensify. The longer the industry delays, 
the more acute the eventual cure" says Dominic Lyle, marketing consultant, working with the 
British Chicken Information Service. 
"He told the Poultry South West Conference in Taunton, Somerset, that the sugar, salt and butter 
industries had suffered because public opinion was ignored for too long". 
I don't want to suggest that Mr. Lyle shares my views about PST, but he does highlight a problem 
of public confidence in meat generally, and we cannot ignore it. 
The European Commission's Eurobarometer Survey asked consumers in 1987 whether they 
agreed or disagreed that the foodstuffs we find nowadays are in many cases not as good as what one 
would buy in times past. 71.1% agreed completely or agreed to some extent. Only 20.2% disagreed 
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to some extent or disagreed completely. This is in spite of the fact that consumers now have a wider 
range of foods to choose from than ever before. 
There is also a growing awareness among consumers throughout the EEC of the link between 
diet and health. 70% said farmers should produce more healthy food, even if this meant an increase 
in price: and that was in spite of the fact that a majority thought food prices were too high. 80% 
agreed that we must cut down on our use of fertilizers, weed-killers and pesticides, even if that also 
meant paying more for produce in order to keep agriculture profitable. These are findings which 
no-one involved in the food production industry can afford to take lightly. 
So it is clear that many consumers today are more interested than before in what they eat and in 
the effects of their diet on the long-term health and well-being of themselves and their families. So 
the question for pig producers and meat retailers is not just the scientific one of is PST safe, 
although it must of course be asked, but what would PST do to public perception of pork and bacon? 
Would sales go up, remain the same or go down? Are the potential commercial benefits greater than 
the costs plus the potential risks? And who would get most of the commercial benefits, the 
manufacturer or the pig producer? 
The current trend, in food buying, in manufactured food products, and in demand for farm 
produce, is clearly for more "natural" food. And there is a growing feeling by consumers that they 
want less intensive production, less use of chemical processes and, in short, that they don't want 
food and animals mucked about with more than is absolutely necessary. 
In the UK, expectations about food are rising all the time. People want an ever wider range of 
foods, they know more about food, and they ask more questions about what they buy and the way it 
has been produced or manufactured. Some, though still only a minority, demand that their food is 
produced in a particular way. Eggs must be free range, meat must be 'real' (whatever that means): 
vegetables must be organic, fruit unsprayed, and so on. Times have changed, and while this sort of 
demand is for some a luxury born of plenty, it is here to stay and is likely to increase. 
Even consumers who don't fall into the organic "Green" category are increasingly concerned 
about modern methods of agriculture which rely on the extensive use of antibiotics, probiotics, 
hormones, pesticides and new genetically engineered products such as BST and PST. 
As I have said, we recognise that many scientific developments have helped to bring us 
attractive, consistent and plentiful supplies of an ever-wider range of foods. However, these very 
advances have also alarmed people who feel their food is no longer "natural". We think that 
consumers are more than entitled to express their views about such concerns, and must be able to 
adjust their buying policy accordingly if they wish. 
Some myths 
Whatever happens, I hope that we can have a sensible debate about PST, one conducted openly 
and fairly. In the case of bovine somatotropin, things have been said by some industry spokesmen 
which can only increase mistrust. We should look at some of these briefly, because many of them 
may, unhelpfully, be said about PST as well. 
Then there is the Black Market argument. If you don't let us sell this legally, it runs, we'll do it 
anyway. That is a very unattractive sentiment. No industry is above the law, and this claim only 
proves the need for tougher enforcement measures. There is also the threat that, if such products do 
not go ahead, companies will be unable to continue vital and much-needed work on new drugs and 
foods. That is pure economic blackmail and no way to conduct an important policy discussion. 
Nor do I think it is good sense when those who ask legitimate questions about safety and need 
are dismissed as Luddites. It is not even good history. The Luddites opposed a useful technological 
process which threatened their jobs. Those who question PST are not seeking to protect themselves: 
they are asking "is this a useful and safe technological process, and who will it benefit?" 
Another bogus argument is that scientists have an obligation to go all out to maximise 
production, regardless of the consequences. We should note that Article 39 of the Treaty of Rome, 
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which concerns the Common Agricultural Policy, refers not to all-out increases in production but to 
the "rational" development of production. Lastly, it really is less than honest to describe some 
animal pharmaceutical products in terms of animal health. A farmer recently wrote to a UK farming 
journal and objected to what he called: "Subtle propaganda which seems to be aimed at twisting our 
minds into thinking that growth promoters, bovine somatotropin and similar substances are 'Animal 
Health Products'. They are not". 
At the moment, we have to agree with this view. The newsletter of the European Federation of 
Animal Health (PEDESA) for February 1988 contains this quite remarkable statement: 
"Animal health products, by definition, improve farmers' efficiency and hence their 
productivity". 
In my dictionary, health products are defined as those which improve health, not farmers' 
incomes. The term "Animal health industry" has more to do with the health of the pharmaceutical 
industry than the health of animals. But since the issue of animal health has been raised, the industry 
must respond to fears that the use of such drugs, particularly the overuse of medicated feeds tuffs, 
could become a substitute for good animal husbandry, rather than an adjunct to it. 
Conclusion 
These are all complicated issues which must be brought out into the open. This is why I much 
appreciate your willingness to have a consumer point of view at your conference. 
In conclusion, I draw your attention to the famous contemporary of Shakespeare who observed 
that "We cannot command nature, except by obeying her". He seems particularly relevant in this 
debate. His name was Bacon. 
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ETHICAL ASPECTS OF THE USE OF BIOTECHNOLOGY FOR THE 
CONTROL OF GROWTH AND PRODUCT QUALITY IN SWINE 
R. Dantzer 
INRA-INSERM U.259, rue Camille Saint-Saens, 33077 Bordeaux Cedex 
Summary 
The development of new biotechnologies for improving growth and product quality in the pig 
industry is raising many concerns, some of which have strong ethical implications. Ethics of the use 
of biotechnologies in animal production need to be addressed at several levels. At the level of the 
animals themselves, there are two questions, one related to the perceived unnaturalness of 
biotechnological products and the other one related to the possible negative influence of the 
treatment on animal health. At the professional level, the increasing use of biotechnology could be 
seen as favoring subordination of animal scientists and veterinarians to economic interests at the 
expense of their more traditional concern for care of animals. At the level of the consumer, moral 
issues call not only for education but also for protection and freedom of choice. At the level of 
society, the potential impact of biotechnologies on the socio-economical structure of animal 
production needs to be addressed. Although biotechnologies have great potential for improving the 
efficiency of animal production, a thorough consideration of ethical issues raised by their 
introduction in agriculture is necessary for their understanding and acceptance by society. 
Keywords: biotechnology, swine, somatotropin, transgenic pigs, ethic. 
Introduction 
Biotechnologies are likely to bring major advances in the swine industry. With a single product 
like recombinant porcine somatotropin, it is possible to obtain increases in growth rate and feed 
efficiency amounting to about 20%, with tremendous improvements in carcass composition and no 
adverse impact on pork palatability (e.g., Evock et al., 1988). Genetic engineering offers the 
possibility of modifying gene expression in specific tissues or organs for the expression of growth 
factors, their mediators or their receptors. Although nothing comparable to the dramatic increase in 
body size observed in transgenic mice that have developed from eggs microinjected with 
metallothionine-growth hormone fusion genes (Palmiter et al., 1982) has yet been obtained in farm 
animals, there is still much hope on this possibility. There is not one week without some press 
release about the potential applications of biotechnology to animal production, ranging from giant 
transgenic salmon and trout to enhanced milk production from cows that have been treated with 
bovine somatotropin. 
Although the search for faster growth and better product quality in animal production is as old 
as agriculture itself, the pace at which such changes can take place has considerably accelerated due 
to the progress in biotechnology. Because of its impact on only a single aspect of animal 
constitution, biotechnology represents not only a quantitative but also a qualitative departure from 
the relatively slow process of modifying animals by traditional genetic methods and husbandry 
practices. The modification of specific genes expression allowed by transgenic techniques is very 
different in essence from the pleiotropic consequences of genetic selection on a single trait like 
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growth rate or feed efficiency. It is therefore appropriate to speak of a true revolution in both the 
biological perspectives created by the use of biotechnology and its potential for industry. 
Periods of fast and profound technological changes always raise ethical concerns, especially 
when such changes are perceived as threatening our socio-cultural standards and our view of what 
surround us. Our opinion about what is good and what is bad for us and the society as a whole is 
profoundly dependent on our socio-cultural environment and, as such, has little to do with the latest 
scientific and technologic advances. The dialectic between right and wrong is the essence of ethic 
and in most occidental cultures, societies have set up ethical committees that are consulted to assess 
what type of progress is ethically acceptable or unacceptable on the basis of scientific evidence and 
social impact. These committees include philosophers, lawyers, religious personalities and very 
few, if any, representatives of the industry and biomedical sciences. 
Whether the present prospects for the use of biotechnology in agriculture will impose the 
recourse to such ethical committees or whether acceptance by a professional administrative body 
will be sufficient for clearance and approval is not yet clear. In animal production, animal right 
activists have already demonstrated that they have a tremendous impact on the perception of the 
way animals are treated in intensive husbandry systems. Their use and abuse of emotional feelings 
of the public are much more efficient in this regard than the cold and objective information provided 
by animal scientists and industry representatives. In line with this perspective, it must be noted that 
it was proposed during the Fourth European Conference on the protection of farm animals which 
was held in Brussels on May 24 and 25 1988, that an international ethical committee be set up in 
order to report, within two years, on the welfare aspects of current and future systems of livestock 
management. 
In view of this situation, it is the responsability of the promoters of a new technology to foresee 
the possible ethical problems raised by the use of this technology and to deal with them in the 
proper manner, in order to facilitate understanding and acceptance by the public. The aim of this 
paper is to identify and review the different aspects of the use of biotechnology to improve pork 
production that may be at the origin of ethical concerns. 
The animal's viewpoint 
A widely held concern about animals kept in intensive husbandry is that they have "unnatural" 
lives. Such ideas are held because animals are no longer able to wander freely in their natural 
environment and to express their natural instincts. There is little doubt of the fact that the life of 
farm animals has drastically changed with domestication and intensification. Whether this is 
sufficient per se to cause suffering is, however, very unlikely. Another concern about animals is that 
they have been changed by genetic selection in such a way that they have become "unnatural" and 
would be unable to survive in the wild. As pointed out by Marian Dawkins (1980), the comparison 
between wild and domestic animals is not straightforward. Experiments on feral animals, i.e. 
domesticated animals living in the wild, demonstrate that modern breeds of pigs and poultry have 
retained their basic behavioural repertoire and are able to deal with adversity of natural 
environments. In more general terms, it is not always easy to dissociate what is due to genetic 
factors from what is related to experience in a given population introduced into a specific 
environment. In addition, there are still important differences between breeds of domestic animals 
so that it is just not possible to generalize from one domestic strain to another. Genetic selection is 
a slow process, even when looked at from the viewpoint of natural evolution. However, genetic 
manipulation of animals has the capacity to introduce major changes in the genetic composition of 
animals within a very short interval. It is therefore felt by some people that there is a high risk of 
producing "unnatural" creatures or even monsters. 
Ethical concerns are not limited to the "unnatural" aspect of animals modified by genetic 
engineering. Some animal rights activists claim that we cannot treat animals as simply assemblies 
of genes that are manipulated at will by humans and that genetic engineering would actually 
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threaten the inherent nature of animals. The present trend for patenting of animals in the US raises 
even more concerns: life seems to be reduced to the status of a manufactured commodity that is 
indistinguishable from other commercial products. These concerns are difficult to deal with. They 
are clearly related to socio-cultural aspects and to profound beliefs on the nature of animals and 
their position on the evolutionary scale. How far this image can be distorted by subordination of 
animals to human actions is a true ethical issue. 
A positive aspect of changing genomic composition through genetic engineering is that, in 
theory, such techniques should allow us to target more precisely the intended changes in the 
organism and, therefore, they should reduce the risk of undesirable side effects related to the 
pleiotropism of some of the traits used for selection. In pig industry, the so-called 
"stress-susceptibility syndrome" is a typical example of the by-product of classical genetic selection 
on lean meat and growth rate, that could be prevented by genetic engineering techniques. 
This is true, however, only if the result of genetic manipulations or the effects of treatments with 
recombinant products does not endanger animal health. Somatotropin stimulates growth, but has 
also important functions in modulation of immune functions and metabolism. On the positive side, 
somatotropin has potential beneficial effects on the health of treated animals since it restores 
suppressed immune functions in stressed mice (Gisler, 1974) and activates macrophages both in 
vitro and in vivo (Edwards et al., 1988). On the negative side, somatotropin affects differentiation 
of cartilage cells and this can lead to significant joint problems. As soon as 1972, Machlin reported 
that some pigs treated with purified porcine growth hormone developed arthritic-like symptoms. In 
a more recent study, Evock et al. (1988) reported that daily treatment of 27 kg pigs for 11 weeks 
with 35 or 70 Hg/kg porcine natural or recombinant growth hormone induced osteochondrosis in 
about half the animals and that at the higher dose used (140 (xg/kg), there were significant mobility 
problems. This is an issue which clearly requires further study. 
The professional's viewpoint 
The traditional purpose of veterinary medicine is to fight disease and improve health of animals. 
This view is apparent in the restriction of the use of sex steroids in EEC countries like France to the 
treatment of infertility problems. In human medicine, the use of recombinant human growth 
hormone is strictly restricted to the treatment of pituitary dwarfism and cannot be extended to other 
possible indications, such as prevention of short stature or doping of athletes. In accordance with 
this position, treatment with a natural or a synthetic product in the absence of a manifest disease 
might be perceived by some professionals not only as a deviation of their professional ethics but 
also as a total subordination of veterinary medicine to economics. 
This somewhat extreme viewpoint is not easy to hold since veterinary medicine and animal 
science have always been profoundly influenced by economic considerations. Sickness in farm 
animals is treated only if the cost of the treatment does not exceed the commercial value of the 
animals under consideration. In addition, the traditional aim of animal science is to improve the 
efficiency of animal production. Welfare and ethical considerations represent constraints rather 
than primary motives for such a quest. 
The consumer's viewpoint 
In contrast to many feed additives and growth promoters, porcine somatotropin (PST) is unlikely 
to give rise to human safety issues. Most of the relevant work has been carried out on bovine 
somatotropin (BST). On the basis of evidence showing that there is no difference in the 
somatotropin content of milk coming from control and treated cows (Torkelson et al., 1987), that 
BST is not absorbed from the digestive tract of humans and that it is not bioactive even when 
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injected in humans because of the species-specificity structure of the hormone, many countries have 
authorized a zero withdrawal time for milk and meat from somatotropin-treated animals. 
This viewpoint is not agreed upon by many consumer associations. They ask for banning of 
"unnatural" products obtained through the use of biotechnologies or, at least, a differential labeling 
to allow consumers' free choice. 
The impact of biotechnology on social structures in agriculture 
The use of biotechnology to improve animal growth in pig industry or milk production in dairy 
farms is seen by some farmers as increasing production surpluses on the short term and as 
accelerating in the future the trend to fewer and larger production units. This would intensify the 
industrial concentration process that is already taking place in agriculture and increase the pressure 
exerted on small scale producers. The risk is an acceleration of the rural desertification process, 
with all its negative consequences on the maintenance of landscape. 
This argument appears to have been taken seriously by the CEC Veterinary Drug Committee 
since it requires from companies interested in commercializing products derived from 
biotechnology a socio-economic impact study in addition to the usual data file necessary for 
approval of a new drug. This is very new and has no known precedent. 
In a prospective study commissioned by Monsanto, Mouchet, from the Department of Animal 
Science of the University of Rennes, concluded that the introduction of BST in dairy plant 
operations would slightly enhance the present trend to a decrease in the number of cows and closing 
of small-scale operations (3-4%). 
Conclusion 
In a book entitled "La valeur humaine de la science" (the human value of science), the famous 
French physicist Paul Langevin wrote more than 30 years ago: "Quelques bienfaisantes que soient 
certaines des applications de la science pour diminuer la peine et la souffrance des hommes, le 
rythme accéléré auquel elles se développent et leur introduction dans une société humaine 
insuffisamment préparée a les recevoir ou trop lente à s'y adapter, nous semblent aujourd'hui n'être 
pas sans danger" (even if technology is good for decreasing hard work and suffering of Man, the 
acceleration of its introduction in a society which is not prepared for it or which cannot adapt to it 
very quickly is risky). Baile and Krestel-Rickert (1988) recently discussed whether society will 
permit the potential of genetic engineering and biotechnology to advance the frontiers of biology 
and improve the efficiency of animal production. They concluded that production and consumer 
groups are likely to delay applications of these techniques because of lack of understanding and 
acceptance and that the only way to proceed for animal scientists involved in biotechnology is "to 
be extremely active in order to counteract the misuse of information by those unalterably opposed 
to biotechnology". This attitude cannot be operant, however, without a full understanding of the 
reasons why the public is reluctant to accept biotechnologies. I hope the present paper will serve 
this purpose. 
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Summary 
Porcine Somatotropin (pST) is likely to be the first product of a class of biotechnological growth 
promotants to achieve commercial application in the U.S. The adoption of pST will undoubtedly 
have economic impacts on nearly all participants in the pork industry, including producers, 
processors, retailers, and consumers. The objective of this report is to assess in advance the likely 
economic impacts pST will have on participants in the pork industry. To accomplish this objective, 
the technical changes associated with pST are incorporated into a dynamic econometric 
supply-demand model of the U.S. pork sector. / 
Keywords: porcine somatotropin, biotechnology, economic impacts. 
Introduction 
Pork production seems poised for potentially revolutionary changes as a consequence of the 
introduction of growth promotants. Until the recent development of recombinant DNA techniques, 
it was not possible, either economically or technically, to apply growth hormones to commercial 
pork production. However, with the use of recombinant DNA techniques, it is possible to produce 
porcine somatotropin (pST) on the large scale basis needed for commercial implementation, which 
may have broad impacts on both the technical and economic aspects of pork production, and the 
interrelationships of pork and competing meat products. The purpose of this report is to provide 
preliminary estimates of the effect pST will have on the typical U.S. pork producer, as well as 
macro effects on the pork industry. 
In the following sections, we present a synopsis of previous economic studies and approaches in 
this area. Following a summary of the expected technical impacts of pST on pork production, they 
are incorporated into partial farm budgets which provide initial changes of cost and returns for the 
average pork producer. Finally, impacts on the U.S. pork industry are simulated through the use of 
a dynamic econometric model of the livestock industry. This analysis provides indications of the 
supply and demand adjustments after pST is adopted, how industry performance is likely to change, 
who is likely to benefit, and how much. 
Previous studies 
There are three previous studies of the economic impacts of growth promotants. The first two, 
one by Meltzer (1987) - the other by Lemieux and Richardson (1988), directly address the firm 
level economic impacts of pST on pork production. The third by Kalter (1985) provides a useful 
framework for analysis, but only looks at the impacts of bovine somatotropin on dairy production. 
We will briefly review the relevant findings of the first two studies. 
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Lemieux addresses the impact of pST on the pork industry alone through the use of linear 
programming techniques. She calculates the net benefits to producers varying in size of operation. 
The results suggest that over a five-year adoption period, the number of hogs produced will increase 
four to five percent, causing hog prices to decline 5.51 to 7.19 percent. Results indicate that 
operators of 50 sow grain - hog farms, experienced an increase in average annual net cash income 
of about $5,400 from the adoption of pST if they received a premium for the improved carcass they 
produced. For operators of 225 sow grain - hog farms the increase was at least $25,600. An 
interesting result emerges from use of pST on lactating sows. By using pST in lactating sows, a 30 
percent increase in sow milk production results, which in turn improves litter size at weaning; this 
increases supply through this effect, and through increases in average daily gain and feed efficiency 
for market hogs. This study does not consider possible changes in consumer preferences due to 
changes in pork product quality. 
Meltzer also uses a linear programming model, but considers the impacts of pST adoption on 
producers with differing production efficiency levels, beef production, crop rotations and 
government programs. This somewhat more comprehensive study shows that if pST improves feed 
efficiency 20 percent, the average pork producer would expect a $5.43 profit increase with the use 
of pST. Producers with average production efficiency achieve an increase in gross margin of 
approximately 12%, depending on the increase in feed efficiency with the use of pST. As a result of 
less corn fed to hogs, more corn was placed on the market, substantially increasing the 
government's price support program costs. 
Although the methods and results provide some useful information, the linear programming 
models are optimization techniques which do not adequately account for the dynamic economic 
impacts which are likely with a technological change. These effects can be better accounted for by 
using the dynamic econometric models of the livestock sectors used in this study. 
Physical impacts and production requirements 
In this study, we focus on the likely effects of pST on growing and finishing swine. After 
injection of pST, there are three primary impacts on market hogs' growth process. First, there is an 
increase in average daily gain (ADG). This means there will be fewer days-on-feed given usual 
market weights. Second, it will require fewer pounds of feed to produce a pound of gain on the hog. 
Third, the carcass will be more lean and have much less fat deposited. Preliminary estimates of the 
magnitude of these impacts are summarized in Table 1. 
Table 1. Technical Impacts from feeding pST from 120 lbs to market. 
w/out pST w/pST Percentage Change 
Average dally gain (lbs) 
Pounds of feed per pound of gain 
Carcass composition 
Backfat (Inches) 
Lean 
1.75 
3.75 
1.10 
-
1.96 
2.81 
0.72 
-
+12 
-25 
-35 
+15 
Source: Various published sources and industry estimates 
These estimates were obtained from published research and interviews with corporate and 
university scientists familiar with pST trials. Of course, with more testing, the true impacts will 
become more defined. However, they represent a general consensus of the likely physical impacts 
of pST in a typical feedlot environment. 
The injections of pST have their greatest impacts during the 120 pound-to-market weight stage 
of the growth process. While the ultimate injection or implant frequency is not yet clear, it seems 
likely that it initially will be in the one to four week range between injections. 
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To obtain these physical impacts, a finishing ration with a higher protein content must be fed 
when pST is administered. The higher protein ration is required to sustain the increased protein 
deposition rate in the hog and make the essential nutrients available despite lower feed intake rates 
noted in hogs being administered pST. In Table 2, the likely finishing rations for the adopters and 
non-adopters of pST are compared. Hogs during the early growth period are typically fed the 14 
percent crude protein ration. This holds true whether pST is subsequently injected or not. Thus, the 
hog growth process and production practices remain unchanged during the first stage of production. 
Table 2. Suggested rations for feeding swine (120-240 pounds) 
Ration without pST Ration with pST 
Ingredients (14% crude protein) (17% crude protein) 
(Pounds) 
Corn, Ground 1653.48 1486.35 
Soybean meal 296.52 463.65 
Premix 50,0 50.0 
Source: Nutrient Requirements of Swine, National Research Council 
Partial budgets ' 
Equipped with the necessary technical information, it is now possible to transform this 
information into economic terms to aid in the analysis of the economic impacts on pork producers. 
To estimate the impacts of pST, we initially incorporate the technical changes into the cost structure 
of a typical Iowa pork producer. Through partial farm budgets, costs and returns are compared for 
pST adopters and nonadopters. The partial budgets do not reflect any dynamic supply and demand 
adjustments. The market impacts (in terms of price changes as a consequence of supply adjustment) 
are not factored into this analysis. The prices used in the partial budgets are average prices for the 
1982 to 1987 period (Table 3). 
Table 3. 1982 to 1987 Average Prices 
Corn ($/bu) 
Soybean ($/cwt) 
Premix ($/50lbs) 
Market hogs ($/cwt) 
Feed pigs ($/lbs) 
2.08 
8.43 
11.25 
49.79 
1.07 
This process is completed by first creating a hog enterprise partial budget based on current 
production technology. Then the technical changes from using pST are incorporated into the budget 
to determine the static impacts of pST on a single hog producer. 
Partial budget assumptions: conventional versus pST technology 
The enterprise budgets directly compare conventional feeding practices to feeding with the use 
of pST (Table 4). As such, the assumptions used for constructing the two scenarios will be directly 
compared. 
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Table 4. Assumptions for partial budgeting: conventional feeding vs. feeding with pST 
Days on feed 
40-120 lbs. 
120-240 lbs. 
Total 
Feed efficiency Obs. feed/lb. gain) 
40-120 lbs. 
120-240 lbs. 
Average dally galn(lbs./day) 
(120-240 lbs.) 
Crude protein requirement 
(120-240 lbs.) 
Feed requirement (lbs.) 
(40-240 lbs.) 
Corn 
Soybean meal 
Supplement 
Total 
Feed costs (40-120 lbs.) 
Corn 
Soybean meal 
Supplement 
Total 
Feed costs (120-240 lbs.) 
Corn 
Soybean meal 
Supplement 
Total 
Facilities, equipment, and machinery ($/hd) 
Facilities S100/3 lltt/yr. 
Feed storage and handling 
Manure handling 
Tractor 
Total Investment 
Interest, taxes. Insurance, 
depreciation a 13% 
Conventional 
Feeding 
56 days 
68 days 
124 days 
2.68 
3.75 
1.73 
14% 
549 
99 
16.40 
664.40 
$6:58 
2.68 
1.21 
10.47 
$ 13.82 
5.62 
2.53 
21.97 
33.33 
10.00 
3.00 
6.00 
52.33 
6.80 
Feeding 
w/pST 
56 days 
60 days 
116 days 
2.68 
2.81 
1.96 
17% 
427 
110 
14.40 
551.40 
$6.58 
2.68 
1.21 
10.47 
$9.31 
6.59 
1.90 
17.79 
31.75 
10.00 
3.00 
6.00 
50.75 
6.60 
Change 
0 
-8 
-8 
0 
+ 25% 
+ 12% 
+ 3% 
-122 
+ 11 
-2 
+ 113 
0 
0 
0 
0 
$-4.51 
+.97 
-.63 
-4.18 
-1.58 
0 
0 
0, 
-1.58 
-.20 
Feed costs, the largest cost item in finishing hogs, are dependent on feed requirements and feed 
prices. Note that changes occur only over the 120-pound-to-market stage of growth, since this is 
when pST is administered. The ration used is comprised of corn, soybean meal, and a 
vitamin-mineral supplement. The cost of each feed ingredient is based on each ingredient's 
respective price average from 1982 through the first quarter of 1987, multiplied by the quantity of 
the ingredient required. 
The hog production unit size is assumed to be 200 market hogs, with a standard turnaround rate 
of three and the non feed cost per unit capacity of $ 100 per hog. As a result of the improved average 
daily gain due to the use of pST, the turnaround rate changes to 3.15. 
Labor is valued at $6.00 per hour and .67 hours are required to finish a feeder pig. However, 
additional variable costs are incurred from the purchase cost of the somatotropin itself, and the 
labor required to administer it. While the actual frequency of injection is not known, it is tentatively 
assumed that four injections will be required in the final two month feeding period. 
The purchase cost of pST was determined by comparing returns of adopters with nonadopters, 
and was priced at one-third the estimated "net" benefits, since that is the rule-of-thumb pricing 
method often used for new products in the animal health products industry. Given the historical 
prices used in the analysis, and the initial assumption of no carcass merit pricing, the total cost of 
pST per hog was $1.53, or $.38 per dose. The additional labor cost due to injections was assumed 
to be offset by the labor savings due to less days on feed. 
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Income is based on selling a 240-pound market hog on a live-weight basis, at the average of the 
past five years' prices. 
Partial budget results 
Table 5 provides the comparison of pST adoption with conventional feeding practices. This 
budget does not include any gains from carcass merit pricing, even though this should be an 
alternative for most producers given the improved carcass composition. The primary benefits of 
adopting pST in Table 5 are from the reduction in feed costs. The reduction in feed cost is due solely 
to increased feed efficiency induced by the pST. Labor cost savings due to less days-on-feed were 
assumed offset by increased labor cost for injections. Some additional cost savings are found in 
interest costs (fewer days to slaughter), marketing and miscellaneous costs (less interest cost), and 
in part to lower machinery and facilities costs (more rapid feedlot turnover). Total income per head 
increases $3.07 with pST adoption. 
The adjustments necessary when carcass merit pricing is considered include the increased 
returns due to carcass merit pricing. According to Robert Kaufman's recent survey of packers' 
carcass merit pricing systems, a 35 percent reduction in backfat will result in an increase in value of 
approximately 2.3 percent of the market price. In addition, if the carcass has a higher muscle 
content, as would be expected with the use of somatotropins, then the market price paid would 
increase by another one percent. Taking the slightly higher cost of pST (since it is assumed to be 
based on the expected, improved returns to adopters) into account, producers selling on a carcass 
merit basis can further enhance their returns, above feed cost savings, by $1.13 per head when pST 
is adopted. 
Table 5. Finishing feeder pigs enterprise budget 
Conventional pST 
Market hog (240lbs x $.4979/lb. x .96) 
Variable costs 
Feeder pig (40 lb.) 
Interest a 11% 
Feed cost (40-120lbs) 
Corn 
Soybean meal 
Premix 
Feed costs (120-240lbs) 
Corn 
Soybean meal 
Premix 
Total feed costs 
Veterinary and medical 
Fuel, repairs, utilities 
Marketing, misc. 
Interest a 11% on feed, other costs 
Labor a $6.00 
Growth promotant cost 
Total variable costs 
Income over variable costs 
Fixed costs 
Machinery, facilities 
Total of all costs 
Income over all costs 
114.72 
42.93 
124 days 1.60 
6.58 
2.68 
1.21 
13.82 
5.62 
2.53 
32.44 
2.00 
2.00 
2.00 
0.66 
4.02 
0.00 
87.66 
27.06 
6.80 
94.46 
20.26 
114.72 
42.93 
116 days 1.50 
6.58 
2.68 
1.21 
9.31 
6.59 
1.90 
28.26 
2.00 
2.00 
2.00 
0.55 
4.02 
1.53 
84.79 
29.93 
6.60 
91.39 
23.33 
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— Somatotropins are priced on a 3:1 return to cost ratio ($.38/dose). 
— No increased labor for somatotropin usage as administration time is offset by fewer days on 
feed. 
— No carcass merit pricing for possible carcass improvements with pST. 
However, the limitation of the partial budget analysis is that the dynamic nature of the pork 
industry and its competitors is not accounted for. The partial budgets assumed constant prices, 
which only provide a first step in understanding the implications of pST on the pork sector if pST 
were to be widely adopted. The livestock model simulations that follow allow for the likely supply 
and demand shifts through time in the U.S. pork, beef and poultry sectors that would result from the 
introduction of pST. 
Dynamic implications of pST 
The impacts of pST on the pork sector over time were estimated using quarterly econometric 
livestock supply and demand models developed at the Center for Agricultural and Rural 
Development, Iowa State University. The detailed structure and specification of the pork model can 
be found in Skold, et al. (1988). The quarterly beef and chicken supply and demand were simulated 
in conjunction with the quarterly pork model to capture cross commodity effects. However, by 
assumption in the simulations, pST was only adopted by pork producers. 
The quarterly pork model provides a complete representation of the aggregate structure of the 
pork industry. The model represents the various supply and demand components of the industry 
with sets of mathematical equations. These expressions are used to capture aggregate industry 
behavior, and thus can be used to explain and predict the pork sector's reaction to technological 
advances such as pST. 
The quarterly pork model is linked to the other livestock models at the retail level, as depicted in 
Figure 1. Thus, consumers' reactions cause relative price changes which reverberate through the 
Figuur 1 .Livestock sector model linkages 
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market, and in turn affect the profitability and subsequent production decisions of pork, beef, and 
chicken producers. Within the structure of the quarterly pork model, the size of the breeding herd 
determines the pig crop. Thus, the pig crop is simply a function of the current breeding herd. 
Barrow and gilt slaughter depends directly on the level of the past pig crop. Total farm pork 
production is determined by multiplying barrow and gilt slaughter and sow slaughter by their 
respective live weights. Farm production, which is in live weight, is transformed into commercial 
pork production in carcass weights through the use of a transformation ratio. 
On the demand side, prices are determined at the retail level, since supply is assumed to be fixed 
in the short run. Consumers respond to changes in the supply of pork, prices of pork, prices of other 
meats, and income as shown in Figure 2. However, it is often true that consumers respond to relative 
changes in prices and income with some delay. Hence, the demand is structured to explicitly 
account for this persistence in demand. The price of slaughter hogs is linked to the retail pork price 
by a retail-farm margin. This margin accounts for both demand and supply shifts as well as 
processing costs. 
Inflation 
Marketing 
Costs 
Retail-Farm 
Margin 
I 
Figure 2. Price determination of the U.S. quarterly pork model 
The total domestic disappearance is solved through the market clearing identity, which equates 
supply and demand. Included in the identity are on-farm production and other variables that are 
exogenous to the system, such as net exports and military use. 
Porcine somatotropin simulation results 
The estimated relationships in the model are based on typical market behavior during the 1967 
to 1986 period. Thus, we're assuming that industry behavior would be very similar to what it has 
been in the past, except for the changes introduced due to the new technology. 
To eliminate the variability caused by outside factors, all exogenous variables were set at their 
mean levels (1984 to 1986 average) for the entire simulation period. Thus, historical changes in 
feed costs and other exogenous variables do not clutter the associated impacts of pST. Also, all 
seasonal components within the model were removed to simplify the simulation process. 
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The model was simulated over a period of 15 years. Since the simulations at mean values do not 
correspond with any particular point in time, the year in which pST is first introduced is designated 
as year one. Subsequent years are numbered up to year 15. This is a sufficient time frame to allow 
pork, beef, and poultry producers to adjust to pST. The first producers adopting the technology will 
begin using pST on pigs born during the first quarter of the first year. Given the biology of the hog 
growth process, these pigs will not reach market weights until approximately the third quarter after 
pST adoption. Thus, the supply effects of pST will not be seen until those hogs are marketed during 
the third quarter of year one. 
The pST adoption rates assumed in the simulations are: a) 12.5 percent of total hog production 
is assumed in each of the first four quarters; b) three percent of total production to adopt pST in each 
of the next eight quarters. Hence, 50 percent of total pork production is injected with pST at the end 
of the first year, and 74 percent by the end of the third year. Subsequently, the total percent of hogs 
injected with pST is held constant at 74 percent. This adoption rate was chosen based upon a New 
York dairy industry survey by Robert J. Kalter, et al. (1985), regarding bovine somatotropin 
adoption. The rate chosen for pST adoption is similar to his survey results. In addition, our survey 
of animal health industry members involved with development of pST indicates that the expected 
market penetration may be 70% in 2 to 3 years, based on similar animal health products. When more 
information is available, the likely producer acceptance of pST in their production processes will 
become more defined. The production cost adjustments due to pST were used to shift the price 
required for pork producers to maintain a particular size of breeding herd. The increased average 
daily gain, the 113 lbs. less feed required for hogs not receiving pST, and the higher protein and 
higher cost ration and the pST cost caused a net production cost decrease which was used to shift 
the supply curves for producers adopting pST. 
In the simulation, feed prices of corn and soybean meal were incorporated into the model as 
endogenous variables. This allows the feed prices to adjust in response to changes in production 
levels and the changes in the feed demanded by pST adopters. This also changes the profitability of 
livestock production and subsequent production decisions by pork, beef, and poultry producers. 
Simulation analyses 
Four possible scenarios of pST adoption in the U.S. pork industry are analysed. The results are 
presented as graphs showing the movement of several key variables: total supply of pork, retail 
price of pork, farm price of pork, profits of adopters and non-adopters, and aggregate profits for the 
pork industry. 
In addition to the key variables already mentioned, the change in hog waste production was 
estimated. According to animal scientists at Iowa State University, typical feed rations are 85% 
digestible. Thus, it is assumed that 15% of the feed is excreted as raw waste products. Thus, waste 
production is a function of the total feed consumed. 
To obtain the baseline values it was necessary to simulate the model until it reached an 
equilibrium. After reaching an equilibrium, the model was simulated for fifteen more years. These 
fifteen years, with all exogenous variables fixed at their equilibrium values and no pST adoption, 
serve as the base against which all pST scenarios are compared. Four alternative scenarios are 
simulated and compared to the base. The assumptions of the four scenarios are shown in the 
following summary. 
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Alternative scenarios with pST adoption 
Scenario I: Production Efficiency Scenario 
- Includes production efficiency changes (feed efficiency, growth rate) 
- Requires 17% crude protein ration 
- Carcass composition improvements not reflected in prices received 
Scenario II: Demand Scenario 
- Scenario I plus 5 percent increase in consumer demand due to leaner pork products 
Scenario III: Carcass Merit Scenario 
- Scenario I plus adopters use carcass merit pricing to capture benefits of improved carcass 
composition 
Scenario IV: Composite Scenario 
- Composite of Scenarios I, II, and III. 
An explanation of the results from each scenario is provided below. The actual results are shown 
in Figures 3-8. 
- 1 0 1 2 3 4 5 6 7 
YEAR 
Figure 3. Change In pork supply 
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Figure 4. Change In adopter profits 
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Figure 5. Change In non-adopter profits 
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+ production efficiency changes 
O prod. eff. and demand changes 
A prod. eff. and carcass merit changes 
x composite changes 
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Figure 6. Change In aggregate Industry profits 
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Figure 7. Change In farm price of pork 
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Figure 8. Change In retail price of pork 
Scenario 1 : Production efficiency improvements 
The immediate impact of the introduction of pST is that producers adopting the new technology 
incur lower production costs. The lower production costs increase profitability, providing incentive 
to increase production by expanding the breeding herd. In the second half of the first year, total 
supply begins to increase as the first pST injected hogs begin to reach slaughter weights. The 
increase in supply shown in Figure 3 reduces both farm and retail prices. Pork producers improve 
their market share as supply increases and retail prices fall, causing per capita consumption of pork 
to rise. Profits of pST adopters increase greatly during the first year. Meanwhile, non-adopter 
profits decline rather rapidly. Note that during this period aggregate pork industry profits increase 
because the increase in profits for adopters exceeds the decline in profits for non-adopters. The 
profitability changes can be seen in Figures 4-6. 
By the second year prices (Figures 7 and 8) fall very rapidly as production increases. Producers 
begin to sell of part of their breeding herd as profitability declines. Roth adopters and non-adopters 
realize a dramatic decline in profitability as a result of the lower farm price.The increasing trend in 
per capita pork consumption and improved market share continues. Beef and broiler production 
both decline in response to lower prices and profitability. Corn and soybean meal prices begin to fall 
as fewer hogs are needed to sustain the growth in total supply of pork. Lower production levels of 
beef and broilers also contribute to the decline as less feed is required in these industries. 
By the fourth year, long-run impacts change from the trend of the first two years. The breeding 
herd continues to decline, but the total amount supplied shows its first drop during this year. Retail 
and farm prices level off by the fourth year and begin to increase in year five.Aggregate producer 
profits (adopters plus non-adopters) bounce back by year five, but never reach the original baseline 
levels in the aggregate, since the decrease for non-adopters exceeds the increase for adopters.This 
may be due to our assumption that adoption levels never exceed 74% which may be unrealistic in 
the long run. An 80% adoption rate would move aggregate industry profits back to previous levels 
in the long run. Feed prices continue their decline. By the seventh year all variables are closely 
approaching their equilibrium values. 
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Scenario 2: Demand expansion plus production efficiency improvements 
The results from this scenario are similar to the first scenario. An assumed 5 percent increase in 
consumer demand due to leaner pork leads to higher breeding herd levels, market supply, and 
continuing expanded production one year longer than in the previous scenario. Both farm and retail 
prices are higher. In this scenario pST adopters realize increased profits during the first year, after 
which profits decline and follow the trend of the first scenario. Corn and soybean meal prices do not 
fall quite as rapidly as in the other scenarios. 
Scenario 3: Carcass merit pricing plus production efficiency improvements 
Short run effects are nearly identical to those in Scenario I. Supply increases and prices fall. 
Profits of pST adopters rise and profits of non-adopters fall. The pork industry continues to take 
market share from the beef and broiler industries because of leaner pork and lower prices. 
By the second year, the breeding herd size and total supply are slightly above the first scenario. 
Farm prices received by adopters are higher as a result of carcass merit pricing, and retail prices are 
slightly below the levels of the previous scenario as a result of the supply increases. Feed prices do 
not decline quite as rapidly. 
Scenario 4: Demand expansion, carcass merit pricing plus production efficiency 
improvements 
This scenario incorporates the assumptions from the first three scenarios to give an aggregate 
result. The trends of this scenario are similar to previous scenarios although more pronounced. 
Profits for adopters reach their highest levels while profits for non-adopters reach their lowest 
levels. Supply increases rapidly in year one and continues upward until year three when it levels off. 
Both farm and retail prices decline. This occurs because the increase in supply as a result of carcass 
merit pricing is greater than demand increases. 
There is less feed required for hogs treated with pST, and it takes fewer hogs to produce the same 
amount of pork. Thus, total feed consumption and waste output decline in all scenarios. 
Summary and implications 
This study provides a comprehensive analysis concerning the impact of pST on the pork sector. 
The study attempts to account for all of the dynamic economic impacts of the introduction of pST. 
However, it must be remembered that the results obtained from this study are limited by the 
assumptions used in the analysis, and by the limited availability of data on pST. 
The overwhelming impact of pST is the reduction in cost combined with an increased lean yield 
per hog. The resulting greater profitability as producers adopt pST causes production to increase 
rapidly. More pork production forces down prices at both the farm and retail levels. Due to the 
lower production costs, producers adopting pST immediately reap higher profits, but the industry as 
a whole realizes lower returns as the expanded production pushes down farm prices. From a 
profitability perspective, there appears to be an incentive to pork producers to adopt the new 
technology due to the short term profit increases and the longer term competitive advantage of 
adopters compared to non-adopters in the pork industry. In addition, pork producers regain some of 
the ground lost to technological advances in poultry production over the last thirty years, and 
become a more viable competitor for the consumer's food dollar. Thus, higher production and lower 
price levels benefit processors and consumers, while late-adopters are on the "technological 
treadmill". Aggregate pork producer profits change very little in the long run, as you would expect 
in a competitive industry with free entry. Feed grain producers are hurt while soybean producers are 
not affected. 
Several questions concerning the production impacts of pST as well as demand response by 
consumers still need to be answered. Until long-term production impacts and any possible side 
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effects are known with reasonable certainty, full scale adoption of pST will not occur.Consumer 
acceptance of meat from hogs injected with pST is still an important question that can have a 
profound impact on pST adoption. Some important issues not considered here include: 
- The potential for meat packers to shift preferences to heavier slaughter hogs because of leaner 
carcasses, and the possible implications. 
- The possible implications of differing international regulations on domestic use of pST and 
import restrictions in major pork producing and consuming countries. 
- The effects of competing technological changes (e.g. other growth promotants, beta agonists, 
etc.) in the pork, beef and poultry industries. 
Such changes could intensify or dramatically diminish some of the changes that we currently 
project as consequences of pST introduction.As more information becomes available we will be in 
a better position to more accurately assess the likely economic impacts of pST. 
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GROWTH CONTROL OF PIGS IN THE EEC EFFECTS ON THE 
COMPETITIVE POSITIONS OF PORK, AND OF PLAYERS IN THE 
PORK CHAIN 
A.H.R. Pease 
SARC, Gex, France, (Formerly with GIRA s.a.) 
Summary 
New growth controlling techniques, of which PST administration is nearest to market, decrease 
the cost of production of lean pork. They are also likely to increase the value of bellies more than 
proportionally to the lean content. 
The total advantage of PST to pork production is estimated as ECU 31 per pig. 
Some of this benefit will accrue to the supplier of the growth promotion technique via the price, 
and the rest could be expected to accrue, at least in the first instance, to pig producers. 
However, reasonable assumptions, based on published results on the effects ofPST, and the 
commercial functioning of EEC Pork Chains, indicate that this is not so for two reasons: 
- The new EUROPA grading system, although far more accurate than the previous system, will 
only pay an estimated 60% of the improved cut-out value of the carcasses; 
- PST carcasses will be leaner, and the extra lean pork arriving on the market will lower market 
prices. 
The producer prices for pigs are sensitive to volume, with estimates of elasticities from 
bi-monthly to annual series generally falling in the range -1 to -5. Estimates based on monthly series 
tend to be smaller. 
Since the value of carcasses lies mainly in their lean pork content, it seems reasonable to assume 
that it is the weight of lean, rather than the weight of carcasses which largely determines prices. A 
conservative assumption was made, that the carcass price/lean pork slaughtered elasticity will be -1 , 
with alternatives of -2 and -3. 
These assumption lead to the following conclusions: 
- For the first pigs slaughtered, 20% of the advantage will go to PST suppliers, 50% to pig 
producers (including EUROPA grading premia) and 30% to slaughterers/cutters. 
- Within a few weeks or months the advantage will be divided 20% to PST suppliers and 80% to 
consumers. 
Keywords: somatotropin, economic impact, Europe, swine. 
Introduction 
Administration of Porcine Somatotropin (PST) is the first of a new type of growth controlling 
techniques for pigs. Following behind are somatotropin related technologies based on 
immunisation, and gene transplant techniques. The magnitude of the technical effects, growth rate, 
feed efficiency and carcass composition have been demonstrated in numerous experiments. 
The object of this paper is to evaluate the commercial value of the technical effects in money 
terms. 
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That is to say: 
- The total value in ECU'S per pig; 
- How this value will be distributed in the first instance; 
- How it will then flow up and down the Pork Chain; 
- How it will effect competitive positions within sectors. 
Social structures 
If the techniques have a greater effect when the base performance is poor, then the social effects 
will be positive in the sense of favouring poor producers, many of whom are small and 
unspecialised. PST is taken as the main example, and differences from the other two techniques are 
discussed. 
If, on the other hand, the techniques are difficult to use, but not particularly related to base 
performance, then they will favour specialised industrial type producers. 
The market 
Pork produced using these techniques will be cheaper and leaner. On the other hand it may carry 
an image of "artificial". In addition, loins and bellies may be sufficiently leaner to have some of the 
characteristics of new products, to which the market will adapt. 
Essential information is lacking on which to draw conclusions on the above subjects, and they 
are, in any case, too complicated to be treated in a paper of this length. In what follows it has 
therefore been assumed that the positive and negative aspects cancel out. Most of the analysis 
applies to all of the new techniques, though PST has been taken as the main example. 
Other assumptions made are as follows: 
- The leanness will have a similar effect on prices as would the same amount of extra lean coming 
from more pigs; 
- The slaughter price on slaughter volume elasticity will be between -1 and -3; 
- The price of PST will represent 25% if the total advantage to pig producers. 
Standard assumption are made as to the technical effects, and these, together with their financial 
implications are given in Table 1. 
There are many examples to show that the results of improved animal production technology 
flow through to the consumer in a few months or years. 
However, the intervening period can be very profitable for some operators. 
The money flow following the introduction of PST in the EEC can be divided into five stages: 
- The first pigs, insufficient in numbers to influence the market; 
- The first half cycle (pig price cycle). The extra weight of lean pork coming on the market can be 
expected to depress prices. Benefit will thus be transferred from pig producers to consumers, 
with the PST supplier and slaughterers maintaining their share of the advantage; 
- Competition between slaughterers. Initially slaughterers will benefit from PST, since the cut-out 
value of PST treated pigs will be greater than is estimated by the EUROPA grading system. As 
the slaughter industry becomes familiar with the effects of PST, competition will drive margins 
down to near their pre-PST level 
- Later cycles. Depressed prices will cause some producers, particularly non-PST producers, to 
decrease or stop production in the classical pig cycle mechanism; 
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- Competition between PST suppliers. Much later, maybe after 10 years, the PST market will 
become saturated. By this time pig producers will no longer need technical support in order to 
use PST effectively, and competition between PST suppliers will drive down margins. 
Table 1. Initial division of PST advantages 
Feed conversion 70-100kg 
Dally gain 
Feed cost 
Other cost 
Cost to 70 kg 
Total production cost 
Fat depth 
Estimated lean 
Actual lean 
Price pa id (EUROPA system) 
Cut-out value 
Production margin 
of which: to PST supplier (25%) 
to p ig producer 
Advantage to slaughterer 
Total advan tage 
g 
ECU 
mm 
ECU 
Untreated 
4.0 
750 
26 
20 
94 
140 
24 
50.0% 
50.0% 
150 
150 
10 
PST 
Treated 
3.0 
863 
20 
18 
94 
132 
18 
54.6% 
55.4% 
163 
173 
31.4 
ECU 
113 
-6 
-2 
-8 
-6 
4.6% 
5.4% 
13.35 
23.1 
21.4 
5.3 
16.0 
9.8 
31.1 
Difference % 
- 25.0% 
+ 15.1% 
-23 .1% (1) 
-10.0% 
-5.7% 
-25.0% 
+ 9,2% (2) 
+ 10.8% 
+ 8.9% (3) 
+ 15.4% (4) 
+ 214% 
17% 
, 5 2 % 
3 1 % 
100% 
[1] = assumed 2% higher protein, slightly more expensive 
[2] = allowing for bias due to using regression of individuals to predict population change 
[3] = EUROPA payments slightly less than estimated lean, due to price classes 
[4] = difference mainly due to the very high value of lean bellies 
Source: GIRA based on various 
The first pig 
A 25% reduction in fat depths is not enough to produce an obviously different product. This 
means that the first pigs, if they are not announced, should be paid according to the EUROPA 
grading system, that is according to the weight of lean estimated by a regression equation. 
This grading system will probably underestimate the lean content of PST pigs because: 
— Grading is by categories, rather than on a continuous scale; 
- The regression equations are calculated from individual pig differences. The slope is flatter than 
from a regression equation for population differences. 
In addition, in Europe, lean weight underestimates the commercial value of lean pigs. The main 
reason for this is that lean bellies, which can be sold without transformation (other than smoking) 
are worth 2 - 5 times as much as fatter bellies which are broken down for manufacturing. The price 
difference is much greater than the difference in lean content. 
GIRA estimates, that on average, about 60% of the extra commercial value of PST pigs will be 
paid for on the EUROPA grading system. 
If the PST pigs are announced as such, then the payment differential will probably be less. The 
first PST users will find themselves in a similar situation to those who tried to introduce once bred 
gilt systems (which would have given a similar increase in productivity had they been allowed to 
develop). The producer will come onto the market with small quantities of an unknown product. He 
will lack negotiating power, and reasons will be found to downgrade his pigs compared to their 
grade value. 
Figure 1 gives the PST benefit by sector, assuming that pigs are paid according to grade. 
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Figure 1. Distribution of benefit from first PST pigs 
If the use of PST is not announced, then small producers will have a competitive advantage, 
since their small batches will be less likely to attract attention. If its use is known to the 
slaughterhouse, then large producers with negotiating power, and individuals with good negotiating 
ability will have a competitive advantage. 
The effects of immunisation or gene manipulation would be similar to those of PST at this stage, 
though the price of the techniques might vary. 
The first half cycle 
During the first half of a price cycle after the introduction of a new technique (15 -18 months) 
production cannot change, other than through pressure on the EEC to protect the market, or through 
varying the slaughter weight (if anything, over-supply tends to lead to heavier slaughter weights). 
The loin represents 40% of the value of a carcass, and it cannot be stored without losing value. 
Possibilities for storing other cuts, for exports or for import substitution are limited, so that when 
there is over-supply, prices continue to fall until the market absorbs all of the loins and most of the 
rest of the pork. 
Much of the adaptation is at the expense of other meats, when the price of pork relative to other 
meats falls, the relative consumption rises (Figure 2). 
Source: GIRA based on wioui 
Figure 2. EEC pork relative price and relative consumption 
* = 5 year moving average 
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This market effect appears in the form of elasticities of slaughter price on slaughter weight 
which generally fall in the range -1 to -5 when periods of one year are used. Elasticities tend to be 
smaller when the time trend is removed, and when shorter periods are used. 
It is assumed that extra lean meat coming on the market in the form of leaner pigs, would have 
a similar, though perhaps smaller effect on prices to that of the same quantity of lean derived from 
increased slaughterings. Taking these factors together it is assumed that the slaughter price on 
weight of lean elasticity will be in the range -1 to -3, with -1 being the most likely figure. 
ECU 
per Pig 
• PST 
» Nm-PST 
Fu*t 10% 10* 30% 40% 50% 60% 70% 80% 90% 100% 
Pig» 
PST Pigs as % of Total Slaughtered 
Source: GIRA 
Figure 3. Slaughter prices by proportion of PST pigs slaughter price/volume elasticity = -1 
The effect on prices of these assumptions are given in Figures 3 and 4 for elasticities of -1 and 
-2. When the elasticity is -1 , the average price paid hardly changes: the improved grading being 
offset by the fall in market price. 
The effect on the income of PST producers and of producers overall, taking account of the 
saving in production costs, and of the price of PST, is given in Figures 5 and 6. The initial effect on 
PST user margins is +16 ECU's per pig. With an elasticity of -1 , this advantage disappears when all 
pigs on the market have been treated with PST. If the elasticity is below -1 , then PST users, and the 
production industry as a whole, both lose margin, in spite of the increased productivity. 
ECU 
per Pig 
— PST 
Fir* 10% 10% 30% 40% 50% 60% 70% 80% 90% 100% 
Pigs 
PST Pigs as % of Total Slaughtered 
Source: G IRA 
Figure 4. Slaughter prices by proportion of PST pigs slaughter price/volume elasticity = -2 
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ECU 
per K g 
• 30 
Fix« 10% 10* 30% 40% 50% 60% 70% 80% 90% 100% 
P i p 
PST Pigs as % of Total Slaughtered 
Figure 5. PST-Producer Income by elasticity - PST Users 
ECU 
per Pig 
• 30 
First 10% 10% 30% 40% 50% 60% 70% 80% 90% 100% 
Pigs 
PST Pigs as % of Total Slaughtered 
Figure 6. PST-Producer Income by elasticity - Average of all pigs 
The benefit of PST by sector is illustrated in Figures 7 and 8 for elasticities of -1 and -2. 
Increasing the proportion of treated pigs leads to a transfer from producers to consumers. PST 
suppliers and slaughterers tend to maintain their share of the advantage over this period. 
* o f 
Total 
PST 
Benefit 
—" Consumer 
,
* ' Slaughterer 
• • PST Supplier 
— PST User 
~™ Non-PSTUser 
„ . PSTPigs as % of Total Slaughtered 
Source: GIRA ^ 
Figure 7. Who benefits? Short term elasticity -1 
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%of 
Total 
PST 
Benefit 
30-
15 
O-
• 1 5 . 
- 30-
- 4 5 
- 60 
- 75-
- 90 
~~ Consumer 
^ ' Slaughterer 
•" PST Supplier 
— PST User 
»» Non-PST User 
Fint 
PH. 
Source: GIRA 
10% 20% 30% 40% 50% 60% 7 0 * 80% 90» 100% 
PST Pigs as % of Total Slaughtered 
Figur© 8. Who benefits? Short term elasticity -2 
The main difference in effect between the three techniques (PST, Immunisation, and Gene 
manipulation), would be due to the speed of introduction. PST supplies, and probably those of a 
vaccine will be limited in the early months, so that the left hand parts of the above Figures are the 
most relevant. 
The introduction of gene manipulation is likely to be slow. Starting from 100 manipulated sows, 
it would take ten years to build up to 2.5 mio slaughter pigs (Pease, 1974). The process would be 
speeded up a little if embryo transplants were used at the grandparent stage. 
Since this intermediate period is limited to 18 months, "first pig" conditions are likely to hold as 
regards gene manipulation. 
This intermediate period is likely to favour organisations which are vertically integrated down to 
slaughter. Such organisations would gain all of the benefit of the growth improvement. It would 
create a greater incentive to obtain priority for pork vs other meats. 
Later cycles 
The EEC pig price cycle only has about 40% of the amplitude of that of the USA, but it is 
nevertheless a major factor in Pork Chains. It can be thought of in terms of oscillation about a trend. 
Depending on the phase of the price cycle at the moment of introduction of PST, the result could be: 
- A flattened peak; 
- An unusually long trough; 
- An unusually deep trough. 
The PST effect may or may not be sufficient to compensate for the effect on market price, 
according to the price elasticity and the proportion of users. Non-users lose under all circumstances, 
and some of them will decide to reduce, or stop production. 
Long term stability (though still with a cycle) will be reached either when: 
- All producers use PST. In this case the pressure on their margins will be much the same as before 
the introduction. At this stage all of their benefit will have been passed on to consumers, or; 
- The proportion of non-users stabilises. In this case the variability in the cost of production of 
lean pork will be increased, particularly if some users obtain better effects than others. Since the 
long term price is basically determined by the "pain level" of the poorest producers, this would 
imply a slight increase in average producer margins. 
If the introduction of the new technique is slow, then the main effect will be on the long terms 
trend, rather than on increasing the cycle. 
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The competitive situation of good producers will be further improved. To the extent that 
specialised producers are better, this will tend to accelerate the long term concentration process. 
Competition between slaughterers 
The sale price of the meat from a PST pig in the standard assumptions is about ECU 173 + 18%, 
or 200 ECU. The short term extra margin is estimated as ECU 9.8, or 5% of turnover. A satisfactory 
net profit for a pork slaughter operation is about 1 % of turnover, so initial profits from PST will be 
very large. 
The competitive situation between slaughterers is analogous to that between pig producers, in 
that: 
- There are sufficient numbers to ensure competition; 
- There is actual or potential over-capacity. 
There is little evidence as to how quickly competition will erode the extra margin, but it is 
reasonable to assume that much of it will have passed to consumers within the first half cycle. 
There do not appear to be significant variations on this scenario, either for other techniques, or 
between countries. 
Competition between suppliers 
This section covers both competition between suppliers of PST and competition between 
competing techniques (PST, Immunisation and Gene Manipulation). 
To treat all 280 mio OECD pigs would require 25 - 50t of PST per year. At present the capital 
requirement is of the order of $ 10 - 15 mio per tonne of capacity. Even allowing for improved 
production biotechnology, it is likely to be a number of years before the market is saturated, and 
prices drop. 
If one of the other techniques comes to market, then it will presumably act as a partial substitute 
for PST, and increase price competition. 
Conclusion 
The most likely results of the introduction of PST are therefore that: 
- for the first pigs slaughtered, 20% of the advantage will go to PST suppliers, 50% to pig 
producers (including EUROPA grading premia), and 30% to slaughterers/cutters; 
— within a few weeks or months the advantage will be shared, with 20% going to PST suppliers 
and 80% to consumers. 
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EFFECT OF PST ON ENVIRONMENTAL N POLLUTION 
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The Netherlands. Department of Animal Nutrition, Agricultural University, 
Wageningen, The Netherlands. 
Summary 
Castrated male crossbred (Dutch Landrace x Dutch Yorkshire) pigs were injected with four mg 
per day recombinant porcine somatotropin (rpST) from 58 kg live weight onwards during ten 
weeks. An untreated placebo group served as a control. Animals were fed at a restricted level of 260 
kcal metabolisable energy per kg body weight ' daily. 
Parameters measured were N-balance in six test periods during the last six weeks of the 
treatment period, weight gain and feed conversion. N-balance was significantly increased with 
31%; 7.7% more of the dietary N was retained in the body of the rpST treated animals. Weight gain 
was 10% faster and feed conversion was 7% more favourable in the rpST pigs. P and Ca balance 
were increased with 18 and 19%, respectively, after rpST treatment. 
From these figures it was calculated that the excretion of N into the environment over the weight 
range 58-110 kg was reduced with 21% after rpST treatment; for P was the reduction in excretion 
16%. The main uncertainty regarding the extent of the effect of rpST on N excretion is the lack of 
knowledge on the dietary levels of protein/amino acids needed to sustain the extremely high 
(approximately 210 g/day) protein deposition in rpST-treated pigs. The experimental data obtained 
sofar give no indications of a dramatic increase of these requirements in rpST-treated pigs. 
Keywords: somatotropin, swine, environment, pollution. 
Introduction 
More than ten years ago rather heavy and confusing discussions already arose on the subject of 
the efficiency of animal production, especially with regard to the low efficiency of protein 
conversion in monogastric animals. That discussion was initiated by the well-known report of the 
"Club of Rome" dealing with the limited world resources for all kinds of raw materials, including 
components for human food. In an E.C.-workshop in 1981, in which another category of hormones, 
the anabolic steroids, was discussed, I showed some figures of output-input relations for protein, 
calculated by Van Es in 1978 (Table 1). 
Table 1, Efficiency of protein conversion (output/Input) 
broiler 0.40 
laying hen 0.40 
fattening pig 0.34 
veal calf 0.33 
From these figures it is clear that the efficiency of protein conversion in monogastric farm 
animals is in the order of 1/3, with 2/3's being excreted via faeces and urine. 
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Whereas in the seventies the discussions were almost exclusively focussed on the term 
"inefficient production of animal protein, competition between animal and man for the scarce 
sources of (plant) protein", the impact of this inefficiency, such as the big losses of protein and the 
polluting effect of the excreted nitrogenous compounds (mainly urea), attracted hardly any 
attention. However, in the past ten years the situation, at least in the Netherlands, has completely 
turned around: There is no longer any discussion on the loss of valuable protein in the animal 
production cycle but only complaints on the environmental pollution with N and also P caused by 
"bioindustry". This drastic change is not illogical when realizing the heavy concentration of farm 
animals in the Netherlands. Especially the numbers of pigs increased considerably during the last 
years; in 198015.6 millions were slaughtered, and in 1987 it has increased to more than 22 millions. 
One must also realize that the pig and poultry industry in the Netherlands is not spread evenly over 
the country but is specifically concentrated the southeastern part. Whereas some years ago the 
concern was mainly on the pollution of the surface water by P orginating from the animal industry, 
recently the attention has been focussed more on the pollution of the groundwater with nitrate and 
the pollution of the air with ammonia. Especially since observations on the rising levels of nitrate 
in wells used for the water-supply and the serious effects of ammonia on the vitality of forests, 
serious discussions are underway aimed at how the N load in these regions can be diminished, 
including suggestions in parliament to force the animal industry to drastically reduce the numbers 
of animals. 
Ways to reduce pollution 
The total output of N and P in the Netherlands originating from the three main categories of farm 
animals was estimated some years ago by Jongbloed et al. (1985). The figures are given in Table 2. 
Table 2. Estimated output of N and P In the Netherlands (1984) (In 1000 kg per year). 
Carrie Swine Poultry 
N 440,000 120,000' 53,000 
P 56,000 32,000 15,500 
* in 1987 estimated at 160,000 tons N. 
Whereas the numbers of cattle and poultry are rather stable (poultry) or slightly going back 
(cattle), by 1987 the number of pigs has increased considerably. 
Besides, cattle are rather uniformly spread over the country in relatively low concentrations, 
whereas the other categories are together much more concentrated in certain areas. 
Reduction via the feed 
Considering the problem described above, the question now arises: which measures, apart from 
a reduction in the number of animals, can be taken to bring the environmental pollution by animal 
industry back to acceptable levels. Research sponsored by the government, together with the mixed 
feed industry, was started some years ago to study the possibilities of reducing the N and P output 
of poultry and swine by changing feeding systems, diet compositions and other measures involving 
the animals. 
In Table 3 a rough calculation regarding the importance of the two main routes of N excretion of 
a fattening pig over the range 20-110 kg is given. 
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Table 3. Routes of N excretion In a fattening pig (20-110 kg live weight) 
Input of total N ( 270 kg feed x 16% crude protein) = 7.0 kg 
Input of faecal digestible N(digestlblllty N = 85%) = 6.0 kg 
N In 110 kg plg(proteln content 15%) 2.5 kg 
1 ) Output of faecal N = 1.0 kg 
2) N In urine 3.5 kg 
(Input of faecal digestible N - N In body at 110 kg) 
The figures for feed conversion (3.0), dietary protein content (16%), digestibility of the protein 
(85%) and protein content in the slaughter pig (15%) are estimations based on present-day practical 
situations in the Netherlands. 
From these figures it can be deducted that the efficiency of N deposition, expressed as a 
percentage of intake of total N, over this weight range is approximately: 36% kjhr 
It is clear that the main route of N excretion is via the urine; therefore in the research programme 
aimed at reducing N output in pigs, the main emphasis is on this aspect. 
Faecal N output can in theory be reduced by a lower dietary N content or an increased 
digestibility of dietary N. A higher N digestibility can be attained by a choice of highly digestible 
feed components or by technological measures to increase digestibility of lower digestible feed 
components, for example via enzymes. / 
Urinary N output can be reduced via dietary measures by optimally balancing the amino acid 
composition of the diets in such a way that the requirements of the animal for maintenance and 
production are adequately covered and no surpluses of amino acids are present. The potentials in 
this direction are considerable; however, progress is limited by a lack of knowledge of the exact 
requirements of amino acids other than lysine and methionine + cystine (threonine, tryptophan, 
isoleucine). The first goal of a research project, in which ILOB and State institutes are cooperating, 
is to determine these requirements. In theory substantial reductions in the protein contents of pig 
diets are possible by supplementing low-protein basal diets with the relevant amino acids. The 
practical application will be mainly dependent on the availability of those fermentatively produced 
amino acids and on the price level of these amino acids in comparison with the protein-bound amino 
acids in natural feedstuff s. 
It was recently estimated (v. Weerden, 1988; Jongbloed et al., 1985) that a reduction of urinary 
N output in the order of 20% may be practically possible. 
Reduction via the intermediary metabolism 
A second potential way to reduce urinary N output is the intervention in the intermediary N 
(amino acid) metabolism via application of hormones or hormone-like compound. Examples are the 
anabolic steroid and related compounds, growth hormone or somatotropine (ST) and, to a certain 
extent, the ß-agonists. The potent zoötechnical effects of the three categories of agents, all acting 
via a shift of the energy deposition in the body from fat to protein, have been extensively discussed 
in a number of conferences (Lu and Rendel, 1975; ASAS, 1987,1988; Hanrahan, 1987). 
Because these agents drastically improve the efficiency with which the protein in the feed is 
converted to protein in the body, it is evident that they will also affect urinary N excretion and in 
this way reduce pollution. 
To quantify the effects of porcine somatotropine (PST) on N and P excretion, the results of a 
recent experiment carried out in a cooperation between the Agricultural University Wageningen and 
ILOB-TNO will be presented. 
Short communications of the data obtained in this experiment have already been reported at the 
ASAS-meeting of this year (Huisman et al., 1988; Van der Hel et al., 1988). 
In this experiment the effects of recombinant porcine somatropine (rpST) on N and P deposition 
were studied in crossbred (Dutch Landrace x Dutch Yorkshine, Fl), Pietrain and Duroc pigs. The 
effects of rpST on N and P balance and on weight gain and feed conversion were of the same order 
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of magnitude in the three breeds. For the calculation of the effects of rPST on N and P excretion 
only the figures obtained in the Fl-animals are used. 
Twelve castrated male pigs of approximately 58 kg live weight were allocated to two groups of 
six animals each, a rpST group (dose, 4 mg per day) and a placebo group. The experiment was 
finished ten weeks later. During the last six weeks N balance was measured six times (P1-P6) 
during 6 days per period. P and Ca balance was measured only in test period P2. 
The animals were fed at a restricted level of 260 kcal M.E. per kg" ' in PI the daily amount of 
feed supplied was approximately 2.4 kg, and in P6 2.9 kg. The diet contained 19.4% crude protein 
and 0.92% faecal digestible lysine, levels which are approximately 25% higher than in normal 
practical feed formulations. 
The result for weight gain, N deposition, and efficiency of N retention in the different parts of 
the experimental period are presented in Tables 4 and 5. 
Table 4. Weight gain and feed conversion In control and rPST group 
Live weight Control 
(kg) (kg) 
rPST 
(% of controD 
at start of experiment 
test period PI 
test period P2 
test period P3 
test period P4 
test period P5 
test period P6 
slaughter 
PI - P6, In g /day 
start-P6, In g /day 
Feed conversion: 
PI - P6, abs. 
start - P6, abs. 
57.7 
80.7 
87.6 
93.6 
100.4 
107.4 
112.9 
119.5 
924 
883 
2.89 
2.74 
58.5 
83.7 
92.0 
98.1 
105.5 
113.6 
118.6 
126.1 
1010.' 
964.* 
2.69* 
2.55* 
101 
104 
105 
105 
105 
106 
105 
106 
110 
109 
93 
93 
* significantly different from control (P < 0.05). 
Table 5. N balance and efficiency of N retention (as % of Intake) 
Test period 
PI 
P2 
P3 
P4 
P5 
P6 
mean 
Control 
(g /day) 
27.9 
30.4 
26.5 
26.1 
23.7 
23.7 
25.7 
N ba lance 
(g/day) 
33.8 
36.4 
34.6 
34.5 
30.7 
31.0 
33.6" 
rpST 
(% of control) 
121 
120 
131 
132 
130 
131 
131 
Efficiency 
Control 
39.1 
40.1 
33.4 
31.3 
27.2 
26.5 
32,9 
rpST 
46.0 
46.2 
42.0 
39.9 
34.6 
34.6 
40.6 
* significantly different from control (P < 0.05) 
Weight gain and feed conversion efficiency of the rpST animals from about 80 kg live weight 
onwards were significantly improved with 10% and 7% respectively compared to controls. N 
deposition was significantly increased with 31 % and 7.7%, more of the dietary N being retained in 
the body of the rpST pigs. 
As was to be expected, the effect of rpST on N balance was only on the excretion of N via the 
urine. Excretion via the faeces was the same in both groups (N digestibility in controls on average 
82.5%, and in the rpST group 82.6%). 
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Results of the measurement of P and Ca balance during the test period P2 are given in Table 6. 
Both mineral balances were increased with 18 and 19%, respectively, in the rpST treated group; the 
efficiencies of P and Ca retention were increased by 4.8 and 4.6%, respectively. 
Table 6. P and Ca balance In test period P2 
Control 
(g/day) 
P balance 6.3 
Ca balance 8.7 
rpST 
(g/day) 
7.5' 
10.3 
(% of control) 
118 
119 
Efficiency 
(% of Intake) 
control rpST 
34.0 38.8 
30.2 34.8 
* significantly different from control (P < .05). 
Calculation of reduction of pollution 
From the results presented in Tables 4,5 and 6 the effects of rpST on excretion of N and P were 
calculated. For these calculations different ways can be applied. First, one can base the estimations 
on an equal time period for the control and rpST group, for example P1-P6. However, at the end of 
test period P6 the rpST animals were approximately 7 kg heavier than the control pigs and, although 
the treated pigs are considerably less fat than the untreated ones, one may not assume beforehand 
that because of that, the growth hormone treated pigs will be slaughtered in practice at a heavier 
weight. It was therefore decided to estimaten and P excretions over a time period during which the 
animals reached a common slaughter weight. 
In this case a rather practical final weight of 110 kg was chosen. Because N balance was only 
measured during the last 6 weeks of the ten-week's treatment period, the figure for the rpST effect 
on N retention during the first four weeks of the treatment period had to be approximated. We have 
assumed that the effect of rpST on N retention during the first four weeks was the same as during 
the last six weeks, i.e. as a percentage of N-intake, 7.7% higher. The results of the calculation are 
given in Table 7 for N and in Table 8 for P. To estimate the effect on P excretion, the figures 
measured in test period P2 were extrapolated to the whole ten week treatment period. 
Table 7. Calculation of N excretion per animal 
Control rpST 
Weight range (kg) 
Number of days 
Feed Intake (kg) 
N intake (g) 
Efficiency of N retention 
(% of Intake) 
N excretion (% of Intake) 
N deposition In body (g) 
N excretion (g) 
Difference (g) 
Difference (%) 
57.7-no 
59 
138 
4280 
32,9 
67.1 
1410 
2870 
58.5-110 
53 
124 
3845 
40.6 
59.4 
1560 
2285 
-585 
-21 
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Table 8. Calculation of P excretion per animal 
Control rpST 
Weight range (kg) 
Number of days 
Feed Intake (kg) 
P Intake (g) 
Efficiency of P retention 
(% of Intake) 
P excretion (% of Intake) 
P deposition In body (g) 
P excretion (g) 
Difference (g) 
Difference (%) 
57.7-110 
59 
138 
950 
34.0 
66.0 
325 
625 
58.5-110 
53 
124 
855 
38.8 
61.2 
330 
525 
-100 
-16 
The figures in Table 8 show that rpST application over the weight range from 58 to 110 kg 
reduced N excretion by approximately 21%. In this period P excretion was diminished by 
approximately 16%. When we assume that from the total amount of feed consumed by a fattening 
pig over the weight range 20-110 kg, approximately 70% is eaten in the range 60-110 kg (Jongbloed 
et al., 1985), then the reduction in N output of that fattening pig amounts to approximately 15% 
when rpST is applied in the second part of the fattening period. 
The calculations given above refer to pigs fed on a restricted scale. European pigs are at present, 
however, fed for a considerable part on an item basis. Data obtained by Kanis et al. (1988) in pigs 
of the same breed fed ad libitum the same basal diet as in our experiment showed an effect of rpST 
treatment over the live weight range 60-100 kg of +6% on daily weight gain and -10% on feed 
conversion. Above 100 kg live weight the effects were greater. These data suggest that the effects 
of rpST on weight gain and feed conversion are of the same magnitude in restricted and ad libitum 
fed finishing swine. It is therefore likely, that the effects of rpsT on N deposition and N excretion 
will also be of the same magnitude. 
Discussion 
The main uncertainty remaining for predicting more precisely the effect of PST treatment on N 
output is the lack of knowledge on the levels of protein/amino acids needed to sustain the extremely 
high (approx. 30% above "normal") protein depositions observed in PST-treated animals. In the 
"Wageningen-experiments", as well as in other studies reported, the protein/amino acid contents of 
the basal diets were considerably higher than normal in order to have a safety margin. At present, 
research is being carried out at different locations, and also in Wageningen, to find out whether or 
not the requirements for amino acids/protein for PST-treated animals are increased. 
Considering former ILOB-results with veal calves implanted with an effective anabolic steroid 
combination (estradiol + trenbolone acetate) and fed diets with different milk protein contents (Van 
der Wal and Berende, 1983), we expect no dramatic increase in these requirements. The somewhat 
irregular weight gain response pattern of PST-treated ad libitum fed pigs given diets with different 
protein levels (Newcomb et al., 1988) seemed to agree with this supposition. Even if dietary protein 
levels appear to be somewhat increased in order to reach the maximum rpST-response, it is still 
questionable whether under these circumstances higher protein doses are economically justifiable. 
In conclusion it can be stated that rpST is an effective tool in reducing N (and P) output of swine. 
More experimental data are needed to calculate more precisely the extent of this effect on N (and 
P) pollution of the environment, but an improvement in the order of 20% N for growing-finishing 
swine in the live weight range of 60-110 kg seems a reliable estimate. 
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ADOPTED CONCLUSIONS OF SESSIONS 
IMPLICATIONS FOR THE PRODUCTION SYSTEM 
Chairman: R.G. Zimbelman 
American Association of Animal Science, Bethesda MD, US 
The undisputed improvement in increasing protein deposition and decreasing fat deposition 
from injections of RPST were markedly consistent across breeds, nutritional level, sexes and 
various management schemes in North America, Europe and China. The magnitude of response 
varied, but even the lowest responses were striking. The results were evident from visualization of 
carcass as well as from numerical data. 
Also consistent was a reduction in feed intake as well as increased feed efficiency. Magnitude of 
increase cannot be expressed specifically because of several factors: 1) no hard data on optimum 
dosage, 2) the apparent interaction of dose with nutrition, i.e. higher protein deposition from higher 
doses may require altered composition of diet whereas more minimal responses may not; studies 
presented varied in length of treatment, dosage used, and initial and ending weightsv 
The potential for an acceptable product will largely depend on a practical slow release delivery 
system. Several companies may be successful to varying degrees, a generic description of efficacy 
may be virtually impossible slight modifications in chemical structure or conformation of PST. 
Prolonged release devices or formulations will likely sacrifice some efficacy and cost benefit 
considerations may influence the usage decision by different producers. 
Grading systems and processing industry needs are quite complex and require serious 
consideration. There are a number of concerns, including pork belly thickness, processing 
procedures, as well as intramuscular fat levels, which may not be optimal with markedly decreased 
fat levels. Some of these may be aided by increasing slaughter weight, but that would be resisted for 
certain fresh cuts or current products. 
An in depth study of how to react to extremely lean pigs is thoroughly needed in both the United 
States and various European markets. Results of research from pigs in the United States or from 
pigs which are not very lean may not apply to European programs in which lean pigs are already 
prevalent. Research in those situations is needed to assess whether benefits occur as well as whether 
there are currently undetected disadvantages in relation to meat quality or processing 
characteristics. 
Genome modification is progressing at an amazing speed in terms of developing theoretical 
approaches to achieving and controlling gene insertion. The advantage of gene insertion over PST 
administration by injection may be greatest in pigs which already have some desirable traits, such 
as high prolificacy. In these pigs growth and carcass improvements would come from added PST or 
GRF genes. On the other hand it is likely to be many years (at least 8 to 10) before a useful breeding 
animal results. It is most probable that the progenitor transgenic will have a single gene insertion 
controllable by some feed or cheap input compatible with commercial production. 
The breeding of that animal after puberty to a large group of mates suggests a requirement for a 
male, the subsequent mating of his offspring to achieve homozygosity. This will require 
considerable time. Finally, a "performance" test long enough to allow time for expression of 
undesirable traits prior to widespread introduction into the gene pool would be prudent. This would 
be costly in resources and time; therefore society should develop mechanisms, such as patents, to 
allow investors a reasonable return on their very risky and substantial investment if this technology 
is to proceed to commercialization. 
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Whether PST usage would require modification of testing and selection procedures used for 
genetic improvement depends on whether there is an interaction of PST usage with other desirable 
traits than performance and carcass characteristics. 
One serious consideration is whether the most lean animal should be the objective. The specific 
description of fatty acid composition changes in PST or transgenic pigs should be a high priority. 
Some caution in applying these new exciting technologies might be very prudent. Enhancing our 
understanding of how effects are achieved will be quite essential in chasing a "moving target". 
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REQUIREMENTS AND WELL BEING OF THE TARGET ANIMAL 
Chairman: P.R. Wiepkema 
Wageningen Agricultural University, The Netherlands 
Animals maintain internal and external homeostasis by means of well-balanced, complex and 
interwoven regulatory systems. Many of the environmental parameters involved are controlled 
actively by the animal. 
When changing relevant production traits of domestic animals the balance of existing 
homeostatis requires attention. For meeting requirements and well-being of the target animals, the 
main and side effects of novel technology need adequate clarification. 
Campbell showed that PST treatment presumably effects fat reduction and protein increase not 
to the same extent. For this latter effect an adequate amount of protein should be available in the 
diet. The two effects interact with dosage of PST and with breed, sex and live weight. 
A decreased feed intake, observed in trials, up to 100 kg body weight is associated with a 
significant decrease in fat deposition and increased protein accretion. The related impact on amino 
acid, fatty acid and glucose metabolism asks for further elucidation. 
Verstegen showed, that PST treatment increased heat production, reflecting a higher metabolic 
rate. This increase may stem from a higher maintenance requirement or/and a reduced efficiency of 
energy utilization above maintenance level. 
Curtis calculated the potential impact of the reduced thickness of the subcutaneous fat layer on 
the thermoregulatory capability of the PST treated pigs. It may lead to a narrowing of the 
thermoregulatory zone at the upper and under limits. For this reason effects on thermoregulation of 
the animals require determination of optimum temperatures for PST animals. 
Information on the behaviour (social organization, feed and water intake, rest, etc.) of group 
housed and PST treated pigs is required, in order to evaluate a priori problems, that may arise under 
practical and intensive husbandry conditions. The reaction of PST treated pigs to being transported 
to the slaughter house, when high demands are made upon the pigs thermoregulatory capacity, 
requires special attention. 
Kelley emphasized the positive role of PST under normal conditions with respect to activating 
the immune system (macrophages). Whether PST treatment may benefit the health of the pigs 
involved cannot be stated at the moment. 
Day showed that PST when used before puberty does not disturb reproductive processes taking 
place some weeks after the end of the treatment. PST treatment during oestrus led to contradictory 
results. 
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CONSUMER ASPECTS 
Chairman: B. Hoffmann 
Justus Liebig University, dessen, Germany 
As was layed out by Norcross, U.S.D.A., in the U.S.A. well established regulatory procedures 
allow an adequate risk-benefit assessment concerning the use of drugs in food animals. As a product 
of recombinant DNA-technology PST falls within the responsibility of the F.D.A.; F.D.A. has 
allowed the use of PST for efficacy in research studies under the NIDA-regulations without a 
withdrawal period; similarly no withdrawal period is necessary for milk concerning the use of BST 
under similar conditions. 
Some still open questions - eg. the relevance of altered IGF-1 levels for consumer safety -
request to be answered prior to a final approval. According to Norcross other regulatory procedures 
are available to deal with approval of transgenic animals. Norcross strongly endorsed 
communication and exchange of views and data between regulatory agencies and others concerned 
with these problems. 
It was made clear during the discussion that, different to the U.S.A. adequate and efficient 
regulatory pathways have evolved in Europe only since the late sixties (U.K.) and late seventies 
(F.R.G.) or they are still being established in other E.E.C.-member states. 
According to Schams, who presented data on PST and IGF-1 from a collaborative study, 
base-line levels in blood plasma are reached within 26 hours for ST and within 4 days for IGF-1 
following treatment with PST. Preliminary data on ST and IGF-1 in muscle have been presented 
indicating that no residues are present 4 days after treatment. No data concerning IGF-1 levels in 
liver and kidney are available and further information on the break down of IGF-1 and the 
formation of fragments likely to be bioactive is necessary. 
Prusa and Demeyer in their presentations confirmed the general trend of leander carcasses and 
decreased intramuscular fat following treatment with PST; however, apparent breed differences 
have to be taken into account. Although measurable differences in nutritional composition and 
sensory quality between PST-treated and untreated animals have been reported, no major concerns 
are evident. Protein and moisture contents of muscle increased slightly similarly as polyunsaturated 
fatty acid contents in raw pork and cholesterol in cooked pork; thiamine contents were reported to 
decrease slightly. Overall sensory quality was not altered, though some deviations from the control 
groups have been reported. 
The possibility to reduce fat and caloric intake from pork by application of PST has been 
discussed as one form to improve human nutritional quality. 
From the consumers point of view Graham requested open communication. Perception by the 
consumers relates to more than safety, it includes other ethical matters, e.g. animal welfare. The 
modern consumer, who is able to handle computers and other sophisticated instruments, wants to be 
consulted, he further is able to be educated, i.e. he will be able to deal with information from 
industry and science. In this sense Graham discussed the problem of labelling of certain products as 
to their origin; she further disagreed in calling products to increase efficiency health products. 
The still open questions, however, are who is the consumer and on what platform he can be met 
and how to spread solid information. 
Dantzer, who presented a philosophical approach to the problem, referred to the normative type 
of the process in establishing ethical values. In order to forward certain ideas at the level of society, 
the potential impact of biotechnology on the socio-economic structure of animal production should 
be addressed. Although biotechnology has great potential for improving the efficiency of animal 
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production, a thorough consideration of ethical issues raised by their introduction is necessary for 
their understanding and acceptance by society. '/'' 
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E N V I R O N M E N T A L A N D E C O N O M I C I M P A C T 
Chairmen: K. AIBARA and G. VAN DIJK 
Food and Drug Safety Research Center, Kanagawa, Japan, Wageningen 
Agricultural University, The Netherlands 
The introduction of recombinant porcine somatotropin (rpST) in pig production will depend on 
a number of factors, most of which are now being quantified. Among these are farm economics, 
effects for the market chain, consumer acceptance, impact on the physical environment, 
government attitudes and ethical considerations. 
Farm economics 
Hayenga has made clear that cost advantages will induce a high adoption rate - all under the 
assumption that there will be no severe restrictions because of consumer acceptability. His figures 
indicate rates of 50-60% in 2-3 years. rpST will result in lower costs and hence early adopters will 
see their profit margins increased. This situation is not a stable one, however. After some time 
competitors will force laggards to adopt and profit margins down as prices in this industry have the 
tendency to equal long run average costs. Eventually consumers will benefit most persistently. 
Under European conditions also the processing and marketing industries will be able to secure part 
of the share. Pease suggests that the processing industry could take a "substantial" share. It seems 
that this statement is essentially valid for the short run. In the longer term similar conditions apply 
as to the farming sector. 
Nevertheless part of the profit will remain in the farming and processing sectors.lt is basically 
via new technologies that general growth in income and parity with general economic growth is 
achieved in those industries. This is normal. 
The market effect 
There will be little growth in demand, apart from substitutes effects. There is also little trade 
from Europe, US, Japan. Increasing islamic proportions of demographic changes makes the 
international pork market more of a stable nature than are, potentially, the prospects for beef, for 
example. 
Steele and discussants pointed out that lower prices for pork will stimulate substitution of beef 
by pork. However, little quantitative information on elasticities of substitutions - assuming 
substantial price changes - is available. Studies are underway (Hayenga). 
As regards the effects of introducing rpST on processing practices McKeith reported that there 
are hardly such effects. In any case such effects occur normal technology would easily master them. 
rpST has positive influence with regard to the environmental constraints. Van Weerden showed that 
per kg product there will be a decrease in polluting emissions (of N and P) ranging from -15 to 
-20%. No doubt these effects are substantial if not decisive for the Netherlands. The economic 
effects and valuation of the ecological argument, however, are still to be quantified. Assuming the 
installment of restrictions on P and N emission are forced by law, the introduction of rpST can be 
regarded as an important instrument in addition to other measures to diminish polluting effects. As 
a whole measures for environmental protection will lead to changes in production systems. 
Consumer acceptance is not a datum. It can be changed via marketing and promotion or 
brand-policies. Progress in this respect has been very modest so that pork still has the status of a 
bulk product. Changing marketing policies however now seem underway. In such a development 
producers will be more integrated in the entire market channel. This may result in contract 
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production and vertical quality management. Under those conditions the consumer acceptance issue 
is dealt with in the normal way: quality is not perceived automatically by consumers and 
consumer's trust has to be won. 
Government policies may resist to the introduction of rpST because of social and economic 
considerations. The structural implications in the country side may be substantial. rpST then could 
easily become an instrument for establishing ingingtrade barriers. However, in Europe this will 
gradually become less likely because of the consumer will obtain a more crucial position. Most of 
the discussants considered that big effects of location changes in pig production would occur 
because of the introduction of rpST. 
Summarizing of effects interacting with economic impact: 
farm economics : stimulating for rpST introduction 
ecological argument : id. 
consumer : "you may convince me" 
feed requirements/health : positive 
tax payer : (probably) neutral 
target animal : requires more in depth discussion 
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EFFETS SUR LA REPRODUCTION ET LA LACTATION 
Répercussions des nouvelles technologies pour l'amélioration des performances de croissance 
sur la reproduction et la lactation chez le porc 
B.N. Day, S. Terlouw et A. Rieke 
5: ASPECTS INTERESSANT LE CONSOMMATEUR 
SECURITE DES PRODUITS COMESTIBLES 
Biotechnologies et contrôle de la croissance et de la qualité du produit chez le porc: sécurité des 
produits comestibles 
M A. Norcross, RA. Carnevale, EA. Brown etA.R. Post 
Apparition potentielle de résidus après traitement des porcs avec de la somatotropine 
recombinante 
D. Schams, E. Kanis et P. van der Wal 
CARACTERISTIQUES NUTRITIONNELLES ET ORGANOLEPTIQUES 
Caractéristiques nutritionnelles et organoleptiques de la viande de porcs traités par la 
somatotropine 
K.J. Prusa 
Effet de la somatotropine porcine recombinante sur la qualité de la carcasse et de la viande de 
porcs belges et hollandais 
D.Demeyer, R. Verbeke, G. van de Voorde, J. Fabry, E. Deroover et RM. et Dalrymple 
L'OPINION DES CONSOMMATEURS 
L'opinion des consommateurs sur les technologies et biotechnologies 
appliquées à l'alimentation 
/ . Graham 
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Aspects éthiques relatifs à l'utilisation des biotechnologies pour le contrôle de la croissance et 
de la qualité du produit chez le porc 
R. Dantzer 
6: REPERCUSSIONS SUR L 'ENVIRONNEMENT ET L 'ECONOMIE 
REPERCUSSIONS ECONOMIQUES ET EFFETS SUR LA POSITION DE L'INDUSTRIE 
DU PORC 
Répercussions de l'utilisation de somatotropine porcine sur l'industrie du porc 
M. Hayenga, B. Buhr, K. Skold, S. Johnson, etE. Grundmeyer 
Stimulation de la croissance des porcs dans la C.E.E.: effets sur la compétitivité de la viande de 
porc et des intervenants dans la filière porc 
A.H.R. Pease 
POLLUTION DE L'ENVIRONNEMENT 
Effets de la somatotropine (PST) sur la pollution azotée de l'environnement 
E.J. van Weerden, et M.W A. Verstegen 
CONCLUSIONS 
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OBJECTIFS DU SYMPOSIUM 
L'accès à des produit carnés de bonne qualité à des prix abordables est devenu un droit pour une 
partie de plus en plus importante de la population mondiale. La mise en pratique des connaissances 
acquises dans le domaine de la recherche animale a permis de répondre à cette demande des 
consommateurs. Le perfectionnement des "outils" scientifiques, grâce au développement des 
biotechnologies est une étape probablement essentielle pour faire face aux demandes futures tout en 
tenant compte des contraintes grandissantes dans le domaine de la production. 
La superficie des cultures destinées à l'alimentation animale est limitée et la capacité 
d'absorption par l'environnement des excreta polluants a déjà été dépassée dans de nombreux 
endroits. Le maintien du système de production animale actuel ne peut donc plus être garanti. Les 
exigences quant à la qualité et la sûreté d'utilisation des produits sont maintenant définies de façon 
précise. De même, le bien-être des animaux demande à être mieux pris en compte. 
Les progrès en biotechnologie ouvrent des perspectives de plus en plus larges pour permettre de 
répondre à ces exigences avec efficacité. Des améliorations significatives de l'efficacité et de la 
qualité de la production animale deviennent possibles. L'objectif de ce symposium est l'étude, dans 
un contexte général, des possibilités et des contraintes des nouvelles technologies pour le contrôle 
de la croissance et de la qualité des produits et dans les réponses apportées aux exigences des 
consommateurs, de l'animal et de l'environnement.
 / 
Priorités pour l 'amélioration de la production animale 
L'amélioration de l'efficacité de la conversion de l'aliment en viande est certainement la 
perspective la plus prometteuse pour le maintien à long terme du système de production animale. 
Elle permet de réduire la superficie des cultures destinées à l'alimentation animale et d'abaisser le 
prix de la viande. Enfin, elle constitue le facteur le plus efficace pour diminuer la pollution de 
l'environnement liée aux excreta animaux. 
Depuis qu'il devient évident qu'un excès d'apport calorique est nuisible à la santé de l'homme, 
un produit de bonne qualité doit être plus maigre et moins gras. La sécurité d'utilisation du produit 
ainsi que son goût et sa tendreté sont aussi des paramètres prioritaires. 
Le bien-être des animaux, à savoir leur santé et leur comportement, peut être mieux appréhendé 
par les progrès réalisés en physiologie animale, en ethologie et en immunologie. 
Les nouvelles biotechnologies 
Diverses technologies appliquées en physiologie et potentiellement à même de combiner 
rentabilité et sécurité ont été sélectionnées afin d'être analysées lors de ce symposium. Ces 
technologies se réfèrent à "l'axe somatotrope". 
La croissance des espèces animales productrices d'aliments est contrôlée par le génome qui 
exprime ses potentialités dans le système d'interactions entre somatocrinine (GRF: somatotropin 
releasing factor) - somatostatine - somatotropine - somatomédines. 
Depuis 6000 ans, l'homme est intervenu sur ce système en modifiant progressivement le génome 
des animaux par la sélection systématique afin d'adapter la production animale à la demande. 
Ces 10 dernières années, ce processus a été accéléré de façon considérable grâce à 
l'insémination artificielle et la transplantation embryonnaire alors que d'autres technologies de 
pointe faisaient leur apparition. 
En effet, une modification plus sélective du génome a été récemment apportée par l'insertion de 
gènes contrôlant la croissance dans le patrimoine héréditaire des animaux producteurs d'aliments. 
Une intervention encore plus sélective sur le système physiologique contrôlant la croissance a 
consisté à modifier le niveau de ses différents constituants. Cela a pu être réalisé, par exemple, en 
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administrant directement de la somatotropine et de la somatocrinine (GRF: growth hormone 
releasing factor). 
La dernière acquisition permettant d'intervenir sur l'axe somatotrope provient des techniques 
d'immunisation. La potentialisation de l'effet de la somatotropine et la neutralisation de l'effet de 
la somatostatine ont été rendues réalisables grâce aux anticorps. 
Evaluation des critères de sécurité et de rentabilité 
Le mode d'action commun de ces technologies conduit de plusieurs façons à des effets 
comparables sur les animaux cibles, leurs produits et l'environnement. Il paraît donc justifié de les 
étudier dans leur ensemble pour leurs dénominateurs communs. 
Durant ces dernières années, les biotechnologies ont permis de fournir à la recherche 
zootechnique les différents éléments clefs de l'axe somatotrope, de façon séparée, ce qui a conduit 
à une meilleure compréhension de leurs effets. 
L'accumulation rapide de nouvelles données scientifiques augmente les possibilités d'analyse 
des implications potentielles des trois types de technologies nouvelles impliquées dans le contrôle 
de la croissance, qui ont été mentionnées dans le paragraphe précédent. 
L'introduction d'innovations dans le domaine de la production animale a déjà montré par le 
passé et de façon répétée que leur réalisation conduit facilement à de profondes divergences 
d'opinion quant à leur agrément. Leur innocuité pour le consommateur a été un objectif primordial 
pendant longtemps. Plus récemment leur innocuité pour l'animal cible, l'impact sur 
l'environnement et les répercussions sur les structures de système de production ont aussi été pris 
en considération. 
Les questions concernant le seuil d'admissibilité des nouvelles technologies ont souvent été 
définies assez tardivement au cours de leur évolution. Le manque d'attention sur la nature de ces 
questions a empêché leur prise en compte effective dans les protocoles expérimentaux. Le résultat 
en a été que les réponses adéquates ont été apportées avec retard et à un coût plus élevé que 
nécessaire. 
Pour une meilleure concertation entre recherche et réglementation des applications de ces 
technologies, l'organisation régulière de consultations internationales réunissant les diverses 
parties impliquées de la communauté scientifique paraît absolument nécessaire. Une telle 
consultation a été réalisée lors de ce symposium. 
L'état des connaissances actuelles est passé en revue et les priorités de la recherche future sont 
définies par la confrontation entre scientifiques des universités, groupes de recherche de l'industrie, 
et institutions impliquées dans les problèmes de réglementation. L'aide financière et la participation 
de ces 3 catégories illustrent bien la compréhension partagée de la nécessité d'une telle évaluation 
scientifique commune. 
De plus, ce symposium pourrait contribuer également à l'harmonisation de l'implantation de ces 
technologies de pointe dans des secteurs géographiques stratégiques. Les conséquences néfastes 
des différences entre ces régions quant aux critères d'agrément et de réglementation n'ont pas 
besoin d'être énumérées pour démontrer l'urgence d'une évaluation scientifique commune. 
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FRENCH RESUME 
BIOTECHNOLOGIE, COBPETITIVITE ET AGREMENT: 1'ENJEU POUR 
L'EUROPE 
Mark F. Cantley 
Directeur de L'Unité de Concertation pour la Biotechnologie en Europe (CUBE: 
Concertation Unit for biotechnology in Europe) Commission des Communautés 
Européennes 
(Les opinions exprimées n'engagent que l'auteur. Aucun énoncé de la politique de la 
Commission n'est clairement exposé, si ce n'est ce qui fait référence à des documents officiels). 
Résumé 
L'auteur n'est pas un spécialiste en biologie, mais il est impliqué dans la conception et 
l'application d'une stratégie des biotechnologies en Europe. Les questions concernant les 
implications et les critères d'agrément ont été à l'ordre du jour depuis quelques années, 
particulièrement en ce qui concerne les applications à l'agriculture des progrès récents de la 
recherche en biologie et des biotechnologies. / 
La stratégie communautaire est présentée dans ses grandes lignes: la compétitivité à l'échelon 
international en est son orientation principale, ce qui permet de renforcer la poursuite des objectifs 
plus vastes du traité de la CEE. Les critiques publiques et politiques des biotechnologies ajoutent 
d'autres dimensions à cette notion, telles que l'écologie, les impacts économico-structurels sur 
l'agriculture, le bien-être de l'animal, les aspects éthiques, les droits et la sécurité des 
consommateurs. Ceux qui se sentent menacés ou outragés pour un de ces points cherchent des alliés 
parmi les autres. 
Dans ce vaste contexte, les problèmes liés à cette prise de conscience générale et aux critères de 
valeur sociaux ou culturels compliquent les priorités généralement accordées à la compétitivité 
économique, sans toutefois nier les bienfaits de l'innovation et de la compétition au sein d'une 
structure globale commune basée sur une perception partagée des intérêts communs - que ce soit 
dans un système mondial de commerce libéral sous le contrôle du GATT ou bien avec des 
contraintes acceptées au bénéfice général de l'écosystème (cf. les limitations maintenant admises 
au plan international de la production des chlorofluorocarbones). 
Il est de l'intérêt public que la communication entre les différentes parties intéressées soit la plus 
efficace possible afin d'obtenir un meilleur partage de ces opinions et d'élever le débat public et 
politique 
Mots clefs: biotechnologie, Communauté Européenne, compétition de marché, agrément, porc. 
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LES "OUTILS" B I O T E C H N O L O G I Q U E S D E R E G U L A T I O N D E LA 
CROISSANCE CHEZ LE PORC 
R. Dean Boyd and Diane Wray-Cahen 
Department of Animal Science 
Cornell University, Ithaca NY 14853-4801 
Résumé 
La croissance est un processus parfaitement orchestré qui implique une multitude d'hormones et 
nécessite des quantités importantes de nutriments. La somatotropine (ST) est une hormone qui 
régule le métabolisme et qui joue un rôle primordial dans le déterminisme de la répartition 
postnatale des nutriments absorbés. Chez le porc en croissance, l'administration de ST exogène 
altère de façon notoire la vitesse et le mode de croissance tissulaire en redistribuant les nutriments 
vers les tissus spécifiques, et ce, de façon hautement coordonnée. Un accroissement sans précédent 
dans la production de tissu maigre a pu être mené de pair avec une diminution de la rétention 
lipidique. Les stratégies qui permettent d'augmenter la concentration sanguine de ce polypeptide 
naturel vont fournir aux producteurs de porcs la possibilité d'augmenter de façon spectaculaire leur 
rendement de production, tout en procurant aux consommateurs un produit alimentaire vraiment 
maigre. Les récentes innovations dans le domaine de la biologie ont fait naître de nouveaux "outils" 
qui vont permettre aux scientifiques d'employer un grand nombre de méthodes pour réguler la 
croissance des animaux. Dans cette revue, nous allons discuter de 5 techniques potentielles qui sont 
actuellement à l'étude, c'est-à-dire l'administration de a) ST exogène, b) secretagogues de la ST, c) 
somatomédine C (IGF-1 - Insulin-like growth factor 1), d) les manipulations immunologiques de la 
sécrétion ou de l'activité biologique de la ST, e) l'insertion de gènes ou la régulation de l'expression 
du génome (i.e. ST, CRF). Dans un futur "proche", l'accélération de la croissance sera réalisée 
grâce à l'administration de ST exogène, de secretagogues de la ST, ou grâce à l'emploi d'anticorps 
spécifiques permettant la potentialisation de l'activité biologique de la ST endogène. En ce qui 
concerne la somatomédine C, de nombreuses questions d'ordre scientifique ne sont tojours pas 
résolues, ce qui ne permet pas son emploi à des fins commerciales. Dans un futur plus "lointain", il 
est fort concevable que les manipulations génétiques de l'axe somatotrope seront en première ligne, 
dans la mesure où les techniques du génie génétique fournissent des méthodes spécifiques et 
sophistiquées permettant le contrôle de l'expression génétique ( i.e. amplification du gène) ou 
l'insertion de gènes (amélioration génétique - ST, GRF). Nous pouvons d'ores et déjà penser que les 
manipulations de l'axe somatotrope seront d'envergure suffisante pour permettre le contrôle de la 
répartition des nutriments et vaincre les réticences du public quant à l'emploi de certaines 
technologies pour la production de viande. Finalement, l'intérêt dominant de la ST réside dans le 
fait qu'elle est devenue une "sonde" inestimable pour mieux comprendre les mécanismes de la 
croissance post-natale et la régulation du métabolisme. 
Mots clefs: biotechnologie, régulation de la croissance, répartition des nutriments, somatotropine, 
somatomédine C (insulin-like growth factor), insertion de gène, porc. 
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BIOTECHNOLOGIES APPLIQUEES AU CONTROLE DE LA 
CROISSANCE ET DE LA QUALITE DU PRODUIT CHEZ LE PORC: 
REGLEMENTATION ET AGREMENT DU PUBLIC. 
P. van der Wal 
Wageningen Agricultural University, Wageningen, Netherlands. 
Résumé 
Le contrôle de la croissance et de la qualité du produit chez le porc peut être réalisé par diverses 
manipulations sur l'axe somatotrope, c'est-à- dire l'administration de ses différents constituants, la 
modulation de leurs effets par les techniques d'immunisation, l'insertion des gènes en question dans 
le génome de l'animal. 
Les réglementations concernant ces trois technologies diffèrent selon le type de technologie, et 
selon les pays. Néanmoins, elles exercent un effet comparable sur les aspects de rentabilité et de 
sécurité d'utilisation par leur mode d'action commun. 
L'harmonisation des critères d'admissibilité de ces technologies est essentielle si l'on veut 
effectivement préserver la sécurité des consommateurs, de l'animal et de l'environnement, tout en 
créant des objectifs bien définis pour la recherche et le développement. Cet enjeu sans précédent 
dans le domaine des sciences animales et des aliments nécessite une coopération internationale, en 
particulier dans le domaine de la recherche. Seuls des efforts communs peuvent permettre de 
répondre aux problèmes généraux de sécurité et de rentabilité posés par ces technologies. Ces 
problèmes n'ont pas de spécificité géographique et ils nécessitent une mise en oeuvre de moyens 
scientifiques et d'expertises spécifiques, qui ont bien sûr leurs limites, où que ce soit. 
La coopération internationale en matière d'expertise dans ces domaines devrait permettre 
l'harmonisation des réglementations internationales et prévenir ainsi toute possibilité de 
mésentente commerciale au plan international. 
Les caractéristiques communes des technologies appliquées à l'axe somatotrope répondent aux 
préoccupations primordiales de la réglementation en vigueur: 
L'efficacité, caractérisée par l'amélioration des rendements de production et de qualité du 
produit, résulte d'une augmentation de la rétention de protéines et d'une diminution du dépôt de 
gras. 
La sécurité du produit, est garantie par la nature protéique des constituants de l'axe 
somatotrope, ce qui les rend plus sensibles à la dégradation par l'intestin ou l'environnement. 
L'agrément du public concernant ces technologies nécessite une information générale tant sur 
leurs contributions potentielles quant au coût et à la qualité des aliments que sur la sécurité 
d'utilisation pour les consommateurs, l'animal et l'environnement. 
Un système de réglementation puissant et bien structuré est absolument nécessaire pour obtenir 
l'agrément des consommateurs. La crédibilité du système dépend de l'amélioration des directives 
et des procedures permettant l'application des décisions réglementaires. 
Mots clefs: contrôle de la croissance, somatotropine, agrément, porc, réglementations. 
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RENTABILITE DE LA PST EN AMERIQUE DU NORD: CRITERES 
D'EXPLOITATION ET AVANTAGES. 
N.C. Steele, R.G. Campbell, T.J. Capema, J,P. McMurtry et M.B. Solomon 
U.S. Department of Agriculture, Agricultural Research Service, Beltsville Agricultural 
Research Center, Nonruminant Animal nutrition Laboratory and Meat Science Research 
Laboratory, Beltsville, MD 20705 USA and Animal Research Institute, Werribee, Victoria 
3030 Australia 
Résumé 
Diverses technologies permettent actuellement de modifier la croissance et la composition 
corporelle des animaux, en particulier en intervenant sur un des maillons de l'axe somatotrope, 
modifiant ainsi la production, la sécrétion ou le metabolisms de l'hormone de croissance (GH). Les 
techniques sont les suivantes: traitement des animaux par une GH exogène, spécifique de l'espèce, 
administration de somatocrinine (GHRF) et autoimmunisation par la somatostatine, 
L'administration de GH ou somatotropine porcine exogène (PST) produit des effets marquants sur 
la croissance et le mode de développement du porc en augmentant le dépôt de tissu maigre avec un 
dépôt de tissu gras minimal. L'intérêt modial que suscite ce type de technologie est basé sur la 
présomption de sa rentabilité sans vraiment tenir compte des systèmes d'exploitation en place. Dans 
le domaine de l'industrie porcine, les systèmes d'exploitation européens favorisent des facteurs 
comme l'alimentation restreinte, la commercialisation de porcs entiers, les mélanges alimentaires 
composés de protéines provenant de sources hétérogènes, la répartition de la production porcine 
pour un marché de porcs lourds ou légers, etc. A l'opposé, le type de production pratiqué en 
Amérique du Nord est en faveur d'une alimentation ad libitum, de la commercialisation de jeunes 
truies et de mâles castrés, d'une consommation élevée de protéines de bonne qualité, enfin d'un 
marché de porcs lourds exclusivement. Dans des expériences récentes, les critères d'exploitation 
affectant la rentabilité de la PST ont été évalués. Selon les résultats obtenus, la PST semble être 
absolument indispensable au développement de tissu maigre aussi bien chez le jeune porc que chez 
le porc à l'engrais. De plus, la prise alimentaire, plus particulièrement la consommation d'énergie 
peuvent limiter la réponse à la PST. Cependant, l'administration de la PST provoque les mêmes 
effets dans les 2 sexes, c'est-à-dire que les truies et les porcs castrés répondent à la PST par des taux 
de rétention protéique comparables à ceux des mâles entiers, Les résultats des recherches en cours 
semblent indiquer que les technologies liées à la PST sont adaptées aux systèmes d'exploitation 
actuels, mais que le type d'exploitation du porc pratiqué en Amérique du Nord semble 
particulièrement propice à son application. Ceci implique que la production de porcs pour 
l'exportation sur le marché mondial deviendra de plus en plus compétitive puisqu'il existe 
maintenant des moyens d'uniformiser la production de porc maigre de haute qualité. 
Mots clefs: porc, hormone de croissance, composition corporelle, systèmes d'exploitation. 
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UTILISATION D E LA SOMATOTROPINE PORCINE R E C O M B I N A N T E 
(rPST) EN EUROPE: ACQUIS ET PERSPECTIVES DE LA RECHERCHE 
1 2 
Vernon R. Fowler and Egbert Kanis 
Rowett Research institute and Schoole of Agriculture, University of Aberdeen, Scotland. 
Wageningen Agricultural University, The Netherlands 
Résumé 
La production porcine en Europe se situe dans un contexte particulier sur le plan agricole, social 
et scientifique. Depuis plusieurs années, d'énormes efforts ont été fournis pour produire des porcs 
qui aient une bonne efficacité alimentaire et qui puissent aussi répondre aux normes de qualité 
fixées par le transformateur. Le problème majeur est de déterminer si l'utilisation de rPST améliore 
de façon significative la rentabilité dans les conditions de production qui prévalent en Europe. 
Les expériences menées dans les élevages européens dans différents centres des Pays Bas, 
d'Allemagne de l'ouest et du Royaume Uni (Ecosse), ont montré clairement que l'utilisation de 
rPST améliorait considérablement la vitesse de croissance, l'efficacité alimentaire et 
particulièrement la teneur en tissu maigre des carcasses. L'augmentation la plus spectaculaire a été 
celle du taux de dépôt de tissu maigre et de la rétention quotidienne d'azote. Ces faits ont été 
constatés pour toutes les catégories de poids entre 35 et 140 kg et dépendent de la période et de la 
dose administrée. 
Dans le travail réalisé en Ecosse, où les traitement ont été appliqués entre 35 et 95 kg de poids 
vif, pour une dose très élevée de 7 mg rPST/jour et un apport de protéines de 190g/kg, le gain 
moyen quotidien du groupe traité était de 20 % supérieur à celui du groupe témoin, et la teneur en 
azote de la carcasse augmentée de 10 %" Dans l'étude effectuée en les Pays Bas sur les bilans azotés 
en alimentation restreinte, l'accroissement du gain moyen quotidien était de plus de 10 %, 
l'augmentation du gain protéique quotidien d'environ 30 % et la diminuition du dépôt quotidien de 
gras d'environ 10 %, même chez le Piétrain. Dans l'ensemble, l'administration de rPST a entraîné 
une réduction de l'ingestion spontanée d'environ 5 % sauf dans l'expérience Néerlandaise menée 
en conditions d'alimentation ad libitum, où l'ingestion spontanée était augmentée de 8 % dans le 
cas des porcs Piétrain ou des porcs croisés, pour la période 100-140 kg de poids vif. 
La teneur en protéines des régimes s'est révélée être un facteur important pour que les effets de 
l'administration de rPST sur le dépôt de protéines puissent pleinement s'exprimer. Il existe 
maintenant d'immenses possibilités de réalisation d'expériences modèles permettant de trouver la 
meilleure combinaison possible entre génotype, régime, poids à l'abattage et administration de 
rPST, afin de tirer les meilleurs avantages de cette nouvelle technologie pleine de promesses. 
Mots clefs: somatotropine, porc, qualité de carcasses, vitesse de croissance, efficacité alimentaire, 
Europe. 
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PERSPECTIVES D'UTILISATION DE LA SOMATOTROPINE PORCINE 
POUR LES PORCS CHINOIS 
K.F. Fung et S.Z. Qi 
South China Agricultural University, Canton, China 
Beijing Agricultural University, Beijing, China 
Résumé 
La somatotropine porcine a été administrée à 44 porcs chinois de race Large Black-White et 
croisés Landrace dans la province de Guangdong. Les effets sur le gain moyen quotidien ont été 
plus importants en FI (+15,3 %) qu'en F2 du croisement d'absorption (+11,3 N). Cependant, ce 
dernier groupe présentait beaucoup moins de lard dorsal (-19,2) et beaucoup plus de tissu maigre 
(+17,0%) que le premier groupe (-10,7 % et + 9,8 %). 
La somatotropine porcine a également été administrée à Beijing à 48 porcs de race Beijing 
Black, en cours de finition tardive. Les porcs dont les régimes étaient composés de 18 % de 
protéines brutes ont présenté un gain moyen quotidien, un indice de consommation et un dépôt de 
tissu maigre plus importants que ceux qui recevaient des régimes à 16 % ou 14 % de protéines 
brutes. 
Les résultats semblent projeter un nouvel éclairage sur les races chinoises qui pourraient, grâce 
à l'administration de somatotropine porcine, accroître leur gain de poids quotidien, leur indice de 
consommation, la teneur corporelle en tissu maigre et réduire l'épaisseur de leur lard dorsal. 
Mots clefs: somatotropine, porc, vitesse de croissance, efficacité alimentaire, Chine. 
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MODIFICATION DIRECTE DU GENOME ANIMAL 
Thomas E. Wagner, Ph.D. Director 
Edison Animal Biotechnology Center, Ohio University, Athens, Ohio 45701 U.S.A. 
Résumé 
Les méthodes actuelles utilisées pour l'introduction de gènes dans les lignées germinates 
d'animaux de laboratoire ou d'intérêt zootechnique sont passées en revue. Les méthodes 
comprennent le transfert direct de gènes par microinjection dans le pronucleus des oeufs fertilisés, 
l'infection des embryons par les retrovirus vecteurs, et la production d'animaux à partir de cellules 
souches embryonnaires multipotentes en culture continue. Bien que des animaux transgéniques 
(porcs) n'aient été obtenus de nos jours qu'à l'aide de la méthode de microinjection dans le 
pronucleus, l'utilisation d'une lignée de cellules-souches embryonnaires de porc qui permettrait la 
production de porcs transgéniques ou clones, est envisagée. Les caractères phénotypiques des porcs 
transgéniques exprimant l'hormone de croissance sont discutés en détail, que ce soient les 
caractères positifs, liés à la réduction de 50% ou plus de la graisse corporelle ou l'amélioration de 
30% ou plus de l'indice de consommation, ou les caractères négatifs dûs à des inconvénients plus 
marqués de structure et à la plus grande sensibilité au stress. Les effets négatifs de l'expression de 
l'hormone de croissance chez les porcs transgéniques pourraient être surmontés si la période 
d'expression de l'hormone de croissance était limitée dans le temps à une partie de la vie de ces 
animaux. Avec cet objectif à l'esprit, des chimères de gènes contenant le promoteur de la 
P-enolpyruvate carboxykinase (PEPCK) lié au gène de structure de l'hormone de croissance bovine 
(bGH) ont été introduites dans des lignées germinales de souris et de porcs. Les résultats confirment 
que l'expression de l'hormone de croissance chez ces animaux ne se produit pas pendant le 
développement embryonnaire et qu'elle peut être contrôlée par le régime alimentaire. Ainsi, chez la 
souris, des régimes riches en glucides réduisent de 5 % la concentration sérique en bGH par rapport 
aux taux de base, alors que la reingestion d'un régime riche en protéines mais dépourvu de glucides 
augmente de 20 fois la bGH sérique en l'espace d'une semaine. Les études de l'impact du régime 
alimentaire sur l'expression de la bGH sont en cours chez le porc, mais il semblerait que les porcs 
transgéniques exprimant le PEPCK/bGH ne présentent pas les mêmes inconvénients que les porcs 
transgéniques exprimant l'hormone de croissance sous le contrôle d'un promoteur constitutif. 
Mots clefs: Transfert de gènes, croissance, porc, régulation, promoteur 
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T E C H N O L O G I E S UTILISANT LA SOMATOTROPINE: IMPLICATIONS 
EN SELECTION PORCINE 
Egbert Kanis 
Wageningen Agricultural University, Department of Animal Breeding, P.O. Box 338, 6700 
Wageningen, The Netherlands 
Résumé 
L'emploi de techniques biotechnologiques actuelles et futures pour le contrôle de la croissance 
et de la composition corporelle des porcs aura des répercussions importantes sur les programmes de 
sélection. Cela est en particulier le cas des technologies faisant appel à la somatotropine, cette 
hormone ayant des effets positifs considérables sur l'indice de consommation et la composition 
corporelle des animaux. L'effet de l'administration de somatotropine porcine (PST) et l'utilisation 
d'animaux transgéniques pour le gène de la somatotropine, vont être traités dans ce rapport. 
L'administration de PST à grande échelle peut avoir des conséquences indirectes sur l'intensité 
de sélection et la réponse génétique. Les caractéristiques génétiques recherchées et leurs valeurs 
économiques doivent être réévaluées. Dans le cas d'interactions entre le génotype et 
l'administration de PST, il est recommandé d'administrer la PST aux animaux reproducteurs de 
base lors du contrôle de performances. Les paramètres génétiques et phénotypiques (héritabilités et 
corrélations) devraient être réestimés. 
La PST offre de nouvelles possibilités d'introduction de races (chinoises) hautement prolifiques 
en tant que lignées maternelles dans les programmes de sélection. L'influence négative des 
génotypes chinois sur la composition des carcasses peut être contrebalancée par l'utilisation de 
PST. L'administration de PST conduit à une augmentation du poids optimum à l'abattage et à une 
diminution du nombre de porcs à produire par an dans le cas d'une production fixe de viande de 
porc. Il en résulte que le nombre de truies diminue ainsi que le coût de production. 
Le transfert du gène de la somatotropine dans la lignée germinale chez le porc pourrait avoir les 
mêmes répercussions sur la croissance et la composition corporelle que l'administration de PST. 
Cependant, il faut signaler que l'emploi de porcs transgéniques aura des conséquences énormes sur 
la stratégie de sélection dans les troupeaux de base. La variation entre les animaux souches 
transgéniques créés risque d'être élevée et beaucoup d'animaux vont être réformés à cause de 
caractéristiques négatives. Les transgéniques restants devraient être utilisés de façon très intensive 
pour la reproduction, ce qui sera à l'origine de problèmes de faible taille de population. La 
recherche d'homozygotie dans le produit fini commercial et l'introduction ou non d'autres gènes 
étrangers dans des lignées déjà transgéniques pour le gène de somatotropine, déterminent la 
stratégie optimale de sélection. 
En conclusion, soulignons que le développement et l'introduction des transgéniques dans le 
noyau d'un programme de sélection porcine revêt une importance capitale et demande une 
recherche intensive. Une telle entreprise ne peut être menée à bien que si les organisations 
d'élevages réunissent leurs efforts dans une action commune. 
Mots clés: Somatotropine, transgéniques, sélection porcine 
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IMPLICATION DE LA SOMATOTROPINE DANS L'INDUSTRIE DE LA 
TRANSFORMATION DE LA VIANDE PORCINE 
F.K. McKeith, PJ. Bechtel et J. Novakovski 
University of Illinois, Urbana, IL U.S.A. 
Résumé 
L'industrie de la transformation de la viande de porc comprend l'abattage ainsi que la découpe 
et le toilettage des carcasses, la préparation des morceaux de viande fraîche et des viandes salées 
ainsi que la fabrication de saucisses. Nos études ont montré que la somatotropine conduira à une 
réduction du gras et à une augmentation de la proportion de maigre chez les porcs en finition. Cette 
évolution de la composition corporelle pourrait affecter certains ou tous les secteurs de l'industrie 
de la viande de porc. Les problèmes potentiels associés à la méthode d'abattage et de toilettage 
impliquent une augmentation de la masse de sous-produits, des difficultés d'écorchage, une 
modification du taux de refroidissement des carcasses et du ressuyage lors du refroidissement. Les 
problèmes potentiels associés à la préparation de pièces ou de morceaux de gros comprennent les 
difficultés de découpe des tissus maigres mous et pliables, la séparation des muscles ou des groupes 
musculaires lors de la préparation des morceaux à détailler et les difficultés rencontrées lors de 
l'écorchement des morceaux en évitant d'exposer la surface musculaire. La proportion accrue de 
masse maigre affectera la teneur en eau et exigera un changement dans le traitement des produits 
afin d'atteindre les ovectifs recherchés de composition et de conservation à l'étalage. L'évolution 
de la composition et de l'épaisseur de la poitrine de porc aura des conséquences pour les fabricants 
de viandes salées, en particulier de bacon (surtout pour le marché Américain). De même, le 
pourcentage de protéines extraites pour la production de jambon sans os devrait être reévalué. Les 
fabricants de saucisses seront concernés par les changements potentiels dans les propriétés de la 
viande telles que la pigmentation, le rapport humidité/protéines, la rétention d'eau, le pH, la teneur 
en protéines myofibrillaires et la composition du gras. 
Il existe un grand nombre de données sur la croissance et la composition corporelle de porcs 
traités à la somatotropine, mais les renseignements concernant les produits de transformation sont 
limités. Selon ces données, les procédures d'abattage et de toilettage des porcs ainsi traités ne 
posent pas de problèmes. Cependant, seulement un nombre très faible de ces porcs ont été soumis à 
des abattages industriels à grande vitesse. Plusieurs équipes de chercheurs ont examiné les 
propriétés de transformation des carcasses; l'amélioration du rendement à la découpe ainsi que de 
la composition des morceaux a été mise en évidence. Nous ne disposons d'aucune information sur 
des problèmes potentiels à l'abattage tels qu'une incidence accrue de PSE (pale soft exsudative 
meat). Les problèmes de salaison et de fabrication de saucisses n'ont pas été étudiés directement; 
cependant, les questions relatives au pH, à la couleur de la viande, à la teneur en gras, aux rapports 
entre humidité et protéines et aux caractéristiques de poitrine ont été examinées et peu de problèmes 
ont été notés. La seule exception concerne l'épaisseur de poitrine qui est en corrélation directe avec 
l'épaisseur du lard dorsal. 
Même si l'utilisation de la somatotropine va conduire à des changements pour les producteurs et 
les transformateurs de viande de porc, nous ne pensons pas qu'elle sera la cause de difficultés 
insurmontables et les problèmes peuvent être traités par la technologie actuelle. 
Mots clés: Somatotropine, rendement à la découpe, transformation, viandes salées, porc 
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MECANISMES PAR LESQUELS L'HORMONE DE CROISSANCE 
PORCINE (pGH) ET LES SOMATOMEDINES (IGF's: Insulin-like growth 
factors) REGULENT LES PERFORMANCES DE CROISSANCE CHEZ LE 
PORC: DU RECEPTEUR A L'ANIMAL ENTIER. 
T.D. Ethertoiï 
Department of Dairy and Animal Science, University Park, PA 16802 U.S.A. 
Résumé 
La GH porcine est une hormone naturelle qui présente une large panoplie d'effets chez le porc. 
Le traitement des porc en croissance par l'hormone de croissance porcine (pGH) augmente de façon 
spectaculaire les performances de croissance de l'animal (i.e. gain moyen quotidien, indice de 
consommation, composition des carcasses). Les actions biologiques de la pGH peuvent 
schématiquement être classées en 2 catégories, somatogéniques ou métaboliques. Dans ce chapitre, 
je discuterai de quelques mécanismes par lesquels la pGH affecte la croissance et le métabolisme. 
La discussion aura pour thèmes 1) les effets de la pGH sur la croissance et le métabolisme du tissu 
adipeux 2) le rôle de la pGH et de la somatomédine C (IGF-1) sur la stimulation de la croissance 
musculaire 3) les mécanismes impliqués dans l'hyperglycémie et l'hyperinsulinémie des porcs 
traités de façon chronique par la pGH 4) les arguments en faveur d'un double rôle des protéines 
liant les IGF-1 (IGF-BP,): transport des IGF, dans la circulation générale, mais aussi modulation de 
leur activité biologique et 5) la signification de la séquence d'acides aminés récemment établie à 
partir de clones d'ADNc qui codent pour les récepteurs de la GH de l'homme et du lapin. 
Bien qu'il soit évident à l'heure actuelle que la pGH modifie la composition corporelle des 
animaux, les mécanismes biologiques par lesquels elle opère ne sont toujours pas élucidés. Il existe 
peu d'informations quant à la façon dont le récepteur de la pGH génère des signaux chimiques et 
sur la nature des molécules qui servent de médiateurs intracellulaires pour l'expression des effets 
biologiques de la pGH. Dans la mesure où notre compréhension des mécanismes d'interaction entre 
pGH et son récepteur s'affine, il devrait bientôt être possible d'établir quels sont les acides aminés 
de la pGH qui permettent sa liaison à son récepteur. Cette information permettrait de "créer" des 
analogues de la pGH qui auraient une plus grande activité biologique. Ainsi, les effets constatés à 
l'heure actuelle quant au traitement des porcs par la pGH exogène ne représentent en fait que la 
première étape d'une série de démarches qui conduiront à des moyens économiques et rentables de 
manipulation des performances de croissance. 
Mots clefs: somatotropine, somatomédines (insulin-like growth factors), croissance, régulation, 
porc 
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I N F L U E N C E DE LA S O M A T O T R O P I N E P O R C I N E SUR LE 
METABOLISME ENERGETIQUE DU PORC 
M.W.A. Verstegen, W. van der Hel, E.J. van Weerden 
Agricultural University Wageningen and Institute of Animal Nutrition and Physiology, 
ILOB, Wageningen, The Netherlands 
Résumé 
L'administration à des porcs de somatotropine exogène a été étudiée pour ses effets sur le dépôt 
de protéines et de gras et sur le taux métabolique. La rPST a été appliquée pendant 10 semaines à 3 
génotypes de porcs (Piétrain, Duroc et croisés Landrace Néerlandais x Yorkshire Néerlandais), à 
partir de 55 kg. Les animaux ont tous reçu le même niveau d'alimentation (2.6 fois le niveau 
d'entretien). Comparés aux animaux témoins, le gain de poids corporel était augmenté d'environ 
lOOg/jour. Le gain protéique augmentait de 40g/jour/animal et le gain de gras diminuait de 40 
g/jour/animal. 
L'administration de rPST conduisait à une augmentation du taux métabolique de 46 
KJ/kg0.75/jour (7.7%). Divers aspects de cette augmentation ont été discutés/ Si l'efficacité 
partielle de synthèse des protéines et de la matière grasse à partir de l'énergie métabolisable n'était 
pas modifiée, les dépenses d'entretien (EMe: énergie métabolisable pour l'entretien) en présence de 
rPST augmentaient de 393 à 451 KJ d'énergie métabolisable (EM) par kg0.75. 
Quand l'augmentation du taux métabolique était associée à une diminution de l'efficacité 
énergétique partielle de synthèse des protéines (kp) et non à l'entretien, l'efficacité énergétique du 
gain protéique diminuait de: 
kp = 0.59 (animaux témoins) à 
kp = 0.48 (animaux traités par PST) 
Une troisième possibilité d'augmentation du taux métabolique aurait pu être celle qui est 
associée à la rétention de gras. En supposant qu'il n'y ait pas d'effet sur l'entretien et la synthèse 
protéique, l'efficacité énergétique partielle pour le gras (kf) serait alors de: 
kf = 0.68 (animaux traités) 
kf = 0.77 (animaux témoins) 
Les conséquences de l'augmentation du taux métabolique pour les dépenses thermiques, ont 
également été discutées. Une diminution de l'adiposité corporelle aurait pour résultat un 
amincissement de la couche de gras sous-cutané et une moindre isolation thermique. Il est 
indispensable d'évaluer quelle pourrait être l'importance des conséquences de ces effets combinés 
(augmentation de la production de chaleur et diminution de l'adiposité) sur les limites inférieures 
de thermoneutralité. Un taux métabolique plus élevé diminuerait la limite supérieure de la tolérance 
thermique. De plus amples investigations devront être menées afin de déterminer les conséquences 
nutritionnelles des modifications des dépôts de gras et de protéines. 
Mots clefs: somatotropine porcine, taux métabolique, entretien, efficacité partielle, porc. 
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REPERCUSSIONS DES TECHNIQUES BIOTECHNOLOGIQUES VISANT 
A LA MANIPULATION DE LA CROISSANCE ET DU DEVELOPPEMENT 
DES ANIMAUX SUR LES BESOINS NUTRITIFS TISSULAIRES ET 
ALIMENTAIRES CHEZ LE PORC. 
R.G. Campbell, RJ. Johnson et R.H. King 
Animal Research Institute, Werribee, Victoria 3030, Australia 
Résumé 
L'administration de somatotropine porcine exogène (PST), de facteurs de libération de la 
somatotropine, mais aussi probablement d'IGF-1 augmente les taux de dépôts protéique et minéral, 
ce qui a pour résultat un développement plus rapide du squelette, une amélioration des 
performances de croissance et une diminution de la teneur en gras de la carcasse. Cependant, les 
effets de ces technologies sur les besoins alimentaires chez le porc en croissance restent obscurs. 
Pour des porcs de 30 à 60 kg, l'administration de PST exogène augmente la rétention protéique de 
25 à 40 %. Cependant, du fait de l'amélioration de l'efficacité d'utilisation des acides aminés par 
des mécanismes demeurés inconnus, le traitement a peu de répercussions sur les niveaux de 
protéines et d'acides aminés alimentaires nécessaires pour permettre des performances de 
croissance presque maximale. Par contre, l'administration de PST à des porcs entre 60 et 100 kg de 
poids vif augmente la rétention protéique de 50 à 80 % (selon le sexe de l'animal) avec une 
augmentation concomittante de 30 à 45 % du niveau de protéines (acides aminés) alimentaires 
nécessaires à des performances de croissance presque maximales. La stimulation du métabolisme 
protéique induite par la PST se fait par l'intermédiaire de IGF-1 qui sert de médiateur et résulte de 
l'augmentation des taux de synthèse et de dégradation des protéines. Cependant, pour pleinement 
évaluer quelles sont les répercussions de la PST, et des technologies qui lui sont rattachées.sur les 
besoins en nutriments, des informations supplémentaires sont indispensables sur l'amplitude de 
l'augmentation des taux de rétention protéique et minérale qui peut être obtenue avec ce type de 
technologie et sur les modifications associées du métabolisme intermédiaire minéral et celui des 
acides aminés. 
Mots clefs: somatotropine, porc, besoins nutritifs, protéines, substances minérales. 
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EFFETS DE LA SOMATOTROPINE SUR LE SYSTEME IMMUNITAIRE 
Keith W. Kelley et Carl K. Edwards, III 
Laboratory of Immunophysiology, Department of Animal Sciences, 162 ASL, 1207 West 
Gregory Drive, University of Illinois 61801 U.S.A. 
Résumé 
Il a longtemps été suggéré que la somatotropine affectait les cellules du système immunitaire. 
On sait maintenant qu'elle accroît la taille du thymus, qu'elle augmente certaines activités des 
cellules lymphoïdes, qu'elle amorce la libération des dérivés oxygénés actifs des macrophages et 
qu'elle augmente la différenciation des neutrophiles et des erythrocytes. La somatotropine est 
même synthétisée par les cellules lymphoïdes. Ces découvertes récentes suggèrent qu'en plus de 
l'augmentation de la vitesse de croissance et de la production laitière, la somatotropine module 
aussi les activités fonctionnelles des lymphocytes et des macrophages. 
Mots clefs: somatotropine, lymphocytes, macrophages, granulocytes. 
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EFFETS SECONDAIRES POTENTIELS DE LA SOMATOTROPINE 
EXOGENE CHEZ LE PORC 
Stanley E. Curtis 
Animal Sciences Department, University of Illinois, Urbana IL 61801, U.S.A. 
Résumé 
Deux aspects spécifiques à la nature du porc et qui pourraient être modifiés par la somatotropine 
exogène sont respectivement sa thermorégulation (et donc les exigences thermiques pour son 
environnement) et son comportement alimentaire (c'est-à-dire l'aménagement des porcheries et des 
systèmes d'alimentation). L'administration de somatotropine exogène à un porc de 75 kg aurait 
pour effet net une augmentation de 6oC de la température minimale critique effective de son 
environnement et une diminution de plusieurs degrés de sa température critique maximale. Ainsi, le 
porc serait plus sensible aux limites thermiques à la fois supérieures et inférieures de son 
environnement. La réduction importante de la consommation de nourriture chez les porcs traités par 
la somatotropine exogène pourrait être due au stress thermique, aux problèmes sociaux ou à la 
mauvaise adaptation de l'accès à la nourriture. Ces différents aspects devraient être examinés afin 
de trouver les moyens d'y remédier. 
Mots clefs: porc, somatotropine, environnement thermique, environnement social, aménagement 
des systèmes d'alimentation, consommation de nourriture. 
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R E P E R C U S S I O N S DES N O U V E L L E S T E C H N O L O G I E S P O U R 
L ' A M E L I O R A T I O N DES P E R F O R M A N C E S DE C R O I S S A N C E SUR LA 
R E P R O D U C T I O N ET LA L A C T A T I O N C H E Z L E P O R C 
B.N. Day, Steve Terlouw et August Rieke 
Department of Animal Science, University of Missouri-Columbia, Columbia, MO 65211 
U.S.A. 
Résumé 
De nouvelles biotechnologies sont apparues dernièrement et se sont révélées des moyens 
efficaces pour modiner considérablement la croissance et la composition des carcasses des porcs en 
croissance-finition. Les récents progrès dans le domaine de l'insertion des gènes ont abouti à la 
production d'animaux transgéniques utilisés pour la reproduction; des descendants ont ainsi été 
produits. Cependant, des problèmes majeurs ont été observés concernant la reproduction des verrats 
et des jeunes truies transgéniques exprimant l'hormone de croissance humaine, y compris 
l'anoestrus et l'absence de libido. Il existe peu de données suggérant que la courbe de lactation des 
truies puisse être modifiée et la production laitière augmentée par le traitement à l'hormone de 
croissance porcine hypophysaire (pCH) ou à l'hormone de croissance porcine recombinante 
(rPST). 
Des troubles de la reproduction, y compris une puberté retardée et des follicules kystiques, se 
sont produits quand les jeunes truies ont été traitées quotidiennement par la pGH à une période 
proche du démarrage de la maturité sexuelle, ou durant la phase de prooestrus du cycle oestrien. Par 
contre, il ne s'est pas produit d'effet négatif sur l'intervalle entre présentation au verrat et oestrus, 
l'âge de la puberté, la proportion des jeunes truies atteignant la puberté avant un âge de 240 jours, 
ou le taux de gestation, quand les jeunes truies ont été traitées par injection quotidienne de 
spmatotropine porcine recombinante (rPST) pendant la phase croissance-finition (50 à 110 kg de 
poids corporel). De même, le taux de gestation et le nombre moyen d'embryons au 25e jour de 
gestation n'ont pas été modifiés par l'administration de rPST entre le 4e et le 18e jour de gestation. 
Ces résultats indiquent que les performances de reproduction des jeunes truies suivant 
l'administration de rPST durant la phase croissance-finition ne sont pas affectées. 
Mots clefs: porc, reproduction, hormone de croissance. 
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BIOTECHNOLOGIES ET CONTROLE DE LA CROISSANCE ET DE LA 
QUALITE DU PRODUIT CHEZ LE PORC: SECURITE DES PRODUITS 
COMESTIBLES 
H.A. Norcross, R.A. Carnevale, E.A. Brown, A.R. Post 
United States Department of Agriculture, Food Safety and Inspection Service, Washington, 
D.C. 20250 
Résumé 
Bien que la plupart des pays développés jouissent d'une alimentation riche en protéines, la 
nécessité de technologies qui améliorent la qualité et la quantité des protéines alimentaires est 
ressentie par une partie importante de la population mondiale. L'utilisation des produits 
pharmaceutiques visant à accélérer la croissance et améliorer l'efficacité alimentaire, 
conjointement à l'amélioration des facteurs génétiques et nutritionnels, a permis de fournir de plus 
importantes quantités de protéines alimentaires à un nombre d'individus plus grand que jamais. Les 
anabolisants, malgré une publicité parfois défavorable, ont été particulièrement avantageux pour 
améliorer l'indice de consommation des animaux. 
La synthèse protéique et sa régulation ont fait l'objet de recherches intensives en génétique, tant 
au plan biochimique que moléculaire. La corrélation qui existe entre les produits de gènes 
spécifiques, tels que les somatotropines, et l'augmentation de la vitesse de croissance, de 
l'efficacité alimentaire et de la répartition matières grasses/protéines a suscité un grand intérêt 
comme représentant une possibilité de contrôle artificiel de la synthèse protéique chez les animaux 
d'élevage. La somatotropine, et les composés afférents, c'est-à-dire les somatostatines, 
somatomédines, et somatocrinines (growth hormone releasing factors), sont les premiers produits 
de la technologie des DNA recombinants qui pourraient être économiquement rentables pour 
augmenter le rendement de production agricole nationale et mondiale. 
Si de tels produits doivent être employés aux Etats-Unis, une approbation doit être obtenue de la 
FDA (United States Food and Drug Administration). La sécurité et la rentabilité de ces produits 
doivent être démontrées par des études scientifiques bien contrôlées et bien conçues. 
La somatotropine, la somatomédine et d'autres facteurs, en particulier les facteurs de libération 
ont été employés dans de nombreux protocoles expérimentaux et soumis à l'approbation de la FDA 
comme étant de nouveaux produits pharmaceutiques à l'étude pour la production animale. La 
réglementation de l'emploi de ces nouveaux agents dans le cadre d'une étude pharmacodynamique 
et une surveillance continue après approbation doivent constituer une protection suffisante pour la 
santé publique et garantir la bonne adaptation des produits à l'utilisation proposée ainsi que leur 
efficacité chez les espèces animales considérées. 
Mots clefs: biotechnologies, somatotropine, santé publique, rentabilité, réglementation. 
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APPARITION POTENTIELLE DE RESIDUS APRES T R A I T E M E N T DES 
PORCS AVEC DE LA SOMATOTROPINE RECOMBINANTE 
D. Schams 1 , E. Kanis 2 et P. van der Wal 2 
Institut fur Physiologie, Technische Universität München 8050 Freising- Weihenstephan, 
FRG and 
Animal Science Departments, Agricultural University of Wageningen, Netherlands. 
Résumé 
Ces dernières années, la somatotropine porcine recombinante (rPST) s'est montrée 
particulièrement rentable pour l'amélioration des caractéristiques de croissance telles que le gain 
moyen quotidien, l'efficacité alimentaire et la faible adiposité des animaux traités. Cette étude rend 
compte de la première tentative d'évaluation des concentrations sanguines et tissulaires de PST, 
ainsi que des concentrations sanguines d'IGF-1 avant et au moment de l'abattage des porcs traités 
àlarPST. 
Dans l'essai nol (94 porcs), cinq paramètres ont été examinés: trois races (Piétrain, Duroc et FI 
de Great Yorkshire x Landrace Néerlandais) quatre portées par race; deux sexes (mâles castrés et 
jeunes truies); deux traitements (rPST et placebo); deux poids à l'abattage (100 kg,et 140 kg). Le 
traitement (bihebdomadaire, 14 mg de rPST dissous dans un tampon arginine HCl en injections 
intramusculaires) commençait à 60 kg de poids vif. Le sang de la veine jugulaire était collecté à 
l'abattage, 4 jours 1/2 après la dernière injection. Dans l'essai no 2, 36 mâles castrés de trois races 
différentes (Piétrain, Duroc et FI) ont été traités de 60 à 120 kg de poids vif par de la rPST deux fois 
par semaine à raison de 14 mg par injection i.m. Le sang de la veine jugulaire était collecté dans 
l'heure suivant la dernière injection et 26 - 27 h après, à l'abattoir. En outre, du tissu musculaire 
provenant de l'épaule droite de 10 porcs (7 traités, 3 placebo) a été collecté, afin d'être analysé pour 
sa teneur éventuelle en résidus de PST. 
La somatotropine porcine et l'IGF-1 ont été évalués par RIA. 
Dans l'essai nol, 4 Jours 1/2 après la dernière injection de rPST, les concentrations sanguines de 
PST chez les animaux traités étaient similaires à celles des animaux témoins, ou significativement 
plus basses dans les races Piétrain et Duroc. Dans l'essai no 2, dans l'heure suivant la dernière 
injection, il y avait une augmentation moyenne spectaculaire des concentrations sanguines de rPST 
de 2 ng/ml jusqu'à 240-321 ng/ml. Vingt-six à vingt-sept heures après, les valeurs trouvées chez les 
animaux traités avaient déjà diminué jusqu'au niveau des valeurs témoins. Les concentrations 
tissulaires n'étaient pas significativement différentes et étaient inférieures à 5 ng/g tissu humide. 
Les concentrations sanguines d'IGF-1 n'étaient pas significativement différentes entre animaux 
témoins et animaux traités, dans l'essai no 1 et dans l'essai no 2 dans l'heure suivant la dernière 
injection. Par contre, les concentrations étaient significativement plus élevées 26 - 27 h après. En 
conclusion, aucun résidu mesurable de la PST ou de l'IGF-1 n'a été trouvé dans le sang ou le 
muscle des animaux traités à la rPST, 4 à 5 jours après la dernière injection. 
Mots clefs: somatotropine, insulin-like growth factors, résidus, porc. 
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C A R A C T E R I S T I Q U E S NUTRITIONNELLES ET O R G A N O L E P T I Q U E S 
DE LA VIANDE DE PORCS TRAITES PAR LA SOMATOTROPINE 
K.J. Prusa 
DepartemEt of food and nutrition, Iowa State University, Ames, Iowa 50011 U.S.A. 
Résumé 
Bien qu'il existe des différences mesurables dans la composition nutritionnelle et la qualité 
organoleptique de la viande de porcs qui ont été traités ou non par la somatotropine, aucun 
problème majeur n'a été mis en évidence. Selon plusieurs études, la teneur en matière grasse 
intramusculaire est abaissée par l'administration de somatotropine porcine (PST). Une teneur 
intramusculaire en matières grasses de moins de 1 % due au traitement par la PST a même été 
signalée. Dans les études qui décrivent une diminution de la graisse musculaire, les contenus 
protéiques et hydriques du tissu musculaire sont légèrement augmentés. Par contre, aucune 
différence n'a été notée dans les profils d'acides gras ou dans la teneur en cholesterol du muscle 
long dorsal chez les animaux traités jusqu'au jour de l'abattage. Toutefois, la teneur en acides gras 
polyinsaturés de la viande de porc crue et la teneur en cholesterol de la viande de porc cuite se sont 
avérées un peu plus élevées chez les animaux dont le traitement avait été suspendu 7 jours avant 
l'abattage. Les concentrations tissulaires en thiamine avaient une tendance à diminuer légèrement 
en réponse au traitement par la PST. Plusieurs études ont signalé que l'administration de PST 
n'avait pas d'effet néfaste sur la qualité organoleptique du muscle long dorsal. Par contre, il a été 
noté une diminution minimale de la tendreté du muscle, de sa succulence et de l'intensité de sa 
saveur après un traitement par de la PST à concentration élevée. 
Mots clefs: somatotropine, composition nutrtionnellle, qualité organoleptique, porc. 
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EFFET DE LA S O M A T O T R O P I C PORCINE RECOMBINANTE SUR LA 
QUALITE DE LA CARCASSE ET DE LA VIANDE DE PORCS BELGES ET 
NEERLANDAIS 
D . Demeyer ' , R. Verbeke , G. van de Voorde , J. Fabry , E .Deroover 
,R.H. Dalrymple5 
University of Ghent, Ghent, Belgium; 
University of Brussels, Belgium; 
Agricultural Resarch Centre, Gembloux, Belgium; 
Cyanamid Benlux NV, Mont-Saint-Guibert, Belgium; 
American Cyanamid Company, Princeton, New Jersey, U.S.A. 
Résumé 
Les résultats illustrant les effets de la somatotropine porcine recombinante (rPST) sur la qualité 
de la carcasse et de la viande de porcs belges et néerlandais sont publiés en détail ailleurs et résumés 
ici. Des porcs belges en fin de croissance (60 à 120 kg environ) ont été traités par 4 concentrations 
de rPST (O; 1,5; 3 et 6 mg/jour) en irvections quotidiennes. Ils ont été nourris ad libitum avec un 
régime à base de céréales et riche en protéines (expérience nol). Les porcs néerlandais nourris de la 
même façon, sur une période de croissance-finition similaire, ont été traités avec 0 ou 14 mg de 
rPST, en injections bihebdomadaires (expérience no2). Dans chaque expérience, des données ont 
été collectées concernant les rendements de carcasse et d'organes, la qualité des carcasses le 
rendement à la découpe, la qualité organoleptique de la viande, la composition globale et la 
composition des muscles (expérience no2 seulement). 
Le traitement par la rPST a entraîné une diminution légère des rendements de carcasse, associée 
à une augmentation de poids du coeur, du foie et des reins. La qualité de la carcasse a été 
considérablement améliorée, comme il ressort de la diminution des différentes mesures de gras de 
la carcasse et de l'amélioration de sa classification. Les rendements en viande de la carcasse ont été 
améliorés, avec des réductions concomittantes des morceaux de gras et du toilettage. Aucune 
différence significative n'a été observée en ce qui concerne la baisse des valeurs de pH musculaire, 
mais il semble que les températures aient été plus élevées peu de temps après la mort. Les valeurs 
de pH tardives étaient légèrement, mais significativement, augmentées. Les diverses mesures 
concernant la texture, la couleur et la capacité de rétention d'eau de la viande ont montré que le seul 
effet statistiquement significatif était une couleur légèrement moins rouge. La composition en 
protéines myofibrillaires et la longueur des sarcomeres du muscle long dorsal n'ont pas été 
modifiées, mais la teneur en protéines brutes était légèrement plus élevée. 
Ces études ont montré que l'utilisation de différentes concentrations de rPST peut augmenter le 
rendement en viande et diminuer le gras de carcasse, même chez des races sélectionnées pour une 
composition de carcasse supérieure, et cela sans effet néfaste sur la qualité organoleptique de la 
viande. 
Mots clefs: somatotropine, qualité de carcasse, qualité de viande, poids d'organes, porc 
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L'OPINION DES C O N S O M M A T E U R S SUR LES T E C H N O L O G I E S ET 
BIOTECHNOLOGIES APPLIQUEES A LA PRODUCTION DES ALIMENTS 
Janet Graham 
Consumers in the European Community Group (CECG), London, United Kingdom 
Résumé 
Ceci est le point de vue d'un consommateur britannique. Il n'est pas spécifique à la PST, puisque 
la prise de conscience du consommateur pour ce produit et son application fait encore défaut. 
Néanmoins, la recherche au CECG sur la BST et les autres technologies alimentaires modernes 
nous ont permis de tirer certaines conclusions en ce qui concerne l'opinion du consommateur sur 
ces nouvelles techniques et leurs applications. 
Les consommateurs se sentent de plus en plus concernés par les méthodes modernes en 
agriculture qui reposent sur l'utilisation d'antibiotiques, d'hormones, de pesticides, de protéines 
obtenues par génie génétique, telles que la BST (somatotropine bovine); la PST (somatotropine 
porcine) est donc susceptible de subir un examen semblab)e en temps utile. Quelques-unes des 
réalisations citées ci-dessus ont contribué à nous approvisionner copieusement et de façon 
attrayante en aliments de plus en plus variés mais les progrès ont aussi conduit à une aliénation des 
consommateurs qui ont l'impression que leur nourriture n'est plus "naturelle". 
Il est nécessaire d'établir des critères permettant de juger ces nouveaux procédés, basés 
également sur une estimation des besoins des consommateurs. Ceci revient à examiner si un 
progrès particulier dans ces domaines pourrait être bénéfique au consommateur. Autrement dit, un 
produit sera-t-il plus sûr, moins cher, plus varié, plus facilement disponible, plus durable, mieux 
adapté, mieux conditionné ? Sera-t-il accepté immédiatement, ou va-t-il rencontrer la suspicion des 
consommateurs, conduisant à leur réticence? Si, ce qui semble probable, quelques nouveaux 
développements ou percées scientifiques ont quelque avantage et quelque répercussion pour les 
consommateurs, alors les aspects positifs et négatifs devraient être éclaircis afin que le public puisse 
prendre une décision. 
Les droits des consommateurs dans nos sociétés d'abondance comprennent celui très important 
de pouvoir choisir la nourriture que nous mangeons et de pouvoir faire ce choix après ample 
information: nous ne souhaitons pas que ce choix soit réduit à néant par ceux qui voudraient bannir 
de principe les nouvelles réalisations. De même, pour que ce choix soit circonstancié, les instances 
impliquées dans la production alimentaire et la commercialisation, depuis la recherche jusqu'à la 
vente finale, doivent être mieux préparées à la diffusion d'une information utile et utilisable. 
Mots clefs: biotechnologie, alimentation humaine, consommateurs, opinion, porc. 
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A S P E C T S E T H I Q U E S RELATIFS A L'UTILISATION DES 
BIOTECHNOLOGIES POUR LE CONTROLE DE LA CROISSANCE ET DE 
LA QUALITE DU PRODUIT CHEZ LE PORC 
R. Dantzer 
INRA-INSERM U.259, rue Camille Saint-Saëns, 33077 Bordeaux Cedex 
Résumé 
Le développement des nouvelles biotechnologies pour l'amélioration des performances de 
croissance et de la qualité du produit dans l'industrie du porc suscite de nombreux problèmes, dont 
certains ont des implications éthiques très importantes. Les considérations éthiques quant à 
l'utilisation des biotechnologies pour la production animale doivent être appréhendées à plusieurs 
niveaux. Au niveau de l'animal, deux questions se posent: l'une concerne la perception de l'aspect 
artificiel, et l'autre est liée à l'influence négative possible du traitement sur la santé de l'animal. Au 
niveau professionnel, l'emploi croissant des biotechnologies semble favoriser la subordination des 
chercheurs dans le domaine animal et des vétérinaires à des intérêts économiques, aux dépens de 
leur rôle plus traditionnel de soins à l'animal. Au niveau des consommateurs, le point de vue éthique 
fait appel non seulement à l'éducation mais aussi à la protection et à la liberté de choix. Au niveau 
de la société, les répercussions potentielles des biotechnologies sur les structures 
socio-économiques de la production animale doivent être évaluées. Bien que les biotechnologies 
représentent un grand potentiel pour l'amélioration de la rentabilité de la production animale, une 
analyse approfondie des problèmes éthiques posés par leur introduction dans l'agriculture est 
nécessaire pour les comprendre et les faire accepter par la société. 
Mots clefs: biotechnologie, porc, somatotropic, porc transgénique, éthique. 
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R E P E R C U S S I O N S E C O N O M I Q U E S D E L'UTILISATION DE 
SOMATOTROPINE PORCINE SUR L'INDUSTRIE DU PORC 
M. Hayenga. B.Buhr, K, Skold, S. Johnson, E. Grundmeier 
Iowa State University, Ames, Iowa, United States 
Résumé 
Cette étude fournit une analyse complète des impacts de l'utilisation de la PST dans le domaine 
de la production porcine; elle tente également d'expliquer toutes les répercussions économiques 
dynamiques de l'introduction de la PST. Cependant, il faut rappeler que les résultats obtenus grâce 
à ce travail sont limités par les hypothèses utilisées dans l'analyse, et par la disponibilité limitée des 
données sur la PST. 
L'impact le plus percutant de la PST est la diminution du coût associée à une meilleure 
production de maigre par porc. L'augmentation de la rentabilité qui résulte de l'adoption de la PST 
par les producteurs entraîne une augmentation rapide de la production. Cette augmentation 
provoque une baisse des prix à la fois au niveau de la ferme et de la vente au détail. Du fait de la 
diminution des coûts de production, les producteurs qui adoptent la PST immédiatement récoltent 
des profits plus importants, mais l'industrie dans son ensemble réalise des recettes moins 
conséquentes à mesure que la production accrue fait baisser les prix à la ferme. Du point de vue de 
la rentabilité, l'adoption de cette nouvelle technologie est stimulante pour les producteurs de porcs 
pour deux raisons: à court terme, accroissement des profits; à long terme, avantages compétitifs 
dans l'industrie du porc pour les adoptants comparés aux non-adoptants. De plus, les producteurs 
de porcs regagnent ainsi une partie du terrain cédé aux avancées technologiques dans le domaine de 
la production avicole, durant ces trente dernières années; ils deviennent aussi des interlocuteurs 
plus compétitifs pour le budget du consommateur. Ainsi, les transformateurs et les consommateurs 
bénéficient d'une production plus élevée associée à une baisse des prix, alors que les adoptants 
tardifs se trouvent dans un "cercle vicieux technologique". Les profits globaux des producteurs de 
porc changent très peu à long terme, comme on aurait pu s'y attendre dans une industrie compétitive 
de libre échange. Les producteurs de céréales sont affectés alors que les producteurs de soja ne le 
sont pas. 
Néanmoins, plusieurs problèmes concernant les répercussions de la PST sur la production ainsi 
que les réponses à apporter aux consommateurs n'ont pas encore été résolus. Avant que les 
répercussions à long terme sur la production, et les effets secondaires éventuels soient appréhendés 
avec une certitude raisonnable, l'adoption à grande échelle de la PST ne se produira pas. 
L'agrément du consommateur pour de la viande provenant de porcs traités par la PST reste un 
problème important qui peut avoir une influence considérable sur l'adoption de la PST. 
Plusieurs paramètres qui n'ont pas été considérés dans ce travail comprennent: 
Le potentiel de conversion des conditionneurs de viande, c'est-à- dire la potentialité d'accorder 
leur préférence à des porcs de boucherie plus lourds, du fait de carcasses plus maigres, et les 
répercussions éventuelles. 
Les implications éventuelles de l'ajournement des réglementations internationales sur l'utilisation 
nationale de PST et sur les restrictions quant aux importations dans les pays producteurs et 
consommateurs de viande de porc les plus importants. 
Les avantages des transformations technologiques en compétition (par exemple les autres 
promoteurs de croissance, les béta-agonistes) sur les industries du porc, du boeuf et de la volaille. 
De tels paramètres pourraient intensifier ou diminuer de façon spectaculaire les changements 
que nous envisageons actuellement en conséquence de l'introduction de PST. A mesure que nous 
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posséderons plus d'informations, nous serons mieux à même d'appréhender de façon plus précise 
les impacts économiques probables de la PST. 
Mots clefs: somatotropine porcine, biotechnologie, impact économique, porc. 
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CONTROLE DE LA CROISSANCE DES PORCS DANS LA CEE: EFFETS 
SUR LA COMPETITIVITE DE LA VIANDE DE PORC ET DES 
INTERVENANTS DANS LA FILIERE PORC. 
A.H.R. Pease 
GIRA S.A.*, Geneva, Switzerland 
Résumé 
Le bénéfice total de l'utilisation de PST dans la production porcine est estimé à 31 ECU/porc. 
Pour les premiers porcs abattus, 20% de ce bénéfice iront aux fournisseurs de PST, 50% aux 
producteurs de porcs (y compris EUROPA grading premia) et 30 % aux bouchers-charcutiers. 
La viande extra-maigre qui apparaîtra sur le marché fera baisser les prix, si bien qu'en l'espace 
de quelques semaines ou de quelques mois, le bénéfice sera réparti différemment: 20% aux 
fournisseurs de PST et 80% aux consommateurs. 
Mots clefs: somatotropine, répercussions économiques, Europe, porc. 
* Actuellement avec Strategie Animal Systems Research and Consultancy 
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EFFECTS D E LA S O M A T O T R O P I N E PORCINE (PST) SUR LA 
POLLUTION AZOTEE DE L'ENVIRONNEMENT 
E J . van Weerden et M.W.A. Verstegen 
TNO Institute of Animal Nutrition and Physiology, ILOB department, Wageningen, The 
Nethi rlands. Department of Animal Nutrition, Agricultural University, Wageningen, The 
Netherlends. 
Résumé 
Des porcs mâles castrés croisés (Landrace Néerlandais x Yorkshire Néerlandais) ont reçu 4 
mg/jour de somatotropine porcine recombinante (rPST) à partir de 58 kg de poids vif et pendant 10 
semaines. Un groupe placebo non traité a servi de témoin. Les animaux ont été nourris 3/4 fois par 
jour à un niveau restreint de 260 Kcal d'énergie métabolisable/kg de poids corporel. 
Les paramètres mesurés étaient les suivants: bilan azoté pendant 6 périodes expérimentales 
durant les 6 dernières semaines de traitement, gain de poids et indice de consommation. 
Le bilan azoté augmentait de façon significative de 31%; 7,7% supplémentaires d'azote 
alimentaire était retenu par l'organisme des animaux traités à la rPST. La vitesse de croissance était 
augmentée de 10% et l'indice de consommation amélioré de 7% chez les porcs traités par la rPST. 
Les bilans de P et de Ca augmentaient respectivement de 18% et de 19% après le traitement à la 
rPST. 
Ces valeurs ont permis de calculer que l'excrétion d'azote dans l'environnement pour des porcs 
de 58 à 110 kg était réduite de 21% après traitement; par ailleurs, la réduction de l'excrétion de P 
était de 16%. 
La grande incertitude quant à l'étendue de l'effet du rPST sur l'excrétion azotée réside dans le 
manque de connaissances des niveaux alimentaires de protéines/acides aminés nécessaires pour 
couvrir le dépôt protéique extrêmement élevé (approximativement 210 g/jour) chez les porcs 
traités. Les données expérimentales obtenues jusqu'à présent ne donnent aucun indice d'une 
augmentation spectaculaire des besoins nutritionnels chez les porcs traités à la PST. 
Mots clefs: somatotropine, porc, environnement, pollution 
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Conclusions, telles qu'elles ont été proposéees par les présidents 
et lesmodérateurs, discutées et adoptées en session plénière 
à la fin du symposium. 
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I M P L I C A T I O N S P O U R L E S S Y S T E M E S D E P R O D U C T I O N 
Président: R.G. ZIMBELMAN 
Les progrès indiscutables apportés par les injections de somatotropine porcine recombinante 
(rPST) pour augmenter le dépôt protéique et diminuer le dépôt de gras ont été considérables quels 
que soient les races, le niveau d'alimentation, le sexe ou les différents systèmes d'exploitation en 
Amérique du Nord, en Europe et en Chine. Bien entendu, il existe des variations dans l'amplitude 
des réponses, mais même la réponse la plus faible est saisissante. Les résultats sont évidents qu'ils 
soient basés sur l'examen des carcasses ou sur les données numériques. 
La diminution de la consommation d'aliments ainsi que l'augmentation de l'efficacité 
alimentaire ont également été significatifs. L'amplitude de cette augmentation ne peut être 
exprimée de façon spécifique pour plusieurs raisons: 1) Le manque de données strictes quant aux 
doses optimales employées 2) L'interaction apparente entre dose et nutrition, i.e. pour que de fortes 
doses entraînent un dépôt protéique plus élevé, la composition du régime doit être modifiée, ce qui 
n'est pas le cas pour des réponses moins importantes; dans les études présentées, il existait des 
variations sur la durée du traitement, les doses employées et enfin le poids initial et final des 
animaux. 
Les conditions pour que le produit soit acceptable dépendront largement de la mise au point d'un 
système pratique permettant la diffusion lente du produit dans l'organisme. Plusieurs firmes 
peuvent réussir plus ou moins bien dans cette voie, compte tenu de l'impossibilité virtuelle de 
décrire de raçon générique l'efficacité du produit en raison de légères modifications dans la 
structure chimique ou la conformation du rPST. Les techniques et les préparations à effet prolongé 
seront probablement un peu moins efficaces et les considérations quant au bénifice économique 
devraient influencer le choix des différents fabricants. 
Les exigences des systèmes de classification des carcasses et de l'industrie de la transformation 
sont assez complexes et méritent d'être sérieusement considérées. Il existe de nombreux problèmes 
à savoir l'épaisseur de la poitrine de porc, les méthodes de transformation, mais aussi la teneur en 
graisse intramusculaire qui pourrait ne pas être optimale avec des niveaux de gras très réduits. 
Certains de ces facteurs pourraient être améliorés par l'augmentation du poids à l'abattage, mais 
ceci peut ne pas être valable pour certains morceaux de viande fraîche ou pour des produits 
courants. 
Une étude approfondie de marché sur la façon de réagir à des porcs extrêmement maigres 
s'avère nécessaire à la fois aux Etats Unis et en Europe. Les résultats de la recherche sur les porcs 
aux Etats Unis ou sur des porcs qui ne sont pas très maigres pourraient ne pas être applicables aux 
programmes Buropéens, dans lesquels les porcs maigres prédominent déjà. Une recherche réalisée 
dans ce type de situation est donc nécessaire afin de déterminer si un bénéfice peut se produire et 
s'il existe des inconvénients non détectés en routine concernant la qualité ou les caractéristiques de 
transformation de la viande. 
Les techniques de modifications du génome progressent à une vitesse surprenante, en particulier 
le développement des approches théoriques pour la réalisation et le contrôle de l'insertion des 
gènes. Les avantages de l'insertion de gènes par rapport à l'administration de rPST par injection 
devraient être plus importants chez les porcs qui présentent déjà des caractères desirables tel qu'une 
prolificité élevée. Chez ces porcs l'amélioration de la croissance et de la carcasse proviendrait 
plutôt de l'insertion des gènes de la somatotropine ou de la somatocrinine (GRF). 
Néanmoins, il faudra probablement de nombreuses années (au moins 8 à 10) avant d'obtenir des 
résultats utilisables chez les animaux reproducteurs. Il est plus que probable que l'animal 
transgénique géniteur aura une insertion de gène unique, qu'on pourra maîtriser par un apport 
alimentaire à bon marché qui soit compatible avec la production commerciale. 
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La nécessité d'accouplements avec un grand nombre de partenaires après la puberté pour un tel 
animal suggère que ce soit un mâle, l'homozygotie étant obtenue par accouplement avec sa 
progéniture. Cela prendra énormément de temps. Finalement, il serait prudent de réaliser un test de 
performances sur une période assez longue pour permettre l'expression de caractères indésirables 
avant l'introduction à grande échelle de rPST dans la banque de gènes. Cela sera onéreux et prendra 
du temps; c'est pourquoi la société devrait développer des mesures telles que le dépôt de brevets 
pour rendre aux investisseurs le bénéfice de leurs investissements risqués et substantiels si cette 
technologie doit être destinée à la commercialisation. Il reste à déterminer si l'utilisation de rPST 
nécessiterait des modifications des procédures de testage et de sélection utilisées pour 
l'amélioration génétique. Ceci dépend de l'interaction éventuelle de l'utilisation de rPST avec 
d'autres caractères désirables que ceux ayant trait aux caractéristiques des performances et de 
carcasse. 
Il faut reconsidérer très sérieusement la question de savoir si l'obtention d'un animal le plus 
maigre possible est un objectif en soi. La description spécifique des variations dans la composition 
en acides gras des porcs traités par le rPST ou transgéniques devrait être une priorité. 
Il semble avisé de prendre des précautions quant à l'application de ces nouvelles technologies 
passionnantes. Une meilleure compréhension de leur mode d'action sera relativement indispensable 
pour partir à la chasse d'une "cible mobile". 
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R E P E R C U S S I O N S SUR LES BESOINS ET LE BIEN-ETRE DE 
L'ANIMAL-CIBLE 
Président: P.R. WIEPKEMA 
Les animaux maintiennent une homéostasie interne et externe au moyen de systèmes de 
régulation bien équilibrés, complexes et étroitement liés. Un grand nombre des paramètres liés à 
l'environnement sont contrôlés activement par l'animal. Quand on modifie les caractères de 
production des animaux domestiques, l'équilibre de l'homéostasie existante doit être pris en 
considération. Les effets principaux et secondaires des nouvelles technologies doivent être mis en 
évidence afin de satisfaire les besoins et le bien-être de l'animal-cible. 
Campbell a montré que le traitement par la somatotropine porcine recombinante (rPST) aurait 
pour effet une diminution du gras et une augmentation de la rétention protéique, mais selon des 
proportions différentes. En particulier, pour le dernier effet cité, il est nécessaire que le régime 
alimentaire contienne une quantité adéquate de protéines. Les deux effets interagissent avec la dose 
de rPST et avec la race, le sexe et le poids vif. 
La diminution de l'ingestion alimentaire observée dans les essais jusqu'à 100 kg de poids 
corporel est associée à une diminution significative du dépôt de gras et une augmentation de la 
rétention protéique. Les répercussions sur le métabolisme des acides aminés, des acides gras et du 
glucose demandent à être mieux élucidées. 
Verstegen a montré que le traitement par le rPST augmente la production de chaleur, ce qui 
reflète un taux métabolique plus élevé. Cette augmentation provient probablement d'un besoin 
d'entretien plus élevé ou bien d'une moindre efficacité de l'utilisation énergétique au dessus du 
niveau d'entretien. 
Curtis a calculé les répercussions éventuelles de la réduction de l'épaisseur de la graisse 
sous-cutanée sur les capacités de régulation thermique des porcs traités à la rPST. Cela pourrait 
conduire à un rétrécissement de la zone de thermorégulation par rapprochement de ses limites. Pour 
cette raison, les effets du traitement des animaux par la rPST sur leur thermorégulation nécessitent 
la détermination des températures optimales pour leur élevage. 
Des informations sur le comportement (organisation sociale, ingestions alimentaire et hydrique, 
repos, etc.) des porcs logés en groupe et traités par la rPST sont nécessaires afin d'évaluer a priori 
les problèmes qui peuvent surgir en pratique dans des conditions d'élevage intensif. D faut ainsi être 
particulièrement attentif aux réactions des porcs traités à la rPST lors de leur transport à l'abattoir 
quand leur capacité de thermorégulation est très sollicitée. 
Kelley a insisté sur le rôle positif normalement joué par la somatotropine dans l'activation du 
système immunitaire (macrophages). Al'heure actuelle il est difficile d'établir quels pourraient être 
les bienfaits du traitement par la rPST sur la santé des porcs. 
Day a montré que l'utilisation de rPST avant la puberté ne perturbe pas les processus de 
reproduction qui se déclenchent quelques semaines après l'arrêt du traitement. L'administration de 
rPST durant l'oestrus fournit des résultats contradictoires. 
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LE POINT DE V U E DES CONSOMMATEURS 
Président: B. H O F F M A N N 
Comme cela a été montré par Norcross (USDA) aux Etats Unis, des procedures bien établies de 
réglementation permettent une estimation adéquate des risques et bénéfices en ce qui concerne 
l'emploi de produits pharmaceutiques chez les animaux destinés à la consommation. Etant un 
produit de la technologie liée aux ADN recombinants, la somatotropine porcine re des Etats Unis, 
des procédures réglementaires efficaces n'ont été mises en place en Europe que depuis la fin des 
années 1960 (GB) et 1970 (DE) ou qu'elles sont toujours en cours d'établissement dans d'autres 
pays membres de la Communauté Européenne. 
Il est nécessaire de répondre à des questions qui restent ouvertes, comme par exemple 
l'innocuité pour la santé des consommateurs des modifications de concentrations de somatomédine 
C (Insulin-like growth factor 1, IGF-1), avant une autorisation définitive. Selon Norcross, d'autres 
procédures réglementaires restent disponibles pour traiter l'autorisation de mise sur le marché des 
animaux transgéniques. Norcross souscrit fortement à toute communication, échanges d'opinions et 
de données entre toutes les instances concernées par les problèmes de réglementation. 
Il est apparu clairement pendant la discussion qu'à la difference des Etats Unis, des procédures 
réglementaires efficaces n'ont été mises en place en Europe que depuis la fin des années soixante 
(GB) et soixante-dix (DE), ou qu'elles sont toujours en cours d'établissement dans d'autres pays 
membres de la Communauté Européenne. 
Selon Schams, qui a présenté des données provenant d'une étude en collaboration sur la rPST et 
l'IGF-1, les concentrations basales sanguines de somatotropine et d'IGF-1 sont atteintes 
respectivement après 26 h et 4 jours de traitement par la rPST. Des résultats préliminaires présentés 
lors de ce symposium ont montré qu'il n'y avait pas de résidus de rPST et de IGF-1 dans les muscles 
après 4 jours de traitement. Il n'existe pas de données concernant les concentrations hépatiques et 
rénales d'IGF-1 et il est de plus nécessaire d'obtenir de plus amples informations quant à la 
dégradation de l'IGF-1 et à la formation de fragments susceptibles d'être biologiquement actifs. 
Prusa et Demeyer dans leurs présentations ont confirmé la tendance générale selon laquelle le 
traitement par rPST conduit à l'obtention de carcasses plus maigres et à une diminution du gras 
intramusculaire; néanmoins, il existe des différences entre races qui doivent être prises en compte. 
Bien que des différences mesurables aient été constatées dans la composition nutritionnelle et la 
qualité organoleptique entre animaux traités ou non par le rPST, aucun problème majeur ne ressort 
avec évidence. En effet, les concentrations protéiques et hydriques augmentent légèrement, de 
façon similaire à la teneur en acides gras polyinsaturés de la viande de porc crue et de celle en 
cholestérol de la viande de porc cuite; par contre la teneur en thiamine diminue, elle, légèrement. La 
qualité organoleptique globale n'est pas altérée bien que quelques déviations par rapport au groupe 
témoin aient été rapportées. 
La possikilité de réduire l'ingestion de matières grasses et de calories à partir de la viande de 
porc grâce à l'emploi de rPST a été discutée comme étant une des façons par lesquelles la qualité de 
la nutrition humaine peut être améliorée. 
Graham s'est fait le porte-parole des consommateurs en demandant l'ouverture du débat. Leurs 
opinions concernent plus que des problèmes d'innocuité, elles comprennent aussi d'autres 
paramètres éthiques, comme le bien-être de l'animal. Le consommateur moderne, qui est capable de 
manipuler les ordinateurs et d'autres instruments sophistiqués, désire être consulté; de plus il est 
capable d'être éduqué, c'est-à-dire qu'il sera capable de traiter les informations apportées par 
l'industrie et la science. C'est dans cette optique que Graham a discuté des problèmes de label 
d'origine de certains produits; en outre, cet auteur s'est montré en désaccord avec l'appellation 
"produits diététiques" pour des produits qui sont destinés au profit commercial. 
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Les questions qui demeurent sans réponse concernent l'identité du consommateur, le terrain 
d'entente, la diffusion d'une information fiable; Dantzer a présenté une approche philosophique du 
problème dans laquelle il faisait référence aux aspects normatifs du processus en faisant ressortir les 
valeurs éthiques. Afin de faire avancer quelques idées au niveau de la société, les répercussions 
potentielles des biotechnologies sur les structures socio-économiques de la production animale 
devraient être mises en valeur. Bien que les biotechnologies représentent un potentiel important 
pour l'amélioration de la rentabilité de la production animale, il est nécessaire de considérer 
sérieusement la portée éthique de leur mise en pratique pour qu'elles soient comprises et acceptées 
par la société. 
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REPERCUSSIONS SUR L'ENVIRONNEMENT ET L'ECONOMIE 
Présidents: K. Aibara et G. van Dijk 
L'introduction de la somatotropine porcine recombinante (rPST) dans la production porcine 
dépend de nombreux facteurs dont la plupart ont été répertoriés. Parmi ceux-ci, on peut citer 
l'économie de l'exploitation, les effets sur la chaine commerciale, l'agrément du consommateur, les 
répercussions sur l'environnement physique, les attitudes gouvernementales et les considérations 
éthiques. 
L'économie de l 'exploitation: 
Hayenga a exposé clairement que les avantages économiques entraînent un taux élevé 
d'adoption de l'utilisation du rPST à la condition qu'il n'y ait pas de réserves notables liées aux 
critères d'agrément des consommateurs. Ses données indiquent des taux de 50 - 60% en 2 - 3 ans. 
L'emploi de rPST conduira à une diminution du coût et de ce fait ceux qui auront adopté cette 
technique très tôt, verront leur marge de profit augmenter. Toutefois, ce type de situation n'est pas 
stable. Après quelque temps, la compétition forcera les retardataires à adopter ce type de technique 
et les marges de profit baisseront puisque les prix pratiqués dans cette industrie ont tendance à 
s'égaliser avec les coûts moyens à long terme. Ce seront éventuellement les consommateurs qui 
seront les bénéficiaires les plus durables. Dans les conditions européennes également, les industries 
de transformation et de commercialisation seront à même de s'assurer une marge bénéficiaire. 
Pease suggère que l'industrie de transformation pourrait prendre une quote-part substantielle. Il 
semblerait que cette constatation soit valable essentiellement pour le court terme. A long terme, les 
conditions seront les mêmes que dans le secteur des exploitations agricoles. Néanmoins, une partie 
du profit restera dans les secteurs d'élevage et de transformation. Il semble normal que ces 
nouvelles technologies soient à la base d'une égalisation entre augmentation générale des revenus 
et croissance économique globale. 
L'effet de marché 
Il y aura peu d'augmentations de la demande, à moins d'effets de substitution. Il y a d'ailleurs 
peu d'échanges commerciaux entre l'Europe, les Etats Unis et le Japon. Les changements 
démographiques, avec l'accroissement de la proportion de la population islamique, rendent le 
marché international du porc de nature plus stable que ne pourraient le laisser prévoir 
potentiellement les perspectives pour le marché du boeuf par exemple. 
Steele et les participants à la discussion ont fait remarquer que la baisse des prix de la viande de 
porc favorisait le remplacement de la viande de boeuf par le porc. Néanmoins, peu de données 
quantitatives sont disponibles quant aux paramètres d'élasticité de telles substitutions, présumant 
de variations de prix considérables. Des études sont en cours (Hayenga). Quant aux répercussions 
de l'introduction de rPST dans les pratiques de la transformation, McKeith souligne qu'il n'y en a 
pas. A chaque fois que de telles répercussions se produiraient, la technologie normale pourrait les 
maîtriser facilement. Par contre, le rPST a une influence positive en ce qui concerne les contraintes 
liées à l'environnement. Van Weerden a montré qu'il y aura une diminution de 15 à 20% des 
émissions polluantes (d'azote et de phosphore) par kg de produit. Il n'y a aucun doute que ces effets 
sont importants à défaut d'être décisifs pour les Pays Bas. Toutefois, les répercussions économiques 
et la validation de l'argumentation écologique sont toujours à quantifier. Même si la loi imposait des 
restrictions quant aux émissions de N et de P, l'introduction de rPST pourrait être considérée 
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comme un moyen important ajouté aux autres mesures visant à diminuer les effets polluants. Au 
total, les mesures pour la protection de l'environnement conduiront à des changements dans les 
systèmes de production. L'agrément du consommateur n'est pas une donnée inamovible. 
Elle peut être modifiée grâce à la commercialisation, la promotion et les campagnes 
publicitaires. Les progrès dans ce domaine ont été si modestes que la viande de porc est toujours 
considérée comme un produit de masse. Il semblerait malgré tout que des modifications de la 
politique de commercialisation soient en cours. Dans une telle évolution, les producteurs seront 
mieux intégrés dans l'ensemble de la chaîne commerciale. 
Cela devrait déboucher sur une production contractuelle et une gestion verticale de la qualité. 
Les problèmes liés à l'agrément du consommateur sont alors traités de façon normale dans ces 
conditions: en effet, la qualité n'est pas perçue automatiquement par les consommateurs et la 
confiance des consommateurs doit être gagnée. 
Les raisons pour lesquelles les politiques gouvernementales résistent à l'introduction de rPST 
sont probablement liées à des considérations sociales et économiques. Les conséquences quant aux 
structures nationales peuvent être très importantes. La rPST pourrait alors devenir facilement un 
instrument pour établir des barrières commerciales. Toutefois, ceci deviendra de moins en moins 
possible en Europe, du fait que le consommateur obtiendra une position plus décisive. La plupart 
des participants à la discussion ont considérés que l'introduction de rPST aurait des répercussions 
importantes liées aux modifications géographiques de la production porcine. 
Résumé des paramètres d'interaction à impact économique: 
économie de la ferme: favorable à l'introduction de rPST 
argumentation écologique: idem 
consommateur: "demande à être convaincu" 
besoins nutritifs/santé: avis favorable contribuable: (probablement) neutre 
animal-cible: nécessite une discussion plus approfondie 
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